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Abstract 
This thesis examined the enzyme dihydrodipicolinate synthase (DHDPS, E.C. 4.2.1.52) from the pathogen 
Mycobacterium tuberculosis. DHDPS is a validated antibiotic target for which no potent inhibitor based on 
substrates, intermediates or product has been found. The importance of the homotetrameric quaternary 
structure in E. coli DHDPS has been demonstrated by the 100-fold decrease in activity observed in a 
dimeric variant, DHDPS-L197Y, created by site-directed mutagenesis. This suggested a new approach for 
inhibitor design: targeting the dimer-dimer interface and disrupting tetramer formation. 
 
DHDPS catalyzes the first committed step in the biosynthetic pathway of meso-diaminopimelic acid, a 
critical component of the mycobacterial cell wall. In this study, wild-type M. tuberculosis DHDPS was 
thoroughly characterized and compared with the E. coli enzyme. A coupled assay was used to obtain the 
kinetic parameters for M. tuberculosis DHDPS: KM(S)-ASA = 0.43 (±0.02) mM, KMpyruvate = 0.17 (±0.01) mM, 
and kcat = 138 (±2) s-1. Biophysical techniques showed M. tuberculosis DHDPS to exist as a tetramer in 
solution. This is consistent with the crystal structure deposited as PDB entry 1XXX. The crystal structure 
of M. tuberculosis DHDPS showed active-site architecture analogous to E. coli DHDPS and a dimeric 
variant of M. tuberculosis DHDPS was predicted to have reduced enzyme activity. 
 
A dimeric variant of M. tuberculosis DHDPS was engineered through a rationally designed mutation to 
analyze the effect of disrupting quaternary structure on enzyme function. A single point mutation resulted 
in a variant, DHDPS-A204R, with disrupted quaternary structure, as determined by analytical 
ultracentrifugation and gel-filtration chromatography. DHDPS-A204R was found to exist in a 
concentration-dependent monomer-dimer equilibrium, shifted towards dimer by the presence of pyruvate, 
the first substrate that binds to the enzyme. The secondary and tertiary structure of DHDPS-A204R was 
analogous to wild-type M. tuberculosis DHDPS as judged by circular dichroism spectroscopy and X-ray 
crystallography, respectively. Surprisingly, this disrupted interface mutant had similar activity to the 
wild-type enzyme, with a kcat of 119 (±6) s-1; although, the affinity for its substrates were decreased: 
KM(S)-ASA = 1.1 (±0.1) mM, KMpyruvate = 0.33 (±0.03) mM. These results indicated that disruption of tetramer 
formation does not provide an alternative direction for drug design for DHDPS from M. tuberculosis. 
 
Comparison with the recently discovered dimeric DHDPS from Staphylococcus aureus shed further light 
on the role of quaternary structure in DHDPS. In M. tuberculosis DHDPS-A204R and the naturally dimeric 
enzyme, the association of monomers into the dimer involves a greater buried surface area and number of 
residues than found in E. coli DHDPS-L197Y. This provides a framework to discriminate which DHDPS 
enzymes are likely to be inactive as dimers and will direct future work targeting the dimer-dimer interface 
of DHDPS as an approach for drug design. 
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Chapter One 
Introduction 
 
The subject of this thesis is the tetrameric enzyme dihydrodipicolinate synthase (DHDPS) 
from Mycobacterium tuberculosis. This enzyme catalyzes the first committed step of the 
(S)-lysine biosynthetic pathway, which also produces meso-diaminopimelic acid (DAP). Both 
(S)-lysine and DAP are essential components of the bacterial cell wall, and the biosynthetic 
pathway is absent in humans, which makes DHDPS an attractive target for drug design. 
Several genomic studies have classed DHDPS as the product of an essential gene, and thus 
validated it as a target for antibiotic design.1 
 
This work explores the connection between quaternary structure and enzyme function. The 
importance of the tetrameric structure of Escherichia coli DHDPS has previously been 
demonstrated: a dimeric E. coli DHDPS, created by mutating one of the residues involved in 
inter-subunit interactions, showed significantly less activity than the tetrameric wild-type 
enzyme.2 If this proves to be a general observation for DHDPS enzymes from pathogenic 
micro-organisms, it could open a new avenue of antibiotic design, as molecules could be 
developed to break up the tetrameric structure and deactivate DHDPS. Therefore, the aim of 
this thesis is to examine the quaternary structure of DHDPS from M. tuberculosis as a 
putative drug target. 
 
1.1 Tuberculosis 
There is a desperate need for new drugs to treat M. tuberculosis infection - it has been 50 
years since a new anti-tuberculosis drug has been approved for treatment.3 M. tuberculosis 
causes more death in the world today than any other bacterial agent,4 and the death toll is set 
to rise as drug-resistant strains emerge.5 In 2005, 1.6 million people died from tuberculosis 
and it is a leading killer among HIV-infected people with weakened immune systems.6 
 
Within a year of the discovery of the first antibiotic against M. tuberculosis, in 1944, there 
were already resistant strains emerging.7 This pattern has continued and consequently current 
treatment involves a multi-drug approach. The symptoms of tuberculosis tend to disappear 
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within the first month of treatment, in spite of the infection still being present, so patients 
often fail to complete an adequate course of antibiotics, which increases the likelihood of drug 
resistance arising.4 The adaptability of M. tuberculosis is alarming and, recently, the World 
Health Organization (WHO) has defined a new kind of drug resistant strain that is not only 
resistant to almost all of the commonly used, so-called “first-line”, drugs but also several of 
the more costly second-line drugs, thus almost eliminating all methods of treatment.6 In a case 
study in South Africa, 52 patients were identified to be infected with such a strain, and all but 
one died as a result.8 It is believed that this extensively drug resistant strain, XDR-TB, has 
developed from MDR-TB, a multi-drug resistant strain which shows resistance to several 
first-line drugs.3 The WHO survey of 76 countries, from 1999-2002, showed 0 to 14 % 
(median 1 %) of new tuberculosis infections were caused by MDR-TB.9 
 
The first vaccine against M. tuberculosis, BCG (bacillus Calmette-Guerin), derived from 
M. bovis by Calmette and Guérin, has been distributed since the 1920s and remains the only 
available vaccine for humans.10 Unfortunately, there is significant regional variation in the 
protection provided by the BCG vaccine against pulmonary tuberculosis, the most common 
form of tuberculosis which occurs in the lungs, with reported variation in efficacy between 0 
and 80 %.11 However, the BCG vaccine is effective against the childhood manifestations of 
M. tuberculosis, miliary or meningeal tuberculosis, occurring in the blood and brain, 
respectively, and its close relative, M. leprae, the causative agent in leprosy, and therefore the 
vaccine continues to be used extensively.10 Consequently, rather than looking for a 
replacement vaccine, much of the current research is exploring the development of a 
“booster” vaccine, from adjuvants containing proteins, or proteins fused to DNA.12 
 
The complete sequencing of the M. tuberculosis strain H37Rv genome is probably the most 
important advance in the mycobacterial field since the identification of the bacillus,13 by 
R. Koch a century ago.4 More than 3900 genes thought to encode proteins were identified and 
at least 52 % of these have been assigned function.14,15 Additionally, several other strains of 
M. tuberculosis have been sequenced and annotated (H37Ra,16 CDC1551,17 and F1118). No 
variation in the amino-acid sequence for DHDPS has been observed, suggesting that the 
enzyme is not linked to the variation in virulence and drug susceptibility in these strains. 
M. bovis, the most closely related species to M. tuberculosis, also has an identical sequence 
for DHDPS but other relatives, such as M. leprae, show some differences (87 % identity 
determined using CLUSTALW).19 
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The conservation of a gene encoding DHDPS, especially in M. leprae, described as the 
minimal mycobacterial gene set,20 provides evidence for the essential nature of the enzyme 
DHDPS. Computer simulations suggest 35 % of the M. tuberculosis genome is essential;21 
however, in vitro experiments have only found 614 genes necessary for optimal growth, 
including the gene coding for DHDPS.22 Most of the enzymes of the (S)-lysine biosynthetic 
pathway have been shown to be necessary or essential for growth under normal conditions in 
various bacterial genome projects.1 
 
1.2 The metabolic role of DHDPS 
The enzyme DHDPS catalyzes the condensation of (S)-aspartate semialdehyde ((S)-ASA) and 
pyruvate in the first committed step of the (S)-lysine/DAP biosynthetic pathway.23 The 
substrate (S)-ASA is derived from (S)-aspartic acid, and can alternatively be reduced by 
homoserine dehydrogenase to give (S)-homoserine, a precursor to (S)-methionine, 
(S)-threonine and (S)-isoleucine (Figure 1.1).24 These four amino acids, together with 
(S)-lysine and DAP, comprise the aspartic acid family of amino acids, and homoserine 
dehydrogenase, together with DHDPS, have key regulator roles as branch point enzymes.25 
 
1.2.1 The role of DHDPS in the DAP pathway 
There are four variants of the DAP/(S)-lysine biosynthetic pathway found in bacteria 
(Figure 1.1) which use slightly different sets of enzymes.26-28 The acetylase pathway appears 
to be limited to certain Bacillus species,26 with the notable exception of Bacillus sphaericus 
which utilizes the dehydrogenase pathway instead.29 Mycobacteria, like E. coli and other 
Gram-negative bacteria, use the succinylase pathway.30 The aminotransferase pathway has 
only recently been discovered in the bacterial genus Chlamydia, which lack a detectable 
peptidoglycan cell wall, and there is growing evidence of its use in plants.27 Comparative 
genomic analysis, coupled with experimental verification, have determined further lineages of 
eubacteria, as well as two archaeal groups, which utilize the aminotransferase pathway.31 
Several of these bacteria are suggested to use two of the four pathways; that is, the 
dehydrogenase pathway in addition to aminotransferase pathway,31 in a similar manner to the 
Gram-positive bacteria, Corynebacterium glutamicum, which uses both the succinylase and 
dehydrogenase pathway.32 Consequently, any antibacterial agent used against these bacteria 
would have to inhibit an enzyme common to both pathways, such as DHDPS. 
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Figure 1.1: A schematic diagram of the four known biosynthetic pathways utilized by bacteria 
to produce DAP and (S)-lysine, which are used as components in the 
peptidoglycan cell wall.26-28 
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All these pathways share initial and terminal steps, so the enzymes catalyzing these steps, 
which include DHDPS, dihydrodipicolinate reductase (DHDPR), and DAP decarboxylase, 
should be conserved in all bacterial species.27,31 DHDPS being crucial in all four pathways, 
therefore, provides an opportunity for developing broad spectrum drugs.33 
 
1.2.2 DAP/(S)-lysine biosynthesis as a target for antibacterial agents 
First discovered by Work in 1950 in Corynebacterium diphtheriae,34 and subsequently in 
M. tuberculosis,35,36 DAP is the precursor to an essential amino acid, (S)-lysine, and also has a 
role unique to bacteria.37,38 In almost all bacteria, either DAP or (S)-lysine are part of the short 
peptides that cross-link the long polymers composing the cell wall.39 They play a crucial role 
linking the tetrapeptide branches (Figure 1.2) that give the peptidoglycan cell wall the 
strength to withstand high intracellular osmotic pressure, and consequently in bacteria the 
absence of (S)-lysine or DAP should result in cell lysis and death.39 
 
 
Figure 1.2: A schematic diagram of peptidoglycan, which is composed primarily of long 
alternating sequences of N-acetylglucosamine (G) and N-acetylmuramic acid 
(M/NAM) interlinked by peptide chains. The peptide cross-link sequences vary; 
(A) is mostly found in Gram-negative bacteria, (B) in Gram-positive bacteria,26 
and (C) is unusual and found in mycobacteria.40 The tetrapeptide branches are 
bonded directly to each other in Gram-negative bacteria and mycobaceria, 
whereas an additional sequence of five glycines (Gly) is required to make the link 
in Gram-positive bacteria. 
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Many existing antibiotics inhibit other key steps in the assembly of the bacterial cell wall and 
the biosynthesis of its components has long been accepted as a target for antibiotic design.41 
An inhibitor which inactivated one of the enzymes in the DAP/(S)-lysine biosynthetic 
pathway and prevented the synthesis of these crucial amino acids would be a very effective 
antibiotic.1,26,38,39,41,42 These antimicrobial molecules would constitute a new class, as no 
naturally occurring antibiotics have been found that act on the DAP biosynthetic pathway.41 
 
Mycobacteria have cell walls with an unusually high DAP content because they contain an 
unusual tetrapeptide linkage, where the second alanine (D-Ala) in the peptide sequence has 
been replaced with DAP (Figure 1.2C).40 The resulting DAP-DAP link within the 
tetrapeptide constitutes one third of the cell wall interpeptide linkages in M. smegmatis,40 and 
half of those in M. bovis,43 and elevates the importance of DAP in the mycobacterium cell 
wall.40 This might mean that bacteria from this classification are more sensitive to compounds 
that inhibit the DAP/(S)-lysine biosynthetic pathway. DAP auxotrophs have been created 
from several bacterial species, including E. coli and M. smegmatis, which in the absence of 
DAP undergo cell lysis and death.25 These gene-knockout experiments demonstrate the 
essential nature of DAP and validate the DAP biosynthetic pathway as a target for 
antibacterial drug design. 
 
Unfortunately, it was also found that M. smegmatis DAP auxotrophs spontaneously mutated 
to suppress their requirement for DAP,44 using the bacterial metabolite lanthionine as an 
alternative cell wall component.45 This provides a possible resistance mechanism against 
antibiotics that inhibit the DAP biosynthetic pathway. Interestingly, these mutants were 
hypersensitive to β-lactam antibiotics,44 reflecting the altered cell wall structure.45 While the 
exact role of the DAP-DAP linkage is unknown, it has been linked to mycobacterial resistance 
to β-lactam antibiotics.46 Developing synergistic combinations of antibiotics has been 
suggested as a means for overcoming β-lactam antibiotic resistance,47 and like β-lactamase 
inhibitors,48 a drug that inhibits DAP synthesis, could be used in combination with β-lactams 
to counteract antibiotic resistance. 
 
Disrupting (S)-lysine production is another rationale for targeting the enzymes of the DAP 
biosynthetic pathway. Unlike DAP, (S)-lysine is an essential amino acid for protein synthesis. 
A (S)-lysine biosynthetic pathway, involving DAP as an intermediate, is also found in 
plants.41 An unrelated (S)-lysine pathway, named the α-aminoadipate pathway, is found in 
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higher fungi and euglenoids.49 Mammals also require (S)-lysine, but acquire it through dietary 
intake rather than producing it themselves.38 The absence of the (S)-lysine/DAP biosynthetic 
pathway in mammals means that inhibitors of this pathway would not be expected to have 
mammalian toxicity.38 
 
Gene knockout experiments suggest that M. tuberculosis is inefficient at acquiring (S)-lysine, 
because M. tuberculosis H37Rv (S)-lysine auxotrophs required media supplemented with 
25-fold higher concentration of (S)-lysine (1 mg.mL-1) than similar M. smegmatis 
auxotrophs.50 The inability of M. tuberculosis to uptake (S)-lysine from the environment also 
seemed evident in research showing that M. tuberculosis growth was unaffected by a toxic 
(S)-lysine analogue.50 The difficulties in (S)-lysine uptake observed for M. tuberculosis would 
make it particularly vulnerable to inhibition of the enzymes critical for (S)-lysine biosynthesis. 
Taken together, the DAP/(S)-lysine pathway, being both essential for bacterial viability and 
absent in animals, provides an excellent target for antibiotic design, especially in 
M. tuberculosis. 
 
1.2.3 Regulation of DHDPS and the (S)-lysine pathway 
DHDPS, as the enzyme catalyzing the first committed step of the (S)-lysine/DAP biosynthetic 
pathway (Figure 1.3), is well positioned to have an important role in regulating metabolic 
flux. The catalytic activity of DHDPS is inhibited, to varying degrees of sensitivity, by 
(S)-lysine (as detailed in section 1.2.4).51 Plant enzymes are orders of magnitude more 
sensitive than enzymes from Gram-negative bacteria, such as E. coli.51 Gram-positive 
bacteria, such as Bacillus licheniformis, have DHDPS that are uninhibited by physiological 
concentrations of (S)-lysine.52 The regulation of DHDPS activity by (S)-lysine, in Gram-
negative bacteria, reflects the importance of DHDPS in regulating flux of metabolites through 
the DAP pathway and is consistent with its role as the first unique step in this pathway. 
 
In E. coli, the expression of the dapA gene encoding DHDPS is regulated by the levels of 
DAP present in the cell,53 in contrast to the other enzymes in the (S)-lysine pathway which are 
regulated by the levels of (S)-lysine.54,55 Gene-knockout experiments with M. smegmatis 
revealed differences in the gene regulation of the (S)-lysine pathway in mycobacteria 
compared with E. coli, because DAP auxotrophs could not be isolated without silencing of an 
additional gene, lysA, which codes for DAP decarboxylase, an enzyme that converts DAP 
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into (S)-lysine.25 The expression of the lysA gene is not regulated by levels of (S)-lysine in 
C. glutamicum,56 which is considered to be a close evolutionary relative to mycobacteria.25 
Without regulation of lysA gene expression, DAP auxotrophs have insufficient DAP to 
support cell wall synthesis because the majority of DAP acquired is converted into 
(S)-lysine.25 The unregulated conversion of DAP to (S)-lysine indicates that decreasing the 
metabolic flux through this pathway, by partial inhibition of DHDPS, may aid in 
mycobacterial cell death, further validating the enzymes of the (S)-lysine/DAP biosynthetic 
pathway as good targets for antibiotic design in mycobacteria. 
 
1.2.4 Trends for (S)-lysine inhibition 
The orthologues of DHDPS were first grouped into three classes based on their sensitivity to 
(S)-lysine inhibition by Blickling (et al. 1997).57 Plant DHDPS enzymes are strongly inhibited 
(IC50 between 10 and 50 µM),57 suggesting their regulatory role in controlling metabolic flux 
through the (S)-lysine biosynthetic pathway.58 The expression of (S)-lysine-insensitive 
DHDPS in plants results in an accumulation of (S)-lysine, providing further evidence for its 
regulatory role.59,60 
 
Bacterial DHDPS enzymes are separated into weakly inhibited (~100 fold less sensitive than 
plant enzymes) and uninhibited classes of DHDPS, associated with Gram-negative and 
Gram-positive bacteria, respectively.57 The regulatory role of the weak inhibition in bacterial 
DHDPS is unclear.58,60 Strong selective agents for (S)-lysine-overproducing mutants failed to 
induce expression of modified, less (S)-lysine sensitive DHDPS in E. coli, unlike similar 
experiments performed with plants.60 This suggests that the (S)-lysine feedback inhibition of 
E. coli DHDPS is not the main point of regulation for the (S)-lysine biosynthetic pathway.60 
 
The same (S)-lysine binding sites have been identified both in weakly inhibited bacterial 
enzymes and strongly inhibited plant enzymes, using X-ray crystallography studies.61,62 
However, in plant enzymes, key active-site residues shift upon (S)-lysine binding suggesting a 
possible mechanism for inhibition, whereas the mechanism is still unclear for bacterial 
enzymes.51,61 The differences in (S)-lysine inhibition have been linked to the differences in 
quaternary structure between plant and bacterial enzymes, which will be discussed in more 
detail in section 1.5.4. 
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Even though the mechanism and regulatory role is unclear for (S)-lysine inhibition in bacterial 
DHDPS, most bacterial DHDPS studied to date fit the trend between Gram-negative and 
Gram-positive bacteria (Table 1.1). These differences in inhibition between Gram-negative 
and Gram-positive bacteria may be connected to the differences in their cell walls; either their 
thickness and/or their composition, using DAP or (S)-lysine, respectively (see Figure 1.2, 
section 1.2.2). 
 
Table 1.1: (S)-Lysine inhibition of DHDPS activity for various bacterial DHDPS enzymes. 
Gram Species IC50a Inhibition @ [lysine] Ref. 
 +  Bacillus brevis  --- None 5 mM 63 
 +  Bacillus cereus  --- 10 % 30 mM 64 
 +  Bacillus licheniformis  --- None 10 mM 52 
 +  Bacillus megaterium  --- None 13 mM 65,66 
 +  Bacillus sphaericus 0.6 mM 100 % 10 mM 29 
+  Bacillus stearothermophilus  --- None 10 mM 67 
 +  Bacillus subtilis  --- None 100 mM 68 
 +  Brevibacterium flavum  --- None  --- 69 
 +  Brevibacterium linens  --- 20 % 20 mM 69 
 +  Brevibacterium lactofermentum  --- None 10 mM 70 
 +  C. glutamicum  660 mM  None  --- 71,72 
 -  E. coli 1 mM 50 % 1 mM 73 
+  Lactobacillus plantarum --- None 10 mM 74 
 -  Methylophilus methylotrophus  1 mM 90 % 50 mM 75 
 -  Methanobacterium thermoautrophicum 0.25 mM 80 % 20 mM 76 
 -  Neisseria meningitidis 0.053 mM 50 % 0.053 mM 77 
 -  Pseudomonas acidovorans L6 0.20 mM 50 % 0.20 mM 78 
 -  Pseudomonas putida T1 0.65 mM 50 % 0.65 mM 78 
 -  Sinorhizobium meliloti 0.7 mM 50 % 0.7 mM 79 
 +  methicillin-resistant Staphylococcus aureus  225 mM None 10 mM 80,81 
 +  Streptococcus faecalis  --- None 16 mM 82 
 +  Streptomyces clavuligerus  --- None 10 mM 83 
 +  Thermoanaerobacter tengcongensis  --- None 20 mM 84 
-  Thermotoga maritima   --- None 10 mM 85 
 
a  The inhibitor concentration which reduces enzyme activity by 50 %. 
 
1.3 The catalytic activity/enzymatic function of DHDPS 
A common approach to rationally designing enzyme inhibitors is through identifying and 
understanding the chemistry and structure of their active site.86 Putative inhibitors often have 
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structures based on the substrates, products or intermediates of the reaction.86 DHDPS 
catalyzes an aldol condensation, that is the formation of a β-hydroxy group from two 
carbonyl-containing compounds, in this case, pyruvate and (S)-ASA (Figure 1.3). Research 
focused on designing an inhibitor for DHDPS has resulted in extensive work elucidating the 
details of its catalytic mechanism. 
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Figure 1.3: The overall reaction catalyzed by dihydrodipicolinate synthase (DHDPS). 
 
1.3.1 Kinetics of catalysis 
Numerous kinetic studies of E. coli DHDPS suggest that catalysis proceeds through a 
ping-pong mechanism.58,73,87-89 This mechanism describes two substrates binding in a specific 
order, with a release of a product before the binding of the second substrate.90 Thus the 
enzyme (E) never contains two unreacted substrates, but the first substrate, in this case 
pyruvate (PYR), reacts to form an enzyme-substrate intermediate (F), with release of H2O and 
it is this intermediate (F) which binds to and then reacts with (S)-ASA (Figure 1.4).89,91 
 
E E:PYR F F:ASA E:HTPA
HTPA(S)-ASAPYR
EF:H2O
H2O
 
Figure 1.4: A schematic diagram of the kinetic mechanism of DHDPS, with substrates, 
pyruvate (PYR) and (S)-ASA, binding in a specific order.89 (4S)-4-Hydroxy-
2,3,4,5-tetrahydro-(2S)-dipicolinic acid (HTPA) is currently thought to be the 
condensation product released from DHDPS.57 
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The ping-pong mechanism has been assigned to DHDPS from various plant species,92-94 
C. glutamicum,71 E. coli,58,73,87,88 methicillin-resistant Staphylococcus aureus (MRSA),80 and 
Thermotoga maritima,85 based on the characteristic parallel lines shown by the double 
reciprocal plots of initial velocity data.91 The existence of an enzyme-pyruvate intermediate 
has been demonstrated by mass spectrometry95 and crystallography,73,80,96,97 and is consistent 
with the inhibition pattern shown by some substrate and product analogues, which reflected 
the existence of two different enzyme forms (E & F) as shown in Figure 1.4.89 
 
The relationship between substrate concentration and the rate of an enzyme-catalyzed reaction 
is reflected in the Michaelis constant, KM, which is determined by fitting initial velocity data 
to the appropriate mechanistic model.91 There is variation in reported KM values for DHDPS 
from different sources (Table 1.2). Importantly, as noted in Table 1.2, several different 
methods have been used for collecting kinetic data for DHDPS (described in detail in chapter 
two, section 2.2) and two of those methods, referred to as the o-aminobenzaldehyde assay and 
the imidazole assay, have inherent lag times. Thus it is questionable whether the rate being 
measured is actually the initial-rate of DHDPS.98 The coupled assay has no lag time, is the 
current method of preference,98 and has repeatedly determined KM values for E. coli DHDPS 
of similar magnitudes: 0.2 mM for pyruvate and 0.1 mM for (S)-ASA (Table 1.2). 
 
The superiority of the coupled assay relative to o-aminobenzaldehyde assay is emphasized in 
the 10-fold difference in the KM for (S)-ASA (0.63 as opposed to 6.2 mM, Table 1.2) 
determined for DHDPS from C. glutamicum.71 E. coli DHDPS has relatively smaller values of 
KM compared with C. glutamicum DHDPS (~0.2 vs. 0.63 mM for pyruvate, Table 1.2), 
showing that lower concentrations of substrates are required to saturate the E. coli enzyme. 
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Table 1.2 Kinetic constants for wild-type DHDPS from various sources. 
Organism KM pyruvate (mM) KM (S)-ASA (mM) Assay method Ref. 
Plants     
Pisum sativum (Pea) 1.7 0.4 o-aminobenzaldehyde 92 
Spiniacia oleracea (Spinach)  - 1.4 o-aminobenzaldehyde 99 
Triticum aestivum (Wheat) 11.8 0.8 o-aminobenzaldehyde 94 
Triticum aestivum (Wheat)  - 1 o-aminobenzaldehyde 100 
Zea mays (Maize) 2.1 0.6 o-aminobenzaldehyde 93 
Bacteria     
Bacillus licheniformis 2.6 5.3 o-aminobenzaldehyde 101 
Bacillus megaterium 0.5 0.46 imidazole 101 
Bacillus sphaericus 9 5.1 o-aminobenzaldehyde 101 
Bacillus subtilis 1.07 3.13 o-aminobenzaldehyde 68 
Brevibacterium lactofermentum 4.4 0.58 o-aminobenzaldehyde 102 
C. glutamicum  - 6.2 o-aminobenzaldehyde 72 
C. glutamicum 0.32 (±0.01) 0.63 (±0.04) coupled 71 
E. coli 0.25 0.13 coupled 23 
E. coli 0.57 0.55 imidazole 73 
E. coli 0.17 0.07 coupled 89 
E. coli 0.25 (±0.03) 0.11 (±0.01) coupled 103 
E. coli 0.26 (±0.03) 0.11 (±0.01) coupled 87 
E. coli 0.14 (±0.03) 0.12 (±0.01) coupled 88 
E. coli 0.16 (±0.03) 0.13 (±0.02) coupled 2 
Methanobacterium thermoautrophicum 0.83  22.2  o-aminobenzaldehyde 76 
Neisseria meningitidis 0.50 (±0.03) 0.052 (±0.03) coupled 77 
Sinorhizobium meliloti  0.27 (±0.02) 0.13 (±0.02) imidazole 79 
S. aureus (MRSA) 0.11 (±0.01) 0.22 (±0.02) coupled 81 
S. aureus (MRSA) 0.12 (±0.01) 0.33 (±0.03) coupled 80 
Streptomyces clavuligerus 1 0.3 imidazole 83 
Thermoanaerobacter tengcongensisa 0.85 (±0.05) 0.38 (±0.05) coupled a 84 
T. maritima 0.05 (±0.01) 0.16 (±0.01) coupled 85 
 
a Coupled assays were performed at 60 °C rather than 30 °C, nearer the in vivo temperatures for the thermophilic bacteria 
Thermoanaerobacter tengcongensis. An enzyme’s KM has been shown to change with changing temperature, therefore 
the elevated KM in comparison to others determined by the coupled assay may reflect mainly a temperature effect.84  
 
1.3.2 Binding of pyruvate 
The reaction catalyzed by DHDPS begins with the ε-amino group of a lysine (K161 in E. coli 
DHDPS) attacking the partially positive carbon of the carbonyl group on pyruvate (Step 1, 
Figure 1.5).61 The resulting dehydration to form an imine, or Schiff base (Step 2, Figure 1.5), 
has been thoroughly demonstrated in several studies.73,95,104 In these studies, sodium 
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borohydride inactivates DHDPS in the presence of pyruvate, by acting as a strong reducing 
agent that converts the reactive Schiff base into a stable amine adduct.104,105 The inactivated 
protein with a reduced imine adduct at its active-site lysine has been shown by both 
crystallography73 and mass spectrometry.95 
 
A protonated Schiff base, acting as an “electron sink”, is one of the key characteristics of the 
DHDPS-like superfamily of enzymes.106 The enzymes of the superfamily, also called the 
N-acetylneuraminate lyase (NAL) family, all contain lysine in their active site for Schiff base 
formation with substrates containing an α-keto acid group, such as pyruvate.107 In comparison 
to DHDPS, the enzyme NAL catalyzes the reverse type of reaction, aldol cleavage rather than 
condensation, resulting in pyruvate and N-acetyl-D-mannosamine.107 
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Figure 1.5: The currently accepted mechanism for E. coli DHDPS.58  
 
Interestingly, NAL has shown low levels of DHDPS activity,108 and crystallization 
experiments of DHDPS and NAL with pyruvate and analogues have helped identify other 
residues important for Schiff base formation/stabilization.107,109,110 The position of the 
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substrate’s carboxyl group indicated hydrogen bond formation with backbone amides from 
two nearby amino acids (threonine 44, threonine 45 in E. coli DHDPS, and serine 47, 
threonine 48 in E. coli NAL) (Figure 1.6).57,107,109 These amino acids are part of glycine-x-x-
glycine motif highly conserved across the NAL superfamily, and it has been suggested that 
these glycines have an important structural role in maintaining the orientation of the backbone 
amides.110-112 
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Figure 1.6: Illustration of interactions between E. coli DHDPS and pyruvate (shown as an 
imine in blue), after Schiff base formation occurs (outlined in Step 2, Figure 1.5). 
Pyruvate reacts to form the Schiff base via the tetrahedral intermediate (outlined 
in Step 1, Figure 1.5). 
 
In addition, crystallography studies with members of the NAL family have identified two 
more interactions that stabilize bound substrate, involving the hydroxyl containing side chain 
of the previously mentioned threonine (T45 in E. coli DHDPS) and a conserved tyrosine 
(Y133 in E. coli DHDPS).57,107,109,111 The hydrogen bond geometry for Y133 in E. coli 
DHDPS is not ideal for stabilizing the bound pyruvate; however, Y133 has been proposed to 
assist the reaction by acting as both a proton donor and acceptor during Schiff base formation 
(Figure 1.5).57,110 This role was supported in DHDPS by the observation of a hydrogen 
bonding network, which was postulated to provide a “back door” through which protons can 
be shuttled in and out of the active site.57 Y133 was observed to be hydrogen bonded via the 
hydroxyl group of T44 to a second conserved tyrosine (Y107, in E. coli DHDPS), which 
reaches into the active site from the adjacent subunit.57 The essential nature of this catalytic 
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triad has been demonstrated by using site-directed mutagenesis to produce three mutant 
E. coli DHDPS enzymes, DHDPS-Y133F, DHDPS-T44V, and DHDPS-Y107F, all of which 
had substantially reduced activity.87 However, only DHDPS-Y133F showed a major change 
in its KM value for pyruvate,87 which is consistent with the hydroxyl group of this residue 
having a specific role in binding pyruvate, as reflected in the enzyme-bound intermediate 
drawn in Figure 1.5. 
 
1.3.3 Formation of the reactive species 
Following Schiff base formation, the imine is converted to an enamine in order to create the 
necessary reactive species (Step 3, Figure 1.5).106 This requires proton removal from the 
methyl group leading to double bond migration, but it is not clear which residue(s) facilitates 
the proton abstraction.96 The main-chain oxygen of isoleucine (I203 in E. coli DHDPS) has 
been suggested to assist due to its orientation and proximity, 3.4 Å from the methyl carbon 
(C3) of the imine, in crystal structures.57,61,96 Another candidate for mediating proton removal 
is the member of the catalytic triad Y133; however, this is more than 4 Å from the methyl 
carbon (C3) of the imine in the crystal structure of E. coli DHDPS.113 
 
Significant polypeptide backbone strain is found between I203 and the adjacent serine (S204 
in E. coli DHDPS) in all structurally and biochemically characterized DHDPS structures, 
suggesting a role in catalysis.96 The distortion in planarity across this peptide bond has an 
estimated energy cost of ~3.5 kcal.mol-1 and is possibly caused by hydrogen bonds between 
S204 and an aspartate (D188 in E. coli DHDPS) adjacent to the aspartate (D187 in E. coli 
DHDPS) postulated to be involved (S)-ASA binding.96 A similar feature is not observed in 
other members of the DHDPS-like superfamily indicating it is associated with the binding of 
(S)-ASA.96,107 The rearrangement of D187 required for its interaction with (S)-ASA is 
postulated to have a cascading effect, causing the rearrangement of D188, S204, I203 and the 
waters bound to them, and thus increasing the basic nature the main chain carbonyl of I203 
and resulting in proton abstraction.96 Site-directed mutagenesis studies have been proposed to 
provide some evidence for this mechanism, although none have been reported to date. 
 
1.3.4 Binding of (S)-ASA 
Several residues suggested to bind (S)-ASA are also implicated in improving the substrate’s 
electrophilicity,38 since in aqueous solution the majority of (S)-ASA is known to exist as a 
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hydrate rather than an aldehyde.114 Initially, the hydrated form of (S)-ASA was postulated to 
be stabilized by T45 and an asparagine (N248 in E. coli DHDPS); however, the latter residue 
is replaced by glycine in Gram-positive bacteria.57,61 Further X-ray crystallographic studies of 
DHDPS with pyruvate and (S)-ASA analogues suggested two residues proximate to the 
active-site lysine residue that could convert (S)-ASA into a more reactive aldehyde form.57 A 
tyrosine (Y133 in E. coli DHDPS) has its side chain in the correct orientation to donate a 
proton to one hydroxyl group, and a glycine (G186 in E. coli DHDPS) has a backbone oxygen 
in the correct orientation to hydrogen bond with the other hydroxyl group, which 
cumulatively results in the loss of water and the re-formation of the oxygen double bond of 
the aldehyde (Step 4, Figure 1.5).38 
 
Analysis of X-ray crystallography data has identified additional residues that may interact 
with (S)-ASA, including the active-site lysine K161, which is within hydrogen bonding 
distance to stabilize it in its aldehyde form.57 Also, D187 (referred to in section 1.3.3) was 
suggested to hydrogen bond to the ammonium group of (S)-ASA.107 A highly conserved 
arginine (R138 E. coli DHDPS numbering) has the proximity and orientation to coordinate 
the carboxyl group.57,115 Interestingly, a mutation to introduce an arginine at the equivalent 
position to R138 in E. coli NAL resulted in increased DHDPS activity. However, this 
mutation only marginally affected the KM for (S)-ASA, suggesting that R138 may have 
another unknown role in catalysis.108,115 The essential nature of R138 was demonstrated by 
using site-directed mutagenesis to produce two mutant E. coli DHDPS enzymes, DHDPS-
R138A, and DHDPS-R138H, both of which had reduced activity, similar to the catalytic triad 
mutants.115 Values determined for KM were entirely consistent with R138 being involved with 
binding of (S)-ASA, but not pyruvate. Structural studies suggested R138 stabilizes the 
catalytic triad; therefore an additional role for R138 was proposed, of modulating the proton-
relay during catalysis.115 
 
1.3.5 Formation of product 
Once both substrates are bound to the enzyme and have been converted into more reactive 
forms, the nucleophilic enamine intermediate attacks the electrophilic protonated aldehyde 
(Step 5, Figure 1.5).38 This is followed by cyclization (Step 6, Figure 1.5) and transimination 
(Step 7-9, Figure 1.5), resulting in the formation of (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-
dipicolinic acid (HTPA).61 HTPA is a precursor to dihydrodipicolinate (DHDP), the substrate 
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for the next enzyme in the pathway, DHDPR. It was previously assumed that DHDP was the 
product of DHDPS, but NMR experiments suggest that HTPA is the final product and non-
catalyzed breakdown results in the formation of DHDP.57 
 
The ambiguity in the exact nature of the product of DHDPS was postulated to have hindered 
the development of inhibitors structurally based on the enzyme’s substrates and products. The 
hypothesis that HTPA, not DHDP, was the product of DHDPS sparked the development of a 
suite of inhibitors based on HTPA.116-118 Like previous studies of inhibitors based on 
pyruvate,39,95,119 (S)-ASA,98,120 and DHDP,98,121 none of the compounds tested showed potent 
inhibition.116-118 Of the HTPA-based inhibitors, the molecule that was the most similar to 
HTPA showed no inhibition at all.116 It seems that the active site of DHDPS is highly specific 
and therefore substrate or product analogues are unlikely to be potent inhibitors.116,122 
 
1.4 Targeting quaternary structure for drug design 
A new approach to designing anti-microbial agents is being developed which utilizes our 
growing understanding of the structural underpinnings of enzyme activity by targeting the 
protein-protein interactions involved in quaternary structure rather than the active site.123 The 
association of subunits to form a specific quaternary structure is critical for catalytic activity 
in many enzymes,124,125 as it is often required to form the active site; either directly at the 
protein-protein interface, or indirectly through conformational changes induced by quaternary 
structure.124 Dissociation and association into quaternary structure acts as a regulator 
mechanism in ~15% of oligomeric proteins.124,126 This potential for regulation and other roles 
for quaternary structure will be discussed more extensively in chapter three. The following 
sections will consider the potential for disrupting quaternary structure as an approach to 
antibacterial design. 
 
1.4.1 Protein-protein interactions as drug targets 
Protein-protein interactions have key roles in most biological processes and thus they are an 
increasingly recognized target for drug design.127-129 These interactions vary from temporary 
associations, such as those involved in cell signalling, to the permanent associations, like 
those of multi-subunit enzymes, where subunit association can be viewed as a continuation of 
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protein folding.130,131 Since many disease states, such as cancer, are closely linked to cell 
signalling, targeting protein-protein interactions has a huge therapeutic potential.129,132 
 
Discovering small-molecule drugs that disrupt protein-protein interactions is an enormous 
challenge since in principle these small organic compounds have to mimic and block the 
interactions of much larger protein surfaces.132 Multiple factors contribute to the apparent 
resistance of protein-protein interactions as pharmaceutical targets including the typical 
flatness of the interface, the lack of naturally occurring small-molecule starting points for 
design, the character of existing small-molecule libraries and difficulties in confirming and 
characterizing small-molecule-protein interactions.127,129 
 
Considering these numerous difficulties, the advances in this field are striking, including 
clinically approved small-molecule drugs for preventing platelet aggregation,128,129 and 
anticancer agents which show robust anti-tumor activity and are currently in phase I/II clinical 
trials.132,133 The field of drug design based on targeting protein-protein interfaces is still in its 
infancy,123,128 but there have been importance advances in understanding which are of 
particular interest with regards to quaternary structure disruptors. 
 
1.4.2 The interfaces of protein-protein interactions 
Interactions between protein surfaces usually involves relatively large interfaces with good 
steric and electrostatic complementarity to each other.134 However, despite the large size of 
interfaces, a study in 1995 of a heterodimeric protein complex found mutation of individual 
interface residues had greatly varied effects on binding affinity.135 It was demonstrated that 
only a small set of contact residues, which were subsequently referred to as “hot spots”, were 
actually important for maintaining binding and these were found to have dimensions 
comparable to drug-like small molecules.132,135 Thus, in theory, an inhibitor can be designed 
to complement the “hot spot” in a targeted complex and block protein-protein interactions. 
 
An overview of successful inhibitors of protein-protein interactions reveals further insight into 
protein interfaces. The overriding importance of side-chain interactions is emphasized by the 
small molecule inhibitors of integrins, interleukin 2, Z-interacting protein A, B-cell 
lymphoma 2, and human protein double minute 2 and homologues, as the chemical structures 
of these inhibitors replicated key side-chain interactions but not the peptide backbone of their 
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protein partners.129 Also, the shapes of side chains are not precisely duplicated in inhibitors 
but rather the general hydrophobic and electrostatic characteristics are matched.129 These 
observations suggest there is great freedom for a diversity of chemical scaffolds,129 and 
highlight the importance of understanding protein-protein interactions for drug design. 
 
1.4.3 Disrupting quaternary structure as an approach to drug design 
The first small molecules designed to inhibit protein-protein interactions were for cell surface 
receptors called integrins.129 This research lead to two new anti-platelet drugs, a cyclic 
peptide, epifibatide, and a synthetic peptide analogue, tirofiban, which are currently used in 
the treatment of patients with acute coronary syndromes.128,129,136 Even though it was the 
functional roles of protein-protein interactions in cell signalling that propagated study, 
disrupting quaternary structure was also investigated, as some cell signalling protein systems 
are regulated by oligomerization.127,129 For example nitric oxide synthase (NOS),137 and 
tumour-necrosis factor (TNF),138 are only functional as dimers and trimers, respectively. 
 
Unexpectedly, inhibitors discovered for NOS were found to inhibit oligomerization by 
binding not to the protein interface, but rather a pocket distal to the interface, inducing 
conformational changes that radiate outwards, ultimately distorting the structure of the 
interface.129,137 Unfortunately, these inhibitors were found to be ineffective against partially 
purified dimeric enzyme, thus it is thought that they bind the monomeric form of the enzyme 
during synthesis.123,137 The small molecule inhibitor discovered for TNF was shown to bind 
the trimer and actively promote the dissociation of one subunit, leaving an inactive dimer 
form.129,132,138 X-ray crystallography revealed that this inhibitor was located in the cleft 
between two of the subunits, acting as a wedge, and thus, similar to the inhibitors of NOS, 
induces conformational changes that propagate outwards, ultimately disrupting 
oligomerization.129,138 Interestingly, several other inhibitors of protein-protein interactions 
have been found to distort the interface in an allosteric manner.127 This type of inhibitor may 
be of particular importance to oligomeric proteins, as interfaces are obviously less accessible 
in permanent complexes than transient complexes. 
 
The majority of inhibitors of protein-protein interaction function as competitive rather than 
allosteric inhibitors, like those mentioned in section 1.4.2. Numerous investigations have 
targeted protein-protein interactions at the interface using peptides which act as starting points 
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for drug-like small molecule design.131,139,140 For example, the homodimer protease from HIV 
was found to be inhibited by peptides corresponding to its interface as early as 1991.141-143 
More recently, AUC experiments with alkyl tripeptides indicated that these optimized 
inhibitors bind to the interface of the active dimer, promoting dissociation and sequestering 
HIV protease monomers.144 This supports the proposal that the dynamic motions of proteins 
enable small molecules to penetrate protein interfaces, thus the binding of an inhibitor to a 
protein interface does not necessarily require the complete dissociation of the complex.132 As 
of yet there are no commercially available drugs that act by disrupting the quaternary 
structure of multi-subunit enzymes, but these representative cases highlight both the obstacles 
and possibilities of this exciting new approach to drug design. 
 
1.5 The structure of DHDPS 
The importance of the homotetrameric quaternary structure of DHDPS was explored through 
site-directed mutagenesis studies with DHDPS from E. coli (section 1.5.3), and suggested that 
molecules designed to disrupt quaternary structure would also inhibit enzyme activity.1,123,145 
Until recently, all structurally and biochemically characterized DHDPS orthologues were 
tetramers (section 1.5.1). However, newly published work revealed the first native non-
tetrameric DHDPS, indicating that the homotetramer quaternary structure is not required for 
activity in all orthologues (section 1.5.5).81 This emphasizes the importance of understanding 
structural details of the enzyme from the pathogen in question when exploring the feasibility 
of designing protein-protein interaction disruptors as inhibitors for DHDPS. 
 
1.5.1 Structural studies of DHDPS 
The solid-state structures of several bacterial DHDPS enzymes have been determined by 
X-ray crystallography (Table 1.3). Additionally, one plant enzyme, Nicotiana sylvestris 
DHDPS has been solved to a resolution of 2.8 Å (Figure 1.7B).61 The structures solved for 
the wild-type E. coli DHDPS show it to be a homotetramer, that is, composed of four identical 
subunits, as shown by crystallographic symmetry (Figure 1.7A). Of the other native 
structures determined, those shown to have DHDPS activity are all homotetrameric in the 
crystal, with the notable exception of the recently discovered dimeric MRSA DHDPS.2,81,85 
 
C-term 
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Table 1.3: Solid-state structures of orthologues of DHDPS, putative DHDPS enzymes and 
DHDPS mutants determined by X-ray crystallography. (TBP = to be published). 
 
a Most structural data is freely availbable from Protein Data Bank (PDB).152 Nicotiana sylvestris DHDPS is not deposited. 
 
PDBa 
code Organism 
Resolution 
(Å) Ligands/mutations Ref. 
Activity 
assayed 
2HMC Agrobacterium tumefaciens 1.90  - TBP No 
2R8W  Agrobacterium tumefaciens 1.80  - TBP No 
3B4U Agrobacterium tumefaciens 1.20  - TBP No 
2EHH Aquifex aeolicus 1.90  - TBP No 
1XL9 Bacillus anthracis 2.23  - 146 Yes 
1XKY Bacillus anthracis 1.94  - 146 Yes 
3E96 Bacillus clausii 1.80  - TBP No 
3CPR  C. glutamicum 2.20  - 71 Yes 
3BI8 Clostridium botulinum 1.96  - TBP No 
1DHP  E. coli 2.30 A207T   62 Yes 
1YXC E. coli 1.90  - 58 No 
1YXD  E. coli 2.00 lysine 58 Yes 
2ATS  E. coli 1.90 lysine TBP No 
3C0J  E. coli 2.40 hydroxypyruvate 96 Yes 
1S5T  E. coli 2.30 T44V 87 Yes 
1S5V E. coli 2.35 Y107F 87 Yes 
1S5W  E. coli 2.32 Y133F  87 Yes 
2A6L  E. coli 2.05 R138H  147 Yes 
2A6N  E. coli 1.94 R138A 147 Yes 
2OJP  E. coli 1.70 L197Y 2 Yes 
3DU0  E. coli 2.00 pyruvate 113 No 
2PUR  E. coli 1.70 T44S TBP No 
3DEN  E. coli 2.20 Y107W 148 Yes 
2RFG Hahella chejuensis 1.50  - TBP No 
2YXG Methanocaldococcus jannaschii 2.20  - TBP No 
1XXX M. tuberculosis 2.28  - 149 Yes 
3FLU Neisseria meningitidis 2.00  - 77 Yes 
 - Nicotiana sylvestrisa 2.79  61 No 
 - Nicotiana sylvestrisa 2.80 lysine 61 No 
3D0C Oceanobacillus iheyensis 1.90  - TBP No 
3DZ1 Rhodopseudomonas palustris 1.87  - TBP No 
3EB2 Rhodopseudomonas palustris 2.04  - TBP No 
3G0S Salmonella typhimurium 1.85  - TBP No 
2VC6 Sinorhizobium meliloti 1.95 pyruvate 97,150 Yes 
3DI0  S. aureus (MRSA) 2.38  - 80 Yes 
3DI1  S. aureus (MRSA) 2.20 pyruvate 80 Yes 
3DAQ S. aureus (MRSA) 1.45  - 81 Yes 
1O5K T. maritima 1.80  - 151 Yes 
2PCQ Thermus thermophilus 2.10  - TBP No 
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Figure 1.7: The differences in quaternary structure between (A) bacterial E. coli DHDPS and 
(B)  plant N. sylvestris DHDPS. Strong protein-protein interactions form 
analogous “tight-dimers”, however these associate via opposite interfaces into two 
alternative tetramers.61 Figures illustrating structural details have been prepared 
using the program PyMOL.153 
 
The putative DHDPS from Agrobacterium tumefaciens (PDB entry 2HMC) seems to be a 
hexamer (generated by crystallographic symmetry) but is likely misclassified as it does not 
appear to possess all of the key catalytic residues of DHDPS.96,149 Additionally, the putative 
DHDPS from Thermus thermophilus (PDB entry 2PCQ) may also be misclassified, as there is 
accumulating evidence that the bacteria utilizes the α-aminoadipate pathway found in fungi to 
synthesize (S)-lysine rather than the DAP pathway common to bacteria.154-156 These possible 
misclassifications emphasize the importance of performing functional studies in conjunction 
with structural determination. 
 
Investigation with biophysical methods, such as gel-filtration liquid chromatography, has 
found DHDPS to be tetrameric, with two exceptions (Table 1.4). Contrary to other plant 
enzymes, gel filtration found DHDPS from Pisum sativum to be trimeric,92 but this anomalous 
result has not been confirmed by other methods. A more quantitative biophysical method, 
analytical ultracentrifugation (AUC), was used to confirmed the dimeric nature of MRSA 
DHDPS, which has similar activity to the tetrameric E. coli DHDPS.2,145 
 
(A) (B) 
Introduction 23 
 
 
Table 1.4: Oligomeric states of DHDPS from various sources. 
Organism Bacterial/Plant Oligomeric state Ref. 
Bacillus licheniformis Bacterial tetramer 101 
Bacillus subtilis Bacterial tetramer 68 
C. glutamicum Bacterial tetramer 71 
E. coli Bacterial tetramer 73,95,104 
N sylvestris Plant (Tobacco) tetramer 157 
Pisum sativum Plant (Pea) trimer 92 
Sinorhizobium meliloti Bacterial tetramer 97 
S. aureus (MRSA) Bacterial dimer 80,81 
Thermoanaerobacter tengcongensis Bacterial tetramer 84 
T. maritima Bacterial tetramer 85 
Triticum aestivum Plant (Wheat) tetramer 94 
Zea mays Plant (Maize) tetramer 93 
 
The structural features of DHDPS have been well characterized, and it has been described as a 
dimer of “tight-dimers” (Figure 1.7A), a quaternary structure which is conserved in most 
bacterial species studied.148 Curiously, the plant enzyme from N. sylvesteris DHDPS adopts a 
similar functional unit, composed of two tight-dimers that interact to form a tetramer, 
although the arrangement of the tight-dimers is completely different (Figure 1.7B).61 The 
existence of two alternative tetramers with essentially the same dimeric subunit, suggest that 
the tetrameric form gives a generic structural advantage rather than specifically contributing 
to the active site formation.158 This leads to the hypothesis that DHDPS evolved from an 
ancestral dimeric protein.61,85 
 
Interestingly, DHDPS from T. maritima, one of the slowest evolving lineages of eubacteria, 
has been demonstrated unequivocally to be a tetramer,85 which suggests that bacterial and 
plant enzymes evolved from a dimeric enzyme that predates T. maritima.85 Sequence 
alignments between bacterial DHDPS and the archaeal DHDPS from Methanocaldococcus 
jannaschii suggested M. jannaschii DHDPS could be dimeric, and thus would provide insight 
into the protein evolution of DHDPS.61 Archaea are considered by many to be the most 
ancient organisms on earth;159 thus, archaeal enzymes may provide the closest modern relative 
of ancestral DHDPS. However, the recently deposited structure of a putative DHDPS from 
M. jannaschii (PDB entry 2YXG) shows it to be tetrameric in the crystal (Table 1.3). 
Biophysical techniques are needed to confirm that this enzyme is tetrameric in solution, as 
well as functional studies to confirm DHDPS activity. 
 
In order to explore the hypothesis of a dimeric ancestral DHDPS, a discrete tight-dimer from 
E. coli DHDPS was engineered using site-directed mutagenesis (discussed in section 1.5.3).2 
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These investigations led to the hypothesis that an ancient monomeric form of the enzyme 
existed,2 and attempts are ongoing to engineer a monomeric variant of E. coli DHDPS.148 The 
tertiary structure of the monomer between bacterial species is conserved, even though the 
bacterial sequences are strongly divergent.61,62 The structure of M. tuberculosis DHDPS had 
been deposited in the PDB at the outset of this work, but had not been published or 
biochemically characterized (to be discussed in chapter 2). Consequently, the best studied 
bacterial DHDPS, from E. coli, will be discussed in detail in the following sections. 
 
1.5.2 The tertiary structure of E. coli DHDPS 
The monomeric unit from E. coli DHDPS has a molecular mass of 31272 Da, as determined 
by electrospray mass spectrometry, which is in agreement with the mass predicted from the 
amino-acid sequence.87,95 It contains two domains: a (β/α)8-barrel N-terminal domain and an 
α-helical C-terminal domain (Figure 1.8A).62 The active-site lysine, K161, is found at the 
C-terminal end of the (β/α)8-barrel, in a 30 Å long by 10 Å deep solvent-accessible pocket 
(Figure 1.8B) that is partially blocked by the adjacent, closely associated monomer.58,62 
 
 
Figure 1.8: The structure of the E. coli DHDPS monomeric subunit, as viewed from the 
C-terminus end of the (β/α)8-barrel. (A) The tertiary structure contains the 
common (β/α)8-barrel fold, composed of β-sheets (blue) surrounded by α-helices 
(green) with an extra α-helix (yellowy green, circled in white) and mainly α-helical 
region (lighter green). (B) The solvent-accessible pocket containing the active-site 
residue K161 (red) is more apparent when using a space-filling model. The extra 
α-helix (circled in white) containing the active-site residue R138 (white square), 
lies over the middle of the pocket. 
(A) (B) 
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The active site is lined with amino acids that orientate substrates, as well as those that directly 
contribute to the chemistry,160 as was described in section 1.3.2-4, and most of these active-
site residues line the β-strands at the C-terminal end of the (β/α)8-barrel.62 The (β/α)8-barrel 
structure of the N-terminal domain is a common structural fold first identified in 
triosephosphate isomerase (TIM).161 DHDPS contains a small departure from this common 
fold with a short extra stretch of helix (residues 136 to 139) that lies perpendicular to the 
(β/α)8-barrel on the C-terminal side (Figure 1.9).62 This helix partially blocks the active-site 
pocket but contains the active-site residue arginine, R138, which is proposed to coordinate the 
carboxyl group of (S)-ASA.61,115 In contrast, the C-terminal domain, which is composed of 
three α-helices, has no obvious function in catalysis or the regulatory mechanism.62 
 
1.5.3 The role of quaternary structure in E. coli DHDPS 
The homotetramer of E. coli DHDPS is commonly described as dimer of dimers,57,87 which 
emphasizes the presence of two different sets of protein-protein interactions (Figure 1.9). The 
monomers closely associate to form dimers and the consequent tight-dimers interact to form a 
tetramer with a large solvent-filled central cavity.62 
 
 
Figure 1.9: The structure of the E. coli DHDPS tetramer. (A) The quaternary structure is a 
homotetramer with subunits a and b and subunits c and d associating strongly to 
form dimers and the consequent dimers interacting more weakly to form the 
tetramer. (B) A schematic representation of the two different interfaces referred 
to as tight and weak, names descriptive of the difference in the number of residues 
involved in the inter-subunit interaction. 
a b 
c d 
a b 
c d 
(B) Tight interface 
Weak  
interface 
(A) 
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The tight-dimer interface of the closely associating monomers buries 12.4 % (1400 Å2) of the 
total monomeric area,62 whereas the weak interface between the two dimers buries only 5.8 % 
(650 Å2) of the total monomeric area,61 shown schematically in Figure 1.9B. There are four 
active sites in E. coli DHDPS,104 and all active-site residues are found near the tight interface 
of the closely associating monomers.61 The crevice containing the active site is partially 
blocked by the adjacent monomer, which effectively closes one end of the cleft and completes 
the catalytic triad with residue Y107 (Figure 1.10A). The catalytic importance of Y107 is 
reflected in the unusual conformation indicated by it existing in the forbidden region of the 
Ramachandran plot.57 The resulting cavity in each monomer is only accessible from the centre 
of the tetramer.62 The active-site residue K161 is within the cavity (Figure 1.10A), in close 
proximity to Y133, which binds pyruvate’s carboxyl group.57,61 Y133 also participates in the 
catalytic triad with T44 and Y107 (discussed in section 1.3.2), providing a “back door” for 
shuttling protons into and out of the active site.57,87 Except for Y107, all active-site residues 
are contained within the monomeric subunit.87 
 
 
Figure 1.10: The structure of the E. coli DHDPS dimeric subunit. (A) Lysine 161 (red) is found 
in the cleft formed between the two domains (green & light green), which is 
partially blocked by adjacent monomer (grey shadow) with tyrosine 107 (yellow, 
in white square), thus creating a cavity only accessible from the centre of the 
tetramer. (B) Tyrosine 107 (yellow) reaches into the active site from the adjacent 
monomer in an interdigitating configuration and is the only active-site residue not 
contained within the monomeric unit. 
 
The interdigitation of the key active-site residue Y107 across the tight-dimer interface 
(Figure 1.10B) provides an explanation for the association of monomers into dimers, but less 
(A) (B) 
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clear is the reason for the association of dimers into a homotetrameric quaternary structure.2 
There is no known communication between the dimeric units across the weak interface.2 In 
order to explore the importance of the tetrameric structure for E. coli DHDPS, dimeric 
variants, DHDPS-L197Y and DHDPS-L197D were created by site-directed mutagenesis.2 
The activity of these dimeric mutants was substantially less than the wild-type tetramer, even 
though X-ray crystallography showed the active site to be undisrupted and no significant 
changes to the tertiary structure.2 Surprisingly, electron density consistent with a tetrahedral 
adduct was found at the active-site K161, which was confirmed by mass spectrometry to be 
α-ketoglutarate, a pyruvate analogue, trapped as a cyclic adduct.2 The observation of this 
adduct, believed to have formed in vivo since no α-ketoglutarate was added to the enzyme 
preparation, suggests that the dimeric variants have lower substrate specificity.2 
 
The decreased substrate affinity of the dimeric variants was proposed to be related to an 
increase in dynamic motion, evident with small-angle X-ray diffraction.2 These dynamic 
fluctuations mean that the completion of the catalytic triad by Y107 is often disrupted as the 
monomers reorientate themselves in relation to each other, and this is proposed to cause the 
reduced binding affinity and specificity for pyruvate observed in the dimeric mutants.2 
Interestingly, the active site of the tetrameric mutant DHDPS-Y107F also had α-ketoglutarate 
trapped as a cyclic adduct, providing evidence for the importance of Y107 in substrate 
specificity.2,87 α-Ketoglutarate is a reversible inhibitor, and incubation at 40 oC in the presence 
of pyruvate increased the activity of the dimeric mutants from ~1 % to 10-15 % of wild-type 
E. coli DHDPS and a similar effect was seen with DHDPS-Y107F, presumably due to the 
removal of the cyclic adduct.2 The failure of the mutants to gain full wild-type activity hints at 
the complex role of the catalytic triad in the activity of DHDPS, and provides evidence of the 
quaternary structure’s importance in maintaining the catalytic triad. 
 
1.5.4 The (S)-lysine binding site in DHDPS 
The binding pocket for the allosteric inhibitor (S)-lysine is not limited to the monomeric unit, 
but found at the tight interface of the closely associating monomers in both E. coli and 
N. sylvestris DHDPS.61 Crystal-soaking experiments show two (S)-lysine molecules in the 
binding pocket within van der Waals contact of each other.57,58,61 Upon binding of (S)-lysine 
the structure of all four units of N. sylvestris DHDPS are significantly changed,61 but in E. coli 
DHDPS relatively few residues in close proximity to the (S)-lysine binding site shift.58 This 
Introduction 28 
 
 
difference results from a dramatic reorientation of the two sets of dimers in relation to each 
other (Figure 1.7) and possibly explains the difference in feedback sensitivity between plant 
and bacterial DHDPS enzymes.61 Additionally, there are differing residues coordinating the 
є-amino group of (S)-lysine (H53, H56 in E. coli DHDPS vs. W77, H80 in N. sylvestris 
DHDPS), which likely cause a difference in (S)-lysine affinity.51,61 
 
The mechanism of (S)-lysine inhibition in E. coli DHDPS is unclear, although kinetic and 
structural studies support the proposal that it is an allosteric inhibitor.58 Structural studies of 
E. coli DHDPS with inhibitor bound identified the residues coordinating (S)-lysine as Y106, 
N80, E84, H53, H56, G78, A49, S48; none of which participate in the active site.57,58 
Structural alterations are observed near the allosteric binding site, as various residues move to 
accommodate the binding of the (S)-lysine, the most notable is a tyrosine (Y106), which 
forms an aromatic stack with a member of the catalytic triad, Y107.51,58 Y106 shifts towards 
the carboxyl group of (S)-lysine, resulting in altered conformations of both the aromatic stack 
and Y107, thus likely affecting the catalytic triad, although whether this change is significant 
enough to be responsible for inhibition is debated.51,58 More clearly refuted is the proposal 
that the decreased flexibility of the catalytic residue R138 is a mechanism for inhibition, as 
subsequent higher resolution structures have shown increased flexibility.58 While the 
mechanism for (S)-lysine inhibition observed in E. coli DHDPS is unknown, the position of 
the allosteric binding site at the tight-dimer interface further supports the importance of the 
dimeric subunit.162 
 
1.5.5 The quaternary structure of MRSA DHDPS 
The tetrameric structure of DHDPS is thought to be essential for enzyme activity by reducing 
the dynamic motion of the dimeric subunit (as discussed in section 1.5.3).2 Thus it was of 
particular interest during the course of this research when two separate publication revealed 
that MRSA DHDPS adopts a dimeric quaternary structure in solution, as shown by various 
biophysical techniques.80,81 X-ray structural analyses revealed that MRSA DHDPS has 
significantly increased contacts and greater buried surface area at the tight-dimer interface 
compared to E. coli DHDPS.81 The interdigitating Y109 (equivalent to Y107 in E. coli 
DHDPS), while maintaining the catalytic triad, was found to adopt an altered confirmation in 
comparison to E. coli DHDPS, making a closer aromatic stacking interaction, presumably 
decreasing its flexibility.81 These differences suggest an alternative mechanism to overcome 
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the effect of dynamic motion hypothesized to decrease enzyme activity in the dimeric E. coli 
DHDPS mutants,81 and indicates the complexity of the interplay between quaternary structure, 
enzyme function and protein dynamics, which are an increasingly recognized component in 
enzyme catalysis.162 
 
1.6 Summary 
M. tuberculosis causes more death than any other bacteria and increasingly with multi-drug 
resistant strains. Accordingly, there is an urgent need to develop new anti-tuberculosis drugs 
and characterize novel drug targets, such as DHDPS. While DHDPS does not appear to 
contribute to variation in virulence or drug susceptibility between strains of M. tuberculosis, it 
is essential for bacterial growth, validating it as a drug target. DHDPS catalyzes a key step in 
the metabolic pathway yielding the essential amino-acid (S)-lysine, and DAP, which forms 
critical DAP-DAP linkages in the mycobacterial cell wall. DAP auxotrophs of M. smegmatis, 
either underwent cell death in the absence of DAP, or exhibited altered cell wall structures, 
which rendered them susceptible to antibiotics. In addition, M. tuberculosis has a 
demonstrated inability to uptake environmental (S)-lysine, suggesting the bacteria would be 
particularly vulnerable to inhibitors of DHDPS. The lack of regulation observed in 
mycobacteria in the conversion of DAP to (S)-lysine suggest thats even partial inhibitors of 
DHDPS may be effective anti-tuberculosis agents, and strengthens the need to fully 
investigate DHDPS as a drug target. 
 
E. coli DHDPS is the best characterized DHDPS enzyme and through its extensive study an 
in-depth understanding of the catalytic mechanism is being developed, which has informed 
the design of inhibitors targeted at the active site. However, it would seem the active site is 
highly specific, as none of these showed potent inhibition. Therefore, an alternative approach 
to drug design is considered, targeting protein-protein interactions rather than the active site. 
Designing inhibitors of protein-protein interaction is more challenging but possible, as 
indicated by the discovery of “hot spots”; that is, only a small subset of the residues involved 
in protein-protein interactions are crucial for the association of complexes. Thus, if 
oligomerization is critical for activity, an inhibitor can be designed to complement the “hot 
spots” and block subunit association. This thesis will explore the feasibility of targeting the 
weak interface of M. tuberculosis DHDPS as an approach to drug design and consequently, 
broaden our understanding of the relationship between structure and function in DHDPS. 
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Chapter Two 
Purification & characterization of wild-type DHDPS 
from M. tuberculosis 
2.1 Introduction 
The aim of this thesis is to examine DHDPS from M. tuberculosis as a putative drug target. 
The first step was to fully characterize the wild-type enzyme, which required the production 
and purification of milligram quantities of active M. tuberculosis DHDPS. Our collaborators, 
at EMBL Hamburg Outstation, Dr Manfred Weiss and Dr Georgia Kefala, cloned the dapA 
gene for M. tuberculosis DHDPS, from the bacterial strain H37Rv, into a plasmid vector, for 
expression in E. coli.1 This vector, pETM-11, coded for a cleavable N-terminal His6-tag 
allowing for purification using affinity chromatography.2 
 
Two methods, a colorimetric and a coupled assay, were used to monitor activity throughout 
the purification procedure to ensure functionally active M. tuberculosis DHDPS was obtained. 
The coupled assay required the additional purification of a coupling enzyme, DHDPR, and 
was used for kinetic characterization. Steady-state kinetics and biophysical methods were 
used to study the catalytic behaviour and solution properties of M. tuberculosis DHDPS. The 
results were considered in the context of the solid-state structure determined by X-ray 
crystallography by our collaborators, Weiss and Kefala, and this characterization of 
M. tuberculosis DHDPS has been published in Biochemical Journal as a joint co-first author 
manuscript with Kefala (see Appendix J): “Crystal structure and kinetic study of 
dihydrodipicolinate synthase from Mycobacterium tuberculosis.”3 
 
As discussed in chapter one, inhibiting the activity of DHDPS by disrupting quaternary 
structure is the approach to drug design primarily considered in this thesis. However, the 
effect of (S)-lysine on the activity of M. tuberculosis DHDPS was also of interest. E. coli 
DHDPS is weakly inhibited by (S)-lysine and contains binding sites for (S)-lysine (discussed 
in chapter one, sections 1.2.4 and 1.5.4, respectively). Several inhibitors designed to interact 
at the active site of E. coli DHDPS were found not potent enough for biological use and their 
mode of inhibition suggested they were interacting at the (S)-lysine binding site instead of the 
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active site.4 Associated with this research, inhibitory activity of compounds designed to 
interact at the active site were examined for DHDPS from several pathogenic species 
including M. tuberculosis, and showed species selective inhibition, perhaps reflecting the 
absence or presence of (S)-lysine binding sites. This work has been published in Bioorganic 
and Biomedical Chemistry Letters in a brief communication (see Appendix K) on which I am 
a co-author, since I supplied the M. tuberculosis DHDPS for this collaborative study.5 
 
2.2 Methods for monitoring DHDPS activity 
The discoverers of DHDPS, Yugari and Gilvarg, developed three different assay systems to 
detect its activity.6 The coupled assay was described as the method of choice for evaluating 
the properties of purified DHDPS, whereas the simpler assay systems, which use imidazole or 
o-aminobenzaldehyde, were deemed primarily useful for detecting enzyme activity during 
purification.6,7 
 
2.2.1 The o-aminobenzaldehyde assay 
o-Aminobenzaldehyde has been shown to interact with cyclized nitrogen containing 
compounds, such as the product of the reaction catalyzed by DHDPS, to form salts with a 
characteristic yellow/orange colour.6 A reddish purple chromophore is produced after a 20 to 
30 minute incubation of o-aminobenzaldehyde with DHDPS and its substrates.6,7 As the exact 
chemical nature of the coloured adduct and the rate determining step in its formation are 
unclear, the assay was suggested to be mainly useful for determining DHDPS activity in crude 
extracts.6 Nevertheless, the o-aminobenzaldehyde assay, monitoring the increase in 
absorbance at 540 nm after a 30 minute lag time, has been used by a number of groups to 
measure initial-rates for kinetic studies,8-17 making the key assumption that the enzyme-
catalyzed reaction, rather than chromophore formation, is the rate limiting step. While this 
assumption may or may not be valid, the assay does have several favourable features. Its high 
specificity, high sensitivity, lack of interfering side reactions, relatively few components and 
colorimetric nature has made it amenable to scaling down for semi-quantitative monitoring of 
DHDPS activity throughout the purification procedure,7 and, thus, the o-aminobenzaldehyde 
assay was used for this purpose throughout this work. 
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2.2.2 The imidazole assay 
The original method recommended for monitoring DHDPS activity during purification was 
the incubation of the enzyme and its substrates in imidazole buffer at pH 7.4, which gives rise 
to a peak at 270 nm after a 10 minute lag time.7 Again, the exact nature of the chromophore 
has not been determined; however, it must be an isomeric or degraded form of physiologically 
active product, since the increase in absorbance at 270 nm corresponds to a decrease in the 
activity of the next enzyme in the (S)-lysine/DAP biosynthetic pathway, DHDPR.6 
Consequently, the imidazole buffer assay, like the o-aminobenzaldehyde assay, was not 
recommended for kinetic analysis,6 but due to its simplicity and ease of use it has been used 
for such purpose by several workers.18-21 
 
2.2.3 The coupled assay 
The development of the coupled assay was based on the simple principle that the rate of an 
enzymatic reaction causing no appreciable spectrophotometric change can be monitored 
through the consumption of its product by a second observable reaction.22-24 When the 
product from the reaction of interest reacts rapidly and does not accumulate then the measured 
rate of the second reaction corresponds to the rate of the first reaction.22 
 
Conveniently, DHDPR, the next enzyme in the DAP/(S)-lysine biosynthetic pathway, both 
consumes the product of DHDPS and utilizes the cofactor NADPH (Figure 2.1).25 In its 
reduced state, NADPH has a strong absorbance peak at 340 nm, which disappears after 
oxidation to NADP+.22 Many spectrophotometric assays take advantage of this naturally 
occurring chromophore with its large molar extinction coefficient (ε340nm = 6220 M-1.cm-1).26 
With an excess of DHDPR, the decrease in absorbance at 340 nm corresponds to DHDPS 
activity,6 which is easily quantifiable since the product of the reaction of DHDPS has a 1:1 
stoichiometric relationship to the oxidation of NADPH (Figure 2.1). 
 
The chief drawback of the coupled assay is that it requires the additional purification of 
DHDPR, so, unsurprisingly, before advances in protein purification such as recombinant 
DNA technology, many early investigators used the other assay methods for kinetic analysis 
(see chapter one, section 1.3.1, table 1.2). However, more recent work, including several 
comprehensive kinetic analysis of DHDPS from E. coli, have utilized the coupled assay.27-29 
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Figure 2.1: The preferred assay for kinetic analysis couples the observable reaction of 
DHDPR oxidizing NADPH to the activity of DHDPS.4 
 
In this work, the coupled assay was used for kinetic study, based on an optimized procedure 
for E. coli DHDPS.30 The coupled assay was also used for quantitative monitoring of enzyme 
activity and purity throughout the purification procedure; however, these results were less 
accurate due to the possible presence of NADPH-utilizing enzymes during various 
purification steps, and therefore it was used in tandem with the o-aminobenzaldehyde assay. 
 
2.3 Enzyme over-expression & purification 
In-depth understanding of gene expression in E. coli has allowed the development of vectors 
and bacterial strains to over-express almost any gene product.31 Unfortunately, the resultant 
over-expression of proteins in E. coli does not necessarily lead to simple protein purification. 
Many recombinant proteins misfold and are insoluble when expressed in E. coli, as opposed 
to their native microorganism.32 In fact, the TB Structural Genomics Consortium 
(http://www.doe-mbi.ucla.edu/TB) has found approximately half of their targeted 
M. tuberculosis proteins were insoluble when expressed in E. coli.32 A more generalized look 
at results from several large structural genomic centres, shows that more than half of the 
recombinant proteins overproduced in E. coli form insoluble aggregates as opposed to 
correctly folded proteins.33,34 The yield of M. tuberculosis DHDPS purified as a recombinant 
protein in E. coli was a limiting factor throughout this research, due to the majority being 
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expressed in insoluble form. The dapA gene for M. tuberculosis DHDPS was cloned into a 
vector, called pETM-11 (Appendix A) by our collaborator, Kefala,1 resulting in the plasmid 
construct pMTB02. The plasmid construct, pMTB02, codes for M. tuberculosis DHDPS as a 
fused protein with a linker sequence and His6-tag (details in Appendix C).1 
 
2.3.1 Original purification protocol developed for M. tuberculosis DHDPS 
Initially, over-expression and purification of M. tuberculosis DHDPS was based on the 
method developed by Kefala.1 LB broth medium was inoculated with cells transformed by the 
plasmid, pMTB02 (Appendix A). These cultures were supplemented with kanamycin and 
chloramphenicol, and over-expression was induced after several hours by isopropyl 
thiogalactoside (IPTG). Following induction, the cells were grown overnight at room 
temperature and then harvested by centrifugation and re-suspended in extraction buffer. The 
extraction buffer contained tris(hydroxymethyl)methylamine (Tris.HCl), NaCl, imidazole, 
glycerol, β-mercaptoethanol (β-ME), BugBusterTM (Novagen) and EDTA-free protease 
inhibitor (Roche). Crude cell-free lysates were produced by extensive ultrasonication, for 
20 minutes in 25 s pulses at 4 °C, followed by clarification using centrifugation. 
Over-expression of His6-tagged M. tuberculosis DHDPS was apparent in the crude cell-free 
lysate, as shown by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
with Coomassie blue staining (Figure 2.2, lane 2), but the majority of protein was lost during 
centrifugation, 60 minutes at 10000 rpm and 4 °C (Figure 2.2, lane 3).  
 
Purification using His6-tag affinity chromatography involved several steps and included 
washing with three different buffers, which was found to improve protein purity (details in 
chapter six, section 6.4.3). The peak fractions were pooled and analyzed by SDS-PAGE 
(Figure 2.2, lane 4), which showed His6-tagged M. tuberculosis DHDPS with several 
additional protein bands reflecting low level impurities. This purification method gave a yield 
of 1.6 mg of His6-tagged protein per L. Initially, the His6-tagged M. tuberculosis DHDPS was 
kinetically characterized (Appendix B), as cleavage of the His6-tag required additional steps 
and therefore led to loss of protein yield. However, as cleavage of the His6-tag was observed 
to increase enzyme activity, subsequent work, therefore, analyzed M. tuberculosis DHDPS 
which had been treated to remove the affinity tag. 
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Figure 2.2: The purification of recombinant M. tuberculosis DHDPS based on the originally 
developed protocol,1 examined using denaturing SDS-PAGE, which separates 
based on subunit molecular weight (MW). M. tuberculosis DHDPS was identified 
as the 34 kDa band (black rectangle) using the MW marker, in lane 1. Protein 
preparations from purification stages were loaded as follows: 2 - crude extract,  
3 - supernatant after centrifugation, 4 - eluted from His6-tag affinity column. 
 
In order to remove the His6-tag, fractions were incubated overnight with TEV protease 
(purchased or purified,35 details in Appendix C) in the presence of 5 mM ethylenediamine 
tetraacetic acid (EDTA) and 1 mM dithiothreitol (DTT), followed by passing the cleaved 
protein through the His6-tag affinity column. Protein purity was increased by gel-filtration 
chromatography, which further decreased protein yield, and in this work resulted in 0.25 mg 
of purified non-tagged protein per L of culture. This is lower yield than that reported by 
Kefala of 1 mg of M. tuberculosis DHDPS from 1 L of culture,1 which accounts for only 1 % 
of the total protein expressed. Consequently, many variables were explored in an effort to 
optimize yield, including extraction techniques, host strains, growth temperature and length of 
induced expression. The most significant results are discussed in the following section. 
 
2.3.2 Optimization of over-expression & purification of M. tuberculosis DHDPS 
Centrifugation 
The first variable explored for optimization was centrifugation. The effect of centrifugation 
for 5 minutes on crude lysate at low speeds of 1000, 2000, 3000, and 4000 rpm, was analyzed 
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by SDS-PAGE and the o-aminobenzaldehyde assay (Figure 2.3). As the speed increased, the 
supernatant showed a marked decrease in the amount of His6-tagged M. tuberculosis DHDPS 
(Figure 2.3A, lanes 2-5) and DHDPS activity (Figure 2.3B), and there was a corresponding 
increase in the amount of M. tuberculosis DHDPS in the pellet (Figure 2.3A, lanes 7-10). 
 
 
  
Figure 2.3: The effect of varied low speed centrifugation for 5 min on crude cell-free lysate 
produced by sonication. (A) In SDS-PAGE the MW marker (lane 1) enabled 
identification of His6-tagged M. tuberculosis DHDPS (34 kDa). Lanes 2 to 6 were 
loaded with supernatant (1 in 20 dilutions) from centrifugation at 4 °C and 
speeds as follows: 2 - 1000 rpm, 3 - 2000 rpm, 4 - 3000 rpm, 5 - 4000 rpm,  
6 - 5000 rpm. Lanes 7 to 10 were loaded with pellet (re-suspended in 500 μL of 
high urea, high SDS) from the same centrifugation at the corresponding speeds:  
7 - 2000 rpm, 8 - 3000 rpm, 9 - 4000 rpm, 10 - 5000 rpm (B) DHDPS activity in 
the supernatant decreased with increasing speeds of centrifugation, as 
determined by the o-aminobenzaldehyde assay. Purified E. coli and 
M. tuberculosis DHDPS were used as positive controls.1,30 
 
The loss of M. tuberculosis DHDPS with centrifugation corresponds to the increasing 
sedimentation of insoluble proteins, and thus it seems to reflect the insoluble nature of the 
recombinantly expressed protein. Filtration was considered as an alternative to centrifugation, 
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but the initial results were not promising and the higher concentration of insoluble proteins in 
samples centrifuged for 5 minutes at 5000 rpm resulted in problems during chromatography; 
hence, further efforts focused on improving the yield of soluble M. tuberculosis DHDPS. 
 
Co-expression of chaperonins GroES and GroEL 
The most significant improvement in the yield of soluble protein came from the co-expression 
of GroES and GroEL proteins. These proteins are part of a subclass of proteins called 
chaperonins, which bind non-native forms of proteins and facilitate their refolding into the 
native conformation.36 Lorimer and colleagues designed a plasmid containing the groEL and 
groES genes, under the control of the p15A replicon, which is compatible for co-expression 
with the pET and pETM vector series.37 The plasmid pGroESL was acquired from Dr Celia 
Webby, who found that co-expression of GroEL and GroES chaperonins produced a small 
amount of soluble, biologically active M. tuberculosis 3-deoxy-D-arabino-heptulosonate-7-
phosphate synthase (DAH7PS), which otherwise was insoluble.38 
 
The plasmid pGroESL was used to transform E. coli BL21 (DE3) competent cells (Novagen). 
Transformants were selected using LB agar plates containing chloramphenicol. Subsequently, 
BL21 (DE3) pGroESL competent cells were transformed by electroporation (Dr Celia 
Webby, pers. comm.) using the plasmid pMTB02 (Appendix A), conferring 
kanamycin-resistance. Transformed cells containing both pGroESL and pMTB02 were 
selected for using LB agar plates containing chloramphenicol and kanamycin, and glycerol 
stocks were made. 
 
Two other E. coli strains were transformed using pMTB02 for comparison of soluble protein 
expression: E. coli BL21-CodonPlus® (DE3) RP and BL21 (DE3) pLysS, both of which have 
a chloramphenicol-resistance phenotype. E. coli BL21-CodonPlus® (DE3) RP cells, are 
engineered to contain extra copies of genes for tRNAs that frequently limit translation of 
recombinant proteins in E. coli,39 and were used in the original purification method developed 
by Kefala.1 E. coli BL21 (DE3) pLysS cells have the benefit of accumulating low levels of 
T7 lysozyme, which prevents low level expression of the cloned gene product before 
induction,40 and facilitates the production of cell extracts.41,42 The plasmid pMTB02 was used 
to transform BL21-CodonPlus® (DE3) RP competent cells (Stratagene), and BL21 (DE3) 
pLysS competent cells (prepared using calcium chloride), by the heat shock method. As 
outlined in the previous paragraph, chloramphenicol and kanamycin were used for selection, 
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and glycerol stocks were prepared. The production of soluble, biologically active protein was 
examined in each of these different bacterial strains by both SDS-PAGE (Figure 2.4) and the 
coupled assay (Table 2.1). 
 
 
Figure 2.4: Comparison of soluble M. tuberculosis DHDPS expression by SDS-PAGE analysis 
of the total (T) and soluble (S) fraction from the cell-free lysate produced by 
sonication from different E. coli strains, loaded as follows: BL21-CodonPlus® 
(DE3) RP (lanes 2, 3), BL21 (DE3) pLysS (lanes 4, 5) and BL21 (DE3) pGroESL 
(lanes 6, 7). The MW marker (lane 1) allows for identification of His6-tagged 
M. tuberculosis DHDPS (34 kDa). Cultures of each strain were grown for 20 hours 
at room temperature following induction. The soluble (S) fraction resulted from 
centrifugation for 30 min, at 11000 rpm and 4 °C. 
 
BL21 (DE3) pGroESL was shown to be the best E. coli strain for expressing soluble, 
biologically active M. tuberculosis DHDPS. Unlike the other bacterial strains, BL21 (DE3) 
pGroESL had an observable band corresponding to DHDPS from M. tuberculosis in the 
soluble fraction (Figure 2.4, lane 7). Most significantly, the activity per gram of cells 
harvested for E. coli BL21 (DE3) pGroESL was much greater than that for BL21-
CodonPlus® (DE3) RP (Table 2.1), even though the over-expression level as judged by 
SDS-PAGE (Figure 2.4) was very similar. 
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Table 2.1: Comparison of enzyme activity from different bacterial strains. 
E. coli strain Harvested cellsa (g) 
Total activityb 
(units)c in cruded 
Total activityb (units)c 
in soluble fractione 
BL21-CodonPlus® (DE3) RP 5.23 2.6 0.77 
BL21 (DE3) pLysS 6.51 6.1 5.4 
BL21 (DE3) pGroESL 5.30 9.0 8.5 
 
a  Wet-weight of cells from 1 L of culture grown in LB media for 33 hours at room temperature after induction. 
b  Enzyme activity was determined using the quantitative coupled assay, detailed in section 2.2.3. 
c  1 unit is defined as the consumption of 1 μmol of NADPH per second. 
d  Crude preparation required cells to be washed and re-suspended in buffer A to give a total volume of  50 mL, followed by 
sonication for 3 minutes in 2 s pulses with 10 s delays at 4 °C. 
e  Soluble fraction was the supernatant from centrifugation for 30 min at 11000 rpm and 4 °C. 
 
Buffer components 
The purification buffers used in the original protocol contained several components, in 
addition to the buffer, which were intended to improve solubility and protect against enzyme 
degradation. The effect of these components on thermal stability was investigated using 
differential scanning fluorescence (DSF), where a sharp increase in fluorescence (as shown in 
Figure 2.5A) corresponds to the protein going from a folded to unfolded state, and therefore 
the mid-point of this transition reflects the apparent melting temperature (Tmapp).43 The 
denaturation of M. tuberculosis DHDPS in 20 mM Tris.HCl, pH 8.0 (Figure 2.5A), gave a 
Tmapp of 71.5 (±0.1) °C. The inclusion of 250 mM NaCl in the buffer increased Tmapp by ~6 °C 
(Figure 2.5B), which is unsurprising given that the majority of proteins are more stable at 
physiological ionic strength,23 and confirmed that NaCl should be included in the buffer. The 
subsequent additions of glycerol and β-ME (giving final concentrations of 5 % and 2 mM, 
respectively) had minimal and counteracting effects (Figure 2.5B). However, both continued 
to be included in the purification buffers, since preparations stored in glycerol were observed 
to be appreciably less degraded over time and β-ME protects against oxidative effects.44 
 
A modification to the original purification buffer was considered; that is the inclusion of one 
of the enzyme’s substrate, pyruvate, as it had been found to increased protein yield and 
stability in previous studies with DHDPS.19 Interestingly, M. tuberculosis DHDPS gave a 
Tmapp of 85.3 (±0.1) °C in 10 mM pyruvate, 2 mM β-ME, 5 % glycerol, 250 mM NaCl, 
20 mM Tris.HCl, pH 8.0, increasing the Tmapp by ~8 °C in comparison to that determined in 
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the same buffer without pyruvate (77.5 (±0.3) °C in 2 mM β-ME, 5 % glycerol, 250 mM 
NaCl, 20 mM Tris.HCl, pH 8.0, as shown in Figure 2.5B), which indicated that pyruvate had 
a substantial stabilizing effect. Consequently, the modified protocol included 10 mM pyruvate 
in all purification buffers, since its stabilizing effect is likely to improve the yield of soluble, 
non-denatured M. tuberculosis DHDPS. Although, it was excluded from the final storage 
buffer as a background concentration of pyruvate would complicate kinetic characterization. 
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Figure 2.5: Determination of Tmapp using differential scanning fluorescence. (A) The melting 
curve of 0.5 mg.mL-1 M. tuberculosis DHDPS (His6-tag removed) in the presence 
of 20 mM Tris.HCl, pH 8.0. (B) The additive effect of different buffer 
components on Tmapp for M. tuberculosis DHDPS. Each Tmapp was measured in 
triplicate and the error bars show standard deviation. Beginning with 20 mM 
Tris.HCl, pH 8.0 (leftmost bar), subsequent buffers had the indicated component 
added to the previous buffer systems. Thus the Tmapp of 85.1 (±0.2) °C on the far 
right corresponds to an extraction buffer composed of 20 mM Tris.HC1, 250 mM 
NaCl, 5 % glycerol, 2 mM β-ME, 10 mM pyruvate and 10 mM imidazole. 
 
The components of the extraction buffer were also considered, as the preparation of cell 
extracts influences both the total quantity of protein recovered and the biological activity 
retained.45 The extraction buffer included a low concentration (10 mM) of imidazole to 
minimize non-specific binding to the chromatography resin in the subsequent step, and thus 
improved enzyme purity.46 Since the effect of imidazole on the Tmapp observed with DSF was 
insignificant (Figure 2.5B), it continued to be added in the extraction buffer. The original 
purification method also included the commercially available mild detergent, BugBusterTM 
(Novagen);1 however, no significant improvements in extraction of active M. tuberculosis 
DHDPS were observed (Dr Simone Weyand, pers. comm.), and therefore the detergent was 
(A) (B) 
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excluded from the purification procedure, as was the EDTA-free protease inhibitor (Roche), 
since no degradation/proteolysis was observed. 
 
2.3.3 Modified purification procedure for M. tuberculosis DHDPS 
The most important modification to the original method was the co-expression of refolding 
chaperonins GroES and GroEL with M. tuberculosis DHDPS. As in the original protocol, 
over-expression of DHDPS was induced by IPTG and cells were grown overnight at 20 °C, 
and then harvested by centrifugation. Crude cell-free lysates were produced by 5 minutes of 
ultrasonication at 4 °C, in 20 s pulses (Figure 2.6, lane 2), in extraction buffer (buffer A) 
including 10 mM pyruvate (as described in the previous section), followed by clarification 
with centrifugation at 10000 rpm. In contrast to the original protocol, soluble M. tuberculosis 
DHDPS could be observed in the supernatant by SDS-PAGE (Figure 2.6, lane 3). 
 
 
Figure 2.6: A typical purification using the modified protocol for M. tuberculosis DHDPS, 
over-expressed in E. coli BL21 (DE3) pGroESL pMTB02, examined using 
SDS-PAGE. The MW marker, in lane 1, enabled identification of His6-tagged 
M. tuberculosis DHDPS as the 34 kDa band (black rectangle). Protein 
preparations from various stages of purification were loaded into other lanes as 
follows: 2 - crude cell-free extract, 3 - after centrifugation, 4 - eluted from His6-tag 
affinity column, 5 - after overnight incubation with TEV protease. In lane 5, the 
cleavage of the 4 kDa His6-tag gives rise to a 30 kDa band corresponding to 
non-tagged M. tuberculosis DHDPS. 
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The supernatant from centrifugation was loaded onto a His6-tag affinity column (HisTrap 
Crude, GE Healthcare) pre-equilibrated with buffer A. The column was washed with three 
buffers at pH 8.0 (chapter six, section 6.4), and buffer D eluted His6-tagged M. tuberculosis 
DHDPS by increasing imidazole concentration to 250 mM, and resulted in 22-fold increase in 
enzyme purity (Table 2.2, and Figure 2.6, lane 4). The yield of ~5 mg of His6-tagged protein 
from 1 L of culture (Table 2.2) was considerably greater than the 1.6 mg obtained using the 
original procedure (section 2.2.1). 
 
Table 2.2: Optimized purification of M. tuberculosis DHDPS from E. coli BL21 (DE3) 
pGroESL pMTB02 (4.5 L culture, 9.2 g of cells). 
Purification step Volume (mL) 
Proteina 
(mg) 
Total activityb 
(unitsc) 
Specific activity 
(unitsc/mg) 
Relative 
total activityd  Purification
d 
Crude 150 990 97.5 0.1  - 1-fold 
Centrifuged 110 575 44.9 0.08 46% 1-fold 
Affinity (His6-tagged) 25.0 24 52.4 2.2 54% 22-fold 
Affinity (cleaved) 25.0 21 82.2 3.9 84% 39-fold 
Concentrated 3.0 2.2 6.9 3.2 7% 32-fold 
Gel filtration 11.0 3.3 11.8 3.6 12% 36-fold 
 
a  Protein concentration was determined using the Bradford assay, detailed in chapter six, section 6.3.1. 
b  Enzyme activity was determined using the quantitative coupled assay, detailed in section 2.2.3.  
c  1 unit is defined as the consumption of 1 μmol of NADPH per second. 
d  Crude preparation may contain inhibitors of NADPH consumption/NADPH-utilizing enzymes, both of which interfere with 
the coupled assay; therefore, values in the last two columns may be inaccurate due to their basis on crude material. 
 
Active fractions were detected using the o-aminobenzaldehyde assay (section 2.2.1) and 
buffer exchanged back into buffer A using desalting columns. The His6-tag was cleaved off 
by overnight incubation with recombinant TEV protease (Appendix B), in the presence of 
0.5 mM EDTA and 1 mM DTT, leaving four linker amino acids, G-A-M-A, at the 
N-terminus.35,47 After SDS-PAGE confirmed the cleavage of the tag (Figure 2.6, lane 5), the 
cleaved M. tuberculosis DHDPS was passed through a His6-tag affinity column, pre-
equilibrated with buffer A, to remove the His6-tag peptide fragment. Cleaved non-tagged 
M. tuberculosis DHDPS had higher specific activity, as reflected by the increase in specific 
activity between purification steps 3 and 4 (Table 2.2). 
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Unfortunately, the protein required a significant concentration step in preparation for gel 
filtration and a substantial loss of yield resulted after the ultrafiltration spin column 
(Vivaspin 15, Vivascience) (Table 2.2). This was likely caused by proteins binding to the 
filtration membrane, as no obvious precipitate formed, and no enzyme activity was found in 
the flow through. The concentrate was loaded onto a gel-filtration column (Superdex 200, 
16/60, GE Healthcare) to remove any remaining impurities; the active fraction, which eluted 
with molecular mass of ~120 kDa, consistent with a homotetramer, was collected. The 
purified M. tuberculosis DHDPS was analyzed by SDS-PAGE and stored in storage buffer 
[20 mM Tris.HCl, pH 8.0, 250 mM NaCl, 5 % glycerol and 2 mM β-ME] at 4 or -20 °C for 
several weeks without detectable degradation. The final yield of ~0.7 mg of non-tagged 
protein per L of LB media from the optimized procedure was comparable to the reported 
yield from the original procedure,1 and enabled preparation of milligram quantities of soluble, 
folded, active M. tuberculosis DHDPS for biochemical and biophysical characterization. 
 
2.3.4 Over-expression & purification of DHDPR 
DHDPR, the coupling enzyme for steady-state kinetic studies of DHDPS, was obtained via 
over-expression from the plasmid pTM1521. This plasmid carries the gene for T. maritima 
DHDPR with a non-cleavable His6-tag at its N-terminus, and was kindly donated by Scott 
Lesley and Heath Klock (Joint Center for Structural Genomics, Genomics Institute of the 
Novartis Research Foundation, San Diego, USA). Since the enzyme was used in excess, the 
species from which the DHDPR was derived was unimportant. T. maritima DHDPR was 
chosen for convenience and its thermal stability, which allowed the addition of a heat shock 
step to the published protocol.48 Incubation for 2 minutes at 95 °C resulted in no significant 
loss of DHDPR activity and protein purity was improved several folds (Table 2.3). Highly 
homogenous DHDPR was eluted from the affinity column, as judged by denaturing 
SDS-PAGE, and stored at -20 °C. 
 
2.3.5 Over-expression & purification of E. coli DHDPS 
For comparison, E. coli DHDPS was also produced, using a procedure modified from the 
protocol developed by Coulter et al.4 The enzyme was expressed and purified from XL1-Blue 
cells containing pJG001, which contains the dapA gene from E. coli. In an analogous fashion 
to DHDPR, the relative thermal stability of E. coli DHDPS allowed for inclusion of a heat 
shock step (for 2 minutes at 70 °C) with no loss of specific activity (Table 2.4). The 
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supernatant was loaded onto ion exchange column (Q-Sepharose, GE Healthcare), and eluted 
with a linear gradient from 0 to 1 M NaCl. The active peak, determined by the 
o-aminobenzaldehyde assay (section 2.2.1), was collected and dialyzed overnight in buffer 
containing 0.5 M ammonium sulfate, in preparation for hydrophobic interaction 
chromatography (phenyl Sepharose, GE Healthcare). Any remaining contaminants were 
removed by the second chromatography step and the active fractions, containing E. coli 
DHDPS, were pooled and stored at -20 °C. 
 
Table 2.3: Typical purification of T. maritima DHDPR (4.5 L culture, 14.0 g of cells). 
Purification step Protein
a  
(mg) 
Total activityb  
(unitsc) 
Specific activity  
(units/mg) 
Relative total 
activityd Purification
d  
Crude 321 6.39 0.020  - 1-fold 
Heat shock 129 6.65 0.051 104% 3-fold 
Affinity 42 5.08 0.12 79% 6-fold 
 
Table 2.4: Purification of E. coli DHDPS (4.5 L culture, 10.7 g of cells). 
Purification step Protein
a  
(mg) 
Total activityb  
(unitsc) 
Specific activity  
(units/mg) 
Relative total 
activityd Purification
d  
Crude 855 324 0.38  - 1-fold 
Heat Shock 361 203 0.56 63% 1-fold 
Ion Exchange 113 147 1.30 45% 3-fold 
Hydrophobic Exchange 74 104 1.41 32% 4-fold 
 
a  Protein concentration was determined using the Bradford assay, detailed in chapter six, section 6.3.1. 
b  Enzyme activity was determined using the quantitative coupled assay, detailed in section 2.2.3.  
c  1 unit is defined as the consumption of 1 μmol of NADPH per second. 
d  Crude preparation may contain inhibitors of NADPH consumption or NADPH-utilizing enzymes, both of which interfere 
with the coupled assay; therefore, values in the last two columns may be inaccurate due to their basis on crude material. 
 
2.4 Biochemical analysis of M. tuberculosis DHDPS 
The determination of the steady-state kinetics of M. tuberculosis DHDPS required a method 
for measuring the initial-rate of reaction, such as the coupled assay (section 2.2.3), as well as 
an understanding of the factors that affect this rate, such as pH, ionic strength and 
temperature. This provided a comprehensive basis of comparison for subsequent work. The 
effect of (S)-lysine and other aspartic family amino acids on enzyme activity was also 
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investigated; both in light of the putative regulatory role of DHDPS in the DAP pathway and 
the (S)-lysine binding pocket providing a possible binding site for inhibitors (section 2.1). 
 
2.4.1 Optimum pH 
Most enzymes are active within a limited pH range and many have optimal activity at a 
specific pH, because changes in pH can influence the enzyme structure and stability, and its 
affinity for its substrate.22 A series of buffers covering a pH range of 6 to 9 with the same 
ionic strength (adjusted by the addition of NaCl)49 was used to determine the optimum pH at 
30 °C in the coupled assay system. The activity of M. tuberculosis DHDPS had an optimum 
pH between 7.75 to 8.25 (Figure 2.7A), which is similar to the literature value for E. coli 
DHDPS of 8.4.6 Therefore, there seemed no reason to modify the coupled assay procedure 
used for steady-state kinetics, where the pH is maintained at 8.0 by 100 mM 
N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) buffer.30 
 
                  
Figure 2.7: The optimum conditions for enzyme activity determined by varying (A) pH with 
different buffers (? MES, ? HEPES, ? Bicine), and (B) ionic strength with salt 
concentration. The data in the second plot are normalized by dividing the 
apparent rate (νapp) by the highest measured rate (νcon). Each data point was 
measured at least in duplicate and the error bars show standard deviation. The 
dashed line shows the general trend of the data. 
 
2.4.2 The effect of ionic strength 
The ionic strength inside the cytoplasm of a typical cell ranges from 0.15-0.2 M.23 Below 
physiological ionic strength, enzyme stability, but not activity, tends to be affected; however, 
above 0.2 M, enzyme activity is often depressed.23 The effect of ionic strength on the 
(A) (B) 
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enzymatic reaction was determined using the coupled assay system and a series of 20 mM 
HEPES buffers covering a range of ionic strengths (adjusted by NaCl and corrected for the 
amount of HCl/NaOH added to bring the pH to 8.25 at 30 °C). Greater variability (±14 %) 
was seen in initial-rate measurements, performed in quadruplicate, at ionic strengths below 
0.20 M, as compared to the variability (±5 % or less) in triplicate measurements at or above 
0.20 M (Figure 2.7B), possibly reflecting enzymatic destabilization at low ionic strengths. 
 
The optimal ionic strength for stabilization and activity seems to be in the physiological range 
of 0.15-0.20 M, since below this ionic strength the assays are less reproducible and above it 
the activity of M. tuberculosis DHDPS decreases. As a consequence, 50 mM of NaCl was 
included in the 200 mM HEPES buffer stock to increase the ionic strength in the coupled 
assay system for kinetic characterization (details in Appendix D). 
 
2.4.3 Thermal stability 
Thermal degradation was investigated by incubating DHDPS for a defined period at various 
temperatures before measuring initial-rates at the standard assay temperature of 30 °C. 
M. tuberculosis DHDPS showed a greater thermal stability than E. coli DHDPS, not 
degrading until 80 (±1) °C (Figure 2.8A). 
 
                   
Figure 2.8: The thermal stability of M. tuberculosis DHDPS (?) was compared to that of 
E. coli DHDPS (?) using the apparent initial-rate (νapp) divided by rate of 
enzyme activity without pre-treatment (νcon). The enzyme activity was 
determined with the coupled assay (A) after pre-treatment by 5 minute 
incubation at increasing temperature and (B) after incubation at 70 °C for 
increasing durations. The dashed line shows the general trend of the data. 
(A) (B) 
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This result is in good agreement with the Tmapp of 77.5 (±0.3) °C determined using DSF for 
M. tuberculosis DHDPS in storage buffer [20 mM Tris.HCl, 250 mM NaCl, 5 % glycerol, 
2 mM β-ME] (section 2.3.3, Figure 2.5). Increasing the temperature to 80 °C, will have 
changed the pH buffered by HEPES during incubation from 8.25 to pH 7.5,49 which is still 
sufficiently near optimum to disregard any pH effects. Further experiments with incubation at 
70 °C (~pH 7.7) showed that M. tuberculosis DHDPS maintained its activity for at least 
40 minutes (Figure 2.8B). The slight increase in activity observed is likely due to evaporation 
concentrating the protein sample over the course of the incubation. 
 
2.4.4 Steady-state kinetics of wild-type M. tuberculosis DHDPS 
Steady-state kinetics enable simple calculation of kinetic parameters in vitro and inform our 
understanding of enzyme action and metabolism.50 Enzymatic rates are measured just 
subsequent to assay initiation, before the rate is affected by product accumulation or substrate 
consumption. There is only a relatively short interval, during which the assumptions of kinetic 
models, such as the Michaelis-Menten, are valid.49 Consequently, prompt measurement and a 
recordable period of linearity is required for accurate initial-rates and kinetic analysis. 
 
Kinetic models describe the binding of substrates and release of products in mathematical 
terms, such as the Michaelis-Menten equation (Equation 2.1), which introduced the 
Michaelis constant (KM) and the maximum velocity attainable (V) to describe the relationship 
between the initial-rate or steady-state velocity (ν), substrate concentration ([S]):50 
 
 
][SK
Vv
M +
=  Equation 2.1 24 
 
Michaelis and Menten developed this equation to reflect a single substrate (S) binding to the 
enzyme (E) to form an enzyme-substrate complex (E:S), in rapid reversible equilibrium, with 
subsequent slow conversion and release of product (P) (Figure 2.9):24 
 
E + S E:S E + P
k1
k-1
k2
 
Figure 2.9: A schematic diagram of the kinetic mechanism described by the Michaelis-Menten 
equation, with the rate constant of the second step, k2, is much smaller than k1.24 
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In this case (Figure 2.9), where k2 << k1 and therefore the second step determines the rate of 
the overall reaction, V is equal to k2 and KM is the dissociation constant (k1/k-1) of the enzyme-
substrate complex.24 Both KM and V are used to describe much more complex kinetic models 
than Michaelis-Menten; however, their meaning is no longer assigned to a particular 
dissociation or reaction step, respectively.50 For example the ping-pong model involves two 
substrates (A, B) binding in a specific order, with a release of a product to form an enzyme-
substrate intermediate (F), prior to the binding of the second substrate (B) (Figure 2.10), and 
therefore V and KM are considered in the more general terms of the overall process.51 
 
E + A E:A E + P
k1
k-1
F + B
k3
k-3
k2
F:B
k4
 
Figure 2.10: A schematic diagram of the ping-pong mechanism. 
 
Kinetic data for M. tuberculosis DHDPS were fitted to the ping-pong (or substituted-enzyme) 
model (Equation 2.2), the compulsory-order ternary-complex model (Equation 2.3) and the 
ping-pong with substrate inhibition model (Equation 2.4). These models all describe two 
substrate systems where substrates bind in a specific order; however, the order of binding is 
ambivalent for the first model due to the symmetry of the equation. In the ternary-complex 
model, the second substrate (B) binds to the enzyme-substrate complex (E:A) prior to the 
release of any product.24  
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Here ν is described in terms of two variable substrate concentrations [A] and [B], 
corresponding to pyruvate and (S)-ASA for DHDPS, and by at least three constants, V and K
M
A 
and K
M
B, the Michaelis constants for the respective two substrates. More specifically, K
M
A 
corresponds to the Michaelis constant when B is saturating, and vice versa for K
M
B, whereas 
Ks
A, which only appears in Equation 2.3, corresponds to this constant for substrate A in the 
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absence of substrate B.24 K
i
B, which appears in Equation 2.4, is a dissociation constant that 
defines the strength of inhibition caused by the second substrate binding first and forming a 
dead-end complex.24 
 
Initial-rate data for M. tuberculosis DHDPS were determined with the coupled assay, using 
the buffer stock described at the end of section 2.4.2, for a five-by-five matrix varying 
pyruvate and (S)-ASA concentrations.26 As recommended by Cornish-Bowden, substrate 
concentrations were chosen based on apparent KM values determined by varying one substrate 
while the other was held constant.24 Accuracy is best when the range of concentrations 
corresponds to the greatest variation in rate, so the concentration of (S)-ASA and pyruvate 
was varied between 0.2 to 10 times the apparent KM (which was determined to be 0.3 mM for 
both substrates).24 The initial-rate of product formation was measured in triplicate, and was 
reproducible (±10 %). The data were analyzed by non-linear curve fitting to appropriate 
kinetic models using the program ENZFITTER (Biosoft, Cambridge, U.K.). 
 
 
 
Figure 2.11: The initial velocity of wild-type M. tuberculosis DHDPS was measured with the 
coupled assay over varying concentrations of both substrates, pyruvate and 
(S)-ASA, shown on the x-axis and with symbols (? 3.0 mM, ? 1.5 mM, 
? 0.30 mM, ? 0.15 mM, ? 0.06 mM (S)-ASA). Each point was measured at 
least in triplicate and the data were fitted with the ping-pong model giving an R2 
of 0.99 using the program ENZFITTER. Plot (B) shows the Lineweaver-Burk 
transformation, fitted with the parallel lines predicted for the ping-pong model. 
 
The ping-pong model provided the best fit (Figure 2.11A and 2.12A), shown by its R2 value 
of 0.99, and yielded a V of 4.2 (±0.1)a µmol.s-1.mg-1 and KM constants of 0.16 (±0.01) mM 
and 0.43 (±0.03) mM for pyruvate and (S)-ASA, respectively. These are similar in magnitude 
(A) (B) 
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to the KM constants determined for other DHDPS enzymes by the coupled assay system (see 
Table 1.2, chapter one, section 1.3.1). The substrate inhibition model also gave a reasonable 
fit, but the K
i
(S)-ASA value of 25 mM is outside the concentration range examined in this study. 
 
 
 
Figure 2.12: The initial velocity of wild-type M. tuberculosis DHDPS was measured over 
varying concentrations of both substrates, (S)-ASA and pyruvate, shown on the 
x-axis and with symbols (? 3.0 mM, ? 1.5 mM, ? 0.30 mM, ? 0.15 mM, ? 0.06 
mM pyruvate). Each point was measured in triplicate and the data were fitted 
with the ping-pong model using ENZFITTER. Plot (B) shows the Lineweaver-
Burk transformation, fitted with the parallel lines predicted for this model. 
 
The molecular weight (expressed at enzyme molarity, e0) of M. tuberculosis DHDPS can be 
used to convert V into the catalytic turnover number, kcat, defined as the number of catalytic 
processes or substrates “turned-over” by an enzyme per unit time.24 M. tuberculosis DHDPS 
has a kcat of 132 (±3)* s-1 per active site in comparison with E. coli DHDPS kcat of 124 (±7) s-1 
(Table 2.5).28 The efficiency of any enzyme is shown by kcat/KM. The efficiency of a perfect 
enzyme cannot be any faster than the rate at which substrates and products diffuse in and out 
of the active site, thus the upper limit due to diffusion means there is a maximum value 
possible for kcat/KM of 108 to 109 s-1.M-1.50 Dividing kcat by KM for pyruvate and for (S)-ASA 
gave values for catalytic efficiency with magnitudes of 105 s-1.M-1 showing that 
M. tuberculosis DHDPS, like many enzymes, is not at the diffusion limit. 
 
*  The V and kcat reported here were calculated using initial-rates determined from recorded data by a linear fit 
to first 10 s measured. Subsequent work (in chapter 5) utilized this approach. The values published elsewhere 
were calculated using initial rates determined from the same data set by fitting an algorithm from 
ENZFITTER called initial rate for the first 50 s, which resulted in a V of 4.42(±0.1) µmol.s-1.mg-1. 
 
(A) (B) 
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Table 2.5: Kinetic parameters determined by fitting initial-rate measurements, compared 
with literature values for E. coli DHDPS.28 
  M. tuberculosis DHDPS E. coli DHDPS 
Kinetic model Ping-pong Ping-pong 
KM for (S)-ASA (mM) 0.43 (±0.02) 0.11 (±0.02) 
KM for pyruvate (mM) 0.17 (±0.01) 0.26 (±0.01) 
Monomer molecular weight (Da) 31156.5 31269.0 
e0 (mgs of subunit per μmol) 31.16 31.27 
kcat per active site (s-1) 132 (±3)a 124 (±2) 
kcat/KM for (S)-ASA (s-1.M-1) 3.0 (±0.2) × 105 1.1 (±0.2) × 106 
kcat/KM for pyruvate (s-1.M-1) 7.8 (±0.6) × 105 4.8 (±0.6) × 105 
 
Further confirmation that substrates bind to M. tuberculosis DHDPS in a ping-pong fashion 
was provided by Lineweaver-Burk (Figure 2.11B and 2.12B) and Hanes plots (Figure 2.13). 
These graphical methods aid in visual detection of the characteristic trends that reflect the 
different kinetic models and any deviations from the model fitted.24,52 The family of 
hyperbolae is transformed into a series of straight lines, most commonly by plotting the 
reciprocal of ν and [S], utilizing the method developed by Lineweaver and Burk.24,49,52 This 
approach compresses high substrate concentration data into a small region, while low 
concentration data, with the slowest rates and therefore highest errors, are emphasized.24,49,52 
Experimental error is much less distorted in the Hanes plot ([S]/ν against [S]); thus it is 
considered more accurate and generally superior.24,49,52 
 
                   
Figure 2.13: The Hanes transformation, reflecting the trend of y-axis intersection predicted 
for the ping-pong model, plotted against (A) varying concentrations of (S)-ASA 
on the x-axis (? 3.0 mM, ? 1.5 mM, ? 0.30 mM, ? 0.15 mM, ? 0.06 mM 
pyruvate) and (B) varying concentrations of pyruvate on the x-axis (? 3.0 mM, 
? 1.5 mM, ? 0.30 mM, ? 0.15 mM, ? 0.06 mM (S)-ASA). 
(A) (B) 
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The ping-pong model manifests itself by parallel lines in the Lineweaver-Burk plot (Figure 
2.11B and 2.12B) and a set of lines intersecting on the y-axis in the Hanes plot (Figure 2.13); 
the lack of curvature seen in both plots indicates the absence of substrate inhibition.24,52 The 
ping-pong mechanism of M. tuberculosis DHDPS is consistent with the kinetic mechanism 
proposed for other DHDPS enzymes, discussed in chapter one, section 1.3.1 & 1.3.2. 
 
2.4.5 The effect of (S)-lysine and other amino acids on M. tuberculosis DHDPS 
The role of DHDPS as a control point in DAP/(S)-lysine biosynthesis in mycobacteria has not 
been elucidated; however, differences in the regulation of this pathway as compared to E. coli 
have been emphasized by gene-knockout experiments (chapter one, section 1.2.3).53 Gram-
positive bacteria tend to have DHDPS that are uninhibited by (S)-lysine (chapter one, section 
1.2.4), and traditionally mycobacteria, such as M. tuberculosis, have been grouped with 
Gram-positive bacteria, although, this classification is debated.54 
 
The coupled assay was performed in the presence of increasing amounts of (S)-lysine, with 
pyruvate and (S)-ASA at concentrations of 0.3 and 0.2 mM, respectively. Except at very high 
concentrations of (S)-lysine (50 mM and above), (S)-lysine did not have any effect on the 
activity of M. tuberculosis DHDPS. The IC50, that is the concentration needed for 50 % 
inhibition, was determined to be ~250 mM (Figure 2.14), which greatly exceeds the level of 
(S)-lysine that could be reasonably expected in a cell. Thus, M. tuberculosis DHDPS can be 
considered insensitive to (S)-lysine, fitting with the trend found in Gram-positive bacteria. 
 
 
 
Figure 2.14: The activity of M. tuberculosis DHDPS, in the presence of increasing of (S)-lysine 
concentration. The data are normalized by dividing the apparent rate (νapp) by 
the highest measured rate (νcon) of activity. Each data point (?, with dashed line) 
was measured at least in duplicate,  and the error bars show standard deviations. 
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Another branch point enzyme, DAH7PS from M. tuberculosis from the pathway responsible 
for the biosynthesis of aromatic compounds, was found to be inhibited by all three aromatic 
amino acids, and combining two gave greater inhibition than the additive effect alone, 
suggesting synergistic inhibition.38 Thus, the effect of the amino acids of the aspartate family 
(listed in chapter one, section 1.2) on the activity of M. tuberculosis DHDPS was of interest. 
DAP, threonine, and methionine were tested and found to cause no significant inhibition of 
M. tuberculosis DHDPS activity, either separately (Table 2.6) or in combination with 
(S)-lysine or each other (Table 2.7). 
Table 2.6: The effects of aspartate family amino acids on the activity of M. tuberculosis 
DHDPS. Each substrate concentration was held at 0.3 mM. 
Amino acid Concentration (mM) Relative activitya  
meso-DAP 1 99 % 
 10 87 % 
 20 57 % 
(S)-Threonine 1 104 % 
 10 86 % 
 20 74 % 
(S)-Methionine 1 100 % 
 10 99 % 
 20 96 % 
 
Table 2.7: The effects of various combinations of aspartate family amino acids on 
M. tuberculosis DHDPS. Each substrate concentration was held at 0.3 mM. 
(S)-Lysine meso-DAP (S)-Threonine (S)-Methionine Relative activitya 
5 mM 5 mM   92 % 
5 mM  5 mM  97 % 
5 mM   5 mM 95 % 
 5 mM 5 mM  86 % 
 5 mM  5 mM 99 % 
  5 mM 5 mM 91 % 
 
a  Activity determined in duplicate/triplicate by the coupled assay and reported relative to that in the absence of inhibitor. 
 
The absence of significant feedback inhibition in M. tuberculosis DHDPS indicates that the 
regulation of the (S)-lysine biosynthetic pathway (if it is indeed regulated in M. tuberculosis) 
is maintained via an alternate strategy to inhibition of DAH7PS activity in M. tuberculosis. In 
E. coli, the DAP pathway has been proposed to be controlled at both the aspartate kinase and 
DHDPS catalytic step.55 The expression of E. coli DHDPS is regulated by the level of DAP,56 
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thus regulating the (S)-lysine biosynthesis at the genetic level; however, whether such an 
approach is adopted in M. tuberculosis is beyond the scope of this study. 
 
2.5 Biophysical analysis of M. tuberculosis DHDPS 
Inhibition of self-association into quaternary structure has been suggested as an alternative 
approach to drug design,57 and was a key focus of this work. Hence it was important to 
determine the state of association of M. tuberculosis DHDPS in solution. All DHDPS 
enzymes that have had their function confirmed are homotetramers, except the recently 
discovered dimeric DHDPS from methicillin-resistant S. aureus (MRSA) (discussed in chapter 
one, section 1.5.1).58 For M. tuberculosis DHDPS, two complementary techniques, 
gel-filtration chromatography and analytical ultracentrifugation (AUC), were employed to 
examine quaternary structure via the determination of solution molecular mass. 
 
2.5.1 Comparison of the two biophysical techniques 
In gel-filtration liquid-chromatography, proteins migrate based on their hydrodynamic radius, 
with larger proteins eluting first. Experiments carried out in this research involved the 
application of a small volume of concentrated protein to a gel-filtration column, with the 
buffer volume required for elution (Ve) corresponding to a peak observed by UV absorbance. 
This can be related to molar mass using standards such as BSA (67 kDa), and ovalbumin 
(43 kDa), but variation in hydrodynamic properties leads to approximately 10 % uncertainty. 
 
In analytical ultracentrifugation (AUC), the effect of centrifugal force on protein is monitored 
and fitted using rigorous theory in order to determine its molecular mass and sedimentation 
coefficient. Inaccuracies caused by non-ideal behaviour can be avoided by using low protein 
concentrations (≤1 mg.mL-1), and by including 100 mM of electrolyte, such as NaCl.59 Two 
experimental approaches, sedimentation velocity (SV) and sedimentation equilibrium (SE), 
allow for the examination of solution behaviour using hydrodynamic and thermodynamic 
models, respectively.60 
 
The lack of dependence on calibration or assumptions about shape allows for more accurate 
determination of molar mass with AUC in comparison to gel-filtration chromatography.61 
Contrastingly, the lack of dependence on models in gel-filtration chromatography means the 
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technique provides an excellent basis of comparison to detect possible artefacts introduced to 
AUC data during model fitting. 
 
2.5.2 Analytical ultracentrifugation 
In sedimentation velocity (SV), the application of a large centrifugal force causes the 
depletion of macromolecules from the meniscus and results in the formation of a 
concentration boundary that gradually migrates down the length of the cell.59,62 The rate of 
sedimentation in SV is dependent on other forces in addition to the centrifugal force, such as 
diffusion.62 Therefore, a hydrodynamic model is used to describe the net effect of these forces 
and from this can be derived the Svedberg equation, which introduces the sedimentation 
coefficient (s) to describe the relationship between the rate of sedimentation (u) and the 
centrifugal force (ω2r): 
 
 
Nf
vM
r
us )ρ1(
ω2
−==  Equation 2.5 59,63 
 
Here s is also described in terms of solution properties, where M is molecular mass, v  is the 
density of the protein (or partial specific volume), ρ is the density of the solvent, f is the 
frictional coefficient (related to the shape of the protein) and N is Avogadro’s number.59,63 In 
SV, the rate of sedimentation is used to determine s, which can be converted into molecular 
mass with the knowledge of the other solution properties.59 Both v  and ρ can be calculated 
but f needs to be extracted from experimental data, and therefore SV experiments are more 
susceptible than sedimentation equilibrium experiments to inaccuracies from non-ideal 
behaviour, including non-heterogeneity and/or self-associating systems.59 
 
For SV experiments with M. tuberculosis DHDPS, protein sample and reference were 
centrifuged at 40000 rpm and data were collected every 8 minutes without averaging 
(Figure 2.15). The partial specific volume ( v ) of the wild-type enzyme (0.7402 mL.g-1), 
buffer density (1.005 g.mL-1) and viscosity (1.021 cP) were determined using the program 
SEDNTERP.64 SV data were fitted to a continuous sedimentation coefficient [c(s)] 
distribution model, using the program SEDFIT.65 The sedimentation coefficient (s*) is taken 
as the ordinate of the peak observed in this distribution and was converted into the 
standardized sedimentation coefficient (s°20,w), using SEDNTERP.64 
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Figure 2.15: SV analysis of M. tuberculosis DHDPS (1.1 mg.mL-1) in 20 mM Tris.HCl, pH 8.0, 
150 mM NaCl, at 20 °C. (A) Absorbance at 280 nm plotted as a function of 
radial position from the axis of rotation (cm). A radial-dependent, time invariant 
(TI) baseline was subtracted from the data to account for optical imperfections.  
The raw data (○) are overlaid with the nonlinear least-squares fit (solid line) to a 
[c(s)] model. (B) The c(s) distribution was fitted using a resolution of 200 species 
with v  = 0.7402 mL.g-1, ρ = 1.005 g.mL-1, η = 1.021 cP and f/f0  = 1.23499. The 
r.m.s.d. and Z-test for the fit were 0.0038 and 12.17, respectively.  
 
Data collected at 280 nm and high concentrations of 1.1 mg.mL-1 M. tuberculosis DHDPS 
showed one main peak of 6.3 S, with a much a smaller secondary peak of 3.1 S (3 % of 
signal) (Figure 2.15B). This second peak resulted in a less than ideal fit, as indicated by the 
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Z-test value of 12.17, but the randomly distributed residuals (Figure 2.15) and low root-
mean-square difference (r.m.s.d.) indicate the relative goodness of the fit. These values were 
converted into standardized sedimentation coefficients (s°20,w) of 6.5 S and 3.2 S. 
 
Data were also collected at 230 nm and lower concentrations of 0.06 mg.mL-1 M. tuberculosis 
DHDPS, and showed a single species in solution and gave a standardized sedimentation 
coefficient (s°20,w) of 6.7 S (Figure 2.16B). The Z-test value of 2.78, the low r.m.s.d. of 
0.0039 and random distribution of the residuals indicates the quality of the fit (Figure 2.16). 
The absence of a second peak at 3.1 S suggests that the peak observed in the higher 
concentration SV data set does not correspond to a lower order oligomeric species, since that 
would become more apparent at lower concentrations due to concentration dependent 
dissociation. It could be that the smaller peak corresponds to a contaminant that absorbs more 
highly at 280 nm than the 230 nm used for collecting SV data at lower protein concentrations. 
 
Using SEDFIT, the c(s) distribution can be converted into a continuous molecular mass 
[c(M)] distribution; however, the accuracy of the distribution depends on the estimate for the 
frictional ratio (f/f0) extracted from the experimental data.59 The c(M) distribution gave an 
apparent molar mass (Mapp) of 114 and115 kDa for the data sets of 280 and 230 nm, 
respectively. These values are closer to the predicted molar mass for a tetramer (124.6 kDa) 
than a dimer (62.3 kDa), and thus indicates that M. tuberculosis DHDPS is a tetramer in 
solution at 1.1 and 0.06 mg.mL-1. Interestingly, at a concentration of 0.05 mg.mL-1 E. coli 
DHDPS shows a significant portion of dimer,57 which suggests that the dimer-dimer 
interactions for M. tuberculosis DHDPS may be stronger than those found in E. coli DHDPS. 
 
Since sedimentation coefficients are standardized to conditions corresponding to pure water at 
20 °C and extrapolated to zero protein concentration, the s°20,w of 6.7 S obtained from the 
lower concentration experiment has better accuracy. The s°20,w values for different geometries 
of tetramer can be predicted using Equation 2.6, where v  is the partial specific volume, M is 
the predicted molar mass of the tetramer, and F the geometric factor.66 
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Using F values determined using hydrodynamic theory, the s°20,w was calculated as 6.5 S for a 
square-planar tetrameric M. tuberculosis DHDPS (F = 0.926) and 6.9 S for a tetrahedral 
tetramer (F = 0.977).66 The experimentally determined s°20,w of 6.7 S suggests that the 
tetramer of M. tuberculosis DHDPS adopts an intermediate spatial arrangement. 
 
 
Figure 2.16: SV analysis of wild-type M. tuberculosis DHDPS (0.06 mg.mL-1) in 20 mM 
Tris.HCl, 150 mM NaCl at 20 °C. (A) The raw data (○) is overlaid with a 
nonlinear least-squares fit (solid line) to a [c(s)] model.65 (B) The [c(s)] 
distribution is plotted as a function of s* (in units of Svedberg, S). The fit was 
obtained using a resolution of 200 species with v  = 0.7402 mL.g-1, ρ = 
1.005 g.mL-1, η = 1.021 cP and f/f0 = 1.22772 and TI noise was removed. The 
r.m.s.d. and Z-test for the fit were 0.0039 and 2.78, respectively. 
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Wild-type M. tuberculosis DHDPS was further analyzed with sedimentation equilibrium (SE) 
ultracentrifugation, incorporating the results obtained from the SV experiments. In SE, the 
application of a smaller centrifugal force allows the process of diffusion to significantly 
oppose the process of sedimentation and given sufficient time, results in the formation of an 
equilibrium concentration gradient across the length of the cell.62,67 The thermodynamic 
model predicts the concentration distributions to adopt an exponential curve, which for the 
simplest case is governed by molar mass, partial specific volume ( v ), and solvent density 
(ρ).59,67 Since two of these three quantities can be calculated, or determined experimentally by 
other means, SE provides the most accurate determination of molar mass. The best results are 
obtained from global analysis of equilibria formed at multiple rotor speeds, which is 
particularly important for more complicated cases, such as self-associating systems.67 In 
contrast to SV, data analysis requires selecting an association model and thus data analysis is 
an important and time-consuming step in SE study.67 
 
For SE experiments with M. tuberculosis DHDPS, samples at initial protein concentrations of 
0.1, 0.3, and 0.9 mg.mL-1 were centrifuged at 10000 and 16000 rpm and until equilibrium was 
reached (~24 hours). Radial absorbance scans were performed at 280 nm and the data 
acquired at both speeds were fitted with the program SEDPHAT,61 to yield the equivalent 
molar mass (Meq) assuming a single species and using the s°20,w of 6.7 S obtained in SV 
experiments. The lowest concentration (0.1 mg.mL-1) data set provided the best fit with a 
χ2 value of 0.37, Z-test value of 2.91 and low r.m.s.d. of 0.0031, and gave a molar mass of 
116 kDa (Figure 2.17), which is in good agreement with the apparent molar mass of 115 kDa 
obtained with SV experiments, and thus confirms that M. tuberculosis DHDPS adopts a 
tetrameric quaternary structure. 
 
Similar molar mass of 116 and 108 kDa were determined from the 0.3 and 0.9 mg.mL-1 data 
sets, respectively, which suggests that self-association of the tetramer is not detectable in the 
concentration range measured. The fits obtained at the higher concentrations had less 
accuracy (with χ2 value of 1.2 and 2.9), possibly due to equilibrium not being fully reached; 
thus, global fitting of all data sets to a single species model gave a Meq of 109 kDa and global 
reduced χ2 of 1.6. Additionally, global fitting of the data sets to various self-associating 
models in SEDPHAT,61 such as the dimer-tetramer, and monomer-dimer-tetramer model, 
gave dissociation constants well below the concentration range measured, clearly indicating 
Purification and characterization of wild-type enzyme 72 
 
that the equilibrium between the oligomeric structures in the self-association of the tetramer 
was not detectable with this analysis. 
 
 
Figure 2.17: SE analysis of M. tuberculosis DHDPS in 20 mM Tris.HCl, 150 mM NaCl, 
pH 8.0 at 20 °C, with an initial protein concentration of 0.1 mg.mL-1. 
Absorbance at 280 nm, plotted as a function of radial position from the axis of 
rotation (cm), after reaching equilibrium at 10000 rpm (○) and 16000 rpm (●). 
Data are overlaid with the nonlinear least-squares fit (solid line) to a single 
species model, yielding a molar mass of 116 kDa and χ2 value of 0.37. The 
residuals are plotted as a function of radial position from the axis of rotation. 
 
2.5.3 Gel-filtration liquid-chromatography 
In gel-filtration liquid-chromatography, unlike conventional filtration or chromatography 
methods, proteins are never bound or retained but, instead, separation is based on differing 
diffusion rates of molecules into the resin pores.68 Smaller molecules equilibrate into the 
volumes accessible to them inside the resin beads and consequently travel more slowly down 
the column, which is reflected in the alternative name of size-exclusion chromatography.68 
This separation based on size allows for the estimating protein molecular masses and thus 
quaternary structure.69 
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The quaternary structure of M. tuberculosis DHDPS was examined using a pre-packed 
Superdex 200 10/300 column (GE Healthcare) pre-equilibrated with 20 mM Tris.HCl, pH 8.0, 
and where protein was diluted to ~0.01 mg.mL-1 over the course of the chromatography. The 
calibration plot was generated with four points, using the dimeric and monomeric forms of 
both BSA and ovalbumin and plotting Ve against the natural log of their molecular masses 
(Figure 2.18B). Chromatographs were produced by measuring absorbance at 205, 215 and 
280 nm as a function of buffer volume, and gave elution peaks with maxima corresponding to 
Ve (Figure 2.18A). M. tuberculosis DHDPS gave a fairly symmetric elution peak indicating 
one main oligomeric state in solution (Figure 2.18A), which is consistent with the absence of 
lower order oligomeric species observed in AUC experiments. 
0
100
200
300
400
500
600
0 2 4 6 8 10 12 14 16 18 20
Eluted (mL)
Ab
so
rb
an
ce
 (m
AU
)
 
Figure 2.18: (A) Analytical gel-filtration chromatographs of wild-type M. tuberculosis DHDPS. 
The experiment was performed at room temperature in 20 mM Tris.HCl, pH 8.0 
and gave an elution peak with a maximum at 10.71 mL as measured by 
absorbance at 205 nm (light grey). Chromatographs were also recorded at 215 nm 
(dark grey) and 280 nm (black). (B) BSA and ovalbumin calibration standards 
(?) were fitted to a linear equation. 
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The relationship between Ve and molecular mass (M) was determined from a linear regression 
of the four point calibration and is shown in the following equation: 
 
 ⎥
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⎢
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⎡ −
= a
bV
eM
e
 Equation 2.7 
 
Here M is related to Ve by the slope, a, and y-intercept, b, of the calibration plot, for this 
experiment, -1.76 and 31.5 respectively. The molecular mass for M. tuberculosis DHDPS was 
calculated using this equation to be 105 kDa, which is close to the molar mass of 116 kDa 
determined with sedimentation equilibrium experiments. It represents a 13 % underestimate 
of the tetrameric molar mass (124.6 kDa), which is only slightly more than the ±10 % 
uncertainty expected due to assumptions related to the hydrodynamic radius.70 Thus the 
analytical gel-filtration experiment is consistent with the AUC analysis and indicates that 
M. tuberculosis DHDPS adopts a tetrameric quaternary structure in solution. 
 
2.6 The crystal structure of M. tuberculosis DHDPS  
The majority of work to date on DHDPS has investigated E. coli DHDPS, providing an 
excellent basis of comparison for the numerous DHDPS orthologues being determined as part 
of genomic projects. Our collaborators, Weiss and Kefala, as part of the TB Structural 
Genomics Consortium, cloned M. tuberculosis DHDPS, and determined and analyzed its 
three-dimensional structure,1,3 which shows many similarities to E. coli DHDPS. These 
structural coordinates for M. tuberculosis DHDPS, at a resolution of 2.28 Å, have been 
deposited in the PDB databank (entry 1XXX). Material that is largely the work of our 
collaborators is referenced to our jointly published journal article,3 whereas work done in the 
course of this thesis remains unreferenced. Figures illustrating structural details have been 
prepared using the program PyMOL,71 unless otherwise stated. 
 
2.6.1 The overall structure 
M. tuberculosis DHDPS crystallizes with two tetramers in the asymmetric unit, each 
comprised of four identical subunits arranged in D2-symmetry.3 This correlates well with the 
sedimentation coefficient (s°20,w) determined with AUC, which predicts an intermediate 
spatial arrangement between a square-planar and tetrahedral tetramer (section 2.5.2). The 
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monomer is composed of 300 amino acid residues and contains the two domains. The 
N-terminal (β/α)8-barrel domain (residues 1 to 233) and a C-terminal domain (residues 234 to 
300) consisting of α-helices,3 which are fold features that have been observed in all 
structurally characterized DHDPS enzymes (Figure 2.19).58,72-78 
 
 
Figure 2.19: The monomeric subunit of (A) M. tuberculosis DHDPS has a (β/α)8-barrel fold 
(β-sheets in blue, α-helices in green), which surrounds the active site lysine (red), 
with an extra α-helix (yellowy green) and a mainly α-helical region (lighter green); 
(B) the same basic fold is found in E. coli DHDPS (overlaid in grey). 
 
The quaternary structure revealed by X-ray crystallography shows M. tuberculosis DHDPS 
existing as a dimer of dimers, with the packing of the “tight-dimer” subunits resembling the 
bacterial enzyme from E. coli, rather than the plant enzyme from N. sylvestris (Figure 2.20). 
The two monomers a and b (and c and d, Figure 2.20A) are tightly bound to form the tight-
dimer, with weaker interactions between the a/b and c/d tight-dimer units.3 There are no 
contacts between subunits a and c (and b and d) as there is a large central cavity in the 
tetramer, like other DHDPS orthologues. Examination of the M. tuberculosis DHDPS crystal 
structure using JavaProtein Dossier suggested that there are more residues involved in the 
dimer-dimer interface in comparison with the E. coli enzyme (to be discussed in more detail 
in chapter three, section 3.4.1).79 This seems consistent with the lack of dissociation observed 
for M. tuberculosis DHDPS at high dilutions in both sedimentation velocity 
ultracentrifugation (0.06 mg.mL-1) and gel-filtration (0.01 mg.mL-1) experiments (section 
2.5.2 and 2.5.3, respectively), in contrast to E. coli DHDPS where dissociation was detected at 
0.05 mg.mL-1.57 
 
(A) (B) 
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Figure 2.20: The quaternary structure of (A) M. tuberculosis DHDPS resembles the 
dimer of dimers packing of (B) bacterial E. coli DHDPS rather than 
(C)  plant N. sylvestris DHDPS. The dimer of dimers structure involves 
subunits a and b and subunits c and d associating strongly to form dimers 
and consequent dimers interacting more weakly to form the tetramer. 
 
The homotetramer of M. tuberculosis DHDPS adopts near 222 (D2) symmetry analogous to 
that observed in the crystal structures of DHDPS from Bacillus anthracis,77 C. glutamicum,76 
E. coli,73 N. sylvestris,74 T. maritima,72 and Sinorhizobium meliloti.78 A least-squares 
alignment of M. tuberculosis DHDPS monomer a on these DHDPS, and other structures 
deposited in the PDB (release date July 2008), was performed using the program LSQMAN,80 
yielded a total of 31 hits, 20 after removing redundancies, with a Z-score above the threshold 
of 60 (Table 2.8). The pair-wise root-mean-square difference (r.m.s.d.) in α-carbon (Cα) 
positions between functionally confirmed DHDPS is small, 1.25 Å for E. coli DHDPS (shown 
in Figure 2.19B), despite relatively low sequence identity (33 %), confirming that the tertiary 
structure is conserved. 
 
Of the available structures, M. tuberculosis DHDPS had the best structural overlay (r.m.s.d. of 
0.60  Å) and highest sequence identity (57 %) with DHDPS from C. glutamicum (Table 2.8), 
a b 
c d 
(A) 
(C) 
(B) 
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which is not surprising given that C. glutamicum is considered a close evolutionary relative to 
mycobacteria.53 Interestingly, the relationships between DHDPS and other enzymes of its 
superfamily, such as NAL,81,82 KDGA,83 and recently added YagE DHDPS-like protein,84 
were observed. 
 
Table 2.8: Structural similarities of M. tuberculosis DHDPS and other available structures, 
obtained using LSQMAN from the DEJAVU package.80 Excludes structures 
from site-directed mutagenesis studies. 
Source 
PDBa 
code 
Resolution 
(Å) 
Cα's 
used/total 
Sequence 
identity (%) 
R.m.s.d. 
(Å) 
Confirmed 
DHDPS 
C. glutamicum DHDPS 3CPR 2.20 292/301 57 0.60   yes76 
Bacillus anthracis DHDPS 1XKY 1.94 288/292 40 1.16   yes77 
Sinorhizobium meliloti DHDPS 2VC6 1.95 282/291 33 1.21   yes78,85 
M. jannaschii putative DHDPS 2YXG 2.28 281/289 35 1.23   no 
Hahella chejuensis putative DHDPS 2RFG 1.50 277/289 35 1.23   no 
T. maritima DHDPS 1O5K 1.80 283/294 33 1.24   yes72 
Aquifex aeolicus putative DHDPS 2EHH 1.90 282/294 33 1.25   no 
E. coli DHDPS 1DHP 2.30 282/292 33 1.25   yes73 
E. coli DHDPS 1YXC 1.90 281/292 33 1.27   yes55 
S. aureus (MRSA) DHDPS 3DAQ 1.45 281/292 32 1.27   yes58,86 
Clostridium botulinum putative DHDPS 3B18 1.96 280/291 33 1.31   yes87 
S. aureus (MRSA) DHDPS 3DI0 2.38 280/291 32 1.34   yes75 
E. coli YagE DHDPS-like protein 2V9D 2.15 282/295 25 1.40   no 
N. sylvestrisa DHDPS  - 2.79 273/307 28 1.41   yes 
Agrobacterium tumefaciens putative DHDPS 2R8W 1.80 271/292 23 1.52   no 
Bacillus clausii putative DHDPS 3E96 1.80 274/295 25 1.55   no 
E. coli NAL 1FDY 2.45 279/292 26 1.58   no 
Oceanobacillus iheyensis putative DHDPS 3D0C 1.90 273/299 21 1.59   no 
Sulfolobus solfataricus KDGAb 1W31 1.70 268/293 22 1.62   no 
Haemophilus influenzae NAL 1F74 1.60 271/293 23 1.63   no 
Rhodopseudomonas palustris putative DHDPS 3DZ1 1.87 265/291 20 1.66   no 
Thermus thermophilus putative DHDPS 2PCQ 2.10 259/279 28 1.65   no 
 
a Most structural data are freely available from Protein Data Bank (PDB).88 Nicotiana sylvestris DHDPS is not deposited. 
b  Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase (KDGA) is a member of the DHDPS-like/NAL superfamily. 
 
2.6.2 Co-crystallized ligands and metals 
The final refined M. tuberculosis DHDPS model contains eight DTT molecules covalently 
bound to cysteine 248 (C248), 8 Mg2+, and 8 Cl- ions.3 There is continuous electronic density 
for DTT extending from the SG of C248, which is found near the dimer-dimer interface.3 That 
the activity of M. tuberculosis DHDPS with DTT bound was comparable to E. coli DHDPS 
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(section 2.4.4) suggests that this motif is not important for catalysis, though further 
investigation is needed. Unfortunately, DTT is required during the His6-tag cleavage reaction; 
thus, differences in activity observed for M. tuberculosis DHDPS unexposed to DTT during 
purification also reflect the effects of His6-tag cleavage (Appendix B). 
 
The activity of the enzyme was found to be unaffected by magnesium ions (<20 mM), as 
determined by the coupled assay. Both the magnesium and chloride ions seen in the structure 
are likely artefacts of the crystallization conditions and unlikely to have functional 
significance.3 
 
2.6.3 The active site 
M. tuberculosis DHDPS contains all active-site residues identified in E. coli DHDPS, except 
asparagine 248 (Table 2.9, Figure 2.21), which is replaced by glycine at the equivalent 
position, a feature previously noted in other Gram-positive bacterial DHDPS isozymes.21 The 
mechanism of the DHDPS catalyzed reaction has been studied in detail for the E. coli enzyme 
(discussed in chapter one, section 1.3) by NMR,21 X-ray crystallography,55,73 and site-directed 
mutagenesis,27,89 and the postulated roles for active-site residues are summarized in Table 2.9. 
 
Table 2.9 Identified active-site residues for E. coli DHDPS, their equivalent positions in 
M. tuberculosis DHDPS and postulated roles in catalysis from literature. 
Active site residues in DHDPS from:  
E. coli M. tuberculosis Postulated role(s) 
Lysine 161 Lysine 171 Binding pyruvate, binding (S)-ASA aldehyde 
Threonine 45 Threonine 55 Binding pyruvate, binding (S)-ASA hydrate 
Threonine 44 Threonine 54 Binding pyruvate, proton abstraction (catalytic triad) 
Tyrosine 133 Tyrosine 143 Binding pyruvate, proton abstraction (catalytic triad), binding (S)-ASA hydrate 
Tyrosine 107 Tyrosine 117 Proton abstraction (catalytic triad) 
Isoleucine 203 Isoleucine 211 Proton abstraction 
Glycine 186 Glycine 194 Binding (S)-ASA hydrate, conversion to aldehyde, binding (S)-ASA aldehyde 
Asparagine 248 not conserved Binding (S)-ASA hydrate 
Aspartate 187 Aspartate 195 Binding (S)-ASA hydrate/aldehyde 
Arginine 138 Arginine 148 Binding (S)-ASA hydrate/aldehyde, stabilizing catalytic triad 
 
The active site of DHDPS occurs near the tight-dimer interface, in a pocket created by the 
association of monomers into a tight-dimer subunit (Figure 1.10, chapter one, section 1.5.3). 
A key feature of the active site is a catalytic triad involving two tyrosine (Y143, Y117) and a 
threonine (T54), which together form a proton-relay network, thought to supply and remove 
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protons at various steps of the reaction catalyzed by DHDPS.21 Y117 is the only active-site 
residue not contained within the monomer, but rather reaches in from the adjacent monomer 
across the tight-dimer interface. All residues, except Y117, fell within the most favoured or 
additionally allowed regions of the Ramachandran plot for M. tuberculosis DHDPS.3 Similar 
conformational strain has been observed at the equivalent residue in E. coli and other DHDPS 
enzymes,21,55,58,72-78 and is consistent with its postulated catalytic role.90 Both the formation of 
the active-site pocket and completion of the proton relay provided a rationale for the 
association of monomers into the tight-dimer subunit in M. tuberculosis DHDPS (in a similar 
manner to E. coli DHDPS, as discussed in chapter one, section 1.5.3). 
 
    
Figure 2.21: Overlays of the key active-site residues of wild-type M. tuberculosis DHDPS (red). 
(A) Comparison of M. tuberculosis DHDPS without and with pyruvate bound (in 
orange) under the same crystallizing conditions shows slightly altered 
conformation for Y143. (B) Comparison of M. tuberculosis DHDPS with the 
equivalent active-site residues found in E. coli DHDPS (in grey, PDB 1XYC) shows 
several residues adopting slightly altered conformations. 
 
Although the overall architecture of the active site is largely conserved (Figure 2.21B), the 
proton relay network comprising Y143-OH, T54-OH, and Y117-OH, appears to be disrupted.3 
However, soaking experiments with pyruvate and M. tuberculosis DHDPS crystals found a 
shift of Y143 upon pyruvate binding (Figure 2.21A), and resulted in the distance between 
Y143-OH and T54-OH shrinking to 3.0 Å (Table 2.10), thus restoring the proton relay 
network. This shrinking of distances upon pyruvate binding, possibly to facilitate proton 
transfer, was also observed in crystal structures of MRSA DHDPS, suggesting that the 
catalytic triad is triggered into operation upon pyruvate binding.75 This has been postulated to 
(A) (B) 
Y117b 
R148 
I211 
T55 
T54 
Y143 
K171 
G194 
D195 
Y117b 
R148 
I211 
T55 
T54 
Y143 
K171 
G194 
D195 
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provide a structural basis for the order of substrate binding, as described by the ping-pong 
reaction mechanism.75 
 
Table 2.10 Comparison of key atomic distances from structures solved for M.  tuberculosis 
DHDPS and E. coli DHDPS, with and without pyruvate bound (for E. coli PDB 
entries 3DU0 and 1XYC). 
Atomic distances for M. tuberculosis DHDPS Atomic distances for E. coli DHDPS 
  no pyruvate pyruvatea   no pyruvate pyruvate 
Y143-OH K171-Nєb 3.3 Å 3.3 Å Y133-OH K161-Nєb 2.9 Å 3.5 Å 
Y143-OH T54-OH 4.7 Å 3.0 Å Y133-OH T44-OH 2.6 Å 2.8 Å 
T54-OH Y117-OH 2.3 Å 2.6 Å T44-OH Y107-OH 2.6 Å 2.6 Å 
Y117-OH Y116-OH 6.4 Å 6.5 Å Y107-OH Y106-OH 8.5 Å 8.2 Å 
Y116-OH Y90-OH 2.6 Å 2.5 Å Y116-OH N80-OH 3.7 Å 3.7 Å 
 
a Structure of M. tuberculosis DHDPS with pyruvate bound DHDPS has not yet been deposited in the PDB. 
b The є-amino group of the key lysine residue that forms a Schiff base with pyruvate. 
 
Another difference in the catalytic triad is that the phenyl ring of Y117 is twisted relative to 
the equivalent residue in E. coli DHDPS (Figure 2.21B). A similar twist has been observed in 
MRSA DHDPS, and was postulated to stabilize the catalytic triad by providing closer aromatic 
stacking.75 In M. tuberculosis DHDPS, this rotation decreases the distance between Y117 and 
another tyrosine, Y116 (Table 2.10). The re-orientation of Y117 may result from an 
additional tyrosine (Y90), in close proximity to Y116 (Table 2.10), which replaces asparagine 
(N80) in E. coli DHDPS (Figure 2.23). Y90 occurs at the tight-dimer interface of 
M. tuberculosis DHDPS and forms aromatic stacking interactions with its counterpart on the 
opposite subunit. In proteins, aromatic residues forming π interactions commonly adopt either 
T-shaped or parallel-displaced geometry.91,92 Y90 together with Y116 and Y117 from both 
subunits forms a cluster of six aromatic residues. The orientational effects of π stacking have 
been found to be less distinct in clusters as opposed to pairs of aromatic side chains;92 thus the 
additional π orbital interactions of Y90 may be responsible for the altered orientation of both 
Y116 and Y117 with respect to the equivalent residues in other DHDPS crystal structures. 
 
2.6.4 The (S)-lysine binding sites 
M. tuberculosis DHDPS was shown to be insensitive to (S)-lysine at physiologically relevant 
concentrations (section 2.4.5). This fits nicely with the observation that most of the (S)-lysine 
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binding site residues are not conserved in M. tuberculosis DHDPS, when compared to 
sequences of DHDPS enzymes that are known to be inhibited by (S)-lysine (Figure 2.22). In 
addition, structural superposition of M. tuberculosis and E. coli DHDPS (Figure 2.20) clearly 
shows that the (S)-lysine can no longer bind in same orientation in the M. tuberculosis 
enzyme. Thus, the further advantage of tight-dimer subunit in E. coli DHDPS of providing an 
allosteric binding site for (S)-lysine is not applicable in M. tuberculosis DHDPS. 
 
 
Figure 2.22: Multiple sequence alignment of the DHDPS sequences from M. tuberculosis, 
E. coli, and N. sylvestris, using the programs CLUSTALW.93 The amino-acid 
residues in grey boxes are conserved in all 3 sequences. The active-site residues 
are indicated in red boxes (*), while the residues that in E. coli and N. sylvestris 
are involved in the (S)-lysine binding are indicated by blue boxes (†). 
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As noted previously, a tyrosine (M. tuberculosis: Y90) replacing asparagine (E. coli: N80) 
seems to extend the aromatic stack of Y116 and Y117 (Figure 2.20). This is particularly 
interesting as detailed crystallographic study and site-directed mutational analysis have 
suggested that the (S)-lysine binding site in E. coli DHDPS is linked to the active site via this 
aromatic stack (E. coli: Y106 & Y107, M. tuberculosis: Y116 & Y117).27 In E. coli DHDPS, 
Y106 changes conformation when lysine binds, which alters the orientation of Y107, possibly 
disrupting its critical role in shuttling protons to and from the active site. Thus the vestigial 
allosteric cleft of M. tuberculosis DHDPS may still provide a binding site for inducing 
inhibition; although, the site is more shallow than the equivalent site of the E. coli DHDPS 
and therefore precludes (S)-lysine from binding (Figure 2.23), as is consistent with the lack of 
(S)-lysine inhibition observed in biochemical characterization (section 2.4.5). 
 
 
Figure 2.23: Overlays of M. tuberculosis DHDPS (in green), with lysine-bound E. coli DHDPS 
(in grey).55 The residues K66 (E. coli: H56) and Y90 (E. coli: N80) spatially impede 
on the position of (S)-lysine (in yellow). In M. tuberculosis DHDPS, the tyrosine 
residues, Y90, Y116 and Y117, seem to adopt a parallel-displaced geometry 
relative to each other, forming an extended aromatic stack. 
 
2.7 Inhibitory studies with M. tuberculosis DHDPS 
The DAP/(S)-lysine biosynthetic pathway has yet to be exploited clinically as a target for 
antibacterial agents, and several reviews over the past decade have described our increasing 
knowledge of the enzymes of this pathway as antibiotic targets.94-98 As discussed in chapter 
one, section 1.2.1, the DAP biosynthetic pathway has been shown to be essential for 
M. tuberculosis, as has the gene for DHDPS, which catalyzes the pathway's first committed 
Y117 
Y116 
Y90 
K66 
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step,99 validating the enzyme DHDPS as an antibiotic target.97 In conjunction with this study, 
further work has been done by our collaborator Dr Voula Mitsakos to determine the effect of 
product analogues, initially designed to inhibit E. coli DHDPS, on the activity of DHDPS 
from M. tuberculosis,5 using protein purified during the course of this thesis. 
 
Several compounds (1a & 1b, Table 2.11) showed variation in inhibition between E. coli and 
M. tuberculosis DHDPS,5 which highlights the importance of studying orthologues from 
pressing antibacterial targets, such as M. tuberculosis, rather than simply focusing on E. coli 
as a model system. Interestingly, the previous studies with E. coli DHDPS indicated that a 
few of these product analogues (2a, 3a, 3b, Figure 2.24) were interacting somewhere other 
than the active site,100 and it was postulated that they may be interacting at the (S)-lysine 
binding site.4 The identical inhibition effect seen in M. tuberculosis DHDPS (2a, 3a, 3b, 
Table 2.11), may suggest binding in the vestigial allosteric cleft (section 6.6.4). 
 
Table 2.11: Inhibitory action of selected product analogues against M. tuberculosis DHDPS 
from the study published by Mitsakos, et al.5 
Inhibition of enzyme activitya Compound 
E. coli DHDPS M. tuberculosis DHDPS 
1a 49 % 43 % 
1b  92 % 24 % 
2a 76 % 75 % 
2b 5 % 0 % 
3a 74 % 73 % 
3b 85 % 84 % 
 
a  Enzyme activity was determined in duplicate using the quantitative coupled assay, detailed in section 2.2.3, and were 
typically within ±3%. Reported as percentage inhibition in the presence of 20 mM compounds 1-3 in Figure 2.24. 
 
N
H
RO2C CO2R NH
RO2C CO2R
O
NRO2C CO2R
1a R = H
1b R = Me
2a R = H
2b R = Me
3a R = H
3b R = Me  
Figure 2.24: Heterocyclic compounds, analogues of the DHDPS product HTPA.5 
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None of these product analogues show themselves to be more potent inhibitors towards 
M. tuberculosis DHDPS as compared to E. coli DHDPS (Table 2.11),4 and the initial study 
found them to act as weak to moderate inhibitors against E. coli DHDPS.100 This previous 
study with E. coli DHDPS concluded that alternative approaches to design are needed which 
are not based on substrate or product mimicry to generate sufficiently potent inhibitors to be 
considered for clinical use.100 This emphasizes the importance of exploring the emerging 
paradigm for drug development based on protein-protein interaction disruptors, postulated to 
be useful antibiotic targets, such as DHDPS, for which no potent active-site inhibitors have 
yet been found.101 
 
2.8 Summary 
A comprehensive biophysical, biochemical and structural characterization of wild-type 
M. tuberculosis DHDPS was carried out. The active site of M. tuberculosis DHDPS is 
generally similar to that of E. coli DHDPS, with the key residues responsible for substrate 
binding conserved, suggesting that lead compounds targeted to the E. coli active site are likely 
to be equally effective against the M. tuberculosis enzyme. However, collaborative work 
testing compounds designed to target the active site against M. tuberculosis DHDPS did show 
some differences. Unfortunately, none of these putative inhibitors showed themselves to be 
potent inhibitors towards M. tuberculosis DHDPS, highlighting the importance of exploring 
the emerging paradigm for drug development based on protein-protein interaction disruptors. 
 
The functional oligomeric unit of the M. tuberculosis DHDPS was confirmed to be a tetramer, 
like the majority of DHDPS orthologues. This was supported by X-ray crystallography as 
well as several biophysical methods, including analytical ultracentrifugation. The active site 
requiring a residue, Y117, from the adjacent monomer, provides a rationale for the association 
of monomers into tight-dimers. The reasons for the association of the tight-dimer subunits 
into a tetramer are less obvious; and yet dimeric mutants of E. coli DHDPS (L197Y and 
L197D) showed decreased activity and substrate affinity, which indicates quaternary structure 
is essential for complete catalytic activity.102 This characterization of M. tuberculosis DHDPS 
provides a basis for comparison in order to understand the effect of disrupted quaternary 
structure in mutant enzymes, designed to simulate the effect of protein-protein interaction 
disruptors. 
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Chapter Three 
Disrupting quaternary structure with mutagenesis 
3.1 Introduction 
As described in chapter one, the central goal of this thesis was to investigate the role of 
quaternary structure in the catalytic activity of DHDPS from M. tuberculosis, in order to 
determine whether tetramer disruption is a viable drug design strategy against this target. 
DHDPS enzymes typically have strong interactions between pairs of subunits, described as 
tight-dimers, which associate through weaker interactions to form a tetramer;1 therefore, the 
particular focus of this study was the disruption of the weak interface to produce discrete 
“tight-dimer” subunits. 
 
In this chapter, different point mutations were introduced into the weak interface, building on 
previous work with the E. coli enzyme.2 Several positions where amino-acid substitution 
could result in the disruption of the tetrameric structure have been determined based on 
analysis of the dimer-dimer interface of M. tuberculosis DHDPS. It was unclear at the outset 
of this work whether a single mutation would be sufficient to disrupt the weak interface or 
whether multiple mutations would be required. Engineering a “dimer” subunit in this way 
enabled the exploration of the consequence of disrupting quaternary structure on the function 
of M. tuberculosis DHDPS, and thus enabled an assessment of whether interface disruption is 
a viable strategy for inhibition. 
 
3.2 The importance of quaternary structure 
Many enzymes are composed of several subunits in a specific three-dimensional arrangement, 
or quaternary structure,3 possibly for reasons of genetic economy,4 or to increase the size-to-
surface ratio of enzymes and lower cellular osmotic pressure.5 Analysis of observed unfolding 
pathways has lead to the proposal that unfolded and partially folded monomers may act as 
chaperones for their partners, guiding proper and rapid assembly, in vivo.6 Oligomerization is 
suggested to increase protein stability, as a comparison between the stabilization energy (free 
energy of unfolding) per residue for some monomeric and dimeric proteins shows an 
exponential decrease as protein size increases.6 In addition, several thermophilic enzymes 
Disrupting quaternary structure with mutagenesis 93 
 
 
which function under conditions that would denature their mesophilic counterparts have been 
found to adopt higher oligomeric states than mesophiles.7-9 
 
Quaternary structure can play a critical role in enzyme activity.3,10 Consequently, dissociation 
into folded subunits, by variation of physical conditions or site-directed mutagenesis, in many 
cases results in inactivation.3,10 However, there are some cases, such as carbamoyl-phosphate 
synthetase, where the monomeric species is more active than the oligomer.3,11 These changes 
in activity have mostly been related to catalytic-site formation at the subunit interface or to 
conformational changes induced by quaternary structure.3 A small subset of these oligomeric 
enzymes shows inducible dissociation due to physiologically relevant conditions, such as the 
binding of a ligand, indicating that quaternary structure also provides the potential for 
regulatory mechanisms.3,12 
 
More recent work has suggested a link between dynamics, quaternary structure and enzyme 
activity in copper-zinc superoxide dimutase (CuZn-SOD),13,14 and E. coli DHDPS (discussed 
in chapter one, section 1.5.3).2 The loss of activity in the disrupted quaternary structure 
mutants of CuZn-SOD and E. coli DHDPS could not be attributed to changes in the active site 
or tertiary structure; however, increased dynamics were shown by NMR and small angle 
X-ray scattering, respectively.2,13,14 
 
Disrupting wild-type quaternary structure by mutation will be discussed in more detail in the 
subsequent section 3.3. Several examples, such as the normally heterotetrameric E. coli 
succinyl-CoA synthetase (SCS), show that disrupting quaternary structure does not always 
adversely affect activity.15 E. coli SCS has been described as a dimer of dimers, like DHDPS, 
with stable heterodimeric subunits that weakly associate into a tetramer. In contrast to E. coli 
DHDPS, however, a dimeric mutant was found to have comparable activity to the wild-type 
enzyme, indicating the tetrameric structure was not essential for enzymatic function.15 It was 
reasoned that there must be alternative benefits from the association of dimers into tetramers 
in E. coli SCS, such as increased stability and solubility.15 
 
Functionality has also been shown to be independent of quaternary structure with monomeric 
variants of normally homodimeric (or hexameric) insulin,16,17 and homotetrameric fructose-
1,6-bisphosphate,10 which had activity similar to their wild-type oligomers. In contrast, 
monomeric variants of triosephosphate isomerase (TIM) were almost inactive.18-21 The 
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importance of the homodimeric quaternary structure in the enzyme TIM has been further 
demonstrated by synthetic peptides which disrupt quaternary structure, thus inhibiting enzyme 
activity,22 and there is ongoing research into small molecule dimer disruptors as leads for drug 
design.23,24 The observation of inactive, moderately active and fully active monomers, 
produced by site-directed mutagenesis suggests that quaternary structure plays a variety of 
roles in nature, including a contribution to enzymatic function in some cases. 
 
3.3 Engineering disrupted quaternary structure 
Subunits of multi-subunit proteins have been successfully produced as separate entities using 
site-directed mutations, both in the exploration of the role of quaternary structure and for 
industrial and medical purposes. These successes were considered in the design of dimeric 
variants of E. coli DHDPS in the PhD thesis ‘Why is dihydrodipicolinate synthase a 
tetramer?’, authored by Griffin,25 which provided an invaluable reference for this work. There 
are a limited number of literature examples where the role of quaternary structure has been 
explored through directed mutation, many of which are discussed in a recent review by 
Devenish and Gerrard.26 
 
The earliest reported designed disruption of quaternary structure involved the homodimeric 
tyrosyl-tRNA synthetase from Bacillus stearothermophilus by Jones et al.27 The residue 
mutated was among those identified as forming inter-subunit interactions in the native 
structure, as determined by X-ray crystallography. The mutation of a phenylalanine to 
aspartate resulted in an enzyme that displayed pH-dependent dissociation into stable, folded 
monomers due to the electrostatic repulsion between subunits produced by the ionization of 
the carboxyl group.27 
 
However, it is difficult to predict which specific mutations will prevent oligomerization. The 
approach of introducing charge repulsion encountered difficulties during the design of a 
dimeric streptavidin, where a histidine to aspartate mutation was predicted to prevent the 
formation of the natural tetramer.28 The high hydrophobicity of the dimer-dimer interface 
caused the mutant streptavidin to form insoluble aggregates rather than discrete, folded 
dimers. Both successful and unsuccessful attempts to produce characterizable mutants with 
disrupted quaternary structure are considered in the following sections, from which the 
principles for designing the mutations in this study were derived. 
Disrupting quaternary structure with mutagenesis 95 
 
 
3.3.1 Loop modification 
The protein streptavidin has strong interactions between pairs of subunits, described as stable 
dimers; however, it normally exists as a tetramer formed from two such stable dimers 
associating weakly through a small contact area.28 Investigators were keen to create dimeric 
streptavidin for industrial purposes, but initial attempts resulted in insoluble aggregates,28 as 
discussed in the previous section. Computation and simulations of binding free energy 
suggested that multiple hydrophobic residues needed to be replaced with polar or charged 
amino acids to improve solubility, so a more drastic approach was applied of truncating a 
hydrophobic loop containing 8 residues, which, in combination with the charge repulsion 
mutation, successfully created soluble, functional, dimeric streptavidin.28  
 
In the case of the homodimer TIM, researchers used extensive mutagenesis to create a 
monomeric variant, by both removing a loop containing 17 of 20 hydrogen bonds formed 
between the subunits and mutating three hydrophobic residues to increase solubility.18 The 
resulting loop-less variant showed no tendency to form dimers or higher aggregates and 
seemed to adopt a (β/α)8-barrel fold similar to wild-type, as reflected by circular dichroism 
(CD) spectroscopy.18 The loop-less mutant was 1000-fold less active than wild-type.18 In 
contrast, only a 4-fold decrease in activity was observed for monomeric variants of a 
homodimeric plant enzyme, acetohydroxy acid isomeroreductase, produced by the same loop-
deletion approach,29 suggesting that loop deletion is not always related to dramatic loss of 
function. However, the extensive mutation involved in loop modification increases the chance 
of disturbing the active site, as well as disturbing the secondary and tertiary structure of the 
protein. This provides alternative explanations for the loss of activity observed with the loop-
less variant of TIM and undermines the assumption that it is solely disruption of quaternary 
structure that is responsible for the loss of catalytic activity in this enzyme. 
 
3.3.2 Introducing repulsive forces 
Charge repulsion 
Closer examination of the mutation choice in the early study with tyrosyl-tRNA synthetase 
illustrates some important guidelines for rational design.25,28 The phenyl residue targeted for 
mutation in this tRNA synthase lies on the symmetry axis of the subunit-subunit interface; 
therefore, its side chain interacts with the equivalent phenyl group on the other subunit.27 This 
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meant that only a single mutation was needed to create the repulsion that separated the 
subunits, which reflects the principle of seeking minimal mutations to lessen the chance of 
disturbing the basic structure of the subunit.25,28 Another guiding principle for engineering of 
individual subunits from higher-order oligomers is to choose mutations that decrease the 
hydrophobicity of the interface that becomes exposed upon dissociation into subunits.25,28 In 
this early study, the hydrophobic phenyl group was replaced by a hydrophilic aspartate,27 
which presumably increased the solubility of the resultant monomeric variant of tyrosyl-tRNA 
synthetase. 
 
The strategy of introducing charge repulsion in order to alter quaternary structure was applied 
to several other systems with varying measures of success. Disruption of oligomerization in 
the homodimer of CuZn-SOD required a double rather than a single mutation.13 Charge 
repulsion was created by the replacement with glutamate of two hydrophobic residues which 
lay opposite each other on different subunits at the dimerization interface.13 The mutation 
successfully produced a completely monomeric CuZn-SOD variant and solution NMR studies 
linked its lower activity to changes in dynamics as no gross structural changes were 
observed.13,14 Contrastingly, double mutations introducing charge repulsion caused significant 
loss of secondary structure for the homodimeric restriction endonuclease EcoR I, whereas a 
single mutation of leucine to aspartate created a monomer with structure analogous to 
wild-type.30 The strategy of introducing electrostatic repulsion by a single mutation was 
successful in engineering folded monomeric variants from natural dimeric insulin,31 and 
dimeric variants from natural tetrameric E. coli DHDPS.2 
 
Steric repulsion 
Monomeric insulin was one of the early success stories of rational design and protein 
engineering, and has been commercially available since 1996.16,32 The introduced mutations 
did not significantly affect the in vivo potency of the hormone,16,17 and yet the monomeric 
quaternary structure allowed for two to three times faster absorption into the blood stream, 
providing a medicinal advantage.31 While the most successful strategy investigated was 
charge repulsion, the effect of steric hindrance was also examined.31 The introduction of steric 
bulk at important residues within the interface was found to disrupt oligomerization to a lesser 
degree than charge repulsion.31 
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In the construction of monomers from the homodimer malate dehydrogenase (MDH), 
mutations were based on three factors: (1) removing electrostatic interactions, (2) introducing 
bad steric contacts, and (3) choosing residues with no direct linkage to the active site.33 These 
studies were designed to probe the debated interplay between monomers during catalysis, 
even though the active sites of MDH are well separated from each other, and distal to the 
monomer-monomer interface.33 Analysis of MDH from E. coli identified a spatially 
constricted aspartate interacting with a serine on the opposing subunit.33 Due to symmetry, 
mutation of the aspartate to a sterically bulky tyrosine caused steric repulsion at two positions, 
distal to each other, within the interface.33 The resulting folded soluble monomer had 14000-
fold less activity than wild-type, indicating the importance of the subunit-subunit interface in 
MDH,33 and demonstrating steric repulsion as an alternative strategy for preventing 
oligomerization. This approach was also successfully applied to the creation of dimeric E. coli 
DHDPS by mutation of a central interface leucine residue to tyrosine.2 
 
3.3.3 Removal of favourable interactions 
Hydrogen bonds, salt bridges and disulfide bonds 
Rather than focusing mainly on the introduction of repulsion, other studies have been more 
interested in the removal of favourable interactions. Monomeric variants have been created by 
disulfide bond removal through mutation of cysteine residues in several instances.34,35 In early 
attempts at producing a monomeric TIM variant a histidine was replaced with an asparagine, 
and thus the mutation was proposed to disrupt a water-mediated interaction between histidine 
and an asparagine on the other subunit.20 Unfortunately, the resulting mixture of dimers and 
monomers existed in a concentration-dependent equilibrium was not useful for quantitative 
measurement of the effect of monomerization.20,21 
 
The removal of salt bridges in combination with introduced charge repulsion was used to 
create a monomeric variant for a homodimeric enzyme response regulator, PhoP, from 
Bacillus subtilis.36 Similarly, in rat prostatic acid phosphatase, the disruption of the 
homodimer was attributed to the removal of hydrogen bonds and aromatic stacking 
interactions by two point mutations to charged residues.37 Mutations were used to invert the 
polarity of a salt bridge in the homodimer dihydrooratate dehydrogenase from Lactococcus 
lactis, and this resulted in a concentration-dependent monomer-dimer equilibrium.38 
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In all of these examples, the main rationale for the mutation was the importance of the 
individual residue in inter-subunit interactions. This focus on a single inter-subunit contact is 
also demonstrated in the exploration of quaternary structure in an extracellular endonuclease 
from Serratia marcescens, where a central interfacial histidine residue, with many inter-
subunit hydrogen-bond interactions, was mutated to several different amino acids in order to 
create a monomeric variant.39 
 
Conserved residues and structural homologues 
It is difficult to predict the importance of particular interactions based on structural data. The 
failure of the mutation of a residue central within the interface of TIM to produce an entirely 
monomeric variant led to the more drastic approach of loop modification, discussed in 
section 3.3.1. However, the extensive mutation used to create the monomeric TIM variant 
undermined the assertion that its lack of activity could be directly attributed to the disruption 
of quaternary structure.21 This spurred the design of yet another monomeric TIM variant. In 
contrast to previous attempts, sequence and structural alignments with 45 different TIM 
enzymes were used to inform design.21 The analysis revealed several residues on the outer 
edge of the interface to be highly conserved, and mutating just two of these residues resulted 
in a monomer with 1000-fold less activity than wild-type, thus providing confirmation of the 
importance of quaternary structure in the enzymatic function of TIM.21 
 
More recently, sequence alignments informed the disruption of oligomerization in a heat 
shock protein from M. tuberculosis.40 The caveat with this approach is that conserved amino 
acids at the interface could play an undetermined role in the catalytic mechanism or a specific 
role in maintenance of the active-site architecture, thus casting doubt as to whether loss of 
activity can be directly related to quaternary structure. 
 
Another approach to designing altered oligomeric states is comparison with structural 
homologues of different quaternary structure. Homotetrameric lactate dehydrogenase (LDH) 
is similar to its dimeric MDH counterparts, as superposition of the structures has shown.41 A 
soluble dimeric form of LDH from Bacillus stearothermophilus was created by replacing a 
surface loop with the larger loop found in dimeric MDH.41 
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Less successful was the incorporation of nine residues from a mammalian heterodimeric SCS 
into the normally heterotetrameric E. coli SCS, which resulted in insoluble aggregates.15 
However, a soluble dimeric variant of the E. coli enzyme with equivalent activity to the 
wild-type tetramer was created by mutation of four of the non-conserved residues between 
bacterial and animal SCS enzymes.15 This suggests that the dimeric subunits act 
independently in the catalytic mechanism of tetrameric SCS from E. coli.15 
 
In the case of the tetrameric biotin-binding proteins, avidin and streptavidin, dimers were 
designed based on an unrelated but structurally similar family of proteins, fibropellins, 
specifically those which are found in the extracellular matrix of sea urchin embryos.42,43 
These fibropellins contain several domains including an avidin-like C-terminal domain.42,43 A 
stable dimer was obtained for both avidin and streptavidin through mutation of a tryptophan 
residue to the lysine found at the equivalent position in the fibropellin C-terminal domain, 
providing a rationale for a seemingly unorthodox substitution.44,45 
 
Alanine scanning 
Important residues for protein-protein interactions are frequently explored through alanine 
scanning mutagenesis, a technique which consists of the systematic replacement of non-
glycine residues with alanine.46 The mutations can be viewed as side chain deletions and are 
usually interpreted as indicating whether or not a particular side chain contributes to 
association.46 This method has shown that relatively few residues, referred to as “hot spots”, 
are crucial for association,47,48 as discussed in section 1.4.2. Obligate oligomers, such as 
DHDPS, tend to have a larger number of interfacial interactions than more transient 
complexes that need to associate and disassociate in vivo. To compensate for the increased 
number of residues involved in the interface, studies of quaternary structure in obligate 
oligomers have used double alanine mutations of residue clusters,49 alanine mutations guided 
by molecular modelling,50 and alanine mutations informed by structural overlay with related 
species.51 
 
3.3.4 Summary of the principles for design 
The previous sections have described diverse approaches for rational design of discrete 
subunits from multi-subunit proteins. Many of these approaches overlap and have often been 
used in tandem with each other. Although most cases described thus far involved mutation 
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and disruption of one interface, in the literature there also have been several examples of 
disrupting multiple interfaces; that is creating monomers from tetramers,10,44 or hexamers.31,52 
These often involve different strategies for mutation(s) on the different interfaces. 
 
The types of mutations can be broadly grouped into four approaches: removal of interactions, 
steric repulsion, electrostatic repulsion and loop modification. These are listed in rough order 
of increasing likelihood to disrupt interface interactions, based on the literature examples 
reviewed. However, the order also seems to reflect an increased risk of unintentionally 
disrupting tertiary and secondary structure. Obviously it becomes more difficult to attribute 
the changes in activity directly to the disruption of quaternary structure given the extensive 
mutagenesis involved in loop modification, and this is a major disadvantage when using this 
approach for investigations regarding the role of quaternary structure. Consequently, only 
strategies based on point mutations were considered for this work. 
 
3.4 Designing mutations for M. tuberculosis DHDPS 
In designing mutations to disrupt the weak interface of the homotetrameric protein, 
M. tuberculosis DHDPS, this study focused on determining positions where maximum 
repulsive forces can be introduced, rather than the removal of important interactions. The 
residues selected for mutation also needed to be remote to the active site, to play no obvious 
role in the secondary structure and to form inter-subunit interactions through the side chains, 
as interactions occurring via the main chain cannot be simply disrupted by mutation. 
 
3.4.1 Protein-protein interface analysis 
In order to design point mutations that might disrupt the association of the dimeric subunits of 
M. tuberculosis DHDPS, the residues involved in the weak interface needed to be determined. 
Visual examination of wild-type M. tuberculosis DHDPS structural data (PDB entry 1XXX) 
using PYMOL,53 identified fourteen residues with orientation and proximity (≤4.0 Å) to 
suggest interaction across the dimer-dimer interface. A total of 32 inter-subunit contacts were 
determined, as shown in Figure 3.1, involving nine hydrophobic and five hydrophilic 
residues. 
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ILE ILE ASN ALA ASN  PRO ARG ALA LEU LEU MET HIS GLN ALA 
234 242 249 197 241  201 238 204 203 177 205 178 182 181 
                 
ILE ALA GLN HIS MET LEU LEU ALA ARG PRO  ASN ALA ASN ILE 
234 181 182 178 205 177 203 204 238 201  241 197 249 242 
 
Figure 3.1: Evaluation of the dimer-dimer interactions of M. tuberculosis DHDPS. Hydrogen 
bonds and charge-charge interactions are indicated by dashed lines with water 
molecules being represented by dark circles. Hydrophobic and van der Waals 
contacts are indicated by solid black lines. Contacts were identified by visual 
inspection, using the program PYMOL,53 in all sets of weak interfaces in the 
asymmetric unit. 
 
The X-ray structure of wild-type M. tuberculosis DHDPS contained two tetramers within its 
asymmetric unit, which provided several sets of weak interface interactions with slight 
differences, and three additional interactions were identified. Another water near histidine 178 
at the dimer-dimer interface allowed for additional water-mediated hydrogen bonds with the 
backbone carbonyl of aspartate 196 and the backbone NH of asparagine 199. Since this 
interaction occurs through the main chain and is water-mediated, these residues were not 
considered as targets for mutation. Of the previously identified interface residues, only 
leucine 177 (L177) adopted different rotamers and, as a consequence, makes weak 
hydrophobic contact (3.9 Å) with its counterpart on the opposite subunit in only one of the 
weak interfaces in the asymmetric unit. 
 
The interface was also examined using stricter criteria with the web-based program 
JavaProtein Dossier (JDP),54 which determines inter-subunit contacts in the crystal structure 
based on maximum distance of 3.2 Å for hydrogen bonds, 6.0 Å for charged (including 
aromatic) interactions and 3.8 Å for hydrophobic contacts. Several of the interactions first 
identified were below this threshold, but all previously identified interface residues were 
predicted to form inter-subunit contacts using JPD (Figure 3.2, more details in Appendix E). 
In addition, five new interface residues were determined: leucine 198, glycine 206, 
phenylalanine 229, alanine 245 and cysteine 248. 
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ILE ILE ASN ALA CYS ALA ASN PRO ARG ALA LEU GLY PHE MET  HIS GLN ALA LEU 
234 242 249 245 248 197 241 201 238 204 203 206 229 205 178 182 181 177 
                  
ILE ALA GLN HIS MET PHE GLY LEU ALA ARG PRO ASN ALA CYS ASN ALA ILE LEU 
234 181 182 178 205 229 206 203 204 238 201 241 197 248 249 245 242 198 
 
Figure 3.2: Evaluation of the “weak” dimer-dimer interaction of M. tuberculosis DHDPS, 
between chain a and d, using the program JPD.54 Hydrogen bonds and charge-
charge interactions are indicated by dashed lines with water molecules being 
represented by dark circles. Hydrophobic and van der Waals contacts are 
indicated by solid black lines. 
 
Interestingly, asymmetry was apparent in the subunit-subunit interactions (Figure 3.2). For 
example, the newly determined inter-subunit interaction between L177 and L198 occurred 
from chain a and d, but not vice versa, presumably due to the different rotamers adopted by 
L177. Interactions between L177 and its counterpart on the opposite subunit, and with proline 
201 were not observed with JPD, due to the shortest atomic distance between the residues 
falling outside the ≤3.8 Å range. 
 
The dimer-dimer interface was further analysed using the web-based bioinformatics tool, 
PISA.55 In this analysis the interface was defined as the protein surface area that becomes 
inaccessible to solvent when two subunits come into contact,55 in contrast to previous 
analyses, which defined the interface as the set of atoms found within the appropriate bonding 
distance from the other subunit. These two methods for defining the inter-subunit interfaces 
are widely used in the analysis of macromolecular complexes and have been found to produce 
roughly equivalent results.56 
 
The surface buried by the dimer-dimer interface was 869 (±7) Å2 in M. tuberculosis DHDPS 
(Figure 3.3B), significantly more than the 496 (±2) Å2 buried by the equivalent interface in 
E. coli DHDPS (Figure 3.3A), as determined with PISA.55 This interface was defined by 24 
(±1) residues, more than had been identified by JPD, and involved six non-water-mediated 
hydrogen bonds of ≤3.2 Å (details in Appendix E), which is consistent with the previous 
analysis using JPD (Figure 3.2). However, only twenty of the interface residues were buried 
more than 45 % by association of subunits (red and orange in Figure 3.3B), which included 
Disrupting quaternary structure with mutagenesis 103 
 
 
eighteen of the interface residues determined by JPD. It was these residues that were 
considered as candidates for mutation. Similarly, the dimer-dimer interface in E  coli DHDPS 
has been previously defined using inter-subunit contacts as nine residues,57 and only nine of 
the 15 (±2) interface residues as defined by PISA are buried more than 45 % (red and orange 
in Figure 3.3A). 
 
 
Figure 3.3: Surface view of the dimer-dimer interface from (A) E. coli DHDPS and 
(B)  M. tuberculosis DHDPS. The residues contributing to the interface are shown 
in various shades depending on their buried surface area (5 - 44 % yellow, 45 - 
84 % orange, ≥85 % red), as defined by PISA.55 
 
The greater buried surface area and number of residues involved in the dimer-dimer interface 
in M. tuberculosis DHDPS compared to E. coli DHDPS (Figure 3.3) suggests that disrupting 
the weak interface will be more challenging for M. tuberculosis DHDPS. It seemed unlikely 
that a single mutation would disrupt the tetrameric structure of M. tuberculosis DHDPS, in 
contrast to the case with E. coli DHDPS. However, it was decided that the first stage of 
investigation would involve single-point mutations. 
 
3.4.2 Considerations and design of mutations 
Conserved residues 
Amino-acid sequence alignments for M. tuberculosis DHDPS were performed with DHDPS 
from E. coli and MRSA. Comparison of the residues involved in the association of dimers into 
the homotetrameric E. coli DHDPS, and the absence of those residues in the naturally dimeric 
MRSA DHDPS, could inform design. Six interface residues of M. tuberculosis DHDPS were 
conserved in the E. coli enzyme; although, only leucine (M. tuberculosis: L177, E. coli: L167) 
(A) (B) 
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and arginine (M. tuberculosis: R238, E. coli: R230) were involved in forming dimer-dimer 
contacts in both DHDPS enzymes (Figure 3.4). 
 
 
Figure 3.4: Multiple sequence alignment of the DHDPS sequences from M. tuberculosis, 
E. coli, and MRSA, using the program CLUSTALW,58 with numbering 
corresponding to M. tuberculosis DHDPS. The amino-acid residues conserved 
shown in bold for E. coli and M. tuberculosis DHDPS, and in grey boxes for all 
three sequences. The dimer-dimer interface residues with identified 
inter-subunit contacts are marked with * for M. tuberculosis DHDPS and † for 
E. coli DHDPS, while the active-site residues are indicated with red boxes. 
 
The details of the inter-subunit interactions of these two conserved residues were considered. 
In M. tuberculosis DHDPS, R238 forms inter-subunit contacts with several residues (see 
Figure 3.2), including a hydrophobic interaction with a glycine, which is conserved in E. coli 
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DHDPS (M. tuberculosis: G206, E. coli: G198); however, the orientation and proximity 
(>8 Å) precludes the equivalent interaction in E. coli DHDPS, and instead R230 forms an 
interaction with an asparagine that is not conserved in the M. tuberculosis enzyme (E. coli: 
N171, M. tuberculosis: A181). In both enzymes, the conserved leucine (M. tuberculosis: 
L177, E. coli: L167) had been found in crystal structures to make hydrophobic contact with its 
counterpart on the opposing subunit; however, as mentioned in the previous section, L177 
adopts several different rotamers in M. tuberculosis DHDPS, disrupting this interaction, 
whereas, L167 adopts the same rotamer in several crystal structures of E. coli DHDPS. 
 
It appears that a distinct set of interactions are involved in the weak interface of DHDPS from 
E. coli and M. tuberculosis. The different interactions, even between residues that align based 
on sequence, highlights the subtle difference in the way the dimers associate in these 
orthologues. This supports the idea that the association of dimers into a homotetrameric 
quaternary structure in DHDPS provides a general, rather than a specific, advantage for 
DHDPS enzymes.2 
 
Secondary structure 
Only one M. tuberculosis DHDPS interface residue, G206, was conserved in MRSA DHDPS, 
the naturally dimeric DHDPS (Figure 3.4). This residue was also conserved in tetrameric 
E. coli DHDPS, although it does not participate in the dimer-dimer interface of this enzyme. 
This seems to suggest that it may have an additional role, possibly structural, hence it was not 
considered as a candidate for mutation. 
 
Proline 201 (P201) was also discounted as target for mutation, as proline residues restrict 
certain peptide torsion angles, and typically play a specific structural role, such as producing 
slight distortions in the α-helix, as was observed in the crystal structure of M. tuberculosis 
DHDPS. However, it was noted that this residue is not conserved in DHDPS from E. coli and 
MRSA, indicating this proline is not a general structural feature in DHDPS enzymes. 
 
Hydrophobicity 
The number of hydrophobic residues in the weak interface of M. tuberculosis DHDPS is 
greater than for E. coli DHDPS, with eleven hydrophobic interface residues identified using 
JPD, as opposed to three in E. coli DHDPS (Dr Sean Devenish, pers. comm.). Insolubility and 
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aggregation problems seemed likely upon disruption of M. tuberculosis DHDPS given the 
more extensive hydrophobic surface to be exposed. Therefore, the targets for mutation were 
narrowed to the eleven hydrophobic residues with identified dimer-dimer interactions, by 
applying the strategy of hydrophobic to hydrophilic mutations in order to maximize solubility 
of the dimeric variant. This strategy has been used successfully in other studies (section 
3.3.2), including the development of a dimeric variant of E. coli DHDPS. 
 
The analysis with JPD provided further criteria to narrow the candidates for mutation, as 
alanine 197 only formed water-mediated hydrogen bonds through its main-chain oxygen. The 
remaining hydrophobic interface residues and their hydrophobic inter-subunit contacts are 
listed in Table 3.1.  
 
Table 3.1: Hydrophobic contacts between chains a and d identified by JPD,54 for the 
hydrophobic interface residues considered as candidates for mutation. 
Residue (from chain a) Distancea(Å) Residue (from chain d) 
Leucine 177 3.7 Leucine 198 
Alanine 181 3.8 Isoleucine 242 
Leucine 198 3.7 Leucine 177 
Proline 201 3.7 Methionine 205 
Alanine 204 3.4 Alanine 204 
Alanine 204 3.7 Arginine 238 
Methionine 205 3.7 Proline 201 
Methionine 205 3.4 Arginine 238 
Glycine 206 3.7 Arginine 238 
Isoleucine 234 3.5 Isoleucine 234 
Isoleucine 242 3.8 Alanine 181 
Alanine 245 3.6 Histidine 178 
Alanine 245 3.8 Glutamine 182 
 
a  The smallest atomic distance observed between the residues observed in the crystal structure. 
 
Due to concerns with regard to disrupting secondary structure previously discussed, P201 and 
G206 were not considered as candidates for mutation. Neither L177, nor its hydrophobic 
contact L198, were considered as a targets for mutation, as a consequence of the apparent 
flexibility of L177 reflected in the multiple conformers observed in the crystal structure. This 
narrowed the candidates for mutation to six residues: alanine 181 (A181), alanine 204 (A204), 
methionine (M205), isoleucine 234 (I234), isoleucine 242 (I242), and alanine 245 (A245). 
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Of these candidates for mutation, I234 and A204 had the advantage of forming a hydrophobic 
interaction with their counterpart on the opposite subunit (Table 3.1). Introduction of 
symmetrically related single mutation will effectively introduce repulsive forces from both 
faces of the interaction; hence, a single mutation of a hydrophobic residue is doubly powerful 
for preventing dimer association. 
 
A204, being a relatively small amino acid and more central within the interface than I234, 
(Figure 3.5) was likely to have tighter steric packing, and therefore could provide more scope 
for applying the strategy of introducing steric contacts to prevent oligomerization (outlined in 
section 3.3.2). This strategy was successfully applied in the development of a dimeric variant 
of E. coli DHDPS.2 Interestingly, the leucine residue (E. coli: L197, M. tuberculosis: M205), 
which was mutated to produce dimeric variants of E. coli DHDPS, occupied a spatially 
similar position as A204 within the dimer-dimer interface (details in Appendix F). Three 
different mutations were designed for A204, introducing steric repulsion (tyrosine), 
electrostatic repulsion (aspartate), and both steric and electrostatic repulsion (arginine) at 
position 204. 
 
 
Figure 3.5: (A) Alanine 204 (in orange) in the weak interface of M. tuberculosis DHDPS 
showing the proximity (3.5 Å) and orientation of this residue between chains a 
(green) and d (light green), and distal to the active site (in red). (B) Removing the 
upper dimeric subunit and looking down onto the weak interface (bright green), 
chains c and d, shows the position of A204 and I234 in the weak interface. 
(A) (B) 
ILE 234 
ILE 234 
ALA 204 
ALA 204 
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3.5 Site-directed mutagenesis 
Site-directed mutagenesis was used to obtain proteins with the specific amino-acid 
substitutions outlined in the previous section. Mutagenesis was achieved by polymerase chain 
reaction (PCR) with a double-stranded, circular DNA template, using a commercially 
available QuikChange® site-directed mutagenesis kit (Stratagene). 
 
3.5.1 Mutagenic primer design 
The sequences of the mutagenic primers were designed to introduce mutations to replace 
alanine at position 204 with tyrosine, aspartate or arginine. These primers were based on the 
nucleotide sequence of the dapA insert carried on the pETM-11 based plasmid designated 
pMTB02, which was the template for the mutagenic PCR reactions. The sequences of all 
primers used for mutagenesis are shown in Table 3.2.  
 
Table 3.2: Primer sequences designed for site-directed mutagenesis of dapA from 
M. tuberculosis in pMTB02. The codon of the altered amino acid is underlined 
and the mismatched bases are shown in blue. 
Primer name Primer sequence 
A204Y Forward 5’-CTG CCC TGG CTG TAC ATG GGC GCC AC G-3’ 
A204Y Reverse 5’-GT GGC GCC CAT GTA CAG CCA GGG CAG-3’ 
A204R Forward 5’-C CTG CCC TGG CTG CGC ATG GGC GCC ACG-3’ 
A204R Reverse 5’-CGT GGC GCC CAT GCG CAG CCA GGG CAG G-3’ 
A204D Forward 5’-CTG CCC TGG CTG GAC ATG GGC GCC AC-3’ 
A204D Reverse 5’-GT GGC GCC CAT GTC CAG CCA GGG CAG-3’ 
 
3.5.2 PCR mutagenesis of plasmid pMTB02 
A high purity preparation of pMTB02, isolated from E. coli DH5α, was used for the PCR 
mutagenesis. The primer concentration was kept in large excess of the template, and a control 
reaction was performed using supplied primers and the control plasmid, pWhitescript, to 
monitor mutation efficiency.59 Subsequent to Dpn I digestion to remove parental DNA, the 
presence of mutated plasmid was confirmed using agarose gel electrophoresis. Plasmids were 
labelled according to the potential mutation carried, e.g. the plasmid from the PCR reaction 
containing A204D forward and reverse primers was designated pMTBA204D. 
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3.5.3 Transformation of XL1-Blue with mutated DNA 
E. coli XL1-Blue supercompetent cells were transformed with the newly synthesized DNA 
from the mutagenic PCR reactions, using the heat-shock method (chapter six, section 6.2.12). 
Transformed cells were selected and cultured on LB agar plates containing kanamycin. From 
these plates, four potential transformant colonies for each mutation were sub-cultured and 
stored as glycerol stocks at -80 °C. The mutation efficiency of the PCR conditions was 
assessed using the control plasmid, pWhitescript,59 which gave 74 % blue colonies. Thus the 
proportion of mutated plasmids was similar to the 80 % efficiency expected. 
 
3.5.4 Sequencing of mutated dapA genes 
The presence of the mutation and the integrity of the full-length dapA insert after mutagenesis 
were determined using bi-directional sequencing performed by Canterbury Sequencing at the 
University of Canterbury. The procedure was based on the dideoxynucleic acid chain 
termination method,60 with DNA samples prepared to a high purity by standard methods. Both 
strands for each mutation of all four potential transformants were examined and the best 
sequence reads gave 700 to 900 bp. This allowed a full length consensus sequence to be 
determined for each mutation, which confirmed the desired mutations (Figure 3.6) and the 
absence of undesired mutations in the rest of the dapA insert. 
 
 
 
 
 
 
Figure 3.6: Chromatograms and sequence assignments near the mutation site, with the 
mutated amino-acid codon underlined. The data shown are the reverse 
complement of the reverse read, which consistently showed a better signal-to-
noise ratio near the mutation site. 
A204D 
A204R 
A204Y 
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3.6 Analysis of quaternary structure 
Small-scale protein preparations were attempted contemporaneously for all three amino-acid 
substitutions and their quaternary structures were investigated using blue native (BN)-PAGE. 
 
3.6.1 Transformation of BL21 (DE3) pGroESL with mutated DNA 
The plasmid DNA that had provided the best read for sequencing was further used to 
transform E. coli BL21 (DE3) pGroESL cells by electroporation. This E. coli strain 
co-expresses the heat chaperonin proteins, GroES and GroEL,61,62 which had been found to 
improve the yield of soluble, biologically active wild-type M. tuberculosis DHDPS (chapter 
two, section 2.3.2). Transformed cells containing both pGroESL and mutated DNA were 
selected using LB agar plates containing chloramphenicol and kanamycin, and glycerol stocks 
were made for storage at -80 °C. 
 
3.6.2 Small-scale protein purifications 
Analogous to the optimized procedure for wild-type M. tuberculosis DHDPS, cells were 
grown overnight at room temperature and then harvested by centrifugation and re-suspended 
in extraction buffer, prior to cell lysis by ultrasonication, followed with clarification by 
centrifugation. Three small-scale purifications were performed with cultures over-expressing 
the interface mutants DHDPS-A204Y, DHDPS-A204R and DHDPS-A204D. 
 
The proteins were purified using affinity and gel-filtration chromatography and the effect of 
each purification step on the total activity of the fraction was monitored (Table 3.3). Since the 
interface mutations were likely to decrease enzyme stability, purifications were performed as 
rapidly as possible, minimizing storage between steps. 
 
The activity of DHDPS-A204Y increased after His6-tag removal, as observed for the 
wild-type enzyme (Table 2.2, chapter two, section 2.3.3). The final purified mutant DHDPS 
enzymes had different specific activities, but all showed an increase from the initial value 
determined, reflecting an increase in protein purity (Table 3.3). DHDPS-A204D showed the 
greatest loss of activity over the course of purification. The decrease in total activity and low 
protein yield observed for DHDPS-A204R and DHDPS-A204D could be related to enzyme 
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degradation or instability over time; DHDPS-A204Y was significantly more stable than the 
other mutants. 
 
Table 3.3: Small-scale purifications of M. tuberculosis DHDPS variants. 
Fraction Volume (mL) 
Proteina 
(mg) 
Total activitya 
(unitsb) 
Specific activity 
(unitsb/mg) 
Relative total 
activity 
DHDPS-A204Y (1 L, 3.93 g of cells)      
Centrifuged (supernatant) 37.5 101 1.2 0.012  
Affinity (His6-tagged) 16.0  - 1.0  - 82%
Dialysed (out of high imidazole) 15.0  1.9  - 156%
Affinity (Non-His6-tagged) 16.0  - 2.0  - 169%
Concentratedc 0.5 - - - 
Gel filtrationc 4.0 2.1 3.0 1.4 252%
DHDPS-A204R (1 L, 3.73 g of cells)      
Centrifuged (supernatant) 37.5 109 1.3 0.012  
Affinity (His6-tagged) 9.0  - 1.1  - 81%
Dialysed (out of high imidazole) 10.0  - 0.35  - 27%
Affinity (Non-His6-tagged) 12.0  - 0.51  - 39%
Concentratedc 0.5 - - - 
Gel filtrationc 2.5 0.4 0.28 0.72 21%
DHDPS-A204D (per 1 L, 3.67 g of cells) d      
Centrifuged (supernatant) 22.5 34 0.9 0.027  
Affinity (His6-tagged) 3.0  - 0.8  - 88%
Dialysed (out of high imidazole) 4.0  - 0.26  - 28%
Affinity (Non-His6-tagged) 7.0  - 0.075  - 8%
Concentratedc 0.5 - - - 
Gel filtrationc 1.0 0.25 0.009 0.038 1%
 
a  Protein concentration and enzyme activity were determined using the Bradford and coupled assay, respectively. 
b  1 unit is defined as the consumption of 1 μmol of NADPH per second. 
c  Protein was concentrated prior to gel filtration using an ultrafiltration spin column, described in section 6.4.7. 
d  2 L preparation; values halved for ease of comparison to other mutations. 
 
3.6.3 Blue native (BN)-PAGE 
BN-PAGE separates proteins on a non-denaturing polyacrylamide gel and has been optimized 
for the analysis of oligomeric structure by the inclusion in the cathode buffer of the anionic 
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dye, Coomassie blue G-250.63 Using this electrophoretic technique, the mutated enzymes 
were compared directly with tetrameric wild-type M. tuberculosis DHDPS (Figure 3.7). 
 
   
Figure 3.7: BN-PAGE of purified DHDPS-A204Y, DHDPS-A204R and DHDPS-A204D (lanes 
2, 3 and 4, respectively), compared with tetrameric wild-type enzyme (lane 1).  
 
DHDPS-A204Y migrated similarly to wild-type M. tuberculosis DHDPS, indicating the 
mutation of alanine to tyrosine to introduce steric bulk was not enough to disrupt the 
quaternary structure of the enzyme. The slight difference in migration between the wild-type 
enzyme and DHDPS-A204Y may reflect the latter absorbing less dye than wild-type DHDPS. 
The non-disrupted quaternary structure of DHDPS-A204Y explains the previously observed 
activity, yield and stability measurements (in section 3.6.2). This is in contrast to E. coli 
DHDPS, where the L197Y mutation resulted in a completely dimeric species,2 and suggests 
some flexibility for rearrangement within the weak interface of DHDPS from M. tuberculosis. 
Consequently, no further analysis was performed with the interface mutant DHDPS-A204Y. 
 
In contrast, the tetrameric structure of M. tuberculosis DHDPS was successfully disrupted in 
both DHDPS-A204R and DHDPS-A204D. In both cases, the bands were less distinct for the 
interface mutants, possibly reflecting protein degradation. DHDPS-A204R was a single 
species, presumed to be dimeric, while the two bands apparent for DHDPS-A204D suggested 
an equilibrium mixture of dimer and tetramer. Thus, the introduction of charge at position 204 
caused enough repulsion to disrupt the weak interface, with the arginine (resulting in DHDPS-
A204R) the more successful of the two substitutions. The reason for the low activity of 
DHDPS-A204D in comparison to DHDPS-A204R remains unclear. 
 
 1   2   3   4 
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3.7 Preliminary analysis of DHDPS-A204R 
Before in-depth characterization of DHDPS-A204R was attempted, the integrity of the 
mutation and the mutant enzyme's secondary structure were investigated using liquid-
chromatography mass spectrometry (LCMS) and circular dichroism (CD) spectroscopy, 
respectively. 
 
3.7.1 Liquid-chromatography mass spectrometry (LCMS) 
Mass spectrometry provided a method for confirming the replacement of alanine by arginine 
in DHDPS-A204R. A freshly prepared sample of M. tuberculosis DHDPS-A204R was 
analyzed using a high-pressure liquid-chromatography (HPLC) system coupled to a mass 
spectrometer equipped with an electrospray ionization (ESI) probe. Data were collected and 
processed, using MassLynx 4.0 software, in collaboration with Dr Marie Squire. The 
molecular mass determined from mass spectrometry was 34248 Da (Figure 3.8), which 
matched that predicted based on sequence (34247.8 Da), thus further confirming the 
successful mutation of alanine to arginine. 
 
 
Figure 3.8: LCMS of DHDPS-A204R revealing one main peak which matches the molecular 
mass predicted from the amino-acid sequence. 
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3.7.2 Circular dichroism (CD) spectroscopy 
Given the apparent instability of DHDPS-A204R, circular dichroism (CD) spectroscopy was 
employed to confirm that the protein was correctly folded in solution. CD is an important 
technique for secondary structure determination,64,65 and monitors the different absorptions of 
left and right circularly polarized light.66 Proteins absorb in the far ultraviolet region (180-240 
nm) because of their peptide bonds, and thus CD spectra from this region reflect the 
secondary structure composition of the protein.67 Each element of the secondary structure 
gives a characteristic pattern, the most clearly defined being an α-helix with an intense 
positive peak near 190 nm, and negative peaks at 208 and 222 nm.64,66 Thus the characteristic 
double minima of 208 and 222 nm observed in the CD spectra of wild-type and mutant 
A204R M. tuberculosis DHDPS reflects the α-helical components of the structure 
(Figure 3.9). 
 
 
Figure 3.9: The CD spectra of interface mutant DHDPS-A204R (?) was compared to 
wild-type M. tuberculosis DHDPS (?) from 200 to 240 nm. Data were collected at 
0.5 nm intervals at 20 °C, for 150 μg.mL-1 protein samples in 20 mM Tris.HCl, 
pH 8.0. The smoothed data (open symbols) in 1 nm intervals is presented, overlaid 
with the best fit (solid line), generated by CONTINLL algorithm,68,69 with the 
reference set SP29.70 
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The broad minimum between 208 and 222 nm observed for both wild-type and A204R 
M. tuberculosis DHDPS is consistent with the (β/α)8-barrel structure of DHDPS, and previous 
CD spectra observed for E. coli DHDPS.71,72 However, there are differences between the CD 
spectra of wild-type and mutant DHDPS. To quantify these differences, the data were 
analyzed using three different algorithms, CONTINLL, SELCON, CDSSTR, in combination 
with various reference data sets from the CDPro software package.65,70 The best overall fit 
using reference set SP29 is summarized in Table 3.4. The analysis suggests that the 
DHDPS-A204R has a slight increase in β-structure. However, these values are not statistically 
significant and are likely to be artefacts reflecting the limitations of analysis, which has been 
shown to have variable accuracy for β-structure determination.66 The majority of the protein 
was clearly folded in solution in an analogous manner to wild-type. Thus, DHDPS-A204R 
was selected for structure determination by X-ray crystallography and for full biophysical and 
biochemical characterization. 
 
Table 3.4: Results from the fits for CD spectra achieved by CONTINLL SELCON, 
CDSSTR, algorithm,68,69 with the reference set SP29.70 The average value 
of these algorithms is reported, with standard deviation reflecting the 
difference between these fits. 
M. tuberculosis DHDPS α-Helix β-Strand β-Turn Unordered R.m.s.d. 
Wild-type 38 (±1) % 15.5 (±0.2) % 20.7 (±0.4) % 25 (±1) % 0.04 (±0.02) 
Mutant A204R 36 (±2) % 18 (±1) % 21 (±1) % 24 (±2) % 0.052 (±0.001) 
 
3.8 Conclusions 
Surprisingly, it appeared that the quaternary structure of M. tuberculosis DHDPS could be 
completely disrupted by a single point mutation. BN-PAGE showed a complete absence of 
any tetrameric species for the interface mutant DHDPS-A204R. The interface mutations 
leading to DHDPS-A204Y and DHDPS-A204D were less successful. DHDPS-A204Y was a 
tetramer, whereas DHDPS-A204D showed disrupted quaternary structure with BN-PAGE, 
but existed as an equilibrating mixture of two different populations. Thus further experimental 
work was focused on DHDPS-A204R. Analysis by LCMS confirmed the alanine to arginine 
mutation and CD spectroscopy showed DHDPS-A204R to be folded in solution with 
secondary structure analogous to the wild-type M. tuberculosis DHDPS. Hence 
DHDPS-A204R was an excellent candidate for complete biochemical and biophysical 
characterization in order to investigate the role of tetrameric quaternary structure in the 
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catalytic activity of M. tuberculosis DHDPS. In addition, the fully disrupted quaternary 
structure of DHDPS-A204R due to a single mutation supports the feasibility of disrupting the 
homotetramer complex of M. tuberculosis DHDPS with a small molecule inhibitor. 
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Chapter Four 
Purification & characterization of interface mutant 
DHDPS-A204R from M. tuberculosis 
4.1 Introduction 
A key goal in this work was to disrupt the weak interface of the tetrameric protein, 
M. tuberculosis DHDPS, and create and characterize discrete, stable, folded dimeric units. As 
presented in the previous chapter, BN-PAGE showed the tetrameric structure to be disrupted 
in two interface mutants A204D and A204R M. tuberculosis DHDPS, in which alanine 204 
was replaced with aspartate and arginine, respectively. The most promising interface mutant 
according to BN-PAGE was DHDPS-A204R, as it seemed to exist predominantly as a dimer. 
DHDPS-A204R, was therefore chosen for detailed characterization and comparison to 
wild-type M. tuberculosis DHDPS. Of particular interest were changes in the catalytic ability 
in comparison to the wild-type enzyme. Excitingly, the solid-state structure was determined 
by X-ray crystallography as part of a collaborative project with Dr Manfred Weiss and Linda 
Schuldt, from the EMBL Hamburg Outstation. This allowed differences between mutant 
A204R and wild-type M. tuberculosis DHDPS to be understood in the context of structural 
data, thus clarifying whether these differences were due to changes at the active site 
propagated by the mutation of alanine to arginine or to the change in oligomeric state. 
 
4.2 Enzyme over-expression & purification 
The rigorous characterization of A204R M. tuberculosis DHDPS required production and 
purification of milligram quantities of protein. As discussed in chapter two, as a recombinant 
protein in E. coli, the majority of M. tuberculosis DHDPS is expressed in insoluble form, 
resulting in a final yield of ~0.7 mg per litre of LB medium using an optimized procedure. 
Similarly, the majority of M. tuberculosis DHDPS-A204R was expressed as an insoluble 
protein in E. coli (Figure 4.1, lane 4); however, an even lower yield of 0.4 mg per litre was 
observed in small scale preparations of DHDPS-A204R (in chapter three, section 3.6.2). This 
is not surprising given that disruption of the weak interface results in exposure of previously 
buried hydrophobic surfaces and therefore is likely to cause decreased enzyme solubility and 
stability. 
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Figure 4.1: Small scale purification of M. tuberculosis DHDPS-A204R, over-expressed in 
E. coli BL21 (DE3) pGroESL pMTBA204R, examined using SDS-PAGE. The MW 
marker, in lane 1, enabled identification of His6-tagged DHDPS-A204R as the 
34 kDa band. Protein suspension from various stages of purification was loaded 
into other lanes as follows: 2 - crude extract, 3 - supernatant after centrifugation, 
4 - re-suspended cell pellet from centrifugation, 5 & 6 - eluted from His6-tag 
affinity column, 7 - dialyzed into pyruvate containing buffer, 8 - dialyzed out of 
pyruvate. Lanes 3 and 4 contain the soluble and insoluble protein fractions, 
respectively. The decreased band intensity in lane 8, suggests loss of protein in 
buffer lacking pyruvate, possibly by the formation of aggregates. 
 
4.2.1 The inclusion of pyruvate in storage buffers 
The stabilizing effect of pyruvate on wild-type M. tuberculosis DHDPS had previously been 
noted (in chapter two, section 2.3.2), and consequently had been included in all purification 
buffers except the final storage buffer of 20 mM Tris.HCl, pH 8.0, 250 mM NaCl, 5 % 
glycerol, and 2 mM β-mercaptoethanol (β-ME). During the purification of A204R 
M. tuberculosis DHDPS, dialyzing the enzyme into a buffer without pyruvate seemed to result 
in a loss of protein as observed by SDS-PAGE (Figure 4.1, lane 8), and of activity (Table 
3.3, chapter three, section 3.6.2). 
 
The thermal stability of DHDPS-A204R was initially investigated using differential scanning 
fluorescence (DSF), an assay where a sharp increase in fluorescence (shown in Figure 4.2A) 
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corresponds to the unfolding temperature, or apparent melting temperature, Tmapp.1 In storage 
buffer containing pyruvate, interface mutant DHDPS-A204R had a Tmapp of 51.6 (±0.1) ºC, 
compared with 85.3 (±0.1) ºC determined for wild-type M. tuberculosis DHDPS. The 
decreased thermal stability of DHDPS-A204R suggested that the interface mutation had 
successfully disrupted quaternary structure, as a decrease in unfolding temperature typically 
reflects either decreased structural order, increased flexibility or protein misfolding,1 and the 
CD spectra showed DHDPS-A204R to be folded (Figure 3.9, chapter three, section 3.7.2). 
 
DSF was also used to quantify the stabilizing effect of pyruvate at two enzyme concentrations 
in a pH 8.0 buffer containing Tris and NaCl at the same concentration as the buffer commonly 
used in AUC analysis (Table 4.1). Increasing concentrations of pyruvate were observed to 
have a stabilising affect on Tmapp (Figure 4.2B). A similar pyruvate effect has been observed 
in other DHDPS enzymes (Dr Grant Pearce, pers. comm.), and is assumed to be due to 
pyruvate introducing rigidity to the active site. 
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Figure 4.2: Determination of Tmapp using differential scanning fluorescence. (A) The melting 
curve for 0.3 mg.mL-1 of DHDPS-A204R in buffer of 20 mM Tris.HCl, pH 8.0, 
150 mM NaCl, 10 mM pyruvate (blue), and in the absence of pyruvate (red).  
(B) An increase in Tmapp with increasing pyruvate concentrations (in 20 mM 
Tris.HCl, 150 mM NaCl, pH 8.0) can be observed. 
(A) (B) 
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Table 4.1: The Tmapp of DHDPS-A204R in pH 8.0 buffer composed of 20 mM Tris.HCl, 
150 mM NaCl and varying pyruvate concentrations, as determined by DSF. 
Apparent melting temperature (ºC) [Pyruvate] 
mM for 0.3 mg.mL-1 DHDPS-A204R for 0.7 mg.mL-1 DHDPS-A204R 
0.0 43.4 (±0.0) 43.4 (±0.0) 
0.5 44.7 (±0.1) 44.6 (±0.3) 
1.0 45.6 (±0.0) 47.0 (±0.0) 
2.0 46.5 (±0.1) 47.6 (±0.0) 
5.0 48.1 (±0.1) 49.4 (±0.0) 
10.0 49.9 (±0.1) 50.6 (±0.0) 
 
A shift of ~7 ºC in Tmapp as a result of the inclusion of 10 mM pyruvate can be observed at 
both concentrations of A204R M. tuberculosis DHDPS (Table 4.1) suggesting that the effect 
of pyruvate is not strongly dependent on protein concentration. A comparable shift of 7.7 
(±0.3) ºC in Tmapp was observed for wild-type M. tuberculosis DHDPS (chapter two, 
section 2.3.2), which indicates that the pyruvate stabilizing effect is not specific for DHDPS-
A204R. The instability of the mutant compared to wild-type resulted in the inclusion of 
pyruvate in all buffers including the final storage buffer for DHDPS-A204R. 
 
4.2.2 Large scale purification of A204R M. tuberculosis DHDPS 
The optimized protocol, as described in chapter two, section 2.3.3, was further improved by 
the use of auto-inducing media, which resulted in high density cultures.2 Auto-inducing media 
uses glucose to suppress protein expression from the pET protein expression system (used in 
the plasmid construct pMTB02 and pMTBA204R, details in Appendix A) until after the 
culture has grown to saturation.2 Several batches of auto-induced culture were harvested and 
cell pellets frozen, allowing for a large scale preparation of M. tuberculosis DHDPS-A204R 
from 67.4 g (wet weight) of E. coli BL21 (DE3) pGroESL pMTBA204R cells (Table 4.2). As 
with previous purifications, crude cell-free lysate was produced by ultrasonication and the 
insoluble proteins removed by centrifugation (Figure 4.3, lane 2 and 3, respectively). Elution 
from the His6-tag affinity column resulted in a 57-fold increase in protein purity (Table 4.2). 
Subsequent to incubation with TEV protease, the cleaved DHDPS-A204R was passed through 
a His6-tag affinity column to remove the His6-tag peptide fragment (Figure 4.3, lane 5) and 
similar to wild-type, an increase in total activity was seen after His6-tag cleavage (Table 4.2). 
Minor impurities were apparent upon concentration (with an ultrafiltration spin column), and 
Purification and characterization of DHDPS-A204R 126 
 
elution from a gel-filtration column yielded 9 mg of protein that was homogeneous as judged 
by SDS-PAGE (Figure 4.3, lane 6). 
 
Table 4.2: Large scale purification of M. tuberculosis DHDPS-A204R from E. coli BL21 
(DE3) pGroESL pMTBA204R (67.4 g of cells). 
Purification step Volume (mL) 
Proteina 
(mg) 
Total activityb 
(unitsb) 
Specific activity 
(unitsb/mg) 
Relative 
total activity Purification 
Centrifuged 150 3281 22.4 0.0068  - 1-fold 
Affinity (His6-tagged) 28.0 23 8.8 0.39 40 % 57-fold 
Affinity (Non-tagged) 45.0 13 13.8 1.05 62 % 154-fold 
Gel filtration 17.5 9 9.7 1.12 43 % 164-fold 
 
a  Protein concentration was determined using the Bradford assay, detailed in chapter 6, section 6.3.1. 
b  Enzyme activity was determined using the coupled assay, described in chapter 2, section 2.2.3 and 1 unit was defined as 
the consumption of 1 μmol of NADPH per second. 
 
 
Figure 4.3: Typical large scale purification for M. tuberculosis DHDPS-A204R, over-expressed 
in E. coli BL21 (DE3) pGroESL pMTBA204R, examined using denaturing 
SDS-PAGE. The MW marker, in lane 1, enabled identification of non-His6-tagged 
M. tuberculosis DHDPS-A204R as the 31 kDa band. Preparations from 
purification steps were loaded into other lanes as follows: 2 - crude extract,  
3 - supernatant after centrifugation, 4 - after His6-tag cleavage by TEV protease 
and affinity chromatography, 5 - concentrated via an ultrafiltration spin column,  
6 - eluted from gel-filtration column. 
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4.3 Biochemical characterization of DHDPS-A204R 
Biochemical characterization of A204R M. tuberculosis DHDPS was carried out to determine 
the effect of the mutation and associated disrupted quaternary structure on enzyme function. 
The coupled assay was used to measure initial-rates by coupling DHDPS activity to the 
activity of DHDPR (chapter two, section 2.2.3). Determination of kinetic parameters in 
combination with the investigation of factors that affect catalytic activity, such as pH, ionic 
strength, and temperature, allowed a comprehensive comparison between wild-type and 
A204R M. tuberculosis DHDPS. Unless otherwise stated, the enzyme used was in storage 
buffer, which includes 10 mM pyruvate. For the kinetic analysis the extra pyruvate added 
with the enzyme into the assay mixture was taken into account (chapter six, section 6.9.4). 
 
4.3.1 The effect of pH, buffer and ionic strength on enzyme activity 
The pH optimum was determined in the manner outlined in chapter two, section 2.4.1, with 
the coupled assay system and using a series of buffers covering a pH range of 6 to 9 adjusted 
to the same ionic strength (IS) by addition of NaCl. The highest activity measurements for 
DHDPS-A204R of 1.02 (±0.10) and 0.97 (±0.11) μmol.s-1.mg-1 were recorded at pH 7.75 and 
8.25 (Figure 4.4A), showing a similar trend to that observed in wild-type M. tuberculosis 
DHDPS (chapter two, section 2.4.1). These values were close to those measured for wild-type 
enzyme at pH 7.75 and 8.25 of 1.34 (±0.05) and 1.39 (±0.04) μmol.s-1.mg-1. Therefore, it 
seemed that the alanine to arginine mutation has not changed the optimal pH range of 7.75 to 
8.25, nor had the overall activity been grossly affected; however, steady-state kinetics were 
needed for detailed comparison. 
 
Unlike the wild-type enzyme, the type of buffer used seemed to have a dramatic effect on the 
catalytic activity of DHDPS-A204R, with an almost two-fold decrease observed at pH 8.0 
between enzyme buffered with bicine compared to HEPES. All of the buffers used were 
zwitterionic buffers, as recommended by Good.3 Thus, it would seem that the activity of the 
interface mutant is more sensitive to differences in buffer components than the wild-type 
M. tuberculosis DHDPS, perhaps reflecting solubility issues. 
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Figure 4.4: The optimum conditions for DHDPS-A204R activity determined for varying (A) 
pH with different buffers (? MES, ? HEPES, ? Bicine), and (B) ionic strength 
with salt concentration. The data in the second plot are normalized, the apparent 
rate (νapp), with units AU/s, was divided by highest measured rate (νcon) of 
enzyme activity. Each data point was measured in at least triplicate, the error 
bars show the standard deviation, and the dashed line show the general trend. 
 
The effect of ionic strength on the enzymatic reaction was examined using a method 
analogous to that described in chapter two, section 2.4.2, with a series of 20 mM HEPES 
pH 8.25 buffers adjusted with NaCl to cover a range of ionic strengths. There was no 
significant difference between the measurements below 0.15 M or above 0.2 M, but a small 
decrease in activity was observed in the physiological range of 0.15-0.2 M (Figure 4.4B). 
Ionic strengths above 0.2 M showed a clear decrease in activity for wild-type M. tuberculosis 
DHDPS, as is typical for most enzymes,4 and 0.15-0.2 M was determined as optimal for its 
activity. For DHDPS-A204R, low ionic strength (0.05-0.15 M) seems to be optimal for 
activity; however, the effect of ionic strength is small. Given these observations with ionic 
strength and the optimal pH range of 7.75 to 8.25, the same buffer stock used for wild-type, 
200 mM HEPES, 50 mM NaCl, pH 8.0, was prepared for kinetic analysis of the interface 
mutant, which gives the assay mixture an overall ionic strength of ~0.18 M (Appendix D). 
 
4.3.2 Thermal stability 
To investigate the thermal stability of enzyme activity, DHDPS-A204R was incubated for five 
minutes at various temperatures before measuring initial-rates with the coupled assay at 30 ºC. 
Wild-type and A204R M. tuberculosis DHDPS were incubated in either storage buffer 
containing 10 mM pyruvate or buffer without pyruvate. For DHDPS-A204R, apparent 
melting temperatures (Tmapp) of 47 (±1) ºC and 53 (±1) ºC were determined in the absence and 
(A) (B) 
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presence of pyruvate, respectively (Figure 4.5). The Tmapp in storage buffer containing 10 mM 
pyruvate is within error of the 51.6 (±0.1) ºC determined by DSF (section 4.2.1). The 6 ºC 
difference in Tmapp caused by 10  mM pyruvate was similar to the ~7 ºC change observed 
using DSF (Table 4.1, section 4.2.1). Parallel experiments with wild-type M. tuberculosis 
DHDPS also showed an increase in Tmapp in the presence of pyruvate, to 86 (±1) ºC from 
77 (±1) ºC (Figure 4.5), confirming that the pyruvate stabilizing effect is not specific to the 
interface mutant. 
 
                   
Figure 4.5: The thermal stability of interface mutant A204R (?) was compared to wild-type 
M. tuberculosis DHDPS (?) in (A) the storage buffer containing pyruvate and 
(B) buffer without pyruvate [20 mM Tris.HCl, pH 8.0, 250 mM NaCl, 5 % 
glycerol, 2 mM β-ME]. The enzyme activity was determined using the coupled 
assay after pre-treatment by a 5 minute incubation at the indicated temperature. 
The data are normalized by dividing the apparent rate (νapp) by the rate after 
incubation at the lowest temperature measured (νcon). Each data point was 
measured in triplicate, the error bars show the standard deviation, and the 
dashed line shows the general trend. 
 
While the effect of pyruvate on Tmapp was similar between the wild-type and mutant enzyme, 
significant differences were observed during thermal melts. While, the activity of 
DHDPS-A204R was lower than that of wild-type DHDPS at all incubation temperatures, the 
removal of pyruvate via buffer exchange substantially lowered the activity of DHDPS-
A204R, decreasing it from 0.89 (±0.04) to 0.156 (±0.005) μmol.s-1.mg-1. Thus, in the absence 
of pyruvate, DHDPS-A204R had approximately 18 % of its original activity and 8 % that of 
the wild-type enzyme. This is consistent with earlier observations during purification (section 
4.2) that suggest DHDPS-A204R becomes unstable in the absence of pyruvate. 
(A) (B) 
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In these thermal stability measurements, data were not normalized to the rate after incubation 
for 5 minutes at 30 ºC. This is in contrast to previous melt experiments (chapter two, section 
2.4.3) which were normalized relative to the rate of enzyme without heat treatment. 
Incubation for 5 minutes at 30 ºC had no effect on wild-type DHDPS whereas the catalytic 
activity of DHDPS-A204R was significantly increased (compared with zero incubation time), 
both in the presence and absence of pyruvate, from 0.89 (±0.04) to 1.39 (±0.03) μmol.s-1.mg-1 
and from 0.156 (±0.005) to 0.528 (±0.002) μmol.s-1.mg-1, respectively. Therefore, the data 
presented in Figure 4.5 were normalized using the rate measured after incubation at the 
lowest temperature. This apparent heat activation of DHDPS-A204R is hard to rationalize. 
Heat activation was also observed for the interface mutants of E. coli DHDPS; however, this 
was caused by the presence of an pyruvate analogue, α-ketoglutarate, and its subsequent 
removal by incubation with pyruvate.5 For DHDPS-A204R, the presence of pyruvate in all 
purification buffers would have prevented binding of pyruvate analogues, such as 
α-ketoglutarate. It seems more likely that the heat activation observed for DHDPS-A204R is 
due to dissociation of protein aggregates in the incubation buffer. However, further 
experiments would be useful to confirm this. 
 
4.3.3 Steady-state kinetics of A204R M. tuberculosis DHDPS 
Steady-state kinetics describes the binding of substrates and release of products in terms of 
mathematical models, such as the Michaelis-Menten outlined in chapter two, section 2.4.4. 
The calculations are simplified by assuming a “steady-state”, where the reaction’s enzyme-
bound intermediates are being consumed as quickly as they are produced; that is the initial-
rate before it is affected by product accumulation or substrate consumption. 
 
Initial-rate data for kinetic characterization of A204R M. tuberculosis DHDPS were 
determined similarly to that outlined for wild-type enzyme, using a five-by-five matrix, 
varying pyruvate and (S)-ASA concentrations from 0.2 to 5 times their apparent KM values 
(which were determined to be 0.20 and 1.1 mM for pyruvate and (S)-ASA, respectively). The 
initial-rate of product formation was measured in at least triplicate, and was reproducible 
(±10 %). Data were fitted with the same models used for wild-type enzyme analysis, 
described in detail in chapter two, section 2.4.4, using the program ENZFITTER. 
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The ping-pong (S)-ASA substrate inhibition model provided the best fit, as shown by its R2 
value of 0.99, and yielded KM constants of 0.29 (±0.03) mM for pyruvate and 1.4 (±0.2) mM 
for (S)-ASA. Whether substrate inhibition with (S)-ASA is observed in DHDPS is debated in 
the literature (details in Appendix G).6-8 However, the determined K
i
(S)-ASA value of 
10 (±4) mM shows low precision due to the value lying outside the range of (S)-ASA 
concentrations (5.5 to 0.22 mM) used in this study; consequently, the ping-pong model 
without substrate inhibition was used to fit these data giving similar KM constants of 0.33 
(±0.03) mM for pyruvate and 1.1 (±0.1) mM for (S)-ASA. The phenomenon of substrate 
inhibition with DHDPS from M. tuberculosis is discussed in more detail in Appendix G. 
 
 
 
Figure 4.6: (A) The initial velocity of A204R M. tuberculosis DHDPS was measured with the 
coupled assay (buffered at pH 8.0 with 20 mM HEPES, 50 mM NaCl) over 
varying concentrations of both substrates, (S)-ASA and pyruvate, shown on the 
x-axis and with symbols (? 1.0 mM, ? 0.50 mM, ? 0.20 mM, ? 0.10 mM, ? 
0.050 mM pyruvate), respectively. Each point was measured in triplicate and the 
data were fitted with the ping-pong model, giving an R2 of 0.98, using the 
program ENZFITTER. (B) Reciprocal values were plotted to give a Lineweaver-
Burk transformation, and compared with the parallel lines predicted by the 
fitted model. 
 
The closeness of data points to the parallel lines in the Lineweaver-Burk plot (Figure 4.6B, 
4.7A) indicates that substrates bind to A204R M. tuberculosis DHDPS in a ping-pong fashion. 
The upward deviation of points near the y-axis (Figure 4.6B) is diagnostic of inhibition at 
high (S)-ASA concentrations.9,10 Kinetic analysis of wild-type M. tuberculosis DHDPS 
showed no substrate inhibition; although, this is likely due to the low (S)-ASA concentrations 
(A) (B) 
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being investigated (further comments in Appendix G). The compulsory ordered nature of the 
ping-pong mechanism suggests that (S)-ASA could inhibit activity at high concentrations by 
binding prior to pyruvate and forming a dead-end complex.11 
A value for V of 3.8 (±0.2) µmol.s-1.mg-1 was determined for DHDPS-A204R, which 
corresponds to a catalytic turnover number, kcat, of 119 s-1 per active site. The kinetic 
parameters are summarized and compared with wild-type M. tuberculosis DHDPS in 
Table 4.3, including kcat/KM, which describes catalytic efficiency. 
 
 
 
Figure 4.7: The initial velocity of A204R M. tuberculosis DHDPS was measured with varying 
concentrations of both substrates, pyruvate and (S)-ASA, shown on the x-axis 
and with symbols (? 5.5 mM, ? 2.2 mM, ?1.1 mM, ? 0.55 mM, ? 0.22 mM, 
(S)-ASA), respectively. Each point was measured at least in triplicate and the 
data were fitted with the ping-pong model, giving an R2 of 0.98, using the 
program ENZFITTER. (B) Reciprocal values of the raw data were plotted to 
give a Lineweaver-Burk transformation. 
 
Investigations with dimeric mutants of E. coli DHDPS saw a decrease in kcat to 1.4 % and 
2.5 % that of the wild-type tetrameric enzyme, for DHDPS-L197Y and DHDPS-L197D, 
respectively.5 In contrast, the kcat and V values determined for the interface mutant 
DHDPS-A204R are very similar to the values determined for wild-type M. tuberculosis 
DHDPS (Table 4.3). However, KM values for both substrates are considerably larger than 
those determined for the wild-type enzyme. This increase in KM of 2-fold for pyruvate and 
3-fold for (S)-ASA (Table 4.3) indicates that the binding of the substrates is not optimal in 
DHDPS-A204R. Consequently it seems that the mutation of alanine to arginine has decreased 
the catalytic efficiency (kcat/KM) of M. tuberculosis DHDPS, although the maximum rate of 
catalysis has not been affected, unlike previous experiments with E. coli DHDPS mutants. 
(A) (B) 
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Table 4.3: Kinetic parameters determined by fitting rate measurements. 
 Wild-type DHDPS DHDPS-A204R Comparison 
Kinetic model Ping-pong Ping-pong  
KM for (S)-ASA (mM) 0.43 (±0.02) 1.1 (±0.1) 3-fold increase 
KM for pyruvate (mM) 0.17 (±0.01) 0.33 (±0.03) 2-fold increase 
V (μmol.s-1.mg-1) 4.42 (±0.08) 3.8 (±0.2) Slight decrease 
Molecular Weight (Da) 31156.5 31241.6  
e0 (mg of enzyme per μmol) 31.16 31.24  
kcat (s-1) 132 (±3) 119 (±6) Slight decrease 
kcat/KM for (S)-ASA (s-1.mM-1) 300 (±20) 110 (±20) 3-fold decrease 
kcat/KM for pyruvate (s-1.mM-1) 780 (±60) 360 (±50) 2-fold decrease 
 
4.4 Determining the quaternary structure of DHDPS-A204R 
The unexpected similarity between the kcat of DHDPS-A204R and the wild-type enzyme 
could reflect that the tetrameric quaternary structure has not been disrupted in the mutant, as 
was indicated with BN-PAGE (chapter three, section 3.6.3). To confirm the quaternary 
structure(s) adopted by DHDPS-A204R in solution, two biophysical techniques, gel-filtration 
chromatography and analytical ultracentrifugation (AUC), were used. 
 
4.4.1 Determining quaternary structure in solution 
Initially, the oligomeric state of DHDPS-A204R was analyzed using sedimentation velocity 
(SV) experiments performed at 40000 rpm, applying a large centrifugal force. The resulting 
concentration boundary and rate of sedimentation were determined by radial scans at 230 or 
280 nm every 8 minutes without averaging. Radial scans were analyzed using the program 
SEDFIT, by fitting the continuous sedimentation coefficient [c(s)] distribution model.12 The 
partial specific volume ( v ) of DHDPS-A204R was calculated to be 0.7400 mL.g-1 using the 
program SEDNTERP.13 As with the wild-type enzyme, AUC experiments were performed at 
20 ºC in 20 mM Tris.HCl, 150 mM NaCl, pH 8.0, which is a commonly used buffer, thus its 
viscosity and density are well known, and easily calculated with SEDNTERP. 
 
Data collected at a low concentration of 0.06 mg.mL-1 DHDPS-A204R and fitted with a [c(s)] 
distribution, showed one main peak of 2.7 S (96 % of signal), with a much smaller secondary 
peak of 5.7 S (Figure 4.8B). Plots of raw data overlaid with the calculated fits were produced 
for visual inspection of the analysis (Figure 4.8A). The random distribution of the residuals 
and low r.m.s.d. of 0.0037 indicate the quality of the fit. The sedimentation coefficients 
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observed (s*) were converted into standardized sedimentation coefficients (s°20,w) of 2.8 and 
5.9 S, using the program SEDNTERP.13 
 
 
Figure 4.8: SV analysis of DHDPS-A204R (0.06 mg.mL-1) in 20 mM Tris.HCl, 150 mM 
NaCl, pH 8.0 at 20 ºC. (A) Absorbance at 230 nm (○) is plotted at time intervals 
of 16 minutes and overlaid with the nonlinear least-squares fit (solid line) to a 
continuous sedimentation coefficient [c(s)] distribution model.12 (B) The [c(s)] 
distribution is plotted as a function of s* (in units of Svedberg, S). The fit was 
obtained using a resolution of 200 species with v  = 0.7400 mL.g-1, ρ = 
1.005 g.mL-1, η = 1.021 cP and f/f0 = 1.22904. The r.m.s.d. and Z-test for the fit 
were 0.0037 and 0.69, respectively. A radial-dependent, time-invariant (TI) 
baseline was subtracted from data to account for optical imperfections. 
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The sedimentation coefficient values for different quaternary structures were calculated by 
hydrodynamic modelling, using the program HYDROPRO.14 The hydrodynamic models for 
different oligomers were based on the X-ray crystal structure for wild-type M. tuberculosis 
DHDPS (PDB entry 1XXX). HYDROPRO predicted the sedimentation coefficients (s) for the 
monomer, dimer and tetramer in the experimental buffer to be 2.8 S, 4.4 S and 6.7 S, 
respectively. This suggests that the primary oligomeric species (s* = 2.7 S) observed for 
DHDPS-A204R is a monomer under the conditions of this experiment, rather than the 
expected dimer. The secondary peak falls between the predicted values for dimer and 
tetramer, possibly suggesting the presence of higher order oligomers. However, there is only a 
trace amount of this oligomeric species, and it may simply be an artefact of analysis. 
 
Using SEDFIT, the [c(s)] distribution was converted into a continuous molar mass [c(M)] 
distribution, with accuracy dependent on the estimate for the frictional ratio (f/f0) extracted 
from the experimental data.15 The [c(M)] distribution gave an apparent molar mass of 
31.6 kDa, showing good agreement with the monomer molar mass (31.2 kDa) calculated 
based on the amino-acid sequence, and further confirming that the main peak corresponds to 
monomeric DHDPS-A204R. 
 
The absence of dimer was surprising, as dimeric DHDPS-A204R had been observed during 
the gel-filtration purification step (Figure 4.13, section 4.4.3). Therefore, a comparative 
experiment was performed at room temperature with an analytical gel-filtration column 
(Superdex 200 10/300), pre-equilibrated with 20 mM Tris.HCl pH 8.0, and where protein was 
diluted to ~0.01 mg.mL-1 over the course of the chromatography. Measuring absorbance at 
205 nm produced a chromatograph revealing two symmetrical elution peaks, with maxima 
corresponding to Ve of 13.89 and 18.82 mL (Figure 4.9A). The absence of a significant peak 
at 10.71 mL, as was observed for tetrameric wild-type DHDPS (in chapter two, section 2.5.3), 
indicates the native quaternary structure is completely disrupted in mutant A204R 
M. tuberculosis DHDPS. 
 
The chromatograph also suggest an absence of dimer, as there is no peak corresponding the 
molar mass (62.5 kDa) for dimeric DHDPS-A204R, which would elute at 12.05 mL based on 
the calibration plot (Figure 4.9B). The peaks observed were converted into molar masses of 
21.9 and 1.3 kDa, which unfortunately fall outside the range of the calibration standards and 
thus contain a large amount of uncertainty, even more than the 10 % intrinsic in this method 
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(discussed in chapter two, section 2.5.1). The first peak is definitely closer to molar mass 
predicted for the monomer (31.2 kDa) than the dimer, with -30 % deviation from the 
monomeric expected molar mass and therefore is consistent with the quaternary structure of 
DHDPS-A204R determined by AUC. The discrepancy between this result and that observed 
during purification is discussed in section 4.4.3. The absence of peaks corresponding to 
tetramer or dimer in gel-filtration chromatography indicates that secondary peak observed in 
AUC is most likely an artefact. 
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Figure 4.9: (A) Analytical gel-filtration chromatograph of A204R M. tuberculosis DHDPS. 
The experiment was performed at room temperature in 20 mM Tris.HCl, pH 8.0, 
and gave elution peaks with maxima at 13.89 mL and 18.82 mL as measured by 
absorbance at 205 nm (light grey). Chromatographs were also recorded at 215 nm 
(dark grey) and 280 nm (black). (B) BSA and ovalbumin calibration standards 
(?) were fitted to a linear equation. 
 
The peak eluting at 18.82 mL seems to correspond to something very small, possibly the 
cleaved His6-tag, which has molar mass of 3.0 kDa. Proteins absorb in the 205 to 220 nm 
range due to their peptide bonds, and typically, absorbance measured at 215 nm is half that 
measured at 205 nm,4 as is seen for the first peak with Ve of 13.89 mL. In contrast, the second 
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peak at 18.82 mL does not follow this pattern but rather absorbs an equivalent amount at 
215 nm (Figure 4.9A). Histidine has an absorbance maximum of 211 nm,16 midway between 
205 and 215 nm; thus the pattern of absorbance at the different wavelengths in the second 
peak is consistent with high histidine content. 
 
Data were also collected at a higher concentration of 1.1 mg.mL-1 DHDPS-A204R, and fitted 
using a [c(s)] distribution, which showed two main peaks of 2.8 and 3.5 S (40 and 55 % of 
signal, respectively) (Figure 4.10B). The fit was less than ideal, as indicated by the higher 
Z-test value of 20.19; however, the randomly distributed residuals and low r.m.s.d. indicate 
the relative goodness of the fit (Figure 4.10A). Since the frictional ratio (f/f0) reflects an 
estimated average of all species present and these data contain multiple peaks, the [c(s)] 
distribution cannot be converted into an accurate [c(M)] distribution.17 However, the 
predictions by HYDROPRO suggest two oligomeric states apparently present in similar 
amounts at this higher concentration, suggesting the s* values of 2.8 and 3.5 S correspond to 
monomer and dimer, respectively. 
 
The first 10 radial scans were analyzed separately and gave a similar shape, indicating that the 
monomer-dimer equilibrium was present from the beginning of the experimental run. 
Subsequently, various sections of data covering different time periods were examined, and it 
was found that while the two peaks were not always as distinct, neither disappeared at any 
point. The limitations in fitting multiple peaks, especially those which overlap, meant that 
they merged into one broad peak in Monte-Carlo distributions* (and when confidence levels 
were lowered to 0.68). The concentration dependence of the monomer-dimer equilibrium is 
indicated by the conspicuous absence of a peak corresponding to dimer in both in the low 
concentration SV experiment and gel-filtration chromatography. Sedimentation equilibrium 
(SE) experiments were needed to provide detail about the nature of the equilibrium between 
oligomeric states, and confirm the absence or presence of trace amounts of tetramer. 
 
*  Monte-Carlo analysis is used to distinguish noise from true peaks. Experimental data is used to generate new 
data sets based on a certain confidence level, thus true peaks sharpen and noise disappears. This sharpening 
of true peaks was observed with the other SV data sets in this work; however, in this case because the peaks 
are of similar size and overlapping they merge into one broad peak. 
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Figure 4.10: SV analysis of DHDPS-A204R (1.1 mg.mL-1) in 20 mM Tris.HCl, 150 mM 
NaCl, pH 8.0 at 20 ºC. (A) Absorbance at 280 nm, presented as open symbols 
(○), plotted at time intervals of 16 minutes is overlaid with the nonlinear least-
squares fit (solid line) to a [c(s)] model.12 (B) The [c(s)] distribution was fitted 
using a resolution of 200 species with v  = 0.7400 mL.g-1, ρ = 1.005 g.mL-1, η = 
1.021 cP and f/f0 = 1.25594 and TI noise was removed. The r.m.s.d. and Z-test 
for the fit were 0.0040 and 20.19, respectively. The residuals are plotted as a 
function of radial position (cm) from the axis of rotation. 
 
4.4.2 Quantifying the equilibrium 
To quantify the equilibrium between the oligomeric states of DHDPS-A204R, sedimentation 
equilibrium (SE) experiments were performed at three different rotor speeds (10000, 16000 
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and 23000 rpm) at three different enzyme concentrations (0.1, 0.3 and 0.9 mg.mL-1). At the 
lower centrifugal forces used for SE experiments, diffusion starts to oppose sedimentation, 
and thus centrifugation for (8-16 hours) resulted in an exponential-shaped concentration 
distribution that was invariant with time. The unchanging concentration distribution indicated 
that equilibrium had been reached; that is, outward sedimentation exactly balanced inward 
diffusion.18 Radial absorbance scans were recorded at 280 nm and data were analyzed at each 
concentration using the program SEDPHAT,19 in similar manner as the wild-type enzyme 
(chapter two, section 2.5.2). Equivalent molar mass values of 37, 40 and 46 kDa were 
observed for the 0.1, 0.3 and 0.9 mg.mL-1 data sets, respectively, when fitted to a single 
species model. This concentration dependent increase in molar mass is characteristic of a self-
associating system,17 and suggests a shift in oligomeric species over this concentration range, 
as is consistent with the results from the SV experiments (Figure 4.8 and 4.10). 
 
Global analyses of all data sets were performed with the mass fixed to the calculated 
monomer, dimer, trimer or tetramer mass of DHDPS-A204R giving badly distributed 
residuals and global reduced χ2 values of 0.57, 0.61, 5.4 and 39, respectively. None of these 
single species models gave a very good fit; however, of these, the best fits were obtained with 
the monomeric and dimeric masses.  
 
Subsequently, the data were globally fitted to multiple self-association models; monomer-
dimer, monomer-trimer, monomer-tetramer and monomer-dimer-tetramer equilibria. When 
the molar mass was constrained to 31 kDa, the best fit was obtained with the monomer-dimer 
equilibrium, yielding a dimerization dissociation constant (KD2?1) of 52 μM with a global 
reduced χ2 value of 0.60. Both the monomer-trimer and monomer-tetramer model gave badly 
distributed residuals and nonsensical dissociation constants. The monomer-dimer-tetramer 
model yielded a similar KD2?1 of 51 μM, with global reduced χ2 value of 0.60; however, the 
tetramerization dissociation constant (KD4?2) was in the molar concentration range, several 
1000-fold higher than the highest loading concentration of 0.9 mg.mL-1 (28.8 μM). This 
indicated that no tetramer is apparent in the concentration range examined, and that the 
appropriate model for DHDPS-A204R over the concentrations investigated is the monomer-
dimer equilibrium. The fit was optimized for the monomer-dimer model, yielding a 
dimerization dissociation constant (KD2?1) of 60 μM with a χ2 value of 0.26. When the molar 
mass was floated, a fit with a χ2 value of 0.25 was obtained for the monomer-dimer model 
with buoyant molar mass for the monomer of 29.7 kDa and KD2?1 of 51 μM (Figure 4.11). 
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Figure 4.11: DHDPS-A204R sedimentation equilibrium data recorded at 280 nm and 20 ºC, 
in 20 mM Tris.HCl, 150 mM NaCl, pH 8.0. Representative data are shown for 
initial protein concentration of 0.1 mg.mL-1 after reaching equilibrium at 
10000 rpm (○), 16000 rpm (●), and 23000 rpm (Δ) overlaid with the nonlinear 
least-squares fit (solid line) to a monomer-dimer self-associating model yielding 
a KD2?1 of 51 μM and buoyant molar mass of 29.7 kDa. The residuals are 
plotted as a function of radial position (cm) from the axis of rotation. 
 
The KD2?1 is the concentration at which the amount of monomer equals the amount of dimer, 
and can also be expressed as 1.6 mg.mL-1. This is slightly higher than the 1.1 mg.mL-1 that 
gave similar sized peaks for monomer and dimer with the SV experimental approach. Since 
KD2?1 describes the ratio of monomer to dimer it can be used to predict the fraction of 
monomer (fm) present at any protein concentration, as described with Equation 4.1: 
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 Equation 4.1 20 
 
Here PT is the total protein concentration, expressed in molar concentration units,20 thus by 
converting 1.1 mg.mL-1 to 35 μM, the fraction of monomer can be calculated as 0.56, or 
56 %, with the remaining 44 % expected to be dimer. In the SV data analysis of DHDPS-
A204R at 1.1 mg.mL-1 (section 4.4.2, Figure 4.10B) the opposite trend was observed, as the 
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monomer peak was smaller than the dimer peak (40 and 55 %, respectively); however, these 
values are still relatively close to those predicted by the KD2?1 determined using the SE 
experimental approach. The difference probably reflects the intrinsic inaccuracy when fitting 
interacting systems with the Lamm equation for SV data analysis, and highlights the 
importance of using SE analysis to characterize rapidly equilibrating, self-associating systems. 
 
4.4.3 Factors affecting equilibrium 
During purification, only dimeric A204R M. tuberculosis DHDPS was observed on the 
preparative gel-filtration column (Superdex 200 16/60) (Figure 4.13). The lower resolution 
preparative-type column meant yeast alcohol dehydrogenase needed to be included to 
generate the four point calibration curve and showed the single slightly asymmetrical peak 
corresponded to 57.3 kDa. This suggested a mainly dimeric DHDPS-A204R, with a small 
fraction of monomer. The gel-filtration purification step was performed at 4 ºC, in storage 
buffer containing pyruvate, and the concentration of enzyme collected was usually 
~0.5 mg.mL-1 (section 4.2.2, Table 4.2), thus less than the KD2?1 of 1.6 mg.mL-1 determined 
in 20 mM Tris.HCl, 150 mM NaCl, pH 8.0 at 20 ºC. Using equation 4.1 (section 4.4.2), the 
KD2?1 predicts that 70 % of DHDPS-A204R will adopt a monomeric quaternary structure at 
0.5 mg.mL-1, therefore, the relative absence of monomer suggested that the monomer-dimer 
equilibrium of DHDPS-A204R has been shifted towards dimer by one or more of the storage 
buffer components. The lower temperature of 4 ºC maintained during purification may have 
also influenced subunit association, as temperature effects have been observed for several 
oligomeric enzymes.21,22 
 
To investigate the effect of the buffer components on equilibrium, SV experiments were 
performed at 20 ºC with 0.6 mg.mL-1 DHDPS-A204R in storage buffer [20 mM Tris.HCl, 250 
mM NaCl, 5 % glycerol, 2 mM β-mercaptoethanol (β-ME), 10 mM pyruvate, pH 8.0]. Due to 
the complexity of the buffer in this case, the computational processing of data relied on 
estimates for protein and solution properties. The limitations of the SEDNTERP program 
meant contributions to buffer density or viscosity from the low concentrations of pyruvate and 
β-ME had to be ignored. Solvent density (ρ) and viscosity (η) were calculated as 1.023 g.mL-1 
and 1.193 cP, respectively, for a pH 8.0 buffer composed of 20 mM Tris.HCl, 250 mM NaCl 
and 5 % (0.68 M) glycerol. The partial specific volume ( v ) of 0.7400 mL.g-1 used in data 
analysis was also an estimate. The presence of glycerol is known to impact the v  of proteins, 
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increasing protein volume at acidic pH by preferential hydration,23 and decreasing protein 
volume at neutral pH through compression of the protein interior.24 Parallel SV experiments 
performed with wild-type M. tuberculosis DHDPS (1.1 mg.mL-1) in the same storage buffer 
and allowed the inaccuracy introduced by these estimates to be monitored. 
 
HYDROPRO predicted sedimentation coefficients for monomer, dimer and tetramer, in 
20 mM Tris.HCl, 250 mM NaCl, 5 % glycerol to be 2.2 S, 3.5 S and 5.5 S, respectively. 
Using SEDFIT, a [c(s)] distribution was fitted to the wild-type data set and gave a peak of 
5.3 S (see Appendix H), which reflects the previously demonstrated tetrameric quaternary 
structure of wild-type M. tuberculosis DHDPS (chapter two, section 2.6.1). The closeness of 
this value to the sedimentation coefficient predicted by HYDROPRO indicates that the 
estimates for solution and protein properties have introduced minimal inaccuracy. 
Furthermore, when s* was standardized to conditions corresponding to pure water at 20 °C, 
s°20,w, using SEDNTERP,13 a value of 6.8 S was obtained, which is similar to 6.5 S found for 
the wild-type enzyme in SV experiments performed in a different buffer. 
 
Analysis of the data set for 0.6 mg.mL-1 DHDPS-A204R in storage buffer revealed a single 
peak of 3.2 S (Figure 4.12B), which is close to the 3.5 S predicted for a dimer by 
HYDROPRO. The random distribution of the residuals and low r.m.s.d. of 0.0036 indicates 
the quality of the fit (Figure 4.12A). The s°20,w of 4.1 S calculated from s* is significantly 
different from 2.8 S obtained in the other buffer [20 mM Tris.HCl, 150 mM NaCl, pH 8.0], 
which corresponded to monomer. The [c(M)] distribution derived from the [c(s)] distribution 
using SEDFIT gave an apparent molar mass of 62.4 kDa, which is consistent with the 
predicted molar mass for a dimer of 62.5 kDa. These three lines of evidence show that the 
single peak observed at 0.6 mg.mL-1 in storage buffer corresponds to a dimer, (Figure 4.12B) 
and the absence of any distinguishable monomer peak confirms that one or more components 
of the storage buffer has shifted the monomer-dimer equilibrium of DHDPS-A204R towards 
dimer. 
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Figure 4.12: Sedimentation velocity analysis of DHDPS-A204R (0.6 mg.mL-1) in storage 
buffer [20 mM Tris.HCl, pH 8.0, 250 mM NaCl, 5 % glycerol, 2 mM β-ME, and 
10 mM pyruvate] at 20 ºC. (A) Absorbance at 280 nm, presented as open 
symbols (○), plotted at time intervals of 12 minutes is overlaid with the 
nonlinear least-squares fit (solid line) to a [c(s)] model.12 (B) The fit was 
obtained using a resolution of 200 species with v  = 0.7400 mL.g-1, ρ = 
1.023 g.mL-1, η = 1.193 cP and f/f0 = 1.20145, and TI noise was removed. The 
r.m.s.d. and Z-test for the fit were 0.0036 and 12.44, respectively. The residuals 
are plotted as a function of radial position (cm) from the axis of rotation. 
 
Two components in the storage buffer were identified as possibly causing the oligomeric 
change. The binding to the enzyme of substrate has been reported in the literature to induce 
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dimerization.25,26 The presence of anti-chaotropic agents, such as glycerol have also been 
observed to affect oligomeric equilibrium.27,28 To investigate which storage buffer component 
was responsible for the observed shift in oligomeric structure, a gel-filtration run was 
performed in storage buffer lacking pyruvate, re-calibrated with BSA, ovalbumin and alcohol 
dehydrogenase (Figure 4.13B). The elution peaks of all proteins shifted in the absence of 
pyruvate, however the peak of DHDPS-A204R shifted more significantly (black line, 
Figure 4.13A), giving an elution volume of 95.34 mL. 
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Figure 4.13: (A) Gel-filtration chromatography of A204R M. tuberculosis DHDPS, performed 
at 4 ºC in a pH 8.0 buffer [20 mM Tris.HCl, 250 mM NaCl, 5 % glycerol, 2 mM 
β-ME] with 10 mM pyruvate (light grey dashes) and without pyruvate (black) 
giving elution peaks corresponding to dimer and monomer, respectively. The 
second, less significant, peak is likely the cleaved His6-tag, which gave a small peak 
in most purification gel-filtration runs. (B) Calibration standards of BSA, 
ovalbumin, and alcohol dehydrogenase (?) in pH 8.0 buffer without pyruvate. 
 
The slightly asymmetrical peak (Figure 4.13A) showing DHDPS activity corresponded to a 
molar mass of 29.3 kDa, as determined with the new calibration plot (Figure 4.13B) and 
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indicated that in the absence of pyruvate, DHDPS-A204R is mostly monomeric. Since the 
preparative-type column has a lower resolution, this profile may fit the prediction of 70 % 
monomeric DHDPS-A204R at 0.5 mg.mL-1 made using the KD2?1 determined by SE 
analysis in 20 mM Tris.HCl, 150 mM NaCl, pH 8.0 at 20 ºC. 
 
Further experiments were performed at 4 °C with an analytical gel-filtration column 
(Superdex 200 10/300) to explore the effect of pyruvate concentration on the oligomeric 
structure of DHDPS-A204R. Relatively low concentration samples (0.16 mg.mL-1) were 
loaded (250 μL) onto the column which had been pre-equilibrated with buffer containing 
varying concentrations of pyruvate (Figure 4.14). At these low concentrations the dimeric 
and monomeric peaks could be distinguished and thus their Ve could be converted into 
molecular masses using BSA and ovalbumin calibration standards (Table 4.4). The 
o-aminobenzaldehyde assay showed DHDPS activity in both monomer and dimer peaks. The 
monomer-dimer equilibrium shifts from majority monomer to majority dimer at low pyruvate 
concentrations, but is only slightly affected by further increasing pyruvate concentration, 
consistent with stoichiometric binding of pyruvate stabilising the dimeric state. 
 
Table 4.4: The molecular masses and corresponding quaternary structures of A204R 
M. tuberculosis DHDPS in pH 8.0 buffer (20 mM Tris.HCl, 150 mM NaCl) and 
varying pyruvate concentrations. (Bold denotes majority species). 
[Pyruvate] 
mM 
Molar mass 
(kDa) Quaternary structure 
0.0 57 34 dimer monomer 
0.5 58 33 dimer monomer 
1.0 56 32 dimer monomer 
5.0 56 31 dimer monomer 
10.0 62 36 dimer monomer 
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Figure 4.14: The effect of pyruvate concentration on A204R M. tuberculosis DHDPS shown by 
analytical gel filtration performed at 4 ºC with 10 mM pyruvate (light grey dots), 
0.5 mM pyruvate (dark grey dashed) and without pyruvate (black) in a pH 8.0 
buffer [20 mM Tris.HCl, 150 mM NaCl]. The column was loaded with 0.04 mg of 
A204R DHDPS (250 μL of 0.16 mg.mL-1), thus eluted at a concentration of 
~0.01 mg.mL-1 (0.04 mgs over ~4 mL). 
 
4.5 The crystal structure of A204R M. tuberculosis DHDPS  
X-ray crystallography provides the level of detail required for the similarities and differences 
between the interface mutant DHDPS-A204R and wild-type M. tuberculosis DHDPS to be 
understood in the context of disrupted quaternary structure 
 
4.5.1 Crystallization, diffraction data collection and processing 
Crystallization experiments were undertaken by our collaborators at the EMBL Hamburg 
Outstation using protein purified during the course of this thesis. The first crystals were 
observed in the condition of 2.0 M (NH4)2SO4, and 100 mM Tris.HCl, pH 8.5, at room 
temperature, and subsequently, this condition was optimized to 2.0 M (NH4)2SO4 and 
100 mM sodium acetate pH 5.5. 
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X-ray diffraction data were collected by our collaborators on the I911-3 beamline at the 
MAX-lab synchrotron in Lund (Sweden) using a MARMosaic CCD detector. The data were 
indexed and integrated using DENZO and scaled with SCALEPACK.29 Data collection and 
processing parameters are given in Table 4.5, and further details on data collection are given 
in chapter six, section 6.10.1. 
 
Table 4.5: Collection and processing statistics for X-ray crystallography of DHDPS-A204R. 
Values in parentheses are for the highest resolution bin. 
No. of crystals 1 
Wavelength (Å) 1.000 
Crystal-detector distance (mm) 225 
Rotation range per image (°) 0.5 
Exposure time per image 30 sec 
Total rotation range (°) a 110.5 
Resolution range (Å) 99.00-2.00 (2.03-2.00) 
Space group P41212 
Unit cell parameters (Å, °) 188.83, 188.83, 130.43, 90.0, 90.0, 90.0 
Mosaicity (°) 0.26 
Total no. of observations 1,458,570 
Total no. of reflections 747,046 
Unique reflections 157,209 
Rejected reflections 9,630 
Redundancy 4.8 (4.3) 
I/σ (I) 14.1 (2.5) 
Completeness (%) 99.2 (97.6) 
Rmerge (%) b 11.8 (58.9) 
Overall B-factor from Wilson plot (Å2) 23.1 
Optical resolution (Å) 1.54 
 
a  Only the first 60° of data were used for final data processing due to radiation damage. 
b  Rmerge ∑ ∑
∑ ∑ −=
hkl i i
hkl i i
hklI
hklIhklI
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4.5.2 Structural determination and initial refinement 
Our collaborators solved the structure by molecular replacement using the program 
MOLREP,30 and a dimer consisting of the chains a and b of wild-type M. tuberculosis 
DHDPS (PDB entry 1XXX) as a search model. The crystal structure of DHDPS-A204R was 
solved in the space group P41212 and contained three independent dimers (Figure 4.15A), 
with no tetramers seen in crystal packing, providing unequivocal evidence that the tetrameric 
structure is disrupted by the alanine to arginine mutation. After correctly orienting and 
positioning the three dimers, the R-factor was already as low as 36.8 %. One round of rigid 
body and restrained refinement, using the program REFMAC5,30,31 reduced the R- and free R-
factor to 32.0 % and 27.8 %, respectively. This partially refined data was then sent to our lab 
for further refinement, which I carried out with support from Prof. Geoff Jameson (University 
of Massey) and Dr Sean Devenish. 
 
                       
Figure 4.15: Comparison of the crystal packing of (A) mutant A204R and (B) wild-type 
M. tuberculosis DHDPS (PDB entry 1XXX) in the unit cell, showing the 
quaternary structures of dimer and tetramer, respectively. 
 
4.5.3 Further structural refinement 
Because of the multiplicity in the asymmetric unit, non-crystallographic similarity (NCS) 
constraints could be used with rigid-body refinement. After two rounds of rigid body 
refinement with NCS constraints, the R- and free R-factors were 26.3 % and 24.4 %, 
respectively. Anisotropic displacement parameters were incorporated into refinement using 
the TLS (translation, rotation, screw-rotation) model with REFMAC5, which can be 
visualized as six thermal ellipsoids, each constraining a monomer.30,32 Manual model 
corrections were implemented using the program WINCOOT,33 and new models were further 
(A) (B) 
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refined using REFMAC5. During the manual model corrections, the alanine of the wild-type 
enzyme was replaced by an arginine residue at the position of the mutation. The mutation was 
clearly visible in the electron density in four of the six monomers and partially visible (due to 
disorder in the side chain) in two monomers. 
 
During refinement, well-defined electron density was observed near the ε-amino group of the 
active-site lysine residue, K171, in all six monomers. The size, shape and orientation of this 
density was consistent with a pyruvate-adduct (Figure 4.16A), as had been observed in 
structures solved for DHDPS from other species, such as the recently determined structure of 
E. coli DHDPS.34 Consequently, pyruvate was modelled into the final structure as a Schiff 
base covalently bound to the ε-amino group of K171 (Figure 4.16B). That pyruvate would be 
bound in the active site was not unexpected given that the enzyme had been purified and 
stored in a buffer containing 10 mM pyruvate, which was also observed to result in formation 
of a pyruvate-adduct in C. glutamicum DHDPS.6 
 
 
Figure 4.16 Omit maps of the density seen at (A) K171 and (C) C248, shown for chain A, 
analogous to that observed in other monomers, and the corresponding fit after 
modelling adducts with (B) pyruvate and (D) β-mercaptoethanol (β-ME). 
(A) (B) 
(C) (D) 
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Additional density was also noticed near the surface cysteine residue, C248, in all monomers 
(Figure 4.16C). In the wild-type M. tuberculosis DHDPS (PDB 1XXX) DTT molecules were 
found to be covalently bound to C248,35 but DTT did not fit the density observed in the 
crystal structure of DHDPS-A204R. Subsequently, another reducing agent used in 
purification, β-mercaptoethanol (β-ME), was modelled into the structure and found to fit the 
density well (Figure 4.16D). 
 
The final refinement rounds involved placement of solvent molecules using WINCOOT, 
followed again by manual corrections and further refinement with REFMAC5. Structural 
quality was assessed using SFCHECK,36 and the structural validation tools of WINCOOT. In 
some cases, the side chains of amino acids could not be clearly observed due to insufficient 
electron density, so the occupancy of these atoms was lowered. The maximum r.m.s.d. for the 
subunits (all atoms) in the asymmetric unit was 0.38 Å, as calculated by SUPERPOSE.30 
Final refinement statistics are presented in Table 4.6. 
 
Table 4.6: Refinement statistics for the DHDPS-A204R crystal structure. Values in 
parentheses are for the highest resolution bin. 
Resolution (Å) 2.1 
Resolution range (Å) 28.51-2.10 (2.213-2.10) 
Rfree (outer shell) a 0.204 (0.234) 
Rcryst (outer shell) b 0.178 (0.196) 
Residues/water molecules 1766/1914 
r.m.s.d. from ideal geometry  
Bond lengths (Å) 0.015 
Bond angles (°) 1.52 
 
a  Rfree based on 5 % of the total reflections excluded from the refinement. 
b  Rcryst
( )
∑
∑ −=
obs
calcobs 
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4.5.4 General features of the structure 
The final model contained six monomers in the asymmetric unit, with 1766 amino-acid 
residues in total, 1914 water molecules, six β-mercaptoethanol (β-ME) moieties covalently 
bound to C248, six pyruvate moieties covalently bound to K171, along with one non-
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covalently bound β-ME and pyruvate from the purification buffer, and 16 sulfate molecules, 
24 glycerol molecules, eleven acetate molecules and three chloride ions from the 
crystallization buffer. The non-covalently bound pyruvate and β-ME were both on the outer 
surface of the enzyme, distal to the active site, and unlikely to have functional significance. 
The model includes all amino-acid residues, with the exception of the first 8 to 10 amino acids 
at the N-terminus of each chain (including the G-A-M-A remaining after cleavage of the 
His6-tag), which are not visible in the electron density. 
 
Almost all non-glycine residues, 99.8 %, fell within the most favoured or additionally allowed 
regions of the Ramachandran plot.37 The only offending residue was the interdigitating 
tyrosine, Y117, which reaches from one monomer to complete the adjacent active site. This 
disfavoured orientation has been associated with the tyrosine residue’s catalytic function and 
has been observed in wild-type M. tuberculosis DHDPS,35 and in DHDPS from other 
species.6,25,38-45 In this structure, three of the six Y117 residues were in the disallowed region 
of the plot, while the others were found just inside the additionally allowed region, due to 
slight adjustments in orientation. This may reflect either the tightness of restraints being used 
during refinement, or slight variation between the monomers in the asymmetric unit. 
 
4.5.5 Alignment of the DHDPS-A204R and the wild-type structures 
Superpositioning of all atoms in monomer a with the wild-type M. tuberculosis DHDPS 
structure (1XXX), and the structure of wild-type soaked with pyruvate, gave r.m.s.d. values of 
0.288 Å and 0.289 Å, respectively. These values are comparable to those of alignments of the 
monomers of DHDPS-A204R within the asymmetric unit (section 4.5.3), also determined 
using SUPERPOSE. This high degree of structural similarity indicates that the mutation of 
alanine to arginine has not introduced any gross disruptions to the secondary or tertiary 
structure of the enzyme. 
 
An alignment of the dimer composed of chains a and b with the corresponding chains in 
1XXX also yielded a low r.m.s.d. of 0.378 Å for all atoms, which is perhaps unsurprising, 
considering chains a and b of 1XXX were used as the search model for the DHDPS-A204R 
structure, and resulted in a low initial R-factor after a single round of rigid body refinement. 
An analogous alignment using the wild-type structure with pyruvate bound at the active site 
gave a slightly better fit, with an r.m.s.d. of 0.337 Å (Figure 4.17A), perhaps reflecting the 
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subtle shift noted in active-site residues, as discussed in chapter two, section 2.6.3. A closer 
look at the active site (Figure 4.17B), shows little change in the substrate binding and 
catalytic residues and will be discussed in detail in the next section. 
 
 
Figure 4.17:  (A) Alignment of the dimer A204R M. tuberculosis DHDPS (in blue) with two 
subunits from wild-type enzyme (in green), both with pyruvate covalently bound 
to K171. (B) Overlay of the active site showing the close alignment of key residues, 
which was produced from an alignment of single monomers of the structures. 
 
4.5.6 The active site 
The active sites of wild-type tetrameric M. tuberculosis DHDPS and dimeric DHDPS-A204R 
are remarkably similar (Figure 4.17B), consistent with their similar kinetically quantified 
catalytic activity. The disrupted quaternary structure mutants of E. coli DHDPS all had greatly 
reduced activity, which was attributed in part to the presence of covalent adduct, 
α-ketoglutarate, in the active site.5,46 The presence of pyruvate rather than α-ketoglutarate at 
the active-site lysine residue of DHDPS-A204R is consistent with the interface mutant having 
comparable activity to the wild-type enzyme. 
 
The proton-relay network, composed of two tyrosines (Y143, Y117) and a threonine (T54), as 
noted in chapter two, appears to be disrupted in the crystal structure of wild-type 
M. tuberculosis DHDPS (PDB entry 1XXX). However, in soaking experiments with pyruvate 
and wild-type M. tuberculosis DHDPS, the hydrogen bond between Y143-OH and T54-OH 
appears to be re-established, thus restoring the proton-relay network. Analogous to the 
Y117b 
T55 
T54 
Y143 
K171 
G194 
I211 
R148 Y116a 
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pyruvate-bound structure of M. tuberculosis DHDPS, the distances between Y143-OH and 
T54-OH indicates hydrogen bond formation in the pyruvate-bound DHDPS-A204R crystal 
structure (representative numbers from monomer a shown in Table 4.7). The atomic 
distances of the proton-relay network determined for DHDPS-A204R were similar in all six 
monomers, indicating that the proton-relay motif remains intact. 
 
Table 4.7 Comparison of key atomic distances within the proton-relay network from 
monomer a of crystal structures solved for wild-type and A204R M. tuberculosis 
DHDPS and wild-type E. coli DHDPS containing a pyruvate adduct. 
Atomic distances for : 
M. tuberculosis 
DHDPSa 
M. tuberculosis 
DHDPS-A204R Atomic distances for: 
E. coli 
DHDPSb 
Y143-OH K171-Nєc 3.3 Å 3.6 Å Y133-OH K161-Nєc 3.5 Å 
Y143-OH T54-OH 3.0 Å 3.2 Å Y133-OH T44-OH 2.8 Å 
T54-OH Y117-OH 2.6 Å 2.6 Å T44-OH Y107-OH 2.6 Å 
 
a Structure of M. tuberculosis DHDPS with pyruvate bound was solved by our collaborators and has not yet been 
deposited in the PDB. 
b Structure of E. coli DHDPS with pyruvate bound is PDB entry 3DU0. 
c The є-amino group of the key lysine residue that forms a Schiff base with pyruvate. 
 
For DHDPS-A204R, in contrast to the wild-type structure with a pyruvate adduct, the 
distance between Y143-OH and the є-amino group of K171 increased from 3.3 to 3.6 Å 
(Table 4.7). This difference of 0.3 Å is near the limit of what can be consider significant with 
this data set. It results from slight re-orientations of K171 and Y143 (Figure 4.17B). 
Interestingly, the shifting of the key active-site lysine away from the proton-relay network 
upon pyruvate binding has also been observed in wild-type tetrameric E. coli DHDPS 
structures (PDB code 1YXC,44 3DU0,34). Thus the re-positioning of the proton-relay network 
may be related to the binding of pyruvate. Regardless, the re-orientations of Y143 and K171 
in this crystal structure is slight and unlikely to be due to the mutation, distal to the active site. 
Thus, the differences observed in the kinetic parameters of DHDPS-A204R and wild-type 
M. tuberculosis DHDPS can be attributed to disrupted quaternary structure rather than 
changes at the active site propagated by the mutation of alanine to arginine. 
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4.6 Summary 
A comprehensive biophysical, biochemical and structural characterization of mutant A204R 
M. tuberculosis DHDPS revealed an enzyme with comparable activity to wild-type tetrameric 
DHDPS, lowered thermal stability, and a completely disrupted quaternary structure. Using 
AUC and gel-filtration chromatography, this interface mutant was shown to exist in a 
monomer-dimer equilibrium, affected by enzyme concentration and by the presence of the 
first substrate, pyruvate. The crystal structure of DHDPS-A204R, solved with pyruvate bound 
in the active site, provided further confirmation of the disrupted quaternary structure. 
 
Additionally, the crystal structure showed DHDPS-A204R to have tertiary and secondary 
structures identical to the wild-type enzyme, and the active site was revealed to be intact in 
the static structure. This meant that DHDPS-A204R provided a valid model for determining 
the role of quaternary structure in M. tuberculosis DHDPS, uncomplicated by changes to 
secondary and tertiary structure. 
 
In summary, the dimeric M. tuberculosis DHDPS was successfully created and characterized. 
Contrary to the hypothesis outlined in chapter one, and unlike its E. coli counterpart, the 
dimeric enzyme retained catalytic competence. This unequivocally rules out interface 
disruption as a mode of inhibition for M. tuberculosis DHDPS. It also demands a re-
evaluation of the role of quaternary structure in DHDPS function, which will be discussed in 
the concluding chapter. 
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Chapter Five 
Summary and conclusions 
5.1 Introduction 
The focus of this work, as outlined in chapter one, was to use protein engineering to disrupt 
the quaternary structure of M. tuberculosis DHDPS and assess the impact of this disruption on 
enzyme function. This was undertaken in light of investigations with E. coli DHDPS, which 
showed the tetrameric quaternary structure to be essential for enzymatic activity and 
specificity,1 and of the emerging paradigm in drug design of targeting protein-protein 
interfaces.2 Chapter four presented the biophysical, kinetic and structural characterization of a 
dimeric variant of M. tuberculosis DHDPS, designed and produced by point mutation, as 
described in chapter three, and compared this protein with the tetrameric wild-type 
M. tuberculosis DHDPS, as detailed in chapter two. This comparison, taken together with 
recent research on DHDPS from other organisms, provides new insights into the relationship 
between oligomeric structure and catalytic function in DHDPS. 
 
This chapter summarizes these results in the context of future drug design strategies and 
offers a rationale for the differing importance of the homotetrameric structure of 
M. tuberculosis DHDPS on enzyme function, in comparison with E. coli DHDPS. Through 
this understanding of the role of quaternary structure in DHDPS, new criteria are proposed to 
aid further investigation into drug design targeting DHDPS from various bacterial species. 
 
5.2 The importance of quaternary structure 
Chapter three (section 3.2) discussed general advantages that result from the association of 
subunits into higher order oligomers, such as functional gain, structural stability,3 increased 
potential for allosteric regulation,4 and decreased enzyme dynamics.1 
 
5.2.1 The quaternary structure of wild-type M. tuberculosis DHDPS 
The tetrameric quaternary structure of DHDPS is conserved in a broad range of species, as 
outlined in Table 1.4, chapter one, section 1.5.1. In chapter two, M. tuberculosis DHDPS was 
characterized and demonstrated unequivocally to be a stable tetramer in solution, consistent 
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with the crystal structure of the enzyme, deposited as PDB entry 1XXX. Wild-type 
M. tuberculosis DHDPS did not observably dissociate at high dilutions (~0.01 mg.mL-1) in 
gel-filtration chromatography, or (0.06 mg.mL-1) in analytical ultracentrifugation (AUC) 
experiments. Kinetic parameters comparable to E. coli DHDPS were determined using the 
coupled assay, as detailed in Table 2.5, chapter two, section 2.4.4, thus it seems wild-type 
M. tuberculosis DHDPS is functional as a non-dissociating tetramer. 
 
X-ray crystallography data indicated that this tetramer was very similar to E. coli DHDPS, 
with near identical active-site geometry. M. tuberculosis DHDPS contains all active-site 
residues identified in E. coli DHDPS, except asparagine 248, as has been noted for other 
Gram-positive bacterial DHDPS orthologues.5 The allosteric (S)-lysine binding site is absent 
from M. tuberculosis DHDPS, which is consistent with the lack of inhibition by (S)-lysine. 
Like the E. coli enzyme, M. tuberculosis DHDPS can be described as a dimer of 
“tight-dimers”, although the “weak” interface between “tight-dimer” subunits had a higher 
buried surface area, with a larger number of interactions, than its E. coli counterpart 
(Figure 3.3, chapter three, section 3.4.1). This may contribute to the observation that a 
tyrosine mutation at the centre of the “weak” interface (L197Y) results in a dimeric version of 
E. coli DHDPS, but the corresponding mutation in M. tuberculosis DHDPS (A204Y) does 
not, as judged by BN-PAGE, Figure 3.7, chapter three, section 3.6.3. 
 
5.2.2 The quaternary structure of DHDPS-A204R 
The tetrameric quaternary structure was successfully disrupted in A204R M. tuberculosis 
DHDPS, as shown by BN-PAGE, gel-filtration chromatography and AUC. A dimeric 
quaternary structure was observed in the crystal structure of DHDPS-A204R; however, both 
monomeric and dimeric oligomeric states were observed with gel filtration and 
ultracentrifugation. The monomer-dimer equilibrium was quantified using sedimentation 
equilibrium AUC experiments, in 20 mM Tris.HCl, pH 8.0 150 mM NaCl yielding a 
dimerization dissociation constant (KD2?1) of 51 μM (or 1.6 mg.mL-1). This KD2?1 is three 
orders of magnitude higher than the value of 33 nM determined for the natural dimer of 
MRSA DHDPS.6 The CD spectra, reported in chapter three, were recorded at 0.2 mg.mL-1 in 
the same buffer, and therefore the similarity between wild-type and DHDPS-A204R, 
predicted to be 85 % monomer by its KD2?1 (using Equation 4.1, chapter four, section 4.4.2), 
indicates that the secondary structure has been preserved in the monomer of DHDPS-A204R. 
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X-ray crystallography shows the dimer of DHDPS-A204R to have analogous secondary and 
tertiary structure to wild-type M. tuberculosis DHDPS. 
 
Pyruvate, the first substrate of DHDPS, was shown by both gel filtration and 
ultracentrifugation to shift the monomer-dimer equilibrium of DHDPS-A204R towards dimer. 
At pyruvate concentrations greater than or equal to 0.5 mM, the KD2?1 shifted to below 
0.01 mg.mL-1 (0.32 μM), as judged by analytical gel filtration (Figure 4.14, chapter four, 
section 4.4.3), and is only slightly affected by increasing pyruvate concentration. Similarly, 
pyruvate affects the KD2?1 of MRSA DHDPS; although it caused only a 20-fold,6 rather than a 
greater than 100-fold decrease. The lack of monomer observed for the interface mutants of E. 
coli DHDPS may be caused by the pyruvate analogue, α-ketoglutarate, found covalently 
bound in crystal structures,1 as it is plausible that α-ketoglutarate may shift the monomer-
dimer equilibrium in a similar manner to pyruvate. 
 
The binding of pyruvate was shown to increase the thermal stability of DHDPS; irrespective 
of oligomeric state, as the apparent melting temperature was similarly increased (~7 °C) for 
both tetrameric wild-type enzyme and DHDPS-A204R (section 4.3.2, chapter four). The 
X-ray crystallographic structure of DHDPS-A204R showed pyruvate to be covalently bound 
to the key catalytic residue, lysine 171, forming polar contacts with backbone amides of two 
absolutely conserved threonines, as has been observed in other DHDPS enzymes (section 
1.3.2, chapter one). One of these threonines (T54) is also a member of the proton relay, and is 
directly hydrogen bonded to Y117, which “reaches in” from the adjacent monomer. This 
provides a direct link between pyruvate and the tight-dimer interface.  
 
The effect of pyruvate can be conceptualized in two different ways. Pyruvate could 
preferentially bind the dimer, stabilizing it thermodynamically and thus shift the equilibrium 
towards dimer (Figure 5.1A). Alternatively, the monomer could be considered to exist in an 
ensemble of conformations,7-9 and binding of pyruvate to the monomer could induce a 
conformation that preferentially forms dimers (Figure 5.1B). Either or both models explain 
the experimental observations. 
 
 
 
 
Summary and conclusions 161 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Schematic representation of the two alternative explanations for the effect of 
pyruvate (purple diamond) on the monomer-dimer equilibrium of 
DHDPS-A204R. In (A) pyruvate binds to the dimer species increasing its 
stability. In (B) the monomer is conceptualized as adopting an ensemble of 
conformers in solution, pyruvate binds to the monomer species inducing a 
structural conformation that preferentially forms dimer. 
 
5.2.3 The quaternary structure of DHDPS-A204R is not critical for catalysis 
Kinetic analysis showed DHDPS-A204R to have a turnover rate (kcat) similar to wild-type 
M. tuberculosis DHDPS (as reported in chapter four, section 4.3.3). This was unexpected 
given that previous results with dimeric E. coli DHDPS showed a substantial drop in kcat to 
1.4 to 2.5 % that of wild-type E. coli DHDPS.1 This decrease was in part due to the presence 
of a covalently bound inhibitor, α-ketoglutarate, believed to be acquired in vivo due to lower 
substrate specificity of the dimeric E. coli mutants.1 Pyruvate was observed to displace 
α-ketoglutarate from the dimeric variants of E. coli DHDPS, as evident by mass spectrometry, 
although the activity was increased to only ~20 % that of wild-type.1 DHDPS-A204R purified 
in the presence of pyruvate had a kcat of ~85 % compared to wild-type M. tuberculosis 
DHDPS. Since wild-type dimeric MRSA DHDPS shows comparable activity to its tetrameric 
orthologues, such as E. coli DHDPS6 and M. tuberculosis DHDPS, kinetic analysis would 
seem to indicate that DHDPS-A204R is more similar to the natural dimer of MRSA DHDPS 
than to the disrupted quaternary structure mutants of E. coli DHDPS. 
 
Although the maximal catalytic rate (kcat) was unaffected by disrupted quaternary structure, a 
decrease in substrate affinity is reflected in the increased Michaelis constant (KM) of DHDPS-
A204R for both pyruvate and (S)-ASA. The value of 0.33 (±0.03) mM for pyruvate is 
º º
ºº
(B) 
(less stable) 
º 
(less stable) (more stable) 
pyruvate 
(A) 
pyruvate 
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increased two-fold in comparison to wild-type M. tuberculosis DHDPS, and three-fold 
compared to the wild-type MRSA DHDPS. A greater increase of ~10-fold was seen in the 
disrupted quaternary structure mutants of the E. coli enzyme, such as dimeric 
DHDPS-L197Y, and the monomer-dimer-tetramer DHDPS-Y107W.1,10 However, in these 
cases the KM values are likely to reflect the presence of the covalent adduct, α-ketoglutarate, 
in the active site,1,10 whereas this adduct is absent in M. tuberculosis DHDPS-A204R, as 
shown by the crystal structure (Figure 4.16B, chapter four, section 4.5.3), and therefore the 
KM values are not directly comparable. 
 
Monomeric DHDPS-A204R, missing the active-site residue, Y117, is predicted to have 
reduced activity, consistent with the concentration-dependent decrease in activity of MRSA 
DHDPS reported in literature and attributed to its dissociation into monomer.6 The percentage 
of monomer under the assay conditions for M. tuberculosis DHDPS-A204R has not been 
determined, since the monomer-dimer equilibrium was quantified in the absence of pyruvate 
with sedimentation equilibrium AUC experiments. In an analogous system, the different 
kinetic parameters for alternative oligomeric forms of porphobilinogen synthase manifest as 
double hyperbolae in the kinetic analysis,11 and these were suggested as being a general 
feature of enzymes existing in multiple oligomeric states.9 The single hyperbola observed for 
DHDPS-A204R, which exhibited a good fit to the models used, seems to suggest that a single 
oligomeric species was characterized, or that the kinetics of the DHDPS-A204R monomer 
and dimer are equivalent.12 However, it should be noted that to successfully fit the kinetic data 
of DHDPS-A204R to double hyperbolae knowledge of the percentage of monomer under 
assay conditions would be required, which was not available in this case. 
 
In summary, the kcat of DHDPS-A204R clearly indicates that tetrameric quaternary structure 
is not critical for catalysis in M. tuberculosis DHDPS. The kcat was only slightly affected by 
disrupted quaternary structure, and was similar to other wild-type DHDPS enzymes, including 
the naturally dimeric MRSA DHDPS. The increased KM values for both substrates, indicate 
that the dimeric species is somewhat less efficient than the wild-type enzyme, with kcat/KM 
values of 360 (±52) and 108 (±15) s-1.mM-1 for pyruvate and (S)-ASA, respectively. However, 
this effect is not substantial enough to justify targeting inhibitors to disrupt the weak interface 
of M. tuberculosis DHDPS, which precludes interface disruption as a means of inhibiting this 
enzyme. 
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5.2.4 The quaternary structure of DHDPS-A204R may decrease stability 
The tetrameric quaternary structure of M. tuberculosis DHDPS may be important for the 
stability of the enzyme. The disrupted quaternary structure of DHDPS-A204R resulted in 
decreased thermal stability shown by the substantial drop in the apparent melting temperature 
(Tmapp) of ~30 ºC compared to wild-type, as shown by both DSF and the coupled assay 
(section 4.2.1 and 4.3.2, chapter four). However, the change in Tmapp needs to be considered 
cautiously, since DHDPS-A204R has been engineered to expose a hydrophobic interface that 
would ordinarily be buried, which undoubtedly contributes to the loss of thermal stability. The 
mutant DHDPS-A204R also seemed prone to aggregation in the absence of pyruvate, 
probably due to dissociation into monomers, which hinted that quaternary structure may play 
a role in protecting against aggregation. 
 
5.2.5 Comparison of the tight-dimer interfaces of characterized DHDPS 
enzymes from different species  
The modulated importance of tetramerization in catalysis for M. tuberculosis DHDPS, 
compared with E. coli DHDPS, suggested similarities with the naturally dimeric MRSA 
DHDPS. The tight-dimer of MRSA DHDPS had an increased number of contacts and greater 
buried surface area than E. coli DHDPS, and this was proposed to reduce the dynamics in a 
manner similar to tetramerization in E. coli DHDPS.6 Since the X-ray crystal structures of 
various DHDPS had been determined, their tight-dimer interfaces were examined in 
comparison with MRSA DHDPS,6 and this analysis is extended here to provide a rationale for 
the range of activities observed for dimeric DHDPS enzymes. 
 
The association of monomers to form the dimer of M. tuberculosis DHDPS-A204R buries 
1414 (±3) Å2 of the solvent-accessible surface area.13 This is within the 1200-2000 Å2 range 
not expected to result in large conformational changes upon complex formation,14 and thus is 
consistent with the unchanged secondary structure of DHDPS-A204R monomer compared to 
the wild-type tetramer (discussed in section 5.2.2). The interface involves 40 (±1) residues, 
seven of which are completely buried, including, Y117, and its hydrophobic stacking partner, 
Y116. The substrate binding residues T54 and R148 form inter-subunit hydrogen bonds with 
Y117, which together contribute four interface hydrogen bonding interactions to the total of 
14 observed in all three dimers in the asymmetric unit. There were only slight differences 
with the equivalent tight-dimer interfaces in the crystal structure of wild-type M. tuberculosis 
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DHDPS, burying a surface area of 1466 (±5) Å2, involving the same 40 interface residues as 
DHDPS-A204R, and with 16 inter-subunit hydrogen bonds apparent in all four tight-dimers 
in the asymmetric unit. 
 
An aromatic stacking interaction between two tyrosines, Y90 and its counterpart on the 
opposite subunit was identified at the tight-dimer interface of M. tuberculosis DHDPS 
(Figure 5.2A), but is absent in the E. coli enzyme (Figure 5.2B). The energetically 
favourable interactions of buried or partially buried aromatic residues contribute to the 
stability of tertiary and quaternary structure,15 and aromatic clusters have been linked with the 
improved thermal stability in enzymes from thermophiles.16 Y90 contributes to the 
hydrophobic stack involving Y116 and Y117, resulting in six tyrosines forming hydrophobic 
and π interactions, with the T-shaped and parallel-displaced geometry common in 
proteins.15,17 The larger network of interacting aromatic side chains of M. tuberculosis 
DHDPS-A204R in comparison to E. coli DHDPS-L197D (Figure 5.2) is proposed to 
decrease the dynamic fluctuations, such as subunits reorientating themselves in relation to 
each other, and consequently maintain a catalytic rate comparable with the wild-type enzyme. 
 
                            
Figure 5.2: The aromatic network buried in the tight-dimer interface of (A) wild-type 
M. tuberculosis DHDPS (green) overlaid with mutant DHDPS-A204R (blue) and 
(B) wild-type E. coli DHDPS (orange) overlaid with mutant DHDPS-L197Y 
(blue). Chain B is indicated by lighter colours. The interface tyrosines and 
proton-relay tyrosines from both subunits are shown as thick lines. 
 
One of the aromatic residues, Y117 in M. tuberculosis DHDPS, is of particular interest, being 
the key catalytic residue that interdigitates across the tight-dimer interface (Figure 5.2A). 
This provides a rationale for dynamic motion affecting enzyme activity (chapter one, 
section 1.5.3). In M. tuberculosis DHDPS, this residue (M. tuberculosis: Y117, E. coli: Y107, 
(A) (B) 
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MRSA: Y109) is twisted relative to the equivalent residue in the E. coli enzyme (chapter two, 
section 2.6.3). In MRSA DHDPS, the twisting of this tyrosine in comparison to the E. coli 
enzyme is postulated to provide closer aromatic stacking interactions than in E. coli DHDPS.6 
 
The aromatic cluster at the tight-dimer interface in MRSA DHDPS involved four tyrosines, 
analogous to E. coli DHDPS, so it is unlikely the aromatic network decreased dynamic 
motions in a manner similar to that postulated for M. tuberculosis DHDPS-A204R. However, 
analysis of the tight-dimer interface in MRSA DHDPS identified a salt bridge involving an 
arginine (R115) and glutamate (E275). Salt bridges have also been linked with the improved 
thermal stability in enzymes from thermophiles.18 The salt bridges in naturally dimeric MRSA 
DHDPS are thus hypothesized to decrease movement, in a similar manner to the aromatic 
cluster in M. tuberculosis DHDPS-A204R. 
 
The largest and smallest tight-dimer interfaces determined for DHDPS to date have been from 
MRSA and E. coli DHDPS, respectively.6 These interfaces, along with the previously 
unexamined interface of E. coli DHDPS-L197Y were analyzed for comparison with the dimer 
interface of M. tuberculosis DHDPS-A204R (Table 5.1). A similar number of hydrogen 
bonds was identified in the tight-dimer interfaces of MRSA and M. tuberculosis DHDPS-
A204R, which was more than double the number identified for E. coli DHDPS-L197Y 
(Table 5.1). 
 
Table 5.1: Comparison of the tight-dimer interface in dimeric DHDPS and their tetrameric 
counterparts, prepared using the web-based PISA program.13 
SISAa due to interface 
Species Enzyme PDB code 
(Å2)  % of total 
H-bonds 
formed 
Interface 
residues 
E. coli DHDPS-L197Y 2OJP 1315 (±1) 11.2 % 7 36 (±0.0) 
E. coli wild-type DHDPS 1YXC 1289 (±7) 11.2 % 7 38 (±0.7) 
M. tuberculosis  DHDPS-A204R pending 1414 (±3) 12.0 % 14 40 (±0.8) 
M. tuberculosis  wild-type DHDPS 1XXX 1466 (±5) 12.5 % 16 40 (±0.4) 
MRSA wild-type DHDPS 3DAQ 1661 (±17) 13.2 % 17 49 (±1.2) 
 
a  SISA = solvent-inaccessible surface area 
 
When considering the dimeric DHDPS variants, E. coli DHDPS-L197Y, M. tuberculosis 
DHDPS-A204R and MRSA DHDPS, there is a trend of increasing interface size, participating 
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residues and number of hydrogen bonds (Table 5.1 and Figure 5.3). This aligns well with 
their catalytic ability, as E. coli DHDPS-L197Y shows a low rate of catalysis and low 
substrate affinity, M. tuberculosis DHDPS-A204R shows a high catalytic rate and somewhat 
reduced substrate affinity, and MRSA DHDPS has a high rate of catalysis and high substrate 
affinity. 
 
 
Figure 5.3: Surface view of the monomer showing the tight-dimer interface from (A) the 
dimeric E. coli mutant DHDPS-L197Y, (B) the dimeric M. tuberculosis mutant 
DHDPS-A204R, and (C) wild-type dimeric MRSA DHDPS. The residues 
contributing to the interface, shown in various shades depending on their buried 
surface area (5 - 44 % yellow, 45 - 84 % orange, ≥85 % red) as defined by 
PISA.13 
 
Previous investigations with homodimers found a lack of correlation between overall binding 
energy and interface size,19 probably because interface size is just one component that 
contributes to the binding energy of dimerization. However, a correlation between interface 
size and strength in DHDPS enzymes seems to be reflected in the dissociation constant KD2?1 
determined in the absence of pyruvate, as the KD2?1 of M. tuberculosis DHDPS-A204R is 
orders of magnitude higher than the value determined for MRSA DHDPS (mentioned in 
section 5.2.2). This analysis is entirely consistent with the hypothesis that increased dynamics 
are associated with decreased catalytic ability, and correlated with the strength of the 
interface, as proposed by Burgess et al.6 
 
5.3 Suggestions for future work 
This work focused on disruption of the weak interface to create a dimeric variant of 
M. tuberculosis DHDPS; however, the observation that DHDPS-A204R exists in 
monomer-dimer equilibrium, suggests a monomeric mutant of M. tuberculosis DHDPS could 
(A) (B) (C) 
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also be created to further probe the role of quaternary structure. Additionally, the 
determination of the KD2?1 of DHDPS-A204R in the presence of pyruvate, with sedimentation 
equilibrium AUC experiments, may allow the kinetic characterization of the monomeric 
species of DHDPS-A204R. The lower concentration needed to investigate this KD2?1 may 
require fluorescent-labelled protein and the recent instrumental advancement of coupling 
fluorescence detection with AUC, used in the study of MRSA DHDPS.6 
 
The interesting effects of the substrate, pyruvate, on the thermal stability and oligomerization 
of DHDPS-A204R has relevance to developing the understanding of the relationship between 
dynamics and oligomerization in DHDPS. Consequently, further studies are suggested 
monitoring the effect of pyruvate and temperature on secondary structure using CD 
spectrometry. The crystal structure without pyruvate bound, or of the monomeric species of 
DHDPS-A204R may also be informative when considering the two alternative hypotheses for 
the effect of pyruvate on oligomerization as outlined in Figure 5.1. 
 
5.4 Conclusion 
Remarkably, the weak interface between the tight-dimer subunits of M. tuberculosis DHDPS 
was disrupted by a single site-directed mutation to create a functioning dimeric species, 
DHDPS-A204R. The catalytic competency of this enzyme can be understood by comparison 
to other species, specifically by comparing the extent of the tight-dimer interactions; that is, 
only DHDPS enzymes with a poorly developed tight-dimer interface require the tetrameric 
structure for catalysis. In the case of M. tuberculosis DHDPS, the homotetrameric quaternary 
structure perhaps plays a role in maintaining protein stability, or maybe the association of 
tight-dimers into the tetramer involves vestigial interfaces which are no longer required for 
function. 
 
New criteria should be considered in the future when exploring interface disruption of 
DHDPS as an approach to drug design. The tight-dimer interface should be analyzed and 
compared with those of E. coli, M. tuberculosis and MRSA DHDPS, and those DHDPS 
orthologues with poorly developed tight-dimer interfaces should be pursued, as it is more 
likely these will exhibit a similar loss of catalytic rate due to disruption of quaternary structure 
as that observed with E. coli DHDPS.  
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For M. tuberculosis DHDPS, future drug discovery efforts will be directed at the active site, 
rather than targeting protein-protein interfaces. However, this work provides a framework 
through which to discriminate DHDPS enzymes that are likely to be inactive as dimers, such 
that future drug discovery efforts using the interface targeting approach can be directed there. 
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Chapter Six 
Experimental 
6.1 Materials and equipment 
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich Chemical Company 
Ltd. (Castle Hill, Australia) and all enzyme manipulations occurred at 4 °C or on ice. 
SDS-PAGE, native PAGE gels, associated buffers, gel boxes, and power units were 
purchased from Invitrogen (Auckland, New Zealand). Protein ladders were purchased from 
Fermentas (via Global Sciences, Christchurch, N.Z.), Sigma-Aldrich, and Invitrogen. Bio-Rad 
protein assay kit and DNA ladders were supplied by Bio-Rad Laboratories (Auckland, N.Z.) 
Restriction enzymes were supplied by Roche (Christchurch, N.Z.). E. coli strains and 
mutagenesis kits were purchased from Stratagene (via Global Sciences, Christchurch, N.Z.). 
Column chromatography media were purchased from GE Healthcare (Auckland, N.Z.) as 
pre-packed columns or loose beads to be packed in XK type columns. 
 
Centrifugation at 4 ºC was mainly carried out in an Eppendorf Centrifuge model 5810R, using 
different Eppendorf rotors for small volumes (≤1.5 mL, F-45-30-11, max speed of 14000 
rpm), moderate volumes (≤50 mL, F-45-30-11, max speed of 12000 rpm), and large volumes 
(≤500 mL, A-4-81, max speed of 4000 rpm). Chromatography columns were run using a 
UPC-900 ÄKTA FPLC (GE Healthcare), which was loaded using either a Gilson Minipuls 
M312 peristaltic pump or a syringe. The fractions were collected with a Frac-950 fraction 
collector (GE Healthcare). Ultraviolet (UV) absorbance was recorded either by using a Diode 
Array spectrophotometer (Hewlett Packard, model 8452A or 8453), a Nanodrop ND 1000 
spectrophotometer (Thermo Scientific) or a Smart Spec Plus spectrophotometer (Bio-Rad). 
 
6.2 Microbiological and molecular biological methods 
The experimental section from the PhD thesis “Why is dihydrodipicolinate synthase a 
tetramer?”, authored by Griffin,1 was an invaluable reference for the development of 
experimental methods. The laboratory text “Molecular Cloning: A laboratory manual”, 
authored by Sambrook et al.,2 provided an excellent resource for protocols for DNA and 
bacterial strain manipulation, as did instruction manuals from Stratagene and Novagen. 
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All bacterial cultures were grown under sterile conditions. All media and equipment were 
sterilized by either autoclaving at 121 ºC for 20 min or filtration through a 0.2 μm syringe tip 
filter from Millipore (via Biolab, Christchurch, N.Z.), or were purchased sterile. All 
manipulations of bacterial cultures occurred within the sterile environment created by a flame 
or a laminar fume hood. Standard sterile technique was employed and when necessary 
appropriate controls were performed alongside experiments to monitor for possible 
contamination. 
 
6.2.1 Bacterial strains 
In this study, several bacterial strains were explored for optimum protein expression. These 
strains were originally derived from E. coli BL21 (DE3), and all derivatives except 
BL21 (DE3) pGroESL were purchased directly from Stratagene. BL21 (DE3) pGroESL was 
produced by transforming competent cells of BL21 (DE3) from Stratagene with pGroESL. 
The plasmid pGroESL, which expresses the E. coli folding chaperone proteins GroES and 
GroEL, was kindly donated by Celia Webby (Massey University, N.Z.). The plasmid 
pGroESL was originally developed by George Lorimer’s Lab (E. I. Dupont De Nemours and 
Company, Wilmington, DE, U.S.A.) and has been shown to increase soluble protein yield.3 
The bacterial strains used in this research are shown in Table 6.1. 
 
Table 6.1: E. coli strains used plasmid manipulation and protein expression. 
Strain Derived from Key features Antibioticr 
XL1-Blue K-12 Cloning, plasmid preps, supports growth of vectors carrying 
mutations, allows for blue/white screening on X-gal plates 
Tetr  
DH5α K-12 Cloning, plasmid preps  -- 
BL21 (DE3) pLysS BL21 (DE3) Lacks Lon & ompT proteases, inducible & supressed basal 
expression (with T7 lysozyme) of T7 RNA polymerase  
Camr  
BL21 (DE3) pGroESL BL21 (DE3) Lacks Lon & ompT proteases, inducible expression of T7 RNA 
polymerase & expression of heat shock folding chaperonins 
GroEL & GroES 
Camr  
BL21-CodonPlus® 
(DE3) RIL 
BL21 (DE3) Lacks Lon & ompT proteases, inducible expression of T7 RNA 
polymerase & expression of tRNAs recognizing rare codons 
(AGA/AGG, AUA, and CUA) 
Camr  
BL21-CodonPlus® 
(DE3) RP 
BL21 (DE3) Lacks Lon & ompT proteases, inducible expression of T7 RNA 
polymerase & expression of tRNAs recognizing rare codons 
(AGG/AGA and CCC) 
Camr  
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Additional E. coli strains used were XL1-Blue and DH5α, also obtained from Stratagene. 
Both strains are recombination (recA) deficient, improving plasmid insert stability, do not 
produce endonuclease I (endA), which degrades DNA, and thus are excellent for mutagenesis 
and plasmid preparation. The genotypes of these and other strains used are listed in Table 6.2. 
 
Table 6.2: E. coli strains used and their associated genotypes. 
Strain Genotype 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac- [F' proAB+ lacIq lacZΔM15 (Tetr)] 
DH5α supE44 ΔlacU169 (Φ80 lacZΔM15 ) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 
BL21 (DE3) F- ompT hsdS(rB- mB-) dcm+ gal λ(DE3) 
BL21 (DE3) pLysS F- ompT hsdS(rB- mB-) dcm+ gal λ(DE3) [pLysS Camr] 
BL21 (DE3) pGroESL F- ompT hsdS(rB- mB-) dcm+ gal λ(DE3) [pGroESL groES groEL Camr] 
BL21-CodonPlus® (DE3) RIL F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ(DE3) endA Hte [argU ileY leuW Camr] 
BL21-CodonPlus® (DE3) RP F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ(DE3) endA Hte [argU proL Camr] 
 
6.2.2 Plasmids 
The plasmids utilized in this work were based on several different vector systems, as listed in 
Table 6.3. The genes dapA and dapB from E. coli had been previously cloned into the 
Stratagene plasmid pBluescript KS+ by others.4-8 pTM1520, containing dapB from 
T. maritima with a purification tag (MGSDKIHHHHHH) at its amino terminus, was a 
generous gift from Scott Lesley and Heath Klock (Joint Center for Structural Genomics, 
Genomics Institute of the Novartis Research Foundation, San Diego, USA). E. coli XL1-Blue 
strains were available that had been transformed with these plasmids. 
 
The plasmid containing dapA from M. tuberculosis was a generous gift from collaborators 
Manfred S. Weiss and Georgia Kefala (EMBL Hamburg Outstation, Hamburg, Germany). 
The plasmid pMTB02 consisted of M. tuberculosis dapA cloned into pETM-11. The vector 
pETM-11 is a modified version of the Novagen plasmid pET-24d containing an N-terminal 
polyhistidine tag with a TEV protease cleavage site (Appendix A). The pET system allows 
for inducible protein expression in which T7 RNA polymerase transcribes genes cloned under 
control of a T7lac promoter (detailed in Appendix A). Thus protein expression in this system 
requires both a bacterial strain with produces T7 RNA polymerase, such as E. coli 
BL21 (DE3),9 and an inducer, such as isopropyl thiogalactoside (IPTG), to bind to the lac 
repressor and allow gene transcription.10 
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The plasmid pMTB02 was introduced into E. coli BL21 (DE3) pLysS and BL21-CodonPlus® 
(DE3) RP using competent cells prepared by the calcium chloride method,1 and into 
BL21 (DE3) pGroESL using the electroporation method.1 Successful transformants were 
identified by the conferred kanamycin resistance (Kanr). 
 
Table 6.3: Plasmids used for protein expression and their associated genotypes. 
Plasmid Ref. Derived from Reference/source Relevant genotype 
pJG001 5 pBluescript KS+ (Stratagene) :: dapA (E. coli), Ampr  
pJK001 4 pBluescript KS+ (Stratagene) :: dapB (E. coli), Ampr  
pTM1520 11 pMH1 12 :: dapB (T. maritima), Ampr  
pTOPO-TM1520 (in-house) pTOPO 11 :: dapB (T. maritima), Ampr  
pMTB02 13 pETM-11 14 :: dapA (M. tuberculosis), Kanr  
pMTBA204Y (this work) pETM-11 14 :: dapA-ala204tyr (M. tuberculosis), Kanr  
pMTBA204D (this work) pETM-11 14 :: dapA-ala204asp (M. tuberculosis), Kanr  
pMTBA204R (this work) pETM-11 14 :: dapA-ala204-arg (M. tuberculosis), Kanr  
pGroESL 3 pACYC184 15 :: groES and groEL (E. coli), Camr  
pRK793  16 pMal-C2 (New England Biolabs) :: NIa protease-ser-219-val (TEV), Ampr 
 
The insertion of the dapB gene from pTM1520 into the pTOPO vector by Dr Grant Pearce 
resulted in a new plasmid called pTOPO-TM1520.11 E. coli BL21 (DE3) pLysS strains that 
had been transformed by pTOPO-TM1520 were available. 
 
The plasmid pRK793 was acquired through the non-profit organization Addgene 
(http://www.addgene.org), which distributes certain useful plasmids found in the published 
literature. Kapust and colleagues rationally designed a tobacco etch virus (TEV) protease 
mutant, S219V, which is 100-fold more stable than wild-type protease and does not 
self-cleave.16 The plasmid pRK793 expresses the mutant TEV protease with a polyhistidine 
tag (GHHHHHHH) and a polyarginine tag, on the N- and C-terminus respectively, for 
purification and solubility purposes.16 E. coli BL21-CodonPlus (DE3)® RIL strains that had 
been transformed by pRK793 were available. 
 
6.2.3 Antibiotics and other media supplements 
Stock and working concentrations of antibiotics used for bacterial selection are shown in 
Table 6.4. Stock solutions were prepared with the appropriate solvent, sterilized by filtration 
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and stored at -20 ºC. For selection of bacterial strains, the appropriate antibiotics were added 
to cultures, using a 1/1000 dilution, to give the final working concentration. 
 
Table 6.4: Antibiotic concentrations used for bacterial selection. 
Antibiotic Abbreviation Solvent [Stock] mg.mL-1 [Working] μg.mL-1 
Ampicillin Amp d-H2O 100 100 
Chloramphenicol Cam EtOH 30 30 
Kanamycin Kan d-H2O 30 30 
Tetracycline Tet MeOH 15 15 
 
Stock solutions of IPTG and arabinose were prepared for inducing protein expression. To 
suppress protein expression in inducible systems prior to induction, glucose was added to 
overnight starter cultures.17 IPTG was also used, along with X-gal, for blue/white screening, 
which is a method for determining mutagenesis efficiency.18 Stock solutions were prepared 
with the appropriate solvent, as listed in Table 6.5, sterilized by filtration and stored at -20 ºC. 
 
Table 6.5: Nutritional supplements and other additives concentrations. 
Additive/supplement Abbreviation Solvent [Stock] mg.mL-1 [Working] μg.mL-1 
Arabinose  -- d-H2O 10 100 
meso-Diaminopimelate DAP d-H2O 10 50 
Glucose  -- d-H2O 50 500 
Isopropyl thiogalactoside IPTG d-H2O 60 60 
5-Bromo-4-chloro-3-indolyl-β-
D-galactopyranoside  X-gal DMF 20  -- 
 
6.2.4 Media and plate preparation 
Luria-Bertani medium (LB) 
LB broth components were supplied in a ready to use mix, in powder form. The LB was 
dissolved in distilled water with a ratio of 20 g to 1 L of water and autoclaved to sterilize. 
Flasks of 0.75 and 1 L were prepared and autoclaved, as well as vials of 3, 5 and 10 mL. 
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Super optimal broth (SOB), with catabolite repression (SOC) 
A stock solution of 250 mM potassium chloride (KCl) was prepared in advance and sterilized 
in an autoclave. For catabolite repression, a 1 M glucose stock solution was also prepared in 
advance, sterilized by filtration and stored at -20 ºC. 
 
To prepare SOB, 10 g of tryptone, 2.5 g of yeast extract and 0.25 g NaCl were dissolved in 
480 mL of distilled water. Before making up to 500 mL with distilled water, 10 mL of 
250 mM KCl was added and the pH adjusted to 7.0 with concentrated NaOH. The SOB 
medium was aliquoted and autoclaved. 
 
For SOC media, 1 M glucose was added to SOB, under sterile conditions just prior to use, to 
give a final concentration of 20 mM glucose. 
 
ZYM-5052 auto-inducing medium 
Based on the protocol developed by Studier,17 several stock solutions were prepared in 
advance and stored at room temperature. For the 50× 5052 stock, 125 mL of glycerol, 12.5 g 
of glucose and 50 g of lactose were dissolved in 500 mL of distilled water, aliquoted into 15 
mL and autoclaved. For the 50× M stock, 167.5 g of disodium phosphate heptahydrate 
(Na2HPO4.7H2O), 85.1 g of monopotassium phosphate (KH2PO4), 66.9 g of ammonium 
chloride (NH4Cl), and 17.8 g of sodium sulfate (Na2SO4) were dissolved in 500 mL of 
distilled water, aliquoted into 15 mL and autoclaved. For the 1000× trace metal solution, a 
stock solution of 0.1 M iron trichloride (FeCl3) was dissolved in 1 % concentrated HCl, and 
subsequently diluted and combined with stock solutions of other metals to give 50 mM FeCl3, 
20 mM calcium chloride (CaCl2), 10 mM manganese dichloride (MnCl2), 10 mM zinc sulfate 
(ZnSO4), 2 mM cobalt dichloride (CoCl2), 2 mM copper dichloride (CuCl2), 2 mM nickel 
chloride (NiCl2), 2 mM sodium molybdate (Na2MoO4), 2 mM sodium selenite (Na2SeO3), 
2 mM boric acid (H3BO3) in approximately 60 mM HCl. For the 1 M magnesium sulfate 
(MgSO4) stock, 6.02 g of MgSO4 was dissolved in 50 mL of distilled water and filter 
sterilized. 
 
In a flask, 7.5 g of tryptone and 3.75 g of yeast extract were dissolved in 750 mL of distilled 
water and autoclaved. Just prior to inoculation and supplementation with appropriate 
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antibiotics, 15 mL of 5052 stock, 15 mL of M stock, 150 μL of trace metal stock, and 750 μL 
of 1 M MgSO4 were added to the flask, under sterile conditions. 
 
Agar plates 
Bacteriological agar was dissolved in LB medium at a ratio of 15 g to 1 L and autoclaved to 
sterilize. Once cooled or reheated to ~50 ºC, the appropriate antibiotics were added and the 
molten media were poured onto sterile Petri dishes in the Bio-hazard hood. Any bubbles were 
removed by flaming the surface before the agar set. For blue/white screening, plates were pre-
treated by spreading 14 μL of 60 mg.mL-1 IPTG and 40 μL of 20 mg.mL-1 X-gal on to the 
surface, and allowing 30 min for the DMF to evaporate. 
 
6.2.5 Bacterial cultures 
Agar plates containing appropriate selective antibiotics were streaked with a bacterial strain 
from a glycerol freeze stock, an overnight culture or a fresh single colony, using a flame-
sterilized nichrome wire loop. The plates were incubated for at least 9 hrs at 37 ºC. Individual 
colonies were selected using a sterile pipette tip and used to inoculate 3 or 5 mL of liquid 
medium containing appropriate selective antibiotics. Starter cultures were grown overnight at 
37 ºC, with shaking at 200 rpm, and subsequently used to inoculate larger quantities of media. 
 
Glucose was included with starter cultures when protein production was under the control of 
the T7lac promoter, preventing low level protein expression.17 Auto-inducing media worked 
on the same principle, with induction repressed by glucose until it was sufficiently depleted, 
and with the addition of many components to support the growth of high density culture.17 
Bacterial cultures grown in LB media required the addition of the inducer IPTG (or arabinose, 
in the case of pTM1520), after sufficient bacterial growth (OD600 of ~0.60), in order to induce 
protein expression. 
 
6.2.6 Bacterial strain storage 
Glycerol freezer stocks were used to store bacterial strains. These were prepared by 
centrifuging (5000 rpm, 3 min, 4 ºC), in a screw-top cryo-storage tube, an aliquot (1.5 mL) 
from an overnight culture (3.0 mL) produced by inoculation with a single bacterial colony. 
The supernatant was removed and the cell pellet was gently re-suspended in 0.5 mL of 
overnight culture and 0.5 mL of sterile 30 % glycerol, and then stored at -80 ºC. 
Experimental 177 
 
 
6.2.7 Plasmid preparation by alkaline lysis 
Based on the protocol outlined in Sambrook et al.,19 the following stocks were prepared: 
Solution #1, pH 8.0 50 mM glucose 
(stored at -20 ºC) 25 mM Tris.HCl 
 10 mM EDTA 
Solution #3 3 M potassium acetate 
(stored at -20 ºC) 11.5 % (v/v) glacial acetic acid 
TE Buffer, pH 8.0 40 mM Tris.HCl 
(stored at room temp.) 1 mM EDTA 
 
Small scale preparation 
A single bacterial colony was selected from an agar plate and used to inoculate a vial of LB 
broth, containing appropriate antibiotics, and incubated overnight (37 ºC, 200 rpm). 
Subsequently, the overnight culture was centrifuged (7000 rpm, 2 min, 4 ºC) in two 
Eppendorf tubes (1.5 mL/tube). Solutions #1 and #3 were defrosted and kept cold on ice. 
Solution #2 was freshly prepared: 
Solution #2 0.2 M NaOH 
(kept at room temp.) 1 % (w/v) SDS 
 
The supernatant was removed from the Eppendorf tubes by aspiration, and the pellet was 
re-suspended in 100 μL of ice-cold solution #1 with vigorous vortexing and chilled on ice. 
After 5 min, 200 μL of freshly prepared solution #2 was added to each tube, mixed by gentle 
inversion, and the tubes were chilled on ice. After 10 min, 150 μL of ice-cold solution #3 was 
added to the preparations, mixed by flicking and inverting until a white precipitate formed, 
and once again chilled on ice (for 10 min). The preparations were centrifuged (12000 rpm, 
5 min, 4 ºC) and the supernatants (400 μL/tube) were carefully transferred to another set of 
Eppendorf tubes and the pellets were discarded. 
 
The DNA was precipitated by the addition of an equal volume (400 μL/tube) of isopropanol, 
mixed by vortexing, and allowed to stand at room temperature for 2 min. After centrifugation 
(12000 rpm, 5 min, 4 ºC), the pellets were rinsed with 70 % ethanol (1 mL) and air-dried for 
at least 10 min, before being dissolved in TE buffer (50 μL). 
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For further purification, RNA was digested by adding 5 μL of DNAse-free RNAse (Roche) 
and incubating at 37 ºC for at least 30 min. RNAse and other impurities were removed either 
by a phenol/chloroform extraction step or using spin-columns from a QIAquick gel extraction 
kit (Biolab Ltd, Auckland, New Zealand). Plasmid identity, purity and concentration were 
examined by restriction digests mapped with agarose gel electrophoresis (as outlined in 
sections 6.2.9 and 6.2.10, respectively). The concentration and purity were determined more 
quantitatively by using a 1/100 dilution in a quartz cuvette and reading the absorbance at 260 
and 280 nm, as outlined in Sambrook et al.2 
 
Phenol/chloroform protein extraction 
After incubation with DNAse-free RNAse, another 350 μL of TE buffer and 400 μL of ice 
cold solution of 25:24:1 phenol:chloroform:isoamyl alcohol was added, mixed with vortexing, 
and centrifuged (12000 rpm, 5 min, 4 ºC). The upper (aqueous) layer (200 μL) was then 
transferred to a new Eppendorf tube, discarding the lower (organic) layer, and 400 μL of ice 
cold solution of 24:1 chloroform:isoamyl alcohol was added. This process repeated several 
times. DNA was precipitated from the upper layer by the addition of isopropanol (500 μL), as 
before, rinsed with 70 % ethanol, air dried, and dissolved in 50 μL TE buffer. 
 
Spin-column DNA cleanup 
Spin-columns contain a silica gel membrane that absorbs DNA in the presence of high salt 
and neutral pH, while impurities are washed through. The method was carried out as 
described in the QIAquick® Spin Handbook,20 using buffers QG, PB and EB supplied in the 
accompanying kit. To the DNA sample, 3 volumes of QG buffer (165 μL) and an equal 
volume of isopropanol (55 μL) were added. The mixture was loaded into the upper 
compartment of the spin-column and centrifuged for 1 min (at 14500 rpm) to bind DNA. 
After washing with PB buffer (0.75 mL), the DNA was eluted from the column with EB 
buffer (10 mM Tris.HCl, pH 8.5) and subjected to centrifugation (14500 rpm, 1 min, 20 ºC). 
 
Large scale/high purity preparation 
When sequencing quality DNA preparations were required, the procedure described above 
was scaled up by doubling the volumes of all stock solutions. A 5 mL vial of overnight 
culture was harvested and re-suspended in 200 μL of ice-cold solution #1, in a 10 mL Falcon 
tube. DNA was extracted as previously described, except additions of 400 μL and 300 μL 
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were made of solution #2 and #3, respectively. After centrifugation, the supernatant was 
retained and DNA was precipitated by adding isopropanol (800 μL). The mixture was 
centrifuged again, and the pellet retained and rinsed with 70 % ethanol, air dried, and 
dissolved in 50 μL TE buffer. Subsequent plasmid purification steps were as outlined for 
small scale preparations. 
 
6.2.9 Restriction digests of plasmids 
Restriction digests were performed in 10 μL volumes. Typically ~1 μg of plasmid DNA (2.5 
to 5 μL) was digested with 1 μL of the appropriate restriction enzyme and specified restriction 
buffer (10× concentration stock). For pGroESL a double digest with EcoR I and Hind III was 
performed. For pMTB02 and variants (map of restriction sites in Appendix A), a single digest 
with Xho I/Nco I and a double digest with Xho I and Nco I were performed. These were 
incubated at 37 ºC for 2 hours before being resolved with electrophoresis. 
 
A typical experimental setup for pMTB02 double digest is as follows: 
Double digest 5 μL plasmid DNA 
 1 μL buffer H 
 1 μL Xho I 
 1 μL Nco I 
 2 μL d-H2O 
 
6.2.10 Agarose gel electrophoresis 
This protocol was based on method outlined in Sambrook et al.:21 
6× Loading buffer 30 % (v/v) glycerol 
(stored at -20 ºC) 0.25 % (w/v) bromophenol blue 
 0.25 % (w/v) xylene cyanol 
1× TAE buffer, pH 8.0 4 mM Tris.acetate 
(stored at 4 ºC) 1 mM EDTA 
 
Restriction fragments were resolved on a 1 % agarose gel against Hyperladder I (Bioline) or 
Read-LoadTM DNA ladder (Bio-Rad), which provide standards ranging from 200 to 10000 bp, 
or 100 to 12000 bp, respectively. A solution of 1 % agarose (0.3 g agarose dissolved in 30 mL 
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of 1× TAE buffer) was heated and allowed to cool slightly (~50 ºC) before being poured into 
a gel casting tray, followed by well comb insertion. The gel was allowed to set completely 
(~30 min) before the comb was removed and transferred into a gel tank containing cold 
1× TAE buffer (stored at 4 ºC). The DNA ladder (5 μL for Hyperladder I, 2.5 μL for 
Read-LoadTM DNA ladder) was loaded with 5 μL of loading buffer. Digested or uncut DNA 
(5 μL) was loaded with an equivalent amount of loading buffer (5 μL). Electrophoresis was 
conducted at 80/90 V for 90 min or until the bromophenol band was nearing the end of the 
gel. The gel was stained with ethidium bromide (0.5 μg.mL-1) for 20 min. The stained DNA 
fragments were visualized under 302 nm UV radiation and photographed using the Chemi 
Genius2 Bio Imaging System (Syngene). 
 
6.2.11 PCR site-directed mutagenesis 
The method was carried out as described in the Stratagene QuikChange site-directed 
mutagenesis manual.18 The advantage of the QuikChange site-directed mutagenesis system is 
that it allows double stranded plasmid DNA, such as that obtained by alkaline lysis, to be used 
as template DNA.18 
 
Primer design 
Mutagenic primers introduce site-specific mutations by being incorporated into the newly 
synthesized DNA during the polymerase chain reaction (PCR) step. For each mutation, two 
primers are required to anneal to both the forward and reverse of the same sequence found on 
opposing strands of template DNA. The primers were designed following guidelines in the 
Stratagene QuikChange site-directed mutagenesis manual.18 
 
Primers were between 25 and 45 bases in length, with the desired mutation in the middle 
flanked by ~10 to 15 bases of correct sequence on both sides. The melting temperatures (Tm) 
were ≥78 ºC as determined by Equation 6.1. 
 
 mismatchNTm %/675)GC(%41.05.81 −−×+=  Equation 6.1 18 
 
Here Tm is calculated from N, the length of the primer, the percentage of bases mismatched to 
the template DNA, and the GC content. Optimally, primers should be composed of 40 % or 
more G and C bases and terminate with either G or C. 
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A typical example of primer design is as follows: 
To introduce a mutation from alanine (A) to arginine (R) at position 204, the dapA sequence 
from pMTB02 was examined (Figure 6.1). 
 
                                                204 
Parent strand            5’-aac ctg ccc tgg ctg gcc atg ggc gcc acg ggc-3’ 
Primer #1                  5’-C CTG CCC TGG CTG CGC ATG GGC GCC ACG-3’ 
Primer# 2                  3’-G GAC GGG ACC GAC GCG TAC CCG CGG TGC-5’ 
Figure 6.1: The DHDPS-A204R primers with the sequence alteration in bold blue and 
with the codon for amino-acid position 204 underlined. 
 
Possible codons for arginine are CGA, CGC, CGG and CGT, only one of which shares a base 
with the codon GCC used for A204, thus CGC was chosen to minimize the mismatch between 
the primer and the parent strand. Taking thirteen bases of correct sequence to flank either side 
resulted in forward (#1) and complementary reverse (#2) primers with melting temperatures 
of 78.2 ºC, as calculated by Equation 6.1. Both primers terminated in two C or G bases and 
had a GC content of 70 %. 
 
Other mutagenic primers were designed in an analogous way (listed in chapter three, Table 
3.2) and purchased from Invitrogen. 
 
PCR reaction conditions 
For each experiment, two PCR reactions were prepared per set of mutagenic primers 
(100 ng.μL-1), using 5 and 50 ng of template DNA (as described in Table 6.6), along with a 
control reaction. The sample reaction used pMTB02 isolated by a high purity preparation (as 
described in section 6.2.7) from E. coli DH5α pMTB02, further purified by spin-column 
technology. 
 
The control reaction was performed using pWhitescript with the mutagenic primers provided 
in the Stratagene QuikChange site-directed mutagenesis kit. The pWhitescript plasmid 
contains a point mutation that generates a stop codon in the middle of lacZ gene, disrupting 
the synthesis of β-galactosidase.18 If the mutagenesis reaction is successful, the stop codon is 
removed, restoring enzyme activity and giving bacterial colonies a blue phenotype on plates 
pre-treated with IPTG and X-gal for blue/white screening.18 Thus, the mutational efficiency 
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can be determined by the proportion of blue versus white colonies resulting from the control 
reaction, prepared as outlined in Table 6.6: 
 
Table 6.6: Preparation for site-directed mutagenesis. 
 Control (μL) 5 ng of Sample (μL) 50 ng of Sample (μL) 
10× Reaction buffer 5.0 5.0 5.0 
Forward primer (#1) 1.25 1.25 1.25 
Reverse primer (#2) 1.25 1.25 1.25 
dNTP mix 1.0 1.0 1.0 
Plasmid 2.0 1.0 10.0 
d-H2O 39.5 40.5 31.5 
Total 50.0 50.0 50.0 
 
The final addition to the 50 μL reaction mixture was 1 μL of PfuTurbo® DNA polymerase. 
This enzyme replicates both plasmid strains with high fidelity without displacing the 
mutagenic primers.18 The reactions were performed in thin-walled PCR tubes, using a 
thermocycler equipped with a “hot top”. The cycling parameters are summarised in Table 6.7. 
After temperature cycling, the amplification reactions were incubated on ice for 2 min. 
 
Table 6.7: PCR cycling parameters for site-directed mutagenesis. 
Segment Cycles Temperature (ºC) Time (min) 
1 1 95 0.5 
2 16 95 0.5 
  50 1.0 
  68 13.0 
 
Template digestion 
Endonuclease enzyme, Dpn I (1 μL), was added to each of the amplification reactions. This 
enzyme is specific for methylated and hemimethylated DNA, and hence digests the 
non-mutated parent template DNA but leaves the mutation-containing amplified DNA intact. 
The enzymatic digestion reaction was gently mixed with a pipette and incubated at 37 ºC for 
at least 1 hour. Agarose gel electrophoresis (as described in section 6.2.10) was used to 
confirm the presence of amplified DNA in the Dpn I treated reactions, prior to it being used to 
transform E. coli XL1-Blue supercompetent cells, as described in the following section.  
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6.2.12 Transformation of E. coli strains with plasmids 
Transforming XL1-Blue supercompetent cells 
Frozen E. coli XL1-Blue supercompetent cells (purchased from Stratagene) were defrosted on 
ice and aliquoted in 50 μL volumes into sterile pre-chilled Eppendorf tubes. To the separate 
aliquots, 2 μL of 0.142 M β-mercaptoethanol and 2 μL of the Dpn I treated DNA was added 
and mixed by swirling, followed by incubation on ice for 30 min. A transformation control 
was also prepared, containing 1 μL of pUC18 (0.1 ng.μL-1). The transformation reactions 
were heat shocked for 45 s at 42 ºC, then immediately put on ice. After 2 min, 900 μL of SOC 
was added to each reaction and cells were allowed to express antibiotic resistance by 
incubation at 37 ºC for at least 1 hour. 
 
Selection of transformants and monitoring transformation efficiency 
For each plasmid, two different types of plate were prepared, one containing antibiotics 
selective for the strain, and another containing antibiotic selective for the strain and plasmid. 
 
For the pWhitescript control for site-directed mutagenesis, the plates were pre-treated with 
IPTG and X-gal for blue/white screening (as outlined in section 6.2.4). On the appropriate 
plates, 200 μL of SOC, followed by 10 μL of transformed cells, were pipetted, then spread out 
with a glass spreader, sterilized by ethanol and flame. 
 
For the plasmid of interest, 100 μL of transformed competent cells was also pipetted and 
spread on plates containing appropriate antibiotics. The remaining transformed cell mixture 
was centrifuged at 14000 rpm for 1 min, the cell pellet re-suspended in 100 μL of SOC and 
spread on the same type of plates. 
 
All plates were incubated overnight at 37 ºC. Site-directed mutagenesis efficiency with 
pWhitescript was calculated from the number of blue bacterial colonies divided by the total 
number of colonies on the agar plate and was reported as a percentage. The introduced 
mutation was confirmed by sequencing (section 6.2.13) of plasmid preparations (section 
6.2.7) from the newly transformed XL1-Blue cells. 
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Competent cell preparation by calcium chloride 
A vial of LB medium, containing appropriate antibiotics, was inoculated with bacteria from a 
freshly streaked agar plate and grown overnight in a 37 ºC shaker. A small flask of LB 
medium (50 mL) was inoculated with 1 mL of starter culture and allowed to grow in a 37 ºC 
shaker until an OD600 of 0.8 was reached (~1.25 hrs). After cooling on ice for 10 minutes, 
cells were harvested by centrifugation (4000 rpm, 10 min, 4 ºC), under sterile conditions, the 
supernatant was removed and the pellet re-suspended, with gentle pipetting, in cold sterilized 
10 mM CaCl2 (10 mL). Again, the cells were centrifuged (4000 rpm, 10 min, 4 ºC), and the 
supernatant was removed. The same volume (10 mL) of cold sterilized CaCl2 at 10× the 
concentration (100 mM), was used to re-suspend the cells. The supernatant was removed from 
the cells for the third time by centrifugation, and the cells were re-suspended in cold 100 mM 
CaCl2 (2 mL). The competent cells were pipetted into sterile Eppendorf tubes in 200 μL 
aliquots and stored on ice for less than five hours before transformation. 
 
Transformation for calcium chloride method 
To each aliquot of calcium chloride competent cells, 0.1 ng of plasmid DNA (dissolved in 
either d-H2O/TE buffer) was added, followed by careful mixing, by swirling or stirring with 
the pipette tip. Two transformation controls were also prepared, one containing no plasmid 
DNA and another containing 1 μL of pUC18 (0.1 ng.μL-1). The competent cells were treated 
in an analogous manner to that previously described for XL1-Blue supercompetent cells. 
 
Competent cell preparation for the electroporation method 
LB medium was inoculated using an overnight culture produced by inoculation with a single 
bacterial colony. The culture was allowed to grow in a 37 ºC shaker until it reached an OD600 
of 0.5 and then put on ice for 30 min. The cells were harvested by centrifugation at 4 ºC for 
5 min at 4000 rpm, the supernatant was removed and the cells re-suspended in one culture 
volume of cold sterilized d-H2O. This process was repeated twice, using 0.5 and 0.05 culture 
volumes, before final re-suspension in 0.05 culture volume of 10 % glycerol. The competent 
cells were pipetted into sterile Eppendorf tubes in 40 μL aliquots and stored at -80 ºC. 
 
Transformation by electroporation 
To each aliquot of competent cells was added 0.1 ng of plasmid DNA (dissolved in either 
d-H2O or TE buffer), with careful mixing by swirling or stirring with the pipette tip. The cells 
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were transferred to sterilized (with ethanol and UV), cooled and dried electroporation glass 
cuvettes and electroporated using a Gene Pulser (BioRad), set to 2.5 kV and 25 μF at 200 Ω. 
Immediately afterwards, the cells were suspended in 1 mL of SOC, and then pipetted into 
sterile Eppendorf tubes. The competent cells were incubated at 37 ºC for 1 hour then 
transformed cells were selected as previously outlined. 
 
6.2.13 DNA Sequencing 
DNA sequencing was performed at Canterbury Sequencing, part of the School of Biological 
Sciences at the University of Canterbury. The plasmids were sequenced using a capillary 
ABI3100 Genetic Analyzer, (Applied Biosystems Inc.) using BigDye® Terminator and T7 
primers with a procedure based on the dideoxynucleic acid chain termination method, 
developed by Sanger.22 
 
6.3 Biochemistry general methods 
Unless otherwise stated, all enzymes were manipulated on ice or 4 ºC and buffered at pH 8.0 
by 20 mM Tris.HCl. pH measurements were carried out using an Ultra Basic UB-10 pH/mV 
meter (Denver Instruments). Proteins were concentrated using spin columns from Vivascience 
(via Global Sciences, Christchurch, N.Z.) The laboratory text “Guide to protein purification”, 
edited by Deutscher,23 provided an excellent resource for biochemistry techniques and protein 
purification, as did various editions of “Protein purification”, authored by Scopes,24,25 and 
“Enzyme assays: a practical approach”, authored by Eisenthal and Danson.26 
 
6.3.1 Determining protein concentration 
Bradford Assay 
The colorimetric assay, originally developed by Bradford,27 utilizes the shift in absorbance 
maximum, from 465 nm to 595 nm, of Coomassie brilliant blue G-250 dye upon protein 
binding, in acidic conditions, to determine protein concentration.28 An 800 μL volume of 
protein, appropriately diluted by distilled water, was placed in a disposable polystyrene 
cuvette. After the addition of 200 μL of Protein Assay Dye Reagent (Bio-Rad), containing 
dye, phosphoric acid and methanol, the assay was incubated at room temperature for 
10 minutes, before measuring absorbance, using water as a blank. 
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As an improvement to the original method developed by Zor & Selinger,29 the ratio of 
absorbances at 590 nm and 450 nm, was recorded, giving a linear relationship for protein 
concentration from 0.2 to 20 μg.mL-1. Protein concentrations were determined based on a 
calibration curve generated using known concentrations of bovine serum albumin (BSA). All 
measurements were carried out in triplicate. Different proteins bind Coomassie blue dye 
slightly differently, depending on their amino-acid sequence; thus the values determined were 
relative rather than actual concentration values.28 
 
Ultraviolet (UV) absorbance methods 
Proteins absorb light at 280 nm due to aromatic amino acids, such as tryptophan and tyrosine, 
hence there is high-level of variability for absorbance at this wavelength between proteins.28 
This method only accurately determines concentration for homogenous solutions of a protein 
with known amino-acid sequence. The relationship between protein concentration (c) and 
absorbance (A) across path-length (l) is described by Beer’s law as outlined in Equation 6.2: 
 
 lcA ⋅⋅ε=  Equation 6.2 
 
The extinction coefficient (ε) for absorbance at 280 nm by specific proteins was predicted 
based on amino-acid sequence using the web-based program “Protein Calculator”.30 This 
allowed for direct determination of protein concentration by reading absorbance at 280 nm 
across a 1 mm path-length using a Nanodrop spectrophotometer blanked with buffer. 
 
6.3.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Protein samples were routinely analyzed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), using the NuPAGE® Bis-Tris system developed by Invitrogen, 
which is similar to the Tris-Glycine system,31 except it operates at neutral pH resulting in 
better protein stability and resolution.32 Concentrated NuPAGE® (4×) sample and (20×) 
running buffer were purchased or made in-house, and gave final concentrations as follows: 
1× MOPS running buffer, pH 7.7 50 mM 3-morpholinopropane-1-sulfonic acid (MOPS) 
(stored at 4 ºC) 50 mM Tris.base 
 0.1 % (w/v) SDS 
 1 mM EDTA 
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1× LDS sample buffer, pH 8.5 10 % (v/v) glycerol 
(stored at -20 ºC) 0.106 M Tris.HCl 
 0.141 M Tris.base 
  2% (w/v) lithium dodecyl sulfate (LDS) 
 0.51 mM EDTA 
 0.22 mM SERVA® Blue G-450 
 0.175 mM phenol Red 
 
The NuPAGE® MOPS running buffer (× 20) was prepared in-house by dissolving 209.2 g of 
MOPS, 121.2 g of Tris.base, 20 g of SDS, and 3 g of EDTA in 750 mL of distilled water to 
make 1 L of buffer.32 
 
Proteins were resolved on pre-cast NuPAGE® 4-12 % Bis-Tris gradient polyacrylamide gels 
(Invitrogen) against protein standards, such as PageRulerTM (Fermentas), Novex® Sharp Pre-
stained (Invitrogen) or Wide Range SigmaMarkerTM (Sigma-Aldrich). Samples were prepared 
as outlined in Table 6.8, using various dilutions to give 10-20 μg of protein per sample for 
optimal resolution. 
 
Table 6.8: Sample preparation for SDS-PAGE. 
 
 
Volume added (μL) 
for 1/10 dilution  
Volume added (μL) 
for 1/5 dilution  
Volume added (μL) 
for 1/2 dilution  
d-H2O 5.5 4.5 1.5 
4× Loading buffer 2.5 2.5 2.5 
10× Reducing agent 1.0 1.0 1.0 
Protein 1.0 2.0 5.0 
Total 10.0 10.0 10.0 
 
The samples were heated in boiling water for 10 min, centrifuged briefly, then loaded on the 
Bis-Tris gel secured in an XCell SureLockTM Mini-Cell gel box (Invitrogen) adequately filled 
with NuPAGE® MOPS running buffer (1×) and with 500 μL of NuPAGE® antioxidant 
pipetted into the upper chamber. 
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Electrophoresis was conducted at 180 V at room temperature for 60 min or until the dye band 
neared the bottom of the gel. The gel was subsequently removed from the plastic casing and 
stained with Coomassie blue dye for 30 min to an hour, with shaking, at ~55 rpm. Standard 
one-dimensional PAGE staining protocols were used and required the preparation of the 
following solutions:31 
Coomassie blue stain 0.1 % (w/v) Coomassie brilliant blue G-250 
(stored at room temp.) 50 % (v/v) methanol 
 10 % (v/v) glacial acetic acid 
De-stain 5 % (v/v) methanol 
(stored at room temp.) 10 % (v/v) glacial acetic acid 
 
The gels were de-stained overnight, or for several hours in microwave heated de-stain. The 
stained protein bands were visible to the naked eye and recorded using the Chemi Genius2 
Bio Imaging System (Syngene). 
 
6.3.3 Blue-native polyacrylamide gel electrophoresis 
BN-PAGE was carried out using a protocol modified from that originally developed by 
Schagger et al.:33  
Anode buffer, pH 8 100 mM Tris.HCl 
Cathode buffer, pH 8 50 mM Tricine 
(stored at 4 ºC) 30 mM Tris.HCl 
 0.02 % (w/v) Coomassie brilliant blue G-250 
4× Sample treatment buffer, pH 8 200 mM Tris.HCl 
(stored at -20 ºC) 1.4 % (w/v) Coomassie brilliant blue G-250 
 20 % (v/v) glycerol 
 
Blue-native polyacrylamide gel electrophoresis (BN-PAGE) was performed with pre-cast 
NativePAGE 4-16 % Bis-Tris gradient polyacrylamide gels (Invitrogen). Protein samples 
were prepared to a final volume of 20 μL and contained 5 μL of sample treatment buffer (4×). 
The samples were loaded directly on to the gel, secured in an XCell SureLockTM Mini-Cell gel 
box (Invitrogen), with blue cathode running buffer in the upper chamber and colourless anode 
running buffer in the lower chamber. Electrophoresis was conducted at 100 V at room 
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temperature for 2 hours or until the Coomassie blue dye had run off the end of the gel, evident 
from colouration in the anode buffer. Gels were de-stained as described in section 6.3.2. On 
occasion, gels were also fixed prior to de-staining, but this was found to be unnecessary. 
Fixing solution 50 % (v/v) methanol 
(stored at room temp.) 10 % (v/v) glacial acetic acid 
 
6.3.4 Preparation of dialysis tubing 
Dialysis tubing (cellulose membrane, MW cut-off >12000 kDa) was prepared according to 
the manufacturer’s instructions by rinsing with continuously flowing distilled water for 1 hour 
or more, followed by 2 min submerged in a solution of 0.3 % (w/v) sodium sulfide, heated to 
80 ºC, before being soaked in freshly boiled distilled water. After 3 min, this water was 
removed and replaced with ~5 L of water and 10 mL of concentrated sulfuric acid. After 3 
min in the 0.2 % (v/v) sulfuric acid, the solution was poured off and the tubing washed twice 
more by submerging in recently boiled distilled water. After the water cooled, the tubing was 
removed and stored in 0.1 % (w/v) sodium azide at room temperature. 
 
6.4 Optimized over-expression and purification of wild-type 
M. tuberculosis DHDPS and variants 
Buffer A 20 mM Tris.HCl, pH 8.0 
 250 mM NaCl 
 10 mM pyruvate 
 5 % (v/v) glycerol 
 2 mM β-mercaptoethanol (β-ME) 
 10 mM imidazole 
Buffer B 20 mM Tris.HCl, pH 8.0 
 1 M NaCl 
 10 mM pyruvate 
 5 % (v/v) glycerol 
 2 mM β-ME 
 10 mM imidazole 
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Buffer C 20 mM Tris.HCl, pH 8.0 
 250 mM NaCl 
 10 mM pyruvate 
 5 % (v/v) glycerol 
 2 mM β-ME 
 50 mM imidazole 
Buffer D 20 mM Tris.HCl, pH 8.0 
 250 mM NaCl 
 10 mM pyruvate 
 5 % (v/v) glycerol 
 2 mM β-ME 
 250 mM imidazole 
Storage buffer 20 mM Tris.HCl, pH 8.0 
 250 mM NaCl 
 5 % (v/v) glycerol 
 2 mM β-ME 
 with/without 10 mM pyruvate 
 
The protocol has been optimized from original method developed by Kefala et al.13 
 
6.4.1 Growth of E. coli BL21 (DE3) pGroESL 
A glycerol freezer stock of E. coli BL21 (DE3) pGroESL containing the relevant DHDPS 
expression plasmid was streaked out on an LB agar plate containing kanamycin and 
chloramphenicol and incubated for ≥9 hours at 37 ºC. Single colonies were used to inoculate 
5 mL of LB broth, containing kanamycin, chloramphenicol and glucose. The starter cultures 
were grown overnight at 37 ºC with shaking (200 rpm). Six flasks containing 750 mL of 
either LB broth or auto-inducing (ZYM-5052) media (see section 6.2.4) were supplemented 
with 750 μL of kanamycin and chloramphenicol and inoculated with 1.5 mL of starter culture. 
These large cultures were grown at 37 ºC with shaking for ~4 hours or until an OD600 of 0.60. 
 
For LB cultures, over-expression was induced with 750 μL of IPTG (60 mg.mL-1, 0.25 M). 
After induction the cells were grown overnight at room temperature. For auto-inducing 
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cultures, the flasks were moved to a room temperature shaker after the initial growth period 
and grown for an additional 12 hours. The cells were then chilled on ice for 30 minutes, 
harvested by centrifugation (4000 rpm, 15 min, 4 ºC), and washed by re-suspension in cold 
buffer A, followed by further centrifugation (8000 rpm, 10 min, 4 ºC). The supernatant was 
discarded and the cell pellets were re-suspended in a small amount of buffer A. Typically, one 
4 L preparation yielded 14-16 g of cells using auto-inducing media and 8-12 g of cells using 
LB broth. Several cell preparations were accumulated and stored at -80 ºC before further 
processing. 
 
6.4.2 Preparation of crude extract 
Several cell pellets (~70 g) were thawed and re-suspended in ~200 mL of buffer A. Crude 
cell-free lysates were produced by ultrasonication for 5 min at 4 °C in 20 s pulses with 4 min 
delays (~80 % amplitude), using a Sonics Vibracell sonicator. Following sonication, the cell 
extract was clarified by centrifugation (10000 rpm, 30 min, 4 ºC). The supernatant was 
collected and further clarified by centrifugation (10000 rpm, 60 min, 4 ºC). A 500 μL aliquot 
of the final supernatant was reserved for analysis. 
 
6.4.3 Affinity chromatography 
Purification using His6-tag affinity chromatography involved several steps, including washing 
with three different buffers, which was found to improve protein purity. The supernatant from 
centrifugation was loaded onto a His6-tag affinity column (2× 5 mL HisTrapTM Crude or 
HisTrapTM FF, GE Healthcare) pre-equilibrated with buffer A, and subsequently washed with 
5 column volumes of the same buffer. This was followed by 5 column volumes each of buffer 
B, buffer C and buffer D. Washing with buffer B increased the concentration of NaCl from 
0.25 to 1 M, eluting proteins associating with the column resin by ionic interactions. Buffer C 
returned the NaCl concentration to 0.25 M and increased imidazole from 10 to 50 mM, 
eluting proteins weakly associating with the Ni2+ column resin. Buffer D increased imidazole 
to 250 mM to elute the His6-tagged M. tuberculosis DHDPS, which was strongly associating 
with the resin. The peak fractions, as determined by absorbance at 280 nm, were tested for 
activity using the o-aminobenzaldehyde assay (section 6.4.4). Active fractions were pooled 
and 500 μL was set aside for further analysis, prior to buffer exchange into buffer A 
(section 6.4.5). 
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6.4.4 o-Aminobenzaldehyde assay 
The colorimetric o-aminobenzaldehyde assay is a semi-quantitative method for monitoring 
DHDPS activity,34 and has been developed for high throughput in our lab. It was carried out 
in a 96 well plate with 5 μL of test solution presumed to contain DHDPS and 160 or 100 μL 
of assay mixture prepared as described in Table 6.9. The 50× preparation can be stored at 
4 ºC for several days (Dr Sean Devenish, pers. comm.). 
 
Table 6.9: The o-aminobenzaldehyde assay mixture for DHDPS activity. 
 
 
Volume added (μL) 
for 1× preparation 
Volume added (μL) 
for 50× preparation 
200 mM Tris.HCl, 40 mM pyruvate, pH 8.0 150 7500 
400 mM o-aminobenzaldehyde (in EtOH) 5 250 
~100 mM (S)-ASA 5 250 
Total added to well 160 100 
 
The assay was incubated at 37 ºC for 20 min. The colour change due to DHDPS activity was 
developed by the addition of 100 μL of 10 % (w/v) trichloroacetic acid (TCA), giving deep 
purple colouration to the active fractions. Negative and positive controls were also prepared, 
with no DHDPS and DHDPS from a previous purification, respectively. 
 
6.4.5 Buffer exchange 
Two methods were used to change the buffer of protein solutions. 
 
Dialysis 
The pooled fractions were transferred into rinsed dialysis tubing (see section 6.3.4) and 
clamped either end. The protein solution was dialyzed overnight against 100 volumes of cold 
buffer, at 4 ºC, with stirring. 
 
Desalting column 
The pooled fractions were loaded in appropriate volumes onto a desalting column (HiPrepTM 
26/10 or HiTrapTM Desalting, GE Healthcare), pre-equilibrated with buffer. The protein was 
eluted with the required volume of buffer, and its corresponding peak was collected based on 
absorbance at 280 nm or the o-aminobenzaldehyde assay. 
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6.4.6 His6-tag cleavage 
In order to cleave His6-tag, protein fractions were incubated overnight in TEV protease 
(purchased or purified as outlined in 6.6) in the presence of 5 mM ethylenediaminetetraacetic 
acid (EDTA) and 1 mM dithiothreitol (DTT).16,35 After SDS-PAGE confirmed the cleavage 
of the tag, the cleaved DHDPS was passed through a His6-tag affinity column, 
pre-equilibrated with buffer A, to remove the His6-tag peptide fragment. Active fractions as 
determined by the o-aminobenzaldehyde assay (described in section 6.4.4) were pooled and 
500 μL was set aside for further analysis. 
 
6.4.7 Gel-filtration chromatography 
The pooled fractions were concentrated using an ultrafiltration spin column (Vivaspin 15, 
MW cut-off >10000 kDa, volume 2-8 mL, Vivascience) in preparation for gel filtration. The 
concentrate was loaded onto a gel-filtration column (HiLoad Superdex, 16/60, GE Healthcare) 
pre-equilibrated with storage buffer to remove any remaining impurities and the active peak 
(as determined by the o-aminobenzaldehyde assay) was collected. 
 
Mutant M. tuberculosis DHDPS-A204R was stored in buffer containing 10 mM pyruvate, 
whereas wild-type was stored in buffer without pyruvate and kept at 4 or -20 °C for several 
weeks without detectable degradation. Aliquots of 500 μL taken at different purification steps 
were analyzed by SDS-PAGE (section 6.3.2), the Bradford assay (section 6.3.1), and the 
coupled assay (as described in sections 6.9.2 and 6.9.4). 
 
6.4.8 Optimization trials 
Several parameters were varied during optimization trials to increase soluble protein yield. 
 
Extraction buffers 
In early trials, full scale protein preparations (4.5 L) were grown in LB media supplemented 
with kanamycin and chloramphenicol, at 37 °C with shaking, until an OD600 of ~0.50 was 
reached. Cells were harvested and ultrasonicated for 25 min at 4 ºC in 2 s pulses with 10 s 
delays (~30 % amplitude), in each of the different extraction buffers listed in Table 6.10. The 
cell extract was clarified by centrifugation and His6-tagged protein was purified in an 
analogous manner to that described in sections 6.4.3 and 6.4.5. 
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Table 6.10: Utilizing different extraction buffers for purification. 
Extraction buffer Strain 
Type Imidazole Other components 
BL21 (DE3) pLysS Tris.HCl, pH 8.0 0 mM NaCl, glycerol, β-ME 
BL21 (DE3) pLysS Tris.HCl, pH 8.0 10 mM NaCl, glycerol, β-ME 
BL21 (DE3) pLysS Phosphate, pH 7.4 5 mM NaCl, glycerol 
BL21 (DE3) pLysS Tris.HCl, pH 8.0 10 mM NaCl, glycerol, β-ME, pyruvate 
 
Bacterial strains 
For subsequent trials, smaller scale preparations (1 L) of LB media containing kanamycin and 
chloramphenicol were grown at 20 ºC for ≥12 hours when they reached an OD600 of ~0.50. 
The smaller culture size allowed for simultaneous growth of three different bacterial strains, 
BL21 (DE3) pGroESL, BL21 (DE3) pLysS, and BL21-CodonPlus® (DE3) RP, all of which 
contained pMTB02. After induction with IPTG, the cultures in each of the three different 
flasks were grown at 20 ºC for 20 hours, and then harvested by centrifugation. After 
re-suspension in buffer A, cells were lysed by ultrasonication for 3 min at 4 ºC in 2 s pulses 
with 10 s delays (~30 % amplitude), and 500 μL was set aside for further analysis. Insoluble 
proteins were removed by centrifugation (11000 rpm, 40 min, 4 ºC). The total and soluble 
protein fractions for each bacterial strain were examined by SDS-PAGE and the coupled 
assay. 
 
Lysis procedures 
The effect of different lysis procedures was also examined with smaller scale (1 L) 
preparations of BL21 (DE3) pGroESL and BL21-CodonPlus® (DE3) RP grown and induced 
as previously described. Cells were harvested and re-suspended in 75 mL of buffer A, and 
separated into three volumes of 25 mL. The suspensions were treated in three different ways, 
cell extract was lysed by ultrasonication (~50 % amplitude) at 4 ºC, either in 2 s pulses with 
10 s delays, in 20 s pulses with 2 min delays or in 20 s pulses with 2 min delays in 
combination with BugBusterTM (2.5 mL of 1× stock) and lysozyme (0.4 mg). Two aliquots 
were taken from each treatment and strain combination after various lengths of sonication. 
One aliquot was centrifuged to pellet out insoluble protein. The pellet was re-suspended in an 
equivalent volume of 3 M urea and 10 % SDS. The total, soluble and insoluble components 
of each protein preparation were examined by SDS-PAGE. 
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6.5 Over-expression and purification of E. coli DHDPS 
This protocol used was based on the procedure developed by Griffin et al.1,36 
 
Buffer A 20 mM Tris.HCl, pH 8.0 
Buffer B 20 mM Tris.HCl, pH 8.0 
 1 M NaCl 
Buffer C 20 mM Tris.HCl, pH 8.0 
 0.5 M ammonium sulfate 
 
6.5.1 Growth of E. coli XL1-Blue 
Glycerol freezer stocks of E. coli XL1-Blue containing the appropriate plasmid were streaked 
out on an LB agar plate containing ampicillin and tetracycline and grown overnight at 37 ºC. 
Single colonies were selected to inoculate 3 mL LB broth, containing the same antibiotics, 
and starter cultures were incubated overnight at 37 ºC with shaking (200 rpm). Six flasks of 
750 mL LB broth were supplemented with 750 μL of the appropriate antibiotics, inoculated 
with 1.0 mL of starter culture and grown at 37 ºC overnight with shaking. 
 
The cells were chilled on ice for 30 min, harvested by centrifugation (5000 rpm, 15 min, 
4 ºC), and washed with cold buffer A. The supernatant was discarded and the cell pellet, 
usually weighing ~10 g, was re-suspended in cold buffer A (1 mL per g of cells). 
 
6.5.2 Preparation of crude extract 
The cell suspension was ultrasonicated for 5 min at 4 °C in 2 s pulses with 10 s delays, using 
a Sonics Vibracell sonicator. Following sonication, the cell extract was clarified using 
centrifugation (10000 rpm, 15 min, 4 ºC), and an aliquot of 500 μL of the supernatant was 
reserved for analysis. 
 
6.5.3 Heat shock 
The supernatant was pipetted in 1 mL aliquots into sterile Eppendorf tubes. These were 
incubated for 2 min at 70 ºC and immediately cooled on ice. After centrifugation (14000 rpm, 
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10 min, 4 ºC), the supernatants were pooled, and a further 500 μL of the supernatant was 
reserved for analysis. 
 
6.5.4 Ion exchange chromatography 
The pooled sample from the heat shock step was loaded onto a Q-Sepharose ion exchange 
column (bed volume 75 mL, 15 × 2.6 cm) pre-equilibrated with buffer A, and subsequently 
washed with 5 column volumes of the same buffer. A salt gradient, increasing NaCl from 0 to 
1 M, was applied with buffer B to elute proteins associating with column resin by ionic 
interactions. The peak fractions, as determined by absorbance at 280 nm, were tested for 
activity using the o-aminobenzaldehyde assay (described in section 6.4.4). Active fractions 
were pooled and 500 μL was set aside for further analysis, prior to dialyzing (detailed in 
section 6.4.5) the protein back into buffer A. 
 
6.5.5 Hydrophobic interaction chromatography 
Ammonium sulfate was added to pooled active fractions from ion exchange to give a final 
concentration of 0.5 M. This was loaded onto a phenyl Sepharose column (bed volume 
125 mL, 25 × 2.6 cm) pre-equilibrated with buffer C, and subsequently washed with 5 column 
volumes of the same buffer. Proteins were eluted with a gradient decreasing in ammonium 
sulfate concentration from 0.5 to 0 M, applied by buffer A. The active fractions, as 
determined by the o-aminobenzaldehyde assay (described in section 6.4.4) were pooled and 
the protein was dialyzed (detailed in section 6.4.5) back into buffer A. Aliquots of 500 μL 
taken at different purification steps were analyzed by SDS-PAGE and by the Bradford and 
coupled assays. 
 
6.6 Over-expression and purification of TEV protease 
Purification of TEV protease involved a simplified protocol based on published methods.16 
 
Buffer A 50 mM Na2HPO4 (dibasic phosphate), pH 8.0 
 100 mM NaCl 
 10 % (v/v) glycerol 
 25 mM imidazole 
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Buffer B 50 mM Na2HPO4 (dibasic phosphate), pH 8.0 
 100 mM NaCl 
 10 % (v/v) glycerol 
 200 mM imidazole 
 
6.6.1 Growth of E. coli BL21-CodonPlus (DE3) RIL 
Starter cultures of E. coli BL21-CodonPlus (DE3) RIL pRK793 were prepared in an 
analogous way to that described in previous sections 6.4.1, using ampicillin and 
chloramphenicol as selective antibiotics. Four flasks containing 750 mL of LB broth were 
supplemented with 750 μL of ampicillin and chloramphenicol and inoculated with 1.5 mL of 
starter culture. These large cultures were grown at 37 ºC with shaking for ~10 hours. 
 
Over-expression was induced with 750 μL of IPTG (60 mg.mL-1, 0.25 M) after this initial 
growth period, and the cells were grown overnight at room temperature. The cells were then 
chilled on ice for 30 minutes, harvested by centrifugation (4000 rpm, 12 min, 4 ºC), and 
washed by re-suspension in cold buffer A, followed by further centrifugation (8000 rpm, 10 
min, 4 ºC). The supernatant was discarded and the cell pellet, weighing ~6 g, was 
re-suspended in cold buffer A (4 mL per g of cells). 
 
6.6.2 Preparation for affinity chromatography  
The cell suspension was ultrasonicated for 5 min at 4 °C in 1.5 s pulses with 10 s delays, 
using a Sonics Vibracell sonicator. Following sonication, the cell extract was clarified using 
centrifugation (10000 rpm, 15 min, 4 ºC), and an aliquot of 500 μL of the supernatant was 
reserved for analysis. 
 
6.6.3 Affinity chromatography 
The supernatant was loaded on a His6-tag affinity column (2× 5 mL HisTrapTM Crude or 
HisTrapTM FF, GE Healthcare) pre-equilibrated with buffer A, and subsequently washed with 
5 column volumes of the same buffer. The His6-tagged T. maritima DHDPR was eluted at 
high imidazole concentration by buffer B. 
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The peak fractions, as determined by absorbance at 280 nm, were analyzed by SDS-PAGE 
(section 6.3.2) for the presence of 27 kDa TEV protease, and buffer exchanged into buffer A. 
Protein concentration was quantified by the Bradford assay (section 6.3.1). The purified TEV 
protease was stabilized by the addition of EDTA and DTT to a concentration of 1 mM and 
stored at -80 oC. 
 
6.7 Over-expression and purification of T. maritima DHDPR 
Buffer A 50 mM Na2HPO4 (dibasic phosphate), pH 8.0 
 300 mM NaCl 
 30 mM imidazole 
Buffer B 50 mM Na2HPO4 (dibasic phosphate), pH 8.0 
 300 mM NaCl 
 300 mM imidazole 
 
Purification of T. maritima DHDPR was based on the procedure developed by Pearce et al.11 
 
6.7.1 Growth of E. coli XL1-Blue and E. coli BL21 (DE3)  
Large cultures of E. coli XL1-Blue pTM1520 or E. coli BL21 (DE3) pTOPO-TM1520 were 
prepared in an analogous way to that described in sections 6.5.1 and 6.4.1, respectively, using 
ampicillin and tetracycline as selective antibiotics. For 750 mL LB cultures of E. coli 
XL1-Blue pTM1520, over-expression was induced with 7.5 mL of arabinose (10 mg.mL-1) 
after an initial growth period at 37 ºC and the cells were grown overnight at room 
temperature. For auto-inducing cultures of E. coli BL21 (DE3) pTOPO-TM1520, the flasks 
were moved to a room temperature shaker after an initial growth period and grown for an 
additional 12 hours. After growth the cultures were treated in the same manner. The cells 
were then chilled on ice for 30 min, harvested by centrifugation (4000 rpm, 15 min, 4 ºC), and 
washed with cold buffer A. The supernatant was discarded and the cell pellet, weighing 
~20 g, was re-suspended in cold buffer A (2 mL per g of cells). 
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6.7.2 Preparation for affinity chromatography  
The cell suspension was ultrasonicated in an analogous manner to that described in section 
6.5.2. Following sonication, the cell extract was centrifuged (11000 rpm, 20 min, 4 ºC), and 
500 μL of the supernatant was set aside for further analysis. Subsequently, the supernatant 
was incubated for 2 minutes at ~95 ºC, followed by centrifugation, with another 500 μL of the 
supernatant set aside for further analysis. 
 
6.7.3 Affinity chromatography 
The supernatant was loaded onto a His6-tag affinity column (2× 5 mL HisTrapTM Crude or 
HisTrapTM FF, GE Healthcare) pre-equilibrated with buffer A, and subsequently washed with 
5 column volumes of the same buffer. The His6-tagged T. maritima DHDPR was eluted with 
high imidazole by buffer B. 
 
The peak fractions, as determined by absorbance at 280 nm, were tested for activity using the 
coupled assay (described in section 6.9). Active fractions were pooled and the protein was 
dialyzed (detailed in section 6.4.5) into 20 mM Tris.HCl, pH 8.0. Aliquots of 500 μL taken at 
different steps were analyzed by SDS-PAGE, and by the Bradford and coupled assays. 
 
6.8 Biophysical methods 
6.8.1 Analytical gel-filtration liquid-chromatography 
Analytical gel-filtration liquid-chromatography was performed using a pre-packed Superdex 
200 (10/300 GL) column with a 24 mL bed volume and the UPC-900 ÄKTA FPLC from GE 
Healthcare at both 4 ºC and room temperature. The column was always pre-equilibrated with 
at least one column volume of 20 mM Tris.HCl, pH 8.0, containing varying concentrations of 
pyruvate, NaCl, glycerol and β-ME. The column was calibrated with BSA and ovalbumin, as 
they have been found to exhibit close to ideal elution behaviour on Sephadex columns.37 For 
each run, 200 μL of protein sample, within the concentration range of ~1.5-0.15 mg.mL-1, was 
loaded and eluted with the same buffer used to pre-equilibrate the column. Occasionally a 
preparative pre-packed Hi-load Superdex (16/60) column with a 120 mL bed volume was 
used at 4 ºC, which required calibration with BSA, ovalbumin and alcohol dehydrogenase. 
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The absorbance of the elutant was monitored at 280 nm or 280, 215, and 205 nm, resulting in 
chromatographs plotting absorbance as a function of buffer volume and showing the protein 
elution peaks. The peak of the elution curve was taken as the elution volume (Ve), which was 
used to either construct a calibration curve of Ve versus the natural log of the known 
molecular weight or to ascertain the molecular weight of unknown sample. Experimentally 
determined molar masses were compared to molar masses predicted from amino-acid 
sequences using the web-based program “Protein Calculator”.30 
 
6.8.2 Differential scanning fluorimetry 
Based on the method developed by Ericsson et al.,38 protein unfolding was monitored by 
fluorescence emission at 575 nm, using an iQ5 Real Time PCR Detection System (Bio-Rad). 
The thermal stabilities of the proteins of interest were assessed in 20 mM Tris.HCl, pH 8.0 
solutions, containing varying concentrations of pyruvate, NaCl, glycerol and 
β-mercaptoethanol in a thin-walled 96 well PCR plate (Bio-Rad). Each 25 μL assay contained 
1 μL of 250× SYPRO Orange fluorescent dye (Molecular Probes) to give a 10× final 
concentration. Each assay was performed in triplicate. Controls contained only buffer and 
fluorescent dye, or only buffer and protein. The plates were sealed with Microseal ‘B’ PCR 
sealer (Bio-Rad) and heated from 20 to 90 °C in increments of 0.2 ºC, with 20 s dwell times at 
each temperature step. Fluorescent changes were monitored simultaneously with a charge 
coupled device camera with an excitation filter of 490 nm and an emission filter of 575 nm. 
The melting temperature was determined as the point of maximum inflection of the 
fluorescence curve.38 
 
6.8.3 Analytical ultracentrifugation 
Analytical ultracentrifuge experiments were performed at the University of Melbourne in a 
Beckman Coulter XL-I analytical ultracentrifuge equipped with a UV/VIS absorbance optical 
system. The protein samples were desalted into 20 mM Tris.HCl, 150 mM NaCl, at pH 8.0 
and loaded into 12 mm double sector cells with quartz windows, along with a reference 
solution of buffer without enzyme. The program SEDNTERP was used to determine the 
partial specific volume ( v ) of the sample (wild-type: 0.7402 mL.g-1, DHDPS-A204R: 
0.7400 mL.g-1 at 20 ºC), and the density (ρ) and viscosity (η) of the buffer (1.005 g.mL-1 and 
1.021 cP, respectively).39 
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Experiments were also performed with protein samples in storage buffer (20 mM Tris.HCl, 
250 mM NaCl, 5 % (0.68 M) glycerol, 2 mM β-mercaptoethanol and 10 mM pyruvate at pH 
8.0). The solution properties were estimated for storage buffer, ignoring the contributions by 
β-ME and pyruvate, because of the limitations of SEDNTERP. A density of 1.023 g.mL-1 and 
viscosity of 1.193 cP were determined for a buffer composed of 20 mM Tris.HCl, 250 mM 
NaCl and 0.68 M glycerol using SEDNTERP. 
 
Sedimentation velocity experiments 
For sedimentation velocity (SV) experiments, protein sample (380 μL) and reference solution 
(400 μL) were loaded into double sector cells in an An-60 Ti 4-hole rotor and centrifuged at 
40000 rpm. Continuous radial scans monitored sedimentation at 230 nm in low concentration 
samples (0.055 mg.mL-1) and at 280 nm in high concentration samples (1.1 mg.mL-1), every 
8 min, without averaging, at 20 ºC. SV experiments were also performed in storage buffer, 
containing samples of both wild-type (1.1 mg.mL-1) and A204R M. tuberculosis DHDPS 
(0.60 mg.mL-1) samples and data were fitted to continuous size-distribution and continuous 
mass-distribution models using the program SEDFIT.40 
 
In all cases, the standardised sedimentation coefficient (sº20,w) was determined using 
SEDNTERP.39 Experimentally determined sedimentation coefficients were compared to 
sedimentation coefficients predicted from the PDB file 1XXX using hydrodynamic modelling 
with the program HYDROPRO.41 
 
Sedimentation equilibrium experiments 
For sedimentation equilibrium (SE) experiments, protein sample (100 μL) and reference 
solution (120 μL) were loaded into double sector cells in an An-60 Ti 8-hole rotor and 
centrifuged at 10000, 16000 or 23000 rpm until sedimentation equilibrium was attained (16-
24 hrs). Radial absorbance scans were taken at 280 nm with 10 averages and 0.001 cm step 
size. Data were prepared for analysis with SEDFIT, and analyzed by globally fitting with 
various models using the program SEDPHAT.42 Both SEDFIT and SEDPHAT are available 
from www.analyticalultracentrifugation.com. 
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6.8.4 Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy data were recorded at the University of Melbourne on 
an Aviv 60DS CD spectrophotometer at 20 ºC in 20 mM Tris.HCl, pH 8.0. The 
spectrophotometer was blanked with the buffer (20 mM Tris.HCl, pH 8.0). Wavelength scans 
were collected using a 1 mm path-length cuvette, 1.00 nm bandwidth, 0.5 nm step-size, from 
250 to 200 nm with an averaging time of 2.0 s. Data were analyzed using CDPro software 
(freely available from http://lamar.colostate.edu/~sreeram/CDPro) to provide estimations of 
secondary structure fractions.43,44 Three different algorithms, CONTINLL, SELCON3 and 
CDSSTR, were used to fit data points from 240 to 200 nm, in combination with the different 
reference sets provided by CDPro.43,44 
 
6.9 Kinetic analysis of wild-type and mutant DHDPS  
Kinetic parameters were determined using two-substrate steady-state initial-rate analysis. 
DHDPS activity was measured by coupling it to the oxidation of NADPH by DHDPR as 
previously described by Coulter et al.8 The coupled assay used in this kinetic study was based 
on an optimized procedure for E. coli DHDPS, where the pH is maintained at 8.0 by 100 mM 
N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) buffer.45 
 
Assays were performed at a constant temperature of 30 ºC, using a circulating water bath, as 
described in the literature.45 All components, except DHDPS and (S)-aspartate-
β-semialdehyde, (S)-ASA, were incubated for 15 minutes at 30 ºC prior to initiation of the 
enzymatic reaction by a small aliquot of (S)-ASA. DHDPS was added just prior to (S)-ASA to 
minimize any possible degradation. (S)-ASA was synthesized using the methods outlined in 
Roberts et al.,46 and was of high quality (>95 %) as judged by 1H nuclear magnetic resonance 
spectroscopy (synthesized by Dr Sean Devenish and Dr Andy Muscroft-Taylor). Double 
distilled water was used as a blank and consumption of NADPH was monitored by change in 
absorbance at 340 nm. Control assays were performed routinely to ensure both the absence of 
contaminating NADPH-utilizing enzymes and that DHDPR was present in excess. 
 
6.9.1 Enzyme stability and optimization 
The optimum pH for enzyme activity was determined using a series of 20 mM buffers (MES, 
HEPES or Bicine) covering a pH range of 6 to 9 at 30 °C with ionic strength (IS) of 0.15 M 
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(adjusted by the addition of NaCl). The optimum IS for the enzymatic reaction was 
determined using a series of 20 mM HEPES buffers with varying NaCl concentrations, 
corrected for the amount of HCl/NaOH added to bring the pH to 8.25 at 30 °C. 
 
For heat stability assays investigating wild-type DHDPS from M. tuberculosis and E. coli, 
enzymes were buffer exchanged into 20 mM HEPES (pH 8.25, IS of ~0.15) prior to 
incubation at various temperatures (30-100 °C) using a solid heat block. Aliquots of 10 μL 
were taken after 5 minutes incubation at various temperatures, or incubation at 70 °C for a 
range of times (0-30 minutes), and stored on ice or added directly to the coupled assay. 
 
Heat stability assays comparing mutant A204R to wild-type M. tuberculosis DHDPS 
examined enzyme stored in 20 mM Tris.HCl, 250 mM NaCl, 5 % glycerol and 2 mM β-ME 
both with and without 10 mM pyruvate. The samples in the different buffers were pre-treated 
by 5 min incubation at a range of temperature (30-100 °C) and added directly to the coupled 
assay. These assays were performed at pH 8.0, buffered by 100 mM HEPES buffer. 
 
6.9.2 Kinetic analysis for wild-type M. tuberculosis DHDPS 
In contrast to most of the stability and optimization experiments, for kinetic analysis the 
coupled assay had an IS of ~0.15 M and a pH of 8.0, maintained by 100 mM HEPES buffer 
(from a stock of 200 mM HEPES, 50 mM NaCl). The coupled assay contained the following 
components: pyruvate, DHDPR, NADPH, HEPES buffer, (S)-ASA, and DHDPS. The nature 
of the assay allowed several components to be premixed. For a final cuvette volume of 1 mL, 
the addition of 580 μL of the premix gave the appropriate concentrations of HEPES, NADPH 
and DHDPR, as outlined in Table 6.11. 
 
Table 6.11: Preparation for kinetic analysis of M. tuberculosis DHDPS. The premix 
stock is sufficient for 95 individual assays. 
 [Stock] mM Per cuvette (μL) [Cuvette] mM Premix (mL) 
HEPES, pH 8.0 (and 50 mM NaCl) 200 500 100 47.5 
NADPH 6.0 30 0.18 2.85 
DHDPR (0.13 mg.mL-1)  -- 50  -- 4.75 
Total  -- 580  -- 55.1 
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Since the activity of DHDPS was monitored by coupling it to the consumption of NADPH by 
DHDPR, care was taken to ensure an excess of the coupling enzyme. Purified T. maritima 
DHDPR was added to the premix to give DHDPR activity in the cuvette which was at least 
four times greater than the largest DHDPS activity to be measured. To confirm this excess, 
the addition of more DHDPR was found to not alter measured rates. Controls were also 
performed to ensure the absence of contaminating NADPH-utilizing enzymes. 
 
To determine the substrate concentrations to be used for accurate determination of KM, 
apparent KM values were determined by varying one substrate while holding the other 
constant, using as wide a range of substrate concentrations as practically possible. 
Determination of true kinetic constants, KM and V, involved concurrent variation of both 
substrate concentrations using 0.2 to 10 times that of the apparent KM values. For wild-type 
DHDPS, pyruvate and (S)-ASA stocks were both added to the cuvette to give final 
concentrations covering the range from 0.060 to 3.00 mM (that is 0.060, 0.15, 0.30, 1.5 and 
3.0 mM). 
 
Preliminary assays were performed in which (S)-ASA was the limiting factor in order to 
accurately determine the concentration of (S)-ASA from the total amount of NADPH 
consumed. The concentration of DHDPS was determined by Bradford assays (section 6.3.1), 
and it was shown to be of high purity with SDS-PAGE (section 6.3.2). Wild-type 
M. tuberculosis DHDPS was added just prior to the addition of (S)-ASA, giving a protein 
concentration of 0.0011 mg.mL-1 in each assay cuvette. 
 
A total of 25 different substrate concentrations were assayed. The initial-rate of NADPH 
consumption was measured in at least triplicate and was reproducible (±10 %). The data were 
fitted with kinetic models using the program ENZFITTER (Biosoft, Cambridge, U.K.) 
 
6.9.3 Inhibition studies with (S)-lysine and other amino acids 
The effect of (S)-lysine on the activity of M. tuberculosis DHDPS was examined using the 
coupled assay. The assay was performed in an analogous way to that previously described, 
but with the addition of (S)-lysine at concentrations ranging from 0 to 400 mM. The 
concentrations of the substrates (0.32 mM pyruvate, 0.20 mM (S)-ASA) were kept constant 
and the activities for each (S)-lysine concentration were determined in triplicate and reported 
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relative to that observed in the absence of the inhibitor. The IC50, that is the concentration 
needed to inhibit enzyme activity by 50 %, was determined by plotting relative activity 
against (S)-lysine concentration. 
 
To investigate the effect of other aspartate family amino acids on M. tuberculosis DHDPS 
activity, the coupled assay was performed, with the addition of either meso-DAP, 
(S)-threonine, or (S)-methionine at concentrations of 1, 10, 20 mM or in combinations of two 
for (S)-lysine, meso-DAP, (S)-threonine, or (S)-methionine at concentrations of 5 mM.. The 
concentrations of the substrates (0.30 mM pyruvate, 0.18 mM (S)-ASA) were kept constant 
and the activities for each amino acid concentration were determined in triplicate/duplicate 
and reported relative to that observed in the absence of the inhibitor. 
 
6.9.4 Kinetic analysis for mutant M. tuberculosis DHDPS 
Kinetic parameters were also determined for mutant A204R M. tuberculosis DHDPS, and the 
coupled assays were performed as described in section 6.9.2, with a few distinctions. DHDPS-
A204R was stored in buffer containing 10 mM pyruvate and therefore the 5 μL aliquot of 
enzyme added just prior to (S)-ASA, increased pyruvate concentration by 0.05 mM. This 
addition was taken into account when preparing stock solutions, and the final pyruvate 
concentrations in the cuvette were 0.50, 0.10, 0.20, 1.0, and 2.0 mM. These concentrations 
were chosen based on apparent KM values determined for DHDPS-A204R. The high apparent 
KM value determined for (S)-ASA meant the cuvette concentrations of (S)-ASA ranged from 
0.22 to 5.50 mM; thus a higher concentration of HEPES was required to buffer pH at 8.0, 
giving an ionic strength of 0.18 M, rather than 0.15 M. Consequently, the premix composed 
of HEPES, NADPH, and DHDPR was prepared as outlined in Table 6.12. 
 
Table 6.12: Preparation for kinetic analysis of A204R M. tuberculosis DHDPS, 
providing enough premixed components for 100 individual assays. 
 [Stock] mM Per cuvette (μL) [Cuvette] mM Premix (mL) 
HEPES, pH 8.0 (and 50 mM NaCl) 200 750 150 75.0 
NADPH 6.0 25 0.15 2.5 
DHDPR (0.58 mg.mL-1)  -- 40  -- 4.0 
Total  -- 815  -- 81.5 
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As in kinetic studies with wild-type M. tuberculosis DHDPS, all components except DHDPS 
and (S)-ASA were incubated for 15 minutes at 30 °C. Prior to the addition of (S)-ASA, which 
initiated the reaction, A204R M. tuberculosis DHDPS was added, giving a protein 
concentration of 0.0026 mg.mL-1 in each assay cuvette. 
 
6.10 X-ray crystallography 
X-ray crystallography of the mutant M. tuberculosis DHDPS-A204R was performed in 
collaboration with Linda Schuldt, under the supervision of Dr Manfred Weiss, from the 
EMBL Hamburg Outstation. The protein was purified in our lab (as described in section 6.4) 
and crystallization experiments were performed by our collaborators at the EMBL High 
Throughput Crystallization Facility, in Hamburg, Germany (details in Appendix I).47 
 
Diffraction data were collected by our collaborators (as described in section 6.10.1), and the 
structure was solved by molecular replacement using the program MOLREP,48 with a search 
model consisting of the chains a and b from the crystal structure of wild-type M. tuberculosis 
DHDPS (PDB entry 1XXX). Initial refinement was performed by our collaborators, using the 
program REFMAC5.48,49 Subsequent refinement was performed by myself, under the 
supervision of Prof. Geoff Jameson and Dr Sean Devenish (section 6.10.2). 
 
6.10.1 Diffraction data collection and processing 
Compact crystals were grown in 2.0 M ammonium sulfate and 100 mM sodium acetate, 
pH 5.5 at room temperature within 4 weeks to a maximum size of 100 × 40 × 20 µm3. 
Diffraction data were collected by our collaborators using a single crystal on a beamline 
equipped with a MARMosaic CCD-detector. Data collection was performed as outlined in 
Table 6.13. The crystal was mounted in a cryo-loop, soaked quickly in 20 % (v/v) glycerol in 
reservoir solution and flash cooled in a nitrogen stream to 100 K. A total of 221 images were 
collected with a rotation increment of 0.5° and an exposure time of 30 seconds per image. 
Due to radiation damage, however, only the first 120 images (60° of data) were used for final 
data processing. Indexing and integration of the data were done using the program DENZO, 
followed by scaling with SCALEPACK.50 
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Table 6.13: Data collection for DHDPS-A204R.  
Date 13.06.2008 
No. of crystals 1 
Beamline I911-3 (Max Lab, Lund, Sweden) 
Detector Mar Mosaic CCD 225 mm 
Wavelength (Å) 1.000 
Crystal-detector distance (mm) 225 
 
Intensities were converted to structure factor amplitudes using the program TRUNCATE.48 
The optical resolution of the data set was calculated with SFCHECK,51 and the self rotation 
function was computed using the program MOLREP,48 based on structure factor amplitudes 
to a maximum resolution of 4.0 Å. The R-factors Rr.i.m. (redundancy-independent merging 
R-factor) as well as Rp.i.m. (precision-indicating merging R-factor)52 were calculated using the 
program RMERGE (available from http://www.embl-hamburg.de/~msweiss/projects/ 
msw_qual.html or from Dr Manfred Weiss upon request) and are listed in Table 6.14. 
 
Table 6.14: R-factors for DHDPS-A204R. Values in parentheses are for the highest 
resolution bin. 
Rmerge (%) 11.8 (58.9) 
Rr.i.m. (%) 13.3 (65.9) 
Rp.i.m. (%) 5.9 (29.7) 
 
6.10.2 Structural refinement 
Partially refined model was received from Germany with R- and free R-factors of 23.6 % and 
28.4 %, respectively. Further refinement was achieved using REFMAC5 with applied NCS 
restraints and anisotropic displacement parameters, using the TLS (translation, rotation, 
screw-rotation) model.48,53 Manual model corrections were made using the program 
WinCOOT.54 The final rounds of refinement involved the placement of solvent molecules and 
waters using WINCOOT. Structural quality was assessed using SFCHECK,51 and the 
structural validation tools of WINCOOT. In some cases, the side chains of amino acids could 
not be completely resolved due to insufficient electron density so the occupancy of these 
atoms was lowered. The maximum r.m.s.d. for the subunits (all atoms) in the asymmetric unit 
was 0.38 Å, as calculated by SUPERPOSE.48 
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Appendix A 
The pET (inducible) protein expression system 
Recombinant DNA technology has resulted in great advances in protein purification including 
inducible protein expression systems.1 The level of gene transcription, and consequently 
protein production, depends on the frequency with which RNA polymerase initiates 
transcription, which is a function of the promoter sequence upstream from the gene.1 The 
dapA gene (Figure A.2) for DHDPS from M. tuberculosis strain H37Rv was cloned into the 
expression vector pETM-11 (Figure A.1), by our collaborators, Weiss and Kefala.2 The 
pETM vectors are derived from Novagen’s pET expression system,3 which uses a strong 
promoter from phage T7 recognized by T7 RNA polymerase.4 
 
pETM-11
6029bp
origin (3946)
kanamycin
lacI
f1 origin
TEV site
His tag
linker
MAD
XhoI (158)
NotI
EagI
HindIII
SalI SacI
EcoRI
BamHI
KpnI
PstI
BamHI
SalI
EagI
NcoI (877)
XbaI
EcoRV
SapI
ClaI
SmaI
DraIII
BcII
 
Figure A.1: Map of the pETM-11 vector developed by the EMBL Protein Expression and 
Purification Facility.3 It is modified from pET24d (Novagen) with a 612 bp MAD 
insert, which contains additional restriction sites. The dapA gene from 
M. tuberculosis was cloned into the vector using the bolded restriction sites, NcoI 
and XhoI. The full sequence is available online at 
www.embl-hamburg.de/~geerlof/webPP/vectordb/bact_vectors/index.html. 
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1      GTGACCACCG TCGGATTCGA CGTCGCAGCG CGCCTAGGAA CCCTGCTGAC CGCGATGGTG 
61     ACACCGTTTA GCGGCGATGG CTCCCTGGAC ACCGCCACCG CGGCGCGGCT GGCCAACCAC 
121    CTGGTCGATC AGGGGTGCGA CGGTCTGGTG GTCTCGGGCA CCACCGGCGA GTCGCCGACC 
181    ACCACCGACG GGGAGAAAAT CGAGCTGCTG CGGGCCGTCT TGGAAGCGGT GGGGGACCGG 
241    GCCCGTGTTA TCGCCGGTGC CGGCACCTAT GACACCGCGC ACAGCATCCG GCTGGCCAAG 
301    GCTTGTGCGG CCGAGGGTGC GCACGGGCTG CTGGTGGTCA CGCCCTACTA TTCCAAGCCG 
361    CCGCAGCGGG GGCTGCAAGC CCATTTCACC GCCGTCGCCG ACGCGACCGA GCTGCCGATG 
421    CTGCTCTATG ACATCCCGGG GCGGTCGGCG GTGCCGATCG AGCCCGACAC GATCCGCGCG 
481    TTGGCGTCGC ATCCGAACAT CGTCGGAGTC AAGGACGCCA AAGCCGACCT GCACAGCGGC 
541    GCCCAAATCA TGGCCGACAC CGGACTGGCC TACTATTCCG GCGACGACGC GCTCAACCTG 
601    CCCTGGCTGG CCATGGGCGC CACGGGCTTC ATCAGCGTGA TTGCCCACCT GGCAGCCGGG 
661    CAGCTTCGAG AGTTGTTGTC CGCCTTCGGT TCTGGGGATA TCGCCACCGC CCGCAAGATC 
721    AACATTGCGG TCGCCCCGCT GTGCAACGCG ATGAGCCGCC TGGGTGGGGT GACGTTGTCC 
781    AAGGCGGGCT TGCGGCTGCA GGGCATCGAC GTCGGTGATC CCCGGCTGCC CCAGGTGGCC 
841    GCGACACCGG AGCAGATCGA CGCGTTGGCC GCCGACATGC GCGCGGCCTC GGTGCTTCGG 
Figure A.2: The dapA gene as cloned into the pETM-11 vector system, and determined by 
DNA sequencing (as described in section 6.2.13). 
 
T7 RNA polymerase does not naturally occur in E. coli, so gene products in pETM or pET 
vectors can only be expressed in bacterial strains engineered to contain its gene,5 such as 
E. coli BL21(DE3).6 The transcription of both the gene for T7 RNA polymerase and the 
cloned gene are blocked by the binding of a lac repressor to a lac operator element in their 
promoters.6,7 Hence, suppressing the binding of the lac repressor, by its natural substrate 
allolactose or an artificial mimic, isopropyl thiogalactoside (IPTG), induces the expression of 
T7 RNA polymerase and the cloned gene product, typically a recombinant protein.7 T7 RNA 
polymerase is so active and selective that, after being induced, almost all of the host cell’s 
resources are used for recombinant protein expression and, after a few hours, the cloned gene 
product comprises up to 50 % of the total cellular proteins.7 
 
Inducible protein expression allows some degree of control over recombinant protein 
production, and prevents cellular resources being diverted while cells are still dividing, during 
the lag phase of culture growth. Typically, IPTG was added after and OD600 of ~0.60 was 
reached. Auto-induction media take advantage of allolactose being a minor by-product of 
lactose metabolism,8 and uses glucose to suppress its production during lag phase growth 
allowing for the growth of a high-density culture before induction of protein expression.9 
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Appendix B 
Kinetic characterization of His6-tagged DHDPS 
 
                  
Figure B.1: The initial velocity of His6-tagged M. tuberculosis DHDPS was measured with the 
coupled assay over varying concentrations of both substrates, pyruvate and 
(S)-ASA, shown on the x-axis and with symbols (? 2.0 mM, ? 1.0 mM, 
? 0.20 mM, ? 0.10 mM, ? 0.04 mM (S)-ASA). Each measurement was made in 
triplicate and the data were fitted with the ping-pong model giving an R2 of 0.99 
using ENZFITTER. Plot (B) shows the Hanes transformation, reflecting the 
trend of y-axis intersection predicted for the ping-pong model. 
 
 
Table B.1: Kinetic parameters determined by fitting rate measurements. 
  His6-tagged M. tuberculosis DHDPS Non-tagged M. tuberculosis DHDPS 
Kinetic model Ping-pong Ping-pong 
V 1.00 (±0.04) 4.2 (±0.1) 
KM for (S)-ASA (mM) 0.28 (±0.02) 0.43 (±0.02) 
KM for pyruvate (mM) 0.35 (±0.01) 0.17 (±0.01) 
Monomer molecular weight (Da) 34173.8 31156.5 
e0 (mgs of active site per μmol) 34.17 31.16 
kcat per active site (s-1) 34 (±1) 138 (±2) 
kcat/KM for (S)-ASA (s-1.mM-1) 122 (±4) 320 (±20) 
kcat/KM for pyruvate (s-1.mM-1) 98 (±4) 820 (±60) 
 
 
(A) (B) 
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Figure B.2: The initial velocity of His6-tagged M. tuberculosis DHDPS was measured with the 
coupled assay over varying concentrations of both substrates, (S)-ASA and 
pyruvate, shown on the x-axis and with symbols (? 0.8 mM, ? 0.4 mM, 
? 0.08 mM, ? 0.04 mM, ? 0.016 mM pyruvate). Each measurement was made 
in triplicate and the data were fitted with the ping-pong model giving an R2 of 
0.99 using ENZFITTER. Plot (B) shows the Hanes transformation, reflecting the 
trend of y-axis intersection predicted for the ping-pong model. 
 
(A) (B) 
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Appendix C 
His6-tag cleavage with TEV protease 
In the vector pETM-11 (Appendix A), M. tuberculosis DHDPS is expressed as a fusion 
protein, with a His6-tag at the N-terminus linked using the sequence E-N-L-Y-F-Q-G-A-M-A. 
The nuclear inclusion protease from tobacco TEV has stringent sequence specificity, cleaving 
between Q and G residues in the sequence E-N-L-Y-F-Q-G, and consequently TEV protease 
is widely used for the removal of protein tags.1 Incubation of TEV protease with the fusion 
protein removes the His6-tag and most of the linker sequence; however, four linker amino 
acids, G-A-M-A, remain at the N-terminus of M. tuberculosis DHDPS. 
 
The advantage of the His6-tag is that it binds Ni2+ cations that are immobilized on 
chromatography resin with high specificity, giving a rapid one-step method of achieving 
greatly increasing protein purity.2 The X-ray crystallography structure determined by Weiss 
and Kefala, shows both termini of M. tuberculosis DHDPS on the outer surface of the 
tetrameric structure. Therefore, the His6-tag would not be expected to interfere with enzyme 
folding, but somewhat surprisingly a noticeable effect on kinetics was observed 
(Appendix B). 
 
Initially, cleavage was performed using commercially available TEV protease, called 
AcTEVTM protease, from Invitrogen, which is more stable than the native protease,3 but 
susceptible to self-cleavage.4 Kapust and colleagues rationally designed a mutant 
TEV-protease, S219V, which is 100-fold more stable than wild-type protease and does not 
self-cleave.4 The plasmid pRK793 expresses the mutant TEV protease with a His6-tag on the 
N-terminus, for purification and solubility purposes,4 and was acquired through the non-profit 
organization Addgene (http://www.addgene.org/pgvec1). TEV protease was expressed and 
purified from BL21-CodonPlus® (DE3)-RIL cells containing pRK793, using a simplified 
protocol (detailed in chapter six, section 6.6) based on published methods,4 and stored 
at -80 oC. Over-expression of TEV protease was apparent in the crude extract produced by 
sonication, as shown by SDS-PAGE with Coomassie blue staining (Figure C.1, lane 2). The 
absence of the TEV protease in the flow-through from the His6-tag affinity column 
(Figure C.1, lane 4) showed that all protein binds, and subsequent elution by high 
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concentrations (200 mM) of imidazole resulted in homogeneous TEV protease, as judged by 
SDS-PAGE (Figure C.1, lane 5). 
 
 
Figure C.1: The purification of recombinant TEV protease examined using denaturing 
SDS-PAGE, which separates proteins based on sub-unit molecular weight 
(MW). TEV protease was identified as the 27 kDa band (black rectangle) 
using the MW marker in lane 1. Protein preparations from various stages 
of purification were loaded into other lanes as follows: 2 - crude cell-free 
extract, 3 - after centrifugation, 4 - flow through from His6-tag affinity 
column, 5 - eluted from His6-tag affinity column. 
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Appendix D 
Ionic strength in the coupled assay 
The ionic strength of 200 mM HEPES, pH 8.0, was calculated using the buffer calculator 
(from www.liv.ac.uk/buffers), taking into consideration that the buffer was prepared at 20 °C, 
but the assay is performed at 30 °C. 
 
Table D.1: Assay setup for wild-type M. tuberculosis DHDPS 
[stock] [cuvette] 
Stock mM  mg.mL-1  
Volume 
μL mM  mg.mL-1 
HEPES, pH 8 200  - 500 100  - 
Pyruvate  varied  - varied varied  - 
NADPH 6.0  - 30 0.18  - 
DHDPR   - 0.3 30  - 0.0040 
d-H2O  -  - varied  -  - 
(S)-ASA  varied  - varied varied  - 
DHDPS  -  - 10  -  - 
Total  -  - 1000  -  - 
 
Table D.2: Assay setup for M. tuberculosis DHDPS-A204R 
[stock] [cuvette] 
Stock mM  mg.mL-1  
Volume 
μL mM  mg.mL-1 
HEPES, pH 8 200  - 750 150  - 
Pyruvate  varied  - varied varied  - 
NADPH 6.0  - 30 0.18  - 
DHDPR   - 0.13 30  - 0.0040 
d-H2O  -  - varied  -  - 
[(S)-ASA]  varied  - varied varied  - 
DHDPS  -  - 10  -  - 
Total  -  - 1000  -  - 
 
Table D.3: Ionic strength (IS) in the cuvette 
 
a Ionic strength calculated using the buffer calculator (from www.liv.ac.uk/buffers). 
b Ionic strength ∑ ⋅= 2][21 zi , where [i] is the molar concentration of the ion, and z2 is the charge of the ion squared. 
Buffer stock components:  IS (M) added to buffer stock as:  
[HEPES] (mM) [NaCl] (mM) HEPESa NaClb pH adjustmentb 
Overall IS (M) 
of buffer stock 
Overall IS (M) of 
assay mixture 
Wild-type DHDPS 200 50 0.156 0.025 0.060 0.241 0.121 
DHDPS-A204R 200 50 0.156 0.025 0.060 0.241 0.181 
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Appendix E 
Analyses of the dimer-dimer interface 
JavaProtein Dossier (JPD) 
The dimer-dimer interface of M. tuberculosis DHDPS (PDB 1XXX) was analyzed with JPD 
(from http://sms.cbi.cnptia.embrapa.br/SMS/index_s.html), which determines the interatomic 
contacts established between residues belonging to two different chains at their interface.1 
There is asymmetry in the inter-subunit contacts determined with this method. For example, 
the hydrogen bond between R238 and L203 (Table E.2) occurred from chain a and d, but not 
vice versa, presumably due to the shortest atomic distance between the residues falling 
outside the ≤3.2 Å range (see Table E.8). 
 
Table E.1: Inter-subunit hydrophobic contacts (range: 2-3.8 Å) between chains a and d 
determined with JPD.1 
Chain1 Residue1 Atom1 Distance (Å) Atom2 Residue2 Chain2 
A LEU 177 CD1 3.70 CD2 LEU 198 D 
A HIS 178 CE1 3.52 CB CYS 248 D 
A ALA 181 C 3.76 CD1 ILE 242 D 
A GLN 182 CD 3.78 CB ALA 245 D 
A ALA 204 CB 3.40 CB ALA 204 D 
A MET 205 CE 3.72 CG PRO 201 D 
A MET 205 CE 3.75 CD PRO 201 D 
A MET 205 C 3.40 CD ARG 238 D 
A GLY 206 CA 3.71 CD ARG 238 D 
A ILE 234 CG1 3.53 CD1 ILE 234 D 
A ILE 234 CD1 3.71 CD1 ILE 234 D 
A ARG 238 CD 3.66 C ALA 204 D 
A ARG 238 CD 3.75 CA MET 205 D 
A ARG 238 CD 3.39 C MET 205 D 
A ARG 238 CZ 3.76 CA GLY 206 D 
A ALA 245 CB 3.60 CE1 HIS 178 D 
A CYS 248 CB 3.79 CE1 HIS 178 D 
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Table E.2: Inter-subunit hydrogen bonds (range: 2-3.2 Å) between chains a and d, involving 
main chain and side chain, determined with JPD.1 
Chain1 Residue1 Atom1 Distance (Å) Atom2 Residue2 Chain2 
A ARG 238 NH1 3.13 O LEU 203 D 
A ARG 238 NH1 2.94 O ALA 204 D 
 
Table E.3: Inter-subunit hydrogen bonds (range: 2-3.2 Å) between chains a and d, involving 
a single water molecule bridging main chain to side chain (main 
chain...water...side chain), determined with JPD.1 
Chain1 Residue1 Atom1 Distance (Å) H2O Distance (Å) Atom2 Residue2 Chain2 
A HIS 178 ND1 2.62 17195 2.97 O ALA 197 D 
A ALA 197 O 3.13 17895 2.62 ND1 HIS 178 D 
 
Table E.4: Inter-subunit hydrogen bonds (range: 2-3.2 Å) between chains a and d, involving 
a pair of water molecules bridging main chain to side chain (main 
chain...water...water...side chain), determined with JPD.1 
Chain1 Residue1 Atom1 Distance (Å) H2O Distance (Å) H2O Distance (Å) Atom2 Residue2 Chain2 
A HIS 178 ND1 2.62 17195 3.16 17962 2.75 O ALA 197 D 
A HIS 178 ND1 2.62 17195 2.84 17894 2.71 O ASN 241 D 
A ALA 197 O 2.75 17177 3.17 17895 2.62 ND1 HIS 178 D 
A MET 205 O 2.69 17234 2.73 17862 2.76 ND2 ASN 241 D 
A ASN 241 O 2.82 17257 2.91 17895 2.62 ND1 HIS 178 D 
A ASN 241 ND2 3.03 17248 2.36 17890 2.97 O MET 205 D 
 
Table E.5: Inter-subunit hydrogen bonds (range: 2-3.2 Å) between chains a and d, involving 
a pair of side chains (side chain...side chain), determined with JPD.1 
Chain1 Residue1 Atom1 Distance (Å) Atom2 Residue2 Chain2 
A HIS 178 NE2 2.83 OD1 ASN 249 D 
A GLN 182 OE1 2.64 ND2 ASN 249 D 
A ASN 249 OD1 2.91 NE2 HIS 178 D 
A ASN 249 ND2 3.00 OE1 GLN 182 D 
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Table E.6: Inter-subunit hydrogen bonds (range: 2-3.2 Å) between chains a and d, involving 
a pair of water molecules bridging side chains (side chain...water...water...side 
chain), determined with JPD.1 
Chain1 Residue1 Atom1 Distance (Å) H2O Distance (Å) H2O Distance (Å) Atom2 Residue2 Chain2 
A HIS 178 ND1 2.62 17195 2.84 17894 3.17 OD1 ASN 241 D 
A HIS 178 ND1 2.62 17195 3.16 17962 2.76 OD1 ASN 241 D 
A ASN 241 OD1 2.67 17177 3.17 17895 2.62 ND1 HIS 178 D 
 
Table E.7: Inter-subunit π-cation interactions (range: 2-6.0 Å) between chains a and d, 
determined with JPD.1 
Chain1 Residue1 Distance (Å) Residue2 Chain2 
A PHE 229 5.50 ARG 238 D 
A ARG 238 5.52 PHE 229 D 
 
 
Protein Interfaces, Surfaces, and Assemblies (PISA) database 
The dimer-dimer interface of M. tuberculosis DHDPS (PDB 1XXX) was also analyzed using 
the PISA service (from http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) developed at the 
European Bioinformatics Institute.2 This defines the interface as the protein surface area 
which becomes inaccessible to solvents when two chains come into contact.2 PISA also 
calculates hydrogen bonds, salt bridges and disulfide bonds; however, neither of the latter two 
types of inter-subunit interactions were found in the dimer-dimer interface of DHDPS from 
M. tuberculosis.  
 
Table E.8: Inter-subunit non-water-mediated hydrogen bonds (range: 2-4.0 Å) between 
chains a and d, determined with PISA.2 
 no. Chain 1 Residue [atom] 1 Distance (Å) Residue [atom] 2 Chain 2 
 1  D HIS 178 [NE2] 2.91 ASN 249 [OD1] A 
 2  D GLN 182 [NE2] 3.89 ASN 249 [OD1] A 
 3  D ARG 238 [NH1] 3.43 LEU 203 [O] A 
 4  D ARG 238 [NH1] 3.27 ALA 204 [O] A 
 5  D ASN 249 [ND2] 2.64 GLN 182 [OE1] A 
 6  D GLN 182 [OE1] 3.00 ASN 249 [ND2] A 
 7  D LEU 203 [O] 3.13 ARG 238 [NH1] A 
 8  D ALA 204 [O] 2.94 ARG 238 [NH1] A 
 9  D ASN 249 [OD1] 2.82 HIS 178 [NE2] A 
 10  D ASN 249 [OD1] 3.45 GLN 182 [NE2] A 
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Table E.9: Inter-subunit non-water-mediated hydrogen bonds (range: 2-4.0 Å) between 
chains b and c, determined with PISA.2 
 no. Chain 1 Residue [atom] 1 Distance (Å) Residue [atom] 2 Chain 2 
 1  B HIS 178 [NE2] 2.73 ASN 249 [OD1] C 
 2  B GLN 182 [NE2] 3.35 ASN 249 [OD1] C 
 3  B ASN 249 [ND2] 3.08 GLN 182 [OE1] C 
 4  B ARG 238 [NH1] 3.11 LEU 203 [O] C 
 5  B ARG 238 [NH1] 3.01 ALA 204 [O] C  
 6  B GLN 182 [OE1] 2.61 ASN 249 [ND2] C 
 7  B LEU 203 [O] 3.11 ARG 238 [NH1] C 
 8  B ALA 204 [O] 3.16 ARG 238 [NH1] C 
 9  B ASN 249 [OD1] 3.85 GLN 182 [NE2] C 
 10  B ASN 249 [OD1] 2.80 HIS 178 [NE2] C 
 
Table E.10: Inter-subunit non-water-mediated hydrogen bonds (range: 2-4.0 Å) between 
chains g and f, determined with PISA.2 
 no. Chain 1 Residue [atom] 1 Distance (Å) Residue [atom] 2 Chain 2 
 1  G ASN 249 [ND2] 2.77 GLN 182 [OE1] F 
 2  G ARG 238 [NH1] 3.04 LEU 203 [O] F 
 3  G ARG 238 [NH1] 2.82 ALA 204 [O] F 
 4  G HIS 178 [NE2] 2.71 ASN 249 [OD1] F 
 5  G GLN 182 [NE2] 3.65 ASN 249 [OD1] F  
 6  G GLN 182 [OE1] 2.80 ASN 249 [ND2] F 
 7  G LEU 203 [O] 3.14 ARG 238 [NH1] F 
 8  G ALA 204 [O] 3.04 ARG 238 [NH1] F 
 9  G ASN 249 [OD1] 3.46 GLN 182 [NE2] F 
 10  G ASN 249 [OD1] 2.71 HIS 178 [NE2] F 
 
The same hydrogen bonds were identified with PISA in all sets of dimer-dimer interactions 
(Table E.8, E.9, E.10) apparent in the asymmetric unit of the crystal structure (PDB 1XXX), 
including between chain e and h (not shown). There are some variation in the hydrogen 
bonding distances for some residues. For example, the shortest atomic distance between R238 
and L203 was found to be 3.13 Å from chain a to d, and 3.43 Å vice versa (Table E.8), 
whereas it was 3.11 Å from chain b to c and vice versa (Table E.9). However, PISA uses 
broader criteria to define a hydrogen bond (≥4.0 Å), in contrast to JPD, which results in the 
identification of the same hydrogen bonds in all sets of dimer-dimer interactions in the crystal 
structure. 
 
 PYMOL  L177 H178 A181 Q182  A197   P201 L203 A204 M205      I234 I242 R238 N241      N249 
JPD  L177 H178 A181 Q182  A197 L198  P201 L203 A204 M205 G206 F229  I234 I242 R238 N241 A245  C248 N249 
Interface 
residues 
PISA A175 L177 H178 A181 Q182 A185 A197 L198 L200 P201 L203 A204 M205 G206 F229 G232 I234 I242 R238 N241 A245 P246 C248 N249 
 L177 D196 M205 I242  H178   L177 R238 A204 A181    I234 A181 L203 H178    H178 
 P201 A197 I242 N249       R238 L200     Q182 A204 L200    Q182 
  N199          R238      M205 M205      
  L200          N241      N241 R238      
  N241                       
PYMOL 
   N249                                       
 L198 A197 I242 A245  H178 L177  M205 R238 A204 P201 R238 R238  I234 A181 L203 H178 H178  H178 H178 
  A245  N249  N241     R238 R238      A204 A197 Q182   Q182 
  N241          N241      M205 M205      
  C248                G206       
JPD 
   N249                            F229          
  N249  N249      R238 R238       L203     H178 
Contacts  
PISA 
                  A204     Q182 
   
Figure E.1: Comparison of interface residues and inter-subunit contacts determined by visual inspection with PYMOL,3 by JDP,1 and 
by PISA.2 The interface residues determined using PYMOL and JDP were defined by inter-subunit contacts, whereas PISA 
defines the interface as the residues buried by the association of subunits. PISA determines the hydrogen bonds, but not 
hydrophobic contacts across the dimer-dimer interface. 
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Appendix F 
The dimer-dimer interface of E. coli DHDPS 
The dimer-dimer interface of M. tuberculosis DHDPS was considerable larger than that of 
E. coli DHDPS, as quantified by the number of interface residues determined using PISA 
(24 (±1) in Table F.2 vs. 15 (±2) in Table F.1).1 In addition, more residues are buried ≥45 % 
by the association of subunits in M. tuberculosis DHDPS, as compared to E. coli DHDPS. 
 
Table F.1: PISA analysis of the dimer-dimer interface of wild-type E. coli DHDPS.1 
Interface residues buried ≥45 % by the association of subunits are shaded grey. 
(A) 
 no.  Chain 1 Residue 1 H-bond BSAa 
  1  A GLY 165      27 % 
  2  A ASN 166      2 % 
  3  A LEU 167      90 % 
  4  A THR 168      70 % 
  5  A ASN 171  H-bond 83 % 
  6  A LYS 174      4 % 
  7  A GLU 175 H-bond 34 % 
  8  A SER 190      68 % 
  9  A ASP 193 H-bond 78 % 
 10  A GLN 196 H-bond 65 % 
 11  A LEU 197      100 % 
 12  A GLY 198      7 % 
 13  A ARG 230  H-bond 52 % 
 14  A GLN 234 H-bond 37 % 
 15  A MET 237      4 % 
 
(B) 
 no.  Chain 1 Residue 1 H-bond BSAa 
  1  B GLY 165          23% 
  2  B  ASN 166          1% 
  3  B LEU 167          89% 
  4  B THR 168          68% 
  5  B ASN 171     H-bond 83% 
  6  B LYS 174          39% 
  7  B GLU 175     H-bond 34% 
  8  B ALA 189          1% 
  9  B SER 190          77% 
 10  B ASP 193     H-bond 80% 
 11  B GLN 196     H-bond 70% 
 12  B LEU 197          99% 
 13  B GLY 198          5% 
 14  B PHE 226          1% 
 15  B ARG 230          58% 
 16  B GLN 234     H-bond 37% 
 17  B MET 237          3% 
 
a  The percentage of the total solvent-accessible surface area buried by the association of subunits. 
 
 
Figure F.1: JDP analysis of the dimer-dimer interface of wild-type E. coli DHDPS 
(Dr Sean Devenish pers. comm.).2 This was figure produced by Dr Sean Devenish.  
Appendix F  227 
 
Table F.2: PISA analysis of the dimer-dimer interface of wild-type M. tubeculosis DHDPS.1 
Interface residues buried ≥45 % by the association of subunits are shaded grey. 
(A) 
 no.  Chain 1 Residue 1 H-bond BSAa 
  1  A ALA 175          2% 
  2  A LEU 177          88% 
  3  A HIS 178     H-bond 80% 
  4  A ALA 181          83% 
  5  A GLN 182     H-bond 71% 
  6  A ALA 185          36% 
  7  A ALA 197          64% 
  8  A LEU 198          54% 
  9  A LEU 200          100% 
 10  A PRO 201          100% 
 11  A LEU 203     H-bond 25% 
 12  A ALA 204     H-bond 100% 
 13  A MET 205          95% 
 14  A GLY 206          41% 
 15  A PHE 229          61% 
 16  A GLY 232          49% 
 17  A ILE 234          80% 
 18  A ARG 238     H-bond 54% 
 19  A ASN 241          76% 
 20  A ILE 242          57% 
 21  A ALA 245          90% 
 22  A CYS 248          54% 
 23  A ASN 249     H-bond 38% 
 
(B) 
 no.  Chain 1 Residue 1 H-bond BSAa 
  1  B ALA 175            4% 
  2  B LEU 177            95% 
  3  B HIS 178      H-bond 82% 
  4  B ALA 181            87% 
  5  B GLN 182     H-bond 62% 
  6  B ALA 185            31% 
  7  B ALA 197            65% 
  8  B LEU 198            59% 
  9  B LEU 200            100% 
 10  B PRO 201           100% 
 11  B LEU 203      H-bond 25% 
 12  B ALA 204      H-bond 100% 
 13  B MET 205           94% 
 14  B GLY 206            40% 
 15  B PHE 229           55% 
 16  B GLY 232            36% 
 17  B ILE 234            81% 
 18  B ARG 238     H-bond 55% 
 19  B ASN 241           77% 
 20  B ILE 242            59% 
 21  B ALA 245            88% 
 22  B PRO 246           3% 
 23  B CYS 248           56% 
 24  B ASN 249     H-bond 41% 
 
a  The percentage of the total solvent-accessible surface area buried by the association of subunits. 
 
The larger surface area of the dimer-dimer interface in M. tuberculosis DHDPS, as compared 
with E. coli DHDPS, is apparent in Figure F.2. The leucine residue (E. coli: L197, 
M. tuberculosis: M205) that successfully resulted in dimeric variants of E. coli DHDPS is 
fairly central in the interface (Figure F.2A)3 and lies among those residues that are buried to a 
relatively high degree (≥85 %) by the association into the homotetramer quaternary structure. 
Similarly, the alanine residue mutated in this study (M. tuberculosis: A204, E. coli: Q196) is 
relatively central within the dimer-dimer interface (Figure F.2B) and is buried 100 % by the 
association of subunits. 
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Figure F.2: Looking down onto the dimer-dimer interface (chains a and b) of (A) E. coli and 
(B) M. tuberculosis DHDPS, showing the position of residues mutated to create 
dimeric variants (circled in black), L197 (in E. coli DHDPS) and A204 (in 
M. tuberculosis DHDPS), respectively. The residues contributing to the interface 
are  shown in various shades depending on their buried surface area (5 - 44 % 
yellow, 45 - 84 % orange, ≥85 % red) as defined by PISA.1 
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Appendix G 
Substrate inhibition at high (S)-ASA concentrations 
Background 
High concentrations of one or more of an enzyme’s substrates are often found to inhibit that 
enzyme’s activity.1 Substrate inhibition happens when a molecule of substrate binds to the 
wrong enzyme form, and thus produces an inactive or dead-end complex.2 However, this 
phenomenon is not commonly observed in kinetic analysis because substrate concentrations 
are kept at or below their physiological values.2 The ping-pong kinetic model assigned to 
DHDPS is a compulsory order mechanism requiring (S)-ASA to bind after pyruvate. 
Therefore, substrate inhibition is expected at high (S)-ASA concentrations, due to (S)-ASA 
binding to DHDPS prior to pyruvate and forming a dead-end (S)-ASA-enzyme complex that 
has to dissociate before the reaction can proceed. 
 
It is difficult to compare literature reports of substrate inhibition for DHDPS, or its absence, 
because of the different assaying and synthetic methods used by workers (Table G.1). 
However, the majority of kinetic studies with bacterial DHDPS orthologues have not 
observed substrate inhibition (Table G.1), probably because low concentrations of (S)-ASA 
were used for kinetic analysis to avoid such complications. The presence of substrate 
inhibition may have also been masked by inaccuracy, due to the lag time in some of the 
assaying methods (chapter two, section 2.2). 
 
Substrate inhibition by (S)-ASA was observed for E. coli DHDPS at low concentration, giving 
a dissociation constant for the (S)-ASA-enzyme complex (K
i
(S)-ASA) of 0.3 (±0.08) mM.3 
However, it was later demonstrated that this inhibition was due to impurities in the (S)-ASA 
synthesized using Black & Wright’s ozonolysis method.4 Parallel experiments were 
performed contrasting (S)-ASA synthesized using different methods and showed that 
inhibition was only observed when (S)-ASA was prepared using ozonolysis,5 in comparison to 
higher (>95 %) purity (S)-ASA, synthesized using the protocol by Roberts et al.,6 which 
showed no inhibition at or below the 2 mM concentration tested.4 
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Table G.1: (S)-ASA inhibition observed or not during kinetic analysis of DHDPS. 
Organism Inhibition @ [(S)-ASA] (S)-ASA synthesis Assay method Ref. 
Bacillus licheniformis Yes 5.22 mM Black & Wright 5 o-aminobenzaldehyde 7 
Bacillus megaterium None 0.01 mM Black & Wright 5 imidazole 8 
Bacillus sphaericus None 3.75 mM Black & Wright 5 o-aminobenzaldehyde 9 
Bacillus subtilis None 0.66 mM Black & Wright 5 o-aminobenzaldehyde 10 
Brevibacterium lactofermentum None 0.2 mM Black & Wright 5 o-aminobenzaldehyde 11 
C. glutamicum Yes 5.6 mM Black & Wright 5 coupled 12 
E. coli Yes 0.3 mM Black & Wright 5 coupled 3 
E. coli Yes 1.1 mM Black & Wright 5 coupled 4 
E. coli None 2 mM Roberts, et al.6 coupled 4 
Methanobacterium thermoautrophicum None 10 mM Black & Wright 5 o-aminobenzaldehyde 13 
Neisseria meningitidis Yes 1.7 mM Roberts, et al.6 coupled 14 
Sinorhizobium meliloti  None 0.45 mM Roberts, et al.6 imidazole 15 
S. aureus (MRSA) None 3.0 mM Black & Wright 5 coupled 16 
S. aureus (MRSA) Yes 2.7 mM Roberts, et al.6 coupled 17 
Streptomyces clavuligerus None 0.03 mM Black & Wright 5 imidazole 18 
Thermoanaerobacter tengcongensis Yes 4.7 mM Roberts, et al.6 coupled 19 
T. maritima None 1.25 mM  Roberts, et al.6 coupled 20 
 
More recently, substrate inhibition has been observed at relatively low concentration of 
(S)-ASA in DHDPS enzymes from Sinorhizobium meliloti, MRSA and Neisseria meningitidis 
(Table G.1).14,15,17 Since in these studies (S)-ASA was synthesized using the protocol by 
Roberts et al.,6 the inhibition observed is unlikely to be due to contaminants. Interestingly, 
MRSA DHDPS has been characterized both with and without substrate inhibition in two 
separate publications (Table G.1).16,17 Similar KM values for pyruvate of 0.11 (±0.01) and 
0.12 (±0.01) mM were determined, whereas a lower KM for (S)-ASA was obtained from data 
fitted with substrate inhibition of 0.22 (±0.02) mM, compared to 0.33 (±0.03) mM from data 
fitted without substrate inhibition.16,17 
 
Substrate inhibition due to (S)-ASA has recently been noted for DHDPS from 
Thermoanaerobacter tengcongensis and C. glutamicum occurring at comparably high (S)-
ASA concentrations of ~5 mM (Table G.1).12,19 However, both experimental setups have 
alternative causes for the inhibition, as commented on by investigators.12,19 The initial-rate 
data of Thermoanaerobacter tengcongensis DHDPS were fitted to the ping-pong (S)-ASA 
substrate inhibition model to give a K
i
(S)-ASA of 4.7 (±0.8) mM.19 In contrast, for C. glutamicum 
DHDPS, even though substrate inhibition was observed at ≥5.6 mM (S)-ASA, the initial-rate 
data were fitted to the ping-pong model without substrate inhibition.12 This was justified by 
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the normal Michaelis-Menten type saturation curves observed within the (S)-ASA 
concentration ranges of 0.14 mM and 2.8 mM used for kinetic characterization.12 
 
M. tuberculosis DHDPS 
Kinetic analysis of wild-type M. tuberculosis DHDPS investigated the (S)-ASA concentration 
range from 0.03 to 3.0 mM and showed no substrate inhibition (chapter two, section 2.4.4). 
However, the kinetic analysis of DHDPS-A204R required higher (S)-ASA concentrations and 
initial investigation showed curvature suggestive of substrate inhibition. De-activation of the 
enzyme due to a decrease in pH due to the acidity of the (S)-ASA solution was eliminated by 
using a high concentration of HEPES buffer in the coupled assay protocol, which neutralized 
the acidity even at the highest concentrations of (S)-ASA investigated. Thus pseudo-single 
substrate kinetic experiments were performed for DHDPS-A204R and wild-type DHDPS 
(Figure G.1). 
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Figure G.1: The effect of (S)-ASA concentration on DHDPS activity, as measured by the 
coupled assay for (A) wild-type and (B) A204R and M. tuberculosis DHDPS. The 
pyruvate in the assay mixture was held constant at high (? 4.0 mM) or low 
concentrations (? 0.15 mM for A204R and 0.05 mM for wild-type). Duplicate 
measurements were recorded for the data points with error bars to show the 
standard deviation. 
 
Substrate inhibition at high (S)-ASA concentrations is more obvious in wild-type 
M. tuberculosis DHDPS with the activity starting to decrease at concentrations above 3 mM 
(Figure G.1A); although, this is above the concentration range used in the characterization of 
the wild-type enzyme. A slight decrease in activity with DHDPS-A204R is observed only at 
low pyruvate concentration (Figure G.1B). The protection against inhibition at higher 
pyruvate concentrations is consistent with the competitive inhibition expected for the ping-
(A) (B) 
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pong model. A normal Michaelis-Menten type saturation curve for DHDPS-A204R is 
observed within the (S)-ASA concentration range of 0.22 to 5.5 mM used for kinetic 
characterization, indicating that the kinetic data can be fitted to the ping-pong model without 
substrate inhibition. 
 
The KM value of 1.1 (±0.1) mM for (S)-ASA determined from fitting the ping-pong model 
without substrate inhibition to the initial-rate data of DHDPS-A204R data is approximately 
triple the KM value previously determined for wild-type of 0.43 (±0.02) mM. This indicates 
that DHDPS-A204R has a lower affinity for (S)-ASA, consistent with the difference in 
observed substrate inhibition at high (S)-ASA concentrations between the variant and wild-
type enzyme. 
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Appendix H 
Analysis of pyruvate effect via biophysical methods 
The effect of pyruvate on the oligomeric state of DHDPS-A204R was examined by two 
biophysical techniques. Experiments performed with wild-type M. tuberculosis DHDPS allow 
monitoring of the inaccuracies that may be involved in these experimental setups. 
 
Wild-type M. tuberculosis DHDPS, like DHDPS-A204R, was purified using a preparative 
gel-filtration Superdex 200 16/60 column (GE Healthcare) pre-equilibrated with purification 
buffer containing 10 mM pyruvate. From the four-point calibration plot that was generated 
(Figure H.1B), the symmetrical elution peak of the wild-type enzyme (Figure H.1A) was 
determined to correspond to a molecular mass of 117 kDa. 
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Figure H.1: (A) Gel filtration chromatography of M. tuberculosis DHDPS, performed at 4 ºC 
in purification buffer [20 mM Tris-HCl, 250 mM NaCl, 5 % glycerol, 2 mM β-ME, 
10 mM pyruvate] gave an elution peak with a maximum at 85.49 mL. (B) BSA, 
ovalbumin, and alcohol dehydrogenase calibration standards (?) were fitted to a 
linear equation. 
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This value of 117 kDa for wild-type M. tuberculosis DHDPS is consistent with its tetrameric 
quaternary structure and the solution molar masses of 116 and 105 kDa determined with 
analytical ultracentrifugation and analytical gel-filtration, respectively (in chapter two, 
section 2.5). Since, the preparative gel-filtration setup gave a similar molar mass as other 
methods, differences observed when analyzing DHDPS-A204R could not be attributed to the 
effect of the buffer components or temperature on the preparative gel-filtration column itself. 
 
Sedimentation velocity experiments with wild-type M. tuberculosis DHDPS were performed 
at 40000 rpm and at 20 ºC, in the storage buffer [20 mM Tris.HCl, 250 mM NaCl, 5 % 
glycerol, 2 mM β-mercaptoethanol (β-ME), 10 mM pyruvate, pH 8.0]. Due to the limitations 
of the SEDNTERP program partial specific volume ( v ), solvent density (ρ) and viscosity (η) 
were estimates (of 0.7402 mL.g-1, 1.023 g.mL-1 and 1.193 cP, respectively), not taking into 
account some possible effects due to buffer components. 
 
The data were collected every 6 minutes and fitted to a continuous sedimentation coefficient 
[c(s)] distribution model, using SEDFIT,1 which gave a main peak of 5.3 S (Figure H.2B). 
The second peak at 3.0 S likely corresponds to the contaminant that absorbs more highly at 
280 nm than 230 nm, which is discussed in detail in chapter two, section 2.5.2. Plots of raw 
data overlaid with the calculated fits were produced for visual inspection of the analysis 
(Figure H.2A). The fit was less than ideal, as indicated by the high Z-test value of 20.49; 
however, the randomly distributed residuals and low r.m.s.d. indicate the relative goodness of 
the fit (Figure H.2). The frictional ratio (f/f0) of 1.28 is significantly different to previous f/f0 
of 1.23 and 1.22 extracted from fitting data of wild-type M. tuberculosis DHDPS in 20 mM 
Tri.HCl, 150 mM NaCl, pH 8.0 (in chapter two, section 2.5.2, Figures 2.12 and 2.13) and may 
reflect effects due to the buffer components not present during these other experiments.  
 
The sedimentation coefficient is relatively unaffected by the frictional ratio (f/f0),2 and thus 
can be provide insight into the oligomeric species present regardless of possible inaccuracies 
in the f/f0. HYDROPRO predicts a sedimentation coefficient of 5.5 S for tetrameric DHDPS, 
indicating that the main peak observed of 5.3 S corresponds to a tetramer, consistent with the 
quaternary structure of M. tuberculosis DHDPS. In addition, when this sedimentation 
coefficient was standardized to conditions corresponding to pure water at 20 °C, using 
SEDNTERP,3 a value of 6.8 S was obtained, which is similar to 6.5 S for s°20,w found for 
wild-type M. tuberculosis DHDPS in 20 mM Tris.HCl, 150 mM NaCl, pH 8.0 (in chapter 
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two, section 2.5.2). This demonstrates that estimations of solution and protein properties for 
SV analysis in storage buffer do not obscure the determination of oligomeric state, even 
though there may be some inaccuracy in the frictional ratio. 
 
 
Figure H.2: Sedimentation velocity analysis of M. tuberculosis DHDPS (1.0 mg.mL-1) in 
storage buffer [20 mM Tris.HCl, pH 8.0, 250 mM NaCl, 5 % glycerol, 2 mM 
β-ME, and 10 mM pyruvate] at 20 ºC. (A) Absorbance at 280 nm (○) is plotted 
at time intervals of 12 minutes and overlaid with the nonlinear least-squares fit 
(solid line) to a [c(s)] model.1 (B) The fit was obtained using a resolution of 200 
species with v  = 0.7402 mL.g-1, ρ = 1.023 g.mL-1, η = 1.193 cP and 
f/f0 = 1.28437, and TI noise was removed. The r.m.s.d. and Z-test for the fit 
were 0.0042 and 20.49, respectively. 
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Appendix I 
Crystallization of DHDPS-A204R 
Crystallization of M. tuberculosis DHDPS-A204R was performed by Linda Schuldt, under the 
supervision of Dr Manfred Weiss, from the EMBL Hamburg Outstation, Germany. Purified 
DHDPS-A204R was concentrated to 10 mg.mL-1 using an ultrafiltration spin column 
(Vivaspin 15, molecular cut-off >10000 kDa, range 2-8 mL) in our lab and sent to Germany. 
 
Our collaborator, Linda Schuldt, screened for initial crystallization conditions and crystals 
were observed in the several conditions, all of which contained 2.0 M ammonium sulfate and 
various buffers at different pH values at room temperature (Figure I.1A). Optimization was 
carried out using the sitting-drop vapor diffusion method in Greiner 96-well plates. 200 nL of 
protein solution and 200 nL of reservoir solution were equilibrated against 30 µL of reservoir 
solution. Compact crystals grew out of 2.0 M ammonium sulfate and 100 mM sodium acetate 
pH 5.5 at room temperature within 4 weeks to a maximum size of 100 µm × 40 µm × 20 µm 
(Figure I.1B). These crystals diffracted X-rays up to a resolution of about 2.0 Å. 
 
 
Figure I.1: (A) Crystals of M. tuberculosis DHDPS-A204R in the initial conditions for 
crystallization of 2.0 M (NH4)2SO4 and 100 mM Tris.HCl, pH 8.5.  
(B) A crystal formed in optimized conditions of 2.0 M (NH4)2SO4 and 
100 mM sodium acetate pH 5.5. 
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Crystal structure and kinetic study of dihydrodipicolinate synthase from
Mycobacterium tuberculosis
Georgia KEFALA*1,2, Genevieve L. EVANS†2, Michael D. W. GRIFFIN‡, Sean R. A. DEVENISH†, F. Grant PEARCE†, Matthew A.
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The three-dimensional structure of the enzyme dihydrodipicolin-
ate synthase (KEGG entry Rv2753c, EC 4.2.1.52) from Mycobac-
terium tuberculosis (Mtb-DHDPS) was determined and refined at
2.28 Å (1 Å = 0.1 nm) resolution. The asymmetric unit of the
crystal contains two tetramers, each of which we propose to
be the functional enzyme unit. This is supported by analytical
ultracentrifugation studies, which show the enzyme to be
tetrameric in solution. The structure of each subunit consists of
an N-terminal (β/α)8-barrel followed by a C-terminal α-helical
domain. The active site comprises residues from two adjacent
subunits, across an interface, and is located at the C-terminal
side of the (β/α)8-barrel domain. A comparison with the other
known DHDPS structures shows that the overall architecture
of the active site is largely conserved, albeit the proton relay
motif comprising Tyr143, Thr54 and Tyr117 appears to be disrupted.
The kinetic parameters of the enzyme are reported: KMASA =
0.43 +− 0.02 mM, KMpyruvate = 0.17 +− 0.01 mM and Vmax = 4.42 +−
0.08 μmol · s−1 · mg−1. Interestingly, the Vmax of Mtb-DHDPS
is 6-fold higher than the corresponding value for Escherichia
coli DHDPS, and the enzyme is insensitive to feedback
inhibition by (S)-lysine. This can be explained by the three-
dimensional structure, which shows that the (S)-lysine-binding
site is not conserved in Mtb-DHDPS, when compared with
DHDPS enzymes that are known to be inhibited by (S)-lysine. A
selection of metabolites from the aspartate family of amino acids
do not inhibit this enzyme. A comprehensive understanding of
the structure and function of this important enzyme from the (S)-
lysine biosynthesis pathway may provide the key for the design
of new antibiotics to combat tuberculosis.
Key words: diaminopimelate pathway, dihydrodipicolinate
synthase (DHDPS), lysine biosynthesis, Mycobacterium
tuberculosis, succinylase branch.
INTRODUCTION
Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis, causes more deaths than any other bacterium
[1,2]. The increase in tuberculosis cases worldwide, particularly
among immunocompromised individuals, combined with the
increase in multidrug-resistant strains, highlights the need for
new antituberculosis drugs [3].
Mycobacterial cell walls are characterized by an unusually
high DAP (diaminopimelic acid) content. DAP, an intermediate
of the (S)-lysine biosynthetic pathway, is a constituent of the short
peptide bridges that cross-link peptidoglycan polymer chains.
Consequently, the absence of DAP results in cell lysis and
death, as has been demonstrated in gene-knockout experiments
with Mycobacterium smegmatis [4]. The process of cell wall
assembly and the biosynthesis of cell wall components have
long been accepted as targets for antibiotic design and many
existing antibiotics inhibit key steps therein [5]. Therefore an
inhibitor that inactivates any of the enzymes that are unique to
the (S)-lysine biosynthetic pathway, preventing the synthesis of
these crucial metabolites, would be a very effective antibiotic [6].
Additionally, the absence of the (S)-lysine pathway in mammals
means that inhibitors of this pathway would not be expected to
have mammalian toxicity [6].
The enzyme DHDPS (dihydrodipicolinate synthase) (KEGG
entry Rv2753c; EC 4.2.1.52) catalyses the first unique reaction
of (S)-lysine biosynthesis [7]: an aldol condensation between (S)-
ASA [(S)-aspartate β-semialdehyde] and pyruvate (Scheme 1)
[8]. The product of the reaction is the unstable heterocycle HTPA
[(4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate], which is
thought to undergo a non-enzymatic dehydration to (S)-2,3-
dihydrodipicolinate, the substrate of the next enzyme in the
(S)-lysine biosynthetic pathway, DHDPR (dihydrodipicolinate
reductase) [9,10]. The proposed Ping Pong mechanism of DHDPS
involves Schiff base formation between pyruvate and an active-
site lysine residue, followed by the release of water and then
enamine formation [7], which has been suggested to be essentially
irreversible [11]. (S)-ASA then binds to the stable substituted
enzyme form, and this event is followed by the release of the
product and the regeneration of the free enzyme [10]. A catalytic
triad, involving residues from two monomers, was shown to have
a crucial role in catalysis; the current hypothesis is that these three
residues are involved in the transport of protons from the active
site to bulk solvent [12].
All DHDPS enzymes that have had both their structure solved
and function confirmed are homotetramers. The three-dimen-
sional structures of DHDPS from Escherichia coli [10,13,14],
Nicotiana sylvestris [9], Thermotoga maritima [15] and Bacillus
Abbreviations used: DAP, diaminopimelate; DHDPR, dihydrodipicolinate reductase; DHDPS, dihydrodipicolinate synthase; DTT, dithiothreitol; HTPA,
(4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate; Mtb, Mycobacterium tuberculosis; (S)-ASA, (S)-aspartate β-semialdehyde.
1 Present address: The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, U.S.A.
2 These authors contributed equally to this work.
3 Correspondence may be addressed to either of these authors (email msweiss@embl-hamburg.de or rdobson@unimelb.edu.au).
The structural co-ordinates for Mycobacterium tuberculosis dihydrodipicolinate synthase will appear in the Protein Data Bank under accession code
1XXX.
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Scheme 1 Reaction catalysed by DHDPS
anthracis [16], as well as the structures of five point mutants of
the E. coli DHDPS [12,17], have been determined.
Characterized DHDPS enzymes display a quaternary structure
best described as a dimer of tight dimers, with many interactions
between the two monomers to form the tight dimer, and, in
the case of the bacterial enzymes, relatively fewer interactions
between the tight dimers that form the tetramer [13]. Recently, the
structure of a putative DHDPS from Agrobacterium tumefaciens
was determined to be a hexamer (PDB code 2HMC), although
the function of this enzyme (and its annotation as a DHDPS) has
yet to be confirmed. Despite originating from different kingdoms
of life, the structure of the monomeric subunits of E. coli and the
plant species N. sylvestris DHDPS enzymes are strikingly similar.
Intriguingly, the quaternary structure of the plant and bacterial
species is quite different. The arrangement of the tight dimer
is the same, but the arrangement of the two tight dimers to form
the tetramer is different. The altered conformation can perhaps
be explained by the proposed mechanism of allosteric inhibition.
The activity of DHDPS is moderately inhibited by (S)-lysine in
some bacteria, such as E. coli [10], whereas, in plants, a greater
degree of inhibition is observed [9]. The structures of DHDPS
from both E. coli and N. sylvestris complexed with (S)-lysine
show that one (S)-lysine molecule is bound to each monomer, but,
at the same time, is co-ordinated by residues from both mono-
meric units at the tight-dimer interface [9,10]. Upon (S)-lysine
binding, a significant conformational change occurs in the N.
sylvestris DHDPS structure [9], which is in striking contrast with
the situation in the E. coli DHDPS, where relatively few residues
shift upon (S)-lysine binding [13].
The focus of the present study is to understand the structure–
function relationship in Mtb-DHDPS, which will underpin the
rational design of antimicrobials. In this paper, we present an
in-depth structural and kinetic study of the ‘toolkit’ used by Mtb-
DHDPS in catalysis.
EXPERIMENTAL
Materials
Unless otherwise stated, all chemicals were obtained from
Sigma Chemical Co., GE Biosciences or Invitrogen, and all
enzyme manipulations were carried out at 6 ◦C or on ice.
Protein concentration was measured by a modification of the
Bradford method, with improved linearity over a broader range
of concentrations [18] using BSA as a standard.
Overexpression and purification of Mtb-DHDPS
For the structural studies, the cloning, expression, purification
and crystallization of Mtb-DHDPS has been described previously
[19]. In brief, the M. tuberculosis dapA gene (Rv2753c) was
cloned and expressed in E. coli cells and purified to homogeneity
by affinity and size-exclusion chromatography.
For functional studies, the pETM11 plasmid containing the
M. tuberculosis dapA gene was transformed into E. coli
BL21(DE3) cells containing the pGroESL plasmid, which codes
for the GroEL and GroES chaperones [20]. This step increased
the amount of Mtb-DHDPS isolated. Cells were grown overnight
at 37 ◦C and induced with IPTG (isopropyl β-D-thiogalactoside)
for 3 h. Both the extraction and elution buffers contained 10 mM
pyruvate, which has been used previously to stabilize E. coli
DHDPS [11]. Following elution from a 5 ml Ni-charged column,
fractions containing DHDPS activity (determined using the o-
aminobenzaldehyde assay [21]) were incubated overnight with
recombinant TEV (tobacco etch virus) protease [1 mM DTT
(dithiothreitol) and 5 mM EDTA] to remove the His6 tag, then
dialysed or exchanged into a storage buffer [20 mM Tris/HCl,
2 mM 2-mercaptoethanol and 5% (v/v) glycerol (pH 8)]. Any
remaining contaminants were removed by gel filtration, and the
active peak, which eluted with a molecular mass of approx.
120 kDa, consistent with a homotetramer, was collected. The
purified Mtb-DHDPS was analysed by SDS/PAGE (4–12%
gel) and blue native PAGE (4–16% gel) (NuPAGE Bis-Tris
gel; Invitrogen) [22], and stored in storage buffer containing
250 mM NaCl at 6 or 22 ◦C for several weeks without detectable
degradation.
Crystallization, structure solution and refinement
Crystals of Mtb-DHDPS were grown in the presence of 28%
(w/v) PEG [poly(ethylene glycol)] 4000, 170 mM MgCl2 and
100 mM Tris/HCl (pH 8.5). Crystals were flash-cooled in a
nitrogen stream at −173 ◦C, using 20% (v/v) MPD (2-methyl-2,4-
pentanediol) in reservoir solution as cryoprotectant. Diffraction
data were collected on the XRD (X-ray diffraction) beamline
at the ELETTRA synchrotron (Trieste, Italy) using a MAR
CCD (charge-coupled device) (165 mm) detector. The crystals
belong to the primitive monoclinic space group P21 with
the following unit cell parameters: a = 94.79 Å (1 Å = 0.1 nm),
b = 87.37 Å, c = 139.85 Å, β = 107.78◦ [19]. Based on the self-
rotation function, it was concluded that the asymmetric unit of
the crystals contained two tetramers exhibiting D2 symmetry. The
structure of Mtb-DHDPS was solved by molecular replacement
using a single monomer of T. maritima DHDPS (PDB code 1O5K
[15]) as a search model. The molecular replacement solution was
then subjected to rigid-body, positional and B-factor refinement
protocols as implemented in CNS [23]. At this point the free
R-factor had fallen to 46%, indicating the correctness of the
solution. The correct amino acid sequence was introduced for
one monomer using GUISIDE [24] and the co-ordinates for the
remaining seven monomers were generated utilizing the non-
crystallographic symmetry. The model was improved further
using iterative manual model corrections using the program O
[25] and refinement in REFMAC5 [26]. Non-crystallographic
symmetry restraints were used throughout the refinement. Water
molecules were placed using the program ARP/wARP [24]. The
refinement statistics are summarized in Table 1. The quality
c© The Authors Journal compilation c© 2008 Biochemical Society
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Table 1 Refinement and model statistics for Mtb-DHDPS
R.m.s.d, root mean square deviation.
Parameter Value
Space group P21
Cell dimensions a = 94.79 A˚, b = 87.37 A˚, c = 139.85 A˚, β = 107.78◦
Resolution limits (A˚) 99–2.28 (2.32–2.28)
Completeness (%) 99.7 (95.0)
Resolution limits for refinement (A˚) 30.0–2.28 (2.34–2.28)
Data cut-off [F /σ (F)] 0.0
Number of reflections 99295
Working set 97308
Test set 1987
Rcryst (%) 14.9 (16.5)
R free (%) 21.5 (23.5)
Number of atoms 18793
Protein 17072
Mg2+ ions 8
Cl− ions 8
Water molecules 1587
DTT molecules 8
R.m.s.d.
Bonds (A˚) 0.018
Angles (◦) 1.63
Average B factors
Protein (A˚2) 29.4
Ions (A˚2) 36.3
DTT (A˚2) 44.4
Water (A˚2) 30.3
Ramachandran plot
Most favoured (%) 90.4
Additionally allowed (%) 9.2
of the model was checked using the program PROCHECK
[27]. The Figures illustrating structural details were prepared
using the program PyMOL (DeLano Scientific), unless stated
otherwise. The refined co-ordinates, as well as the corresponding
structure factor amplitudes, were deposited with the PDB under
the accession number 1XXX.
Sequence alignments were derived from the three-dimensional
alignments of the DHDPS structures, which were carried out
using the programs ALIGN [29], STAMP [30] and LSQKAB
[31]. Buried surface areas were calculated with DSSP [31], the
EBI PISA server [32] and the Protein–Protein Interaction server
(http://www.biochem.ucl.ac.uk/bsm/PP/server).
Enzyme activity assay
The activity of DHDPS was studied using a coupled assay
as described previously [12], with the following components:
pyruvate, (S)-ASA, DHDPR, NADPH and Hepes buffer. (S)-
ASA was synthesized using the methods of Roberts et al. [33]
and was of high quality (>95%) as judged by 1H-NMR. Control
assays were performed to ensure the absence of contaminating
NADPH-utilizing enzymes and to ensure an excess of DHDPR.
The coupled assay follows the consumption of NADPH by the
next enzyme in the (S)-lysine biosynthetic pathway, DHDPR
[12,34,35]. Coupling enzyme was purified from T. maritima. All
components were incubated for 15 min before initiation of the
reaction by the addition of DHDPS. The temperature was kept
constant at 30 ◦C by the use of a circulating water bath and
the pH was maintained at 8.0 by 100 mM Hepes buffer (from
a stock of 200 mM Hepes, pH 8.0, at 22 ◦C). Selwyn’s test [36]
was performed to ensure that enzymes and substrates were stable
over the course of the assay (results not shown). The initial rate
of NADPH consumption was measured in triplicate, and was
reproducible ( +− 10%). The data were fitted with the appropriate
kinetic models using the program ENZFITTER (Biosoft).
Enzyme stability
The optimum pH for enzyme activity was determined using a
series of 20 mM buffers (Mes, Hepes or Bicine) covering a pH
range of 6–9 at 30 ◦C with ionic strength of 0.15 M (adjusted by the
addition of NaCl). The optimum ionic strength for the enzymatic
reaction was determined using a series of 20 mM Hepes buffers
with various NaCl concentrations, corrected for the amount of
HCl/NaOH added to bring the pH to 8.25 at 30 ◦C. For heat-
stability assays, DHDPS from M. tuberculosis or E. coli was
buffer-exchanged into 20 mM Hepes (pH 8.25, at 30 ◦C with an
ionic strength of 0.15 M) before incubation at various temper-
atures (30–100 ◦C) using a solid heat block. Aliquots of 10 μl
were taken after an incubation of 5 min, at a range of temperatures
(30–100 ◦C), or at 70 ◦C with a range of incubation times (0–
60 min), and stored on ice or added directly to initiate the coupled
assay. The heat stability of DHDPS from M. tuberculosis and
E. coli was also analysed with a thermal melt in 15 mM Tris/HCl
solutions (ionic strength of 0.15 M) containing 10× Sypro
Orange (Molecular Probes) with protein unfolding monitored
by fluorescence emission at 575 nm [37]. The wavelength of
excitation was 490 nm, and the plate was heated from 20 to
90 ◦C by an iQ5 Real Time PCR Detection System (Bio-Rad
Laboratories).
Analytical ultracentrifugation
Sedimentation velocity experiments were performed with purified
Mtb-DHDPS using an An-60 Ti four-hole rotor in a Beckman
Coulter Model XL-I analytical ultracentrifuge equipped with
a UV–visible absorbance optical system. Double-sector cells
with quartz windows were loaded with 400 μl of reference
(20 mM Tris/HCl and 0.15 M NaCl, pH 8.0) and 380 μl of
sample (0.055 mg · ml−1) and centrifuged at 40000 rev./min and
20 ◦C. Radial absorbance data were collected at 230 nm every
6 min without averaging. Data were fitted to a continuous
size-distribution model using the program SEDFIT [38]. The
program SEDNTERP [39] was used to determine the partial
specific volume (v¯) of the sample (0.7402 ml · g−1), buffer density
(1.005 g · ml−1), buffer viscosity (1.021 cP), and the standard-
ized sedimentation coefficient (S020,w). The predicted standardized
sedimentation values for three different geometries of tetramer
were calculated using eqn (1) [40], where M is the predicted
molar mass of the tetramer, and F is the geometric factor.
s020,w =
0.01M2/3(1 − vρ)
v
1/3 F (1)
RESULTS AND DISCUSSION
Overall structure
Mtb-DHDPS is a tetramer comprising four identical subunits
arranged in D2 symmetry (Figure 1A). Each monomer (300 amino
acid residues) comprises an N-terminal (β/α)8-barrel domain
(residues 1–233) and a C-terminal domain (residues 234–300)
consisting of three α-helices (Figures 1B–1D). The residues
responsible for substrate binding and catalysis are located in
the (β/α)8-barrel domain. The crystallographic asymmetric unit
contains two tetramers of the enzyme. Each tetramer can be
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Figure 1 The oligomeric and monomeric structure of the Mtb-DHDPS
(A) The two monomers forming the tight dimer AB are coloured red and light red, and the two monomers forming the second tight dimer CD are coloured green and light green respectively. Monomer
structure (B) and topology plot (C) of Mtb-DHDPS. (D) Superposition of DHDPS structures on to the A-subunit of Mtb-DHDPS (1XXX, cyan). R.m.s.d. (root mean square deviation) values (in A˚)
and number of superposed residues (out of 296), are also given in parentheses: E. coli (1YXC, purple, 1.37, 285); T. maritima (1O5K, orange, 1.32, 286); N. sylvestris (structural data from R. Huber,
green, 1.53, 276); B. anthracis (1XKY, grey, 1.17, 287); and A. tumefaciens (2HMC, yellow, 1.75, 272).
described as a dimer of dimers, with the two monomers A and
B (and C and D, Figure 1A) tightly bound to each other to form
the tight dimer, and weaker interactions between the AB and CD
dimeric units.
The final refined Mtb-DHDPS model contains 2364 residues
in total, 1587 water molecules, eight DTT molecules covalently
bound to Cys248, eight Mg2+ and eight Cl− ions. The model
includes all amino acid residues, with the exception of the first
four or five amino acids at the N-terminus, which are not visible
in the electron density. Of all residues, 90.4% are in the most
favoured regions of the Ramachandran plot [41] and 9.2% of
residues are in additionally allowed regions. Only Tyr117 lies in
the forbidden region of the Ramachandran plot, with the exact
values being ϕ = 74.9◦ and ψ =−52.5◦ for Tyr117 in chain A. The
unusual conformation of Tyr117 is well supported by the electron
density in each of the monomers. The same observation has been
made previously for the corresponding residue in all other DHDPS
enzymes of known structure. Tyr117 lies at the tight-dimer interface
of two monomers and takes part in formation of the active site of
the neighbouring monomer.
A secondary structure matching search against all structures
deposited in the PDB using subunit A of Mtb-DHDPS yielded a
total of 21 hits above a Q-score threshold of 0.32. After removing
redundancies, 12 entries were left (Q-score = 0.57–0.78) (see
Supplementary Table 1 at http://www.BiochemJ.org/bj/411/
bj4110351add.htm). The most similar structure was found to be
DHDPS from B. anthracis followed by DHDPS from T. maritima.
At the time of solving the structure of Mtb-DHDPS, only the
latter was available in the PDB. This in retrospect validates
the choice of the search model for molecular replacement, which
was based solely on amino acid sequence comparison. An inter-
esting observation is the apparent relationship of DHDPS to N-
acetylneuraminate lyases, which has been noted previously [42].
Active site and metal-binding sites
The active site is located at the centre of each monomer, fac-
ing the central cavity of the tetramer. It is situated in a pocket at
the C-terminal side of the (β/α)8-barrel, as in all known (β/α)8-
enzymes. The active site centres about Lys171, the amino acid that
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Figure 2 Multiple sequence alignment
Multiple sequence alignment of the DHDPS sequences from M. tuberculosis (1XXX), E. coli (1YXC), T. maritima (1O5K), B. anthracis (1XKY), N. sylvestris (Nsyl) and A. tumefaciens (2HMC). The
alignment was derived from the three-dimensional alignments of the DHDPS structures, which were carried out using the programs ALIGN [29] and STAMP [30]. The secondary-structure elements
(α-helices and β-strands) observed in the structure of Mtb-DHDPS are indicated and labelled. Amino acid residues in black boxes are conserved in four or more of the six DHDPS enzymes listed.
Hash marks (#) indicate those residues involved in catalysis, and an asterisk (*) indicates those residues that are involved in (S)-lysine binding in the E. coli, T. maritima and N. sylvestris enzymes.
forms a Schiff base with the first substrate, pyruvate. In the E.
coli enzyme, the equivalent amino acid is Lys161, as previously
identified via tryptic digest studies [7]. Three amino acid residues
form the conserved catalytic triad: Tyr143, Thr54, and Tyr117,
whereby Tyr117 is contributed from the adjacent monomer across
the tight-dimer interface. Both the identity, as well as the relative
spatial orientation of these functional groups, is conserved among
characterized DHDPS enzymes, but not conserved in the putative
A. tumefaciens DHDPS enzyme (Swiss-Prot accession number
Q8U6Y1), where the corresponding residues are Tyr136, Ser48 and
Leu108 (Figure 2). As mentioned above, the exact function of
the A. tumefaciens enzyme remains to be established. A detailed
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Figure 3 Survey of the Mtb-DHDPS active site
The active site, defined by the position of Lys171, is found in a cleft within the (α/β)8-barrel
(secondary structure is transparent). Tyr117 from the adjacent monomer reaches through the
interface (AB from Figure 1) to interact with Thr54.
examination of the Mtb-DHDPS active site, however, shows the
distance between Tyr143-OH and Thr54-OH is somewhat increased
(4.7 Å) compared with E. coli DHDPS (2.7 Å), and the geometry
is such that hydrogen-bonding is unlikely (Figure 3). In addition,
the active site also contains a methionine residue (Met251) and a
cysteine residue (Cys248), which, in Mtb-DHDPS, binds a DTT
molecule. These residues sit opposite Lys171, lining the active-site
cavity (Figure 3), and could be exploited in rational inhibitor
design. We have noted recently the potential for a species-
specific inhibitor designed to target DHDPS [43]. Whether these
motifs are utilized in Mtb-DHDPS catalysis is under investigation.
The mechanism of the DHDPS-catalysed reaction has been
studied in detail for the E. coli enzyme by X-ray crystallography,
NMR [10] and site-directed mutagenesis [12]. After Schiff base
formation between pyruvate and the active-site lysine residue, (S)-
ASA binds to the stable substituted enzyme form. The product
heterocycle (HTPA) is then released and undergoes dehydration
and the enzyme is regenerated [10].
An Mg2+ ion is co-ordinated by Ala162-O, His164-O and Ile167-O
and three water molecules. In the E. coli (PDB codes 1DHP and
1YXC [13,14]) and B. anthracis (PDB entry 1XKY [16]) DHDPS
structures, a K+ ion is found in the same position as the Mg2+ ion
in the Mtb-DHDPS structure. The function of this metal-binding
site is unclear, especially since it is located far from the enzyme
active site. We note that, via the coupled assay, the activity of
the enzyme is unaffected by Mg2+ ions (<20 mM). It is likely
that the Mg2+ ions seen in the structure are an artefact of the
crystallization conditions. A Cl− ion, co-ordinated by Lys174-NZ,
Ser179-OG and two water molecules, was also observed in Mtb-
DHDPS. In contrast with the model of the E. coli enzyme (PDB
code 1YXC [13]), where a Cl− ion is found in the active site, co-
ordinated by the catalytic Lys161, Thr44 and two water molecules
[13], the Cl−-binding site in Mtb-DHDPS is distal to the active
site, leaving its functional significance unclear.
Dimer–dimer interface of Mtb-DHDPS
In order to confirm the biologically significant unit of the enzyme,
all the potential interfaces were examined using the EBI PISA
server [32], and the Protein–Protein Interaction server. Within
the tetrameric unit shown in Figure 1(A), each of the two tight-
dimer interfaces (AB and CD) bury approx. 1470 Å2 per mono-
mer, which corresponds to roughly 13% of the surface area
of the monomer, whereas the interfaces between monomers A
and D, and monomers B and C, bury a surface area of approx.
860 Å2 per monomer (see Supplementary Table 2 at http://www.
BiochemJ.org/bj/411/bj4110351add.htm). Polar residues repres-
ent 40% of the tight interface area, and 30% of the AD and
BC interfaces. For the E. coli enzyme, each of the two tight-
dimer interfaces (AB and CD) bury approx. 1300 Å2 per monomer
(roughly 11% of the surface area of the monomer), whereas
the weaker dimer interfaces AC and BD bury a surface area of
approx. 500 Å2. The polar residues represent 35% of the tight-
dimer interface area, and 44% of the weak AC and BD interfaces.
The T. maritima DHDPS structure buries an interface-accessible
area similar to that of the Mtb-DHDPS structure (see Supple-
mentary Table 2). Figure 4(A) shows a schematic diagram of
the E. coli DHDPS and Mtb-DHDPS dimer–dimer interface.
This comparison suggests that the oligomeric structure of Mtb-
DHDPS may be somewhat more stable than the structure of
E. coli DHDPS.
In order to corroborate the apparent oligomeric state seen in the
crystal structure, further study of Mtb-DHDPS in solution was
performed via analytical ultracentrifugation. Sedimentation
velocity experiments, fitted to a continuous size-distribution
model [38], confirmed that Mtb-DHDPS was a single species
in solution with a molecular mass of 115 kDa, taken from the
ordinate maximum of the peak observed in the c(M) distri-
bution (Figure 4C). Based on c(s) distribution analysis (results
not shown), the tetrameric species has a sedimentation coefficient
(S020,w) of 6.7 S. We note that, at a concentration of 0.055 mg · ml−1,
Mtb-DHDPS shows no dimer in solution. This is in contrast with
the E. coli enzyme, which shows a significant proportion of dimer
at a similar concentration (0.05 mg · ml−1) [44], suggesting that
the dimer–dimer interface for Mtb-DHDPS is indeed stronger than
in the E. coli enzyme. Using eqn (1), the spatial arrangement of
the Mtb-DHDPS tetramer in aqueous solution (S020,w = 6.7 S) is
intermediate between square planar (calculated S020,w = 6.540 S,
F = 0.926) and tetrahedral (calculated S020,w = 6.903 S, F = 0.977),
which correlates well with the particular D2-symmetric shape
shown in the X-ray crystal model (Figure 1). The homotetrameric
structure of Mtb-DHDPS in solution has been corroborated
further by gel filtration and blue native PAGE (results not
shown).
Enzyme kinetics
The coupled enzyme assay was used to characterize the kinetic
properties of Mtb-DHDPS. Initially, the stability and pH optimum
for activity was assessed. For enzymatic activity of Mtb-DHDPS,
the optimum pH was determined to be 8.25 at 30 ◦C in Hepes
buffer (Figure 5A). Additionally, a steady decrease in activity
was seen when the ionic strength was increased above 0.1 M
(Figure 5B). In a buffer of 20 mM Hepes (pH 8.25) at 30 ◦C
(ionic strength 0.15 M), Mtb-DHDPS showed a greater thermal
stability than E. coli DHDPS, with an apparent Tm (melting
temperature) of ∼82 ◦C compared with ∼57 ◦C for the E. coli
enzyme (Figure 5C). Further experiments showed that Mtb-
DHDPS maintained its activity for 40 min when incubated at
70 ◦C, whereas E. coli DHDPS showed degradation within the
first few minutes (results not shown). This result was supported by
following protein unfolding monitored by fluorescence emission
(Figure 5D). The thermal stability of the Mtb-DHDPS is probably
in part due to the greater number of intersubunit contacts as
compared with the E. coli enzyme (Figure 4A).
A full matrix of initial rates was determined with both substrates
varied, and these data were fitted with different kinetic models:
ternary complex, Ping Pong and Ping Pong with substrate inhib-
ition. The Ping Pong model provided the best fit (Figure 6), and
yielded KM constants for pyruvate (0.17 +− 0.01 mM) and (S)-ASA
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Figure 4 Analysis of the dimer–dimer interface and sedimentation velocity of Mtb-DHDPS
(A) Analysis of the dimer–dimer interface of tetrameric Mtb-DHDPS (1XXX) and E. coli DHDPS (1YXC). Interfaces were probed using JavaProtein Dossier [51] and manual inspection. Dotted lines
indicate hydrogen-bonding, continuous lines indicate hydrophobic interactions, and circles represent water. The thicker lines indicate that the interactions are in both symmetrical interfaces (i.e.
interfaces AD and BC of Figure 1) of the tetramer. Amino acids are identified using single-letter codes. (B) Sedimentation velocity absorbance data plotted as a function of radial position from the axis
of rotation (cm) for Mtb-DHDPS at a concentration of 0.055 mg · ml−1 in 20 mM Tris/HCl and 150 mM NaCl, at pH 8.0. The raw data are presented as open symbols () plotted at time intervals of
6 min overlaid with the non-linear least squares best-fit (solid line) to a continuous size distribution model [c(M)] [38]. The residuals (top) for the c(M) distribution best-fit are plotted as a function
of radial position (cm) from the axis of rotation. (C) The c(M) distribution is plotted as a function of molar mass (kDa) for Mtb-DHDPS. The fit was obtained using a resolution of 200 species
between Mmin of 2.5 kDa and Mmax of 350 kDa with v¯ = 0.7402 ml · g−1, ρ = 1.00 499 g · ml−1, η = 1.0214 cP, and f /f 0 = 1.21902. The r.m.s.d. (root mean square deviation) and Z test for the fit
were 0.003895 and 3.49 respectively.
(0.43 +− 0.02 mM). Interestingly, a 6-fold increase in the Vmax(4.42 +− 0.08 μmol · s−1 · mg−1) was observed over E. coli DHDPS,
which may reflect the increased importance of DAP in the
peptidoglycan layer of mycobacteria [45]. That the ordered
Ping Pong kinetic mechanism is conserved in Mtb-DHDPS, is
consistent with the ordered kinetic mechanism proposed for other
DHDPS enzymes. We note that the Ping Pong mechanism is
symmetrical, but speculate that, in the case of Mtb-DHDPS,
pyruvate is the first substrate to bind, followed by (S)-ASA.
Whether the catalytic triad, as proposed for the E. coli enzyme,
operates in this enzyme remains to be elucidated; as we have
observed above, this motif is conserved, yet its geometry probably
precludes function without structural changes occurring, perhaps
during catalysis. The structure of Mtb-DHDPS complexed with
various inhibitors or substrates will be helpful in this regard.
Previous studies suggest that the real power of an enzyme
lies not only in the mechanistically important residues that
form the catalytic unit, but also in a combination of the very
‘local’ structural features of the catalytic unit and more ‘global’
features, such as the dynamics of the structure and the overall
microenvironment of the active site [46]. Despite the high degree
of overall structure similarity (both in the solid state and in
solution) and active-site conservation, Mtb-DHDPS shares little
sequence identity with other DHDPS enzymes, and our data
reveal important differences in their structural, biophysical and
biochemical properties.
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Figure 5 Effect of pH, ionic strength and temperature on catalytic
activity
The effect of varying (A) pH with different buffers ( Mes,Hepes and Bicine), and (B) ionic
strength on enzyme activity was measured using the coupled assay. The data in (B) are normalized
to the highest measured rate (vcon) of enzyme activity. (C) Enzyme activity determined using
the coupled assay after pre-treatment using a 5 min incubation at increasing temperature. The
thermal stability of Mtb-DHDPS (H17009) was compared with E. coli DHDPS (	) using the apparent
initial rate (vapp) divided by rate of enzyme activity without pre-treatment (vcon). Results are
means +− S.D. of triplicate measurements. (D) The melting temperature as determined by a
fluorescence melt for Mtb-DHDPS () and E. coli DHDPS () was comparable with that
determined using activity assays.
Figure 6 Kinetic analysis of Mtb-DHDPS
The initial velocity was measured using the coupled assay over various concentrations of
each substrate, (S)-ASA and pyruvate (× 3.0 mM,  1.5 mM,  0.30 mM,  0.15 mM
and ♦0.06 mM). Each point was measured at least in triplicate and the data were fitted
with the Ping Pong model (R2 of 0.9945) using the software program Enzfitter (A and
B). (C, D) Lineweaver–Burk transformations reflect the trend predicted for the Ping Pong
model.
Figure 7 Comparison of the (S)-lysine-binding site in E. coli DHDPS and
cleft in Mtb-DHDPS
(A) Surface representation of the tight dimer showing the (S)-lysine-binding site of the E. coli
DHDPS (1YXD) with the bound (S)-lysine in yellow. (B) Superposition of the corresponding
Mtb-DHDPS (1XXX) residues (in red) on to the (S)-lysine-binding residues (grey) of E. coli
DHDPS (1YXD). The bound (S)-lysine residues (from 1YXD) are shown in yellow.
Mtb-DHDPS is not feedback-regulated by (S)-lysine
Except at very high concentrations (50 mM and above), (S)-lysine
did not have any effect on the activity of Mtb-DHDPS. The
IC50 was determined to be 250 mM, which greatly exceeds that
which could be reasonably expected in a cell. Thus, in contrast
with plant and Gram-negative DHDPS enzymes [8,35,47–49],
Mtb-DHDPS can be considered insensitive to inhibition by
(S)-lysine. This observation is explained nicely by structural
superposition of the two enzymes and examination of the (S)-
lysine-binding site observed in E. coli (Figure 7). Most residues
identified as important for the (S)-lysine allosteric binding site
are not conserved in Mtb-DHDPS (Table 2) [9,10,13]. Mtb-
DHDPS is the only DHDPS enzyme with a known structure
in which the asparagine residue of the (S)-lysine-binding site is
not conserved, but replaced by a tyrosine residue. Additionally,
the (S)-lysine-binding cavity in the M. tuberculosis enzyme is
shallow compared with the equivalent site of the E. coli or
N. sylvestris enzymes, leaving little space for (S)-lysine to bind.
Interestingly, other aspartate family amino acids (DAP, threonine
and methionine) showed no significant inhibition of Mtb-DHDPS
activity (Table 3).
The regulation of the (S)-lysine biosynthetic pathway (if it
is indeed regulated in M. tuberculosis) is maintained via an
alternative strategy. In E. coli, the DAP pathway is likely to be
controlled at both the aspartate kinase and DHDPS catalytic step.
Moreover, it has been suggested that E. coli DHDPS expression
is regulated by the level of DAP [50]; whether such an approach is
adopted by M. tuberculosis remains to be elucidated.
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Table 2 Allosteric inhibition site residues
The (S)-lysine-binding residues are identified in E. coli DHDPS (second column), followed by
an alignment of corresponding residues in the other known structures. N. sylvestris DHDPS
co-ordinates were kindly provided by R. Huber.
M. tuberculosis E. coli T. maritima B. anthracis
(1XXX) (1YXD) (1O5K) N. sylvestris (1XKY)
Ser58 Ser Ser Gly Ser
Pro59 Ala Pro Gln Pro
Asp63 His Glu Trp Ser
Lys66 His Arg His Lys
Gly88 Gly Gly Gly Gly
Tyr90 Asn Asn Asn Asn
His94 Glu Lys Glu Ala
Tyr116 Tyr Tyr Tyr Tyr
Table 3 Potential inhibitors of Mtb-DHDPS
The activity of Mtb-DHDPS in the presence of aspartate family amino acids. Each substrate
concentration was held at 0.3 mM. Relative activity is relative to that in the absence of inhibitor.
Amino acid Concentration (mM) Relative activity (%)
meso-DAP 1 99
10 87
20 57
(S)-threonine 1 104
10 86
20 74
(S)-methionine 1 100
10 99
20 96
Accordingly, the most valid approach for generating inhibitors
and novel antibiotics targeting DHDPS from M. tuberculosis
should focus on the highly conserved active-site geometry of the
enzyme, rather than the vestigial allosteric cleft (Figure 7).
In conclusion, the increasing prevalence of tuberculosis cases,
and especially that of antibiotic resistance, necessitates the
development of novel antibiotics. Pivotal to such endeavours is
an extensive understanding of the proposed antibiotic targets. In
the present paper, we describe a structural and biochemical study
of an important antibiotic target from M. tuberculosis. We have
found that the active site of Mtb-DHDPS is generally similar
to that of E. coli DHDPS. However, we note that the proton-
relay residues are such that the hydrogen-bonding network may
be disrupted. Given that the residues responsible for substrate
binding are generally conserved, lead compounds targeted to the
E. coli active site are likely to also be effective against the M.
tuberculosis enzyme. Additionally, the presence of a cysteine
residue and a methionine residue within the active site may be
exploited to develop inhibitors tailored to Mtb-DHDPS. The M.
tuberculosis enzyme, unlike E. coli DHDPS, is not allosterically
affected by (S)-lysine, which may reflect the requirement for DAP
in the bacterial cell wall. Continued investigation into the catalytic
mechanisms, the consequences of this enzyme’s oligomeric state
and the DAP/(S)-lysine biosynthetic pathway in M. tuberculosis
are necessary to explain the regulatory mechanism of this essential
pathway in bacteria.
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Available online 13 November 2007Abstract—Dihydrodipicolinate synthase (DHDPS) is a key enzyme in lysine biosynthesis and an important antibiotic target. The
specificity of a range of heterocyclic product analogues against DHDPS from three pathogenic species, Bacillus anthracis,Mycobac-
terium tuberculosis and methicillin-resistant Staphylococcus aureus, and the evolutionarily related N-acetylneuraminate lyase, has
been determined. The results suggest that the development of species-specific inhibitors of DHDPS as potential antibacterials is
achievable.
 2007 Elsevier Ltd. All rights reserved.The development of narrow-spectrum antibacterials has
several advantages, including limiting the development
of drug-resistance1 and minimising imbalances on
important natural gut and intestinal flora.2–4 While tar-
geting genus-/species-specific proteins or membrane
components has been one method used to achieve nar-
row-spectrum activity,5 another is to target specific iso-
forms of essential bacterial enzymes.6
The bacterial diaminopimelate (DAP) pathway is
responsible for the biosynthesis of the essential amino
acid lysine and its immediate precursor meso-DAP,
both of which are major constituents of the bacterial
peptidoglycan cell wall.7–9 Lysine is a constituent in
Gram-positive bacteria (for example, the pathogenic
bacterium Staphylococcus aureus) while the cell wall
of Gram-negative bacteria, such as Escherichia coli,
contains meso-DAP. Compounds that inhibit the
DAP pathway may therefore represent a novel class
of antibacterial agents. We have been engaged for some
time in a study of the enzyme dihydrodipicolinate syn-0960-894X/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2007.11.026
Keywords: Dihydrodipicolinate synthase; DHDPS; Antibacterials;
Species specificity; N-Acetylneuraminate lyase; NAL.
* Corresponding author. Tel.: +61 3 8344 6482; fax: +61 3 9347
5180; e-mail: chutton@unimelb.edu.authase (DHDPS, E.C. 4.2.1.52) which, as the first com-
mitted step of the biosynthetic pathway, is of particular
interest as a drug target.7,10–12 As part of this pro-
gramme, we herein report on the potential for achiev-
ing species-specificity in the development of DHDPS
inhibitors.
DHDPS is a homotetrameric enzyme that belongs to the
N-acetylneuraminate lyase (NAL) sub-family of en-
zymes.13 Each of the four monomeric units of DHDPS
and NAL has a (b/a)8 barrel fold and these enzymes
are believed to have evolved from a common ancestor.14
The reactions catalyzed by DHDPS and NAL follow
similar mechanisms, as shown in Figures 1 and 2.13 Each
enzyme has an active site lysine residue that condenses
with pyruvate 1 to form a Schiff base. Tautomerization
to the corresponding enamine is then followed by reac-
tion with the relevant aldehyde-containing substrate
(aspartate semi-aldehyde 2 or N-acetylmannosamine 6)
to generate a 4-hydroxy-2-iminoacid intermediate (3 or
7), which then proceeds to the heterocyclic product
(HTPA 4 or sialic acid 8). In the case of the DHDPS-
catalyzed reaction, subsequent dehydration gives
DHDP 5.15 Note that the NAL-catalyzed reaction is
drawn in the reverse direction to the dominant physio-
logical process, for comparison.13
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Figure 1. DHDPS-catalyzed reaction.
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Figure 3. Heterocyclic compounds 9–18 tested for inhibition of
DHDPS and NAL.
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hydroxytetrahydrodipicolinate (HTPA 4) were screened
against E. coli DHDPS and shown to be moderate, non-
competitive inhibitors.10 Accordingly, we have investi-
gated the efficacy of these compounds against DHDPS
from a range of pathogenic bacterial species, in order
to establish whether species selectivity of such com-
pounds is feasible. The compounds were also screened
against E. coli NAL, in order to establish whether the
binding site for these inhibitors has been conserved
across related enzyme families.Table 1. Inhibition assays against bacterial DHDPS and NALa
Compound Inhibitio
E. coli DHDPS B. anthracis DHDPS M
9a 49 73 43
9b 92 99 24
10a 76c 80 75
10b 5 13 0
11a 74d 0 73
11b 85e 0 84
12 35 23 0
13 12 19 0
14 0 7 0
15 20 22 14
16 8 8 1
17 0 19 6
18 14 6 7
a Assays were performed in duplicate and were typically within ±3%.
b% Inhibition in the presence of 20 mM 9–18.
cKi = 11 mM versus 1, 18 mM versus 2 (Ref. 20).
dKi = 22 mM versus 1, 25 mM versus 2 (Ref. 10).
eKi = 7 mM versus 1, 14 mM versus 2 (Ref. 10).DHDPS from three pathogenic bacterial species, Bacil-
lus anthracis,16 Mycobacterium tuberculosis17 and meth-
icillin-resistant S. aureus (MRSA),18 and E. coli
NAL13,18 were expressed in and purified from E. coli.
Compounds 9–18 (Fig. 3) were synthesised according to
the reported methods10 and were screened against all en-
zymes (Table 1). In the DHDPS inhibitor screen, our
standard coupled assay was employed, in which the cou-
pling enzyme was DHDPR.12,19,20 For screening NAL,
an analogous assay was used employing lactate dehy-
drogenase as a coupling enzyme21,22.n of enzyme activityb
. tuberculosis DHDPS MRSA DHDPS E. coli NAL
51 21
58 18
67 1
0 0
83 27
88 64
0 1
0 0
7 7
12 38
10 0
0 3
0 0
Figure 4. Inhibition of E. coli growth by chelidamic acid 11a.
844 V. Mitsakos et al. / Bioorg. Med. Chem. Lett. 18 (2008) 842–844The DHDPS assays show that piperidine-2,6-dicarbox-
ylate 9a and dipicolinic acid 10a are relatively potent
inhibitors across all species with little selectivity.
In a dramatic example of species selectivity, chelidamic
acid 11a, and its diester 11b, are potent inhibitors of
DHDPS from E. coli, M. tuberculosis and MRSA, but
in contrast display no inhibition at all of B. anthracis
DHDPS. Similarly, several compounds, including piper-
idine diester 9b and the thiazanes 12 and 13, exhibit sig-
nificantly greater inhibitory activity against E. coli and
B. anthracis DHDPS than DHDPS fromM. tuberculosis
and MRSA.
Few of the compounds studied exhibited significant inhi-
bition of E. coli NAL, with dimethyl chelidamate 11b
being the only one to show >50% inhibition at the con-
centration tested, and thiazane-S-oxide 15, piperidine-
diacid 9a and chelidamic acid 11a exhibiting lower activ-
ity. That E. coli NAL was inhibited to some degree by
several of the compounds suggests that the inhibition
site has been conserved across families and may there-
fore have some functional significance.
In order to validate the inhibitors as potential leads for
the development of antibacterial agents, the antibacte-
rial activity of selected compounds against E. coli was
determined. Compounds 9b, 11a and 17 were chosen
for analysis: piperidine diester 9b as it exhibited the most
potent inhibition of E. coli DHDPS, chelidamic acid 11a
as it shows significant species selectivity and sulfone 17
as a control as it displayed very low levels of DHDPS
inhibition across all species tested. Chelidamic acid 11a
at a concentration of 20 mM displayed strong inhibition
of bacterial growth (Fig. 4) relative to the control cul-
ture in the absence of 11a. Piperidine ester 9b also at a
concentration of 20 mM displayed moderate inhibition
of growth, whereas sulfone 17 displayed virtually no
inhibition. These results suggest that DHDPS inhibitors
are able to confer significant antimicrobial activity.
In conclusion, several compounds displayed clear
differentiation in inhibition of DHDPS enzymes from
different bacterial species, which suggests that latter gen-eration compounds could be targeted to specific patho-
gens. Validation of the potential of these compounds
as leads for the development of antibacterials was dem-
onstrated; for example, chelidamic acid 11a displayed
high levels of inhibition of both DHDPS activity and
bacterial growth, in contrast to sulfone 17, which dis-
played no enzyme inhibition and no antibacterial
activity.Acknowledgments
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